1
00:00:24,098 --> 00:00:27,068
>> A WARM WELCOME TO DR.
DOUG

2
00:00:27,068 --> 00:00:28,035
LOWY.

3
00:00:28,035 --> 00:00:30,605
IT'S GREAT TO HAVE YOU AT THE

4
00:00:30,605 --> 00:00:31,706
TOP OF THE HELM AND LOOKING

5
00:00:31,706 --> 00:00:35,476
FORWARD TO YOUR COMMENTARY TOD 

6
00:00:35,476 --> 00:00:35,676
TODAY.

7
00:00:35,676 --> 00:00:37,478
AND HAPPY THANKSGIVING TO

8
00:00:37,478 --> 00:00:38,713
EVERYONE.

9
00:00:38,713 --> 00:00:40,148
KEITH, I DON'T KNOW IF YOU HAD A

10
00:00:40,148 --> 00:00:41,315
FEW OPENING REMARKS?

11
00:00:41,315 --> 00:00:44,051
>> I'D LIKE TO ECHO YOUR
WARM

12
00:00:44,051 --> 00:00:45,520
WELCOME AND ESPECIALLY TO DOUG.

13
00:00:45,520 --> 00:00:47,321
THIS IS THE SECOND TIME IN MY

14
00:00:47,321 --> 00:00:50,792
TENURE THAT YOU HAVE STEPPED IN

15
00:00:50,792 --> 00:00:52,193
TO GUIDE US THROUGH A TRANSITION

16
00:00:52,193 --> 00:00:53,694
PERIOD.

17
00:00:53,694 --> 00:00:56,164
SO, THANK YOU AGAIN AS ALWAYS

18
00:00:56,164 --> 00:00:57,432
FOR YOUR STEADFAST COMMITMENT TO

19
00:00:57,432 --> 00:01:00,034
KEEPING THIS ORGANIZATION

20
00:01:00,034 --> 00:01:00,635
MOVING.

21
00:01:00,635 --> 00:01:03,404
AND THIS IS MY LAST MEETING.

22
00:01:03,404 --> 00:01:05,273
I'M SAD TO SAY.

23
00:01:05,273 --> 00:01:09,577
AND WITH THAT, I'D LIKE TO

24
00:01:09,577 --> 00:01:12,046
PARTICULARLY ACKNOWLEDGE

25
00:01:12,046 --> 00:01:12,413
DR. PAULA GRAY.

26
00:01:12,413 --> 00:01:14,816
I THINK YOU HAVE ALL HAD AN

27
00:01:14,816 --> 00:01:18,920
OPPORTUNITY TO ADMIRE HER WORK

28
00:01:18,920 --> 00:01:20,455
IN SUPPORT OF THESE BOARDS, BOTH

29
00:01:20,455 --> 00:01:21,189
OF THEM.

30
00:01:21,189 --> 00:01:23,224
OBVIOUSLY MY PERSPECTIVE WITHIN

31
00:01:23,224 --> 00:01:26,127
THE BSA EXTENDS BACK INTO THE

32
00:01:26,127 --> 00:01:27,628
BEGINNING OF MY TERM AND

33
00:01:27,628 --> 00:01:30,665
PARTICULARLY THESE PAST TWO

34
00:01:30,665 --> 00:01:33,201
YEARS WHERE I AND JOHN HAVE

35
00:01:33,201 --> 00:01:35,102
GOTTEN TO WITNESS HOW IT IS THAT

36
00:01:35,102 --> 00:01:38,005
PAULA WORKS BEHIND-THE-SCENES TO

37
00:01:38,005 --> 00:01:41,509
REALLY MAKE THESE BOARDS WORK IN

38
00:01:41,509 --> 00:01:44,412
THEIR INTEND PURPOSE.

39
00:01:44,412 --> 00:01:45,546
PAULET YOU'RE THE CONSTANT

40
00:01:45,546 --> 00:01:45,880
PROFESSIONAL.

41
00:01:45,880 --> 00:01:48,049
I HAVE NEVER HAD THE HONOR OF

42
00:01:48,049 --> 00:01:49,917
WORKING WITH SOMEONE WHO YOU IS

43
00:01:49,917 --> 00:01:52,453
SO COMMITTED AND SO EXCELLENT IN

44
00:01:52,453 --> 00:01:53,154
THEIR JOB.

45
00:01:53,154 --> 00:01:55,289
YOU ARE THE INSTITUTIONAL MEMORY

46
00:01:55,289 --> 00:01:57,558
AND KNOWLEDGE OF THIS

47
00:01:57,558 --> 00:01:57,892
ORGANIZATION.

48
00:01:57,892 --> 00:02:00,294
I CANNOT IMAGINE HOW THIS BOARD

49
00:02:00,294 --> 00:02:00,862
WILL FUNCTION WITHOUT YOU.

50
00:02:00,862 --> 00:02:03,030
BUT I'M VERY, VERY GRATEFUL FOR

51
00:02:03,030 --> 00:02:04,966
YOUR HELP AND SUPPORT IN THIS

52
00:02:04,966 --> 00:02:06,133
TIME.

53
00:02:06,133 --> 00:02:09,637
LASTLY, I'D LIKE TO PASS THE

54
00:02:09,637 --> 00:02:11,172
MICROPHONE TO KEN TO PROVIDE US

55
00:02:11,172 --> 00:02:12,306
WITH A FEW THOUGHTS BEFORE WE

56
00:02:12,306 --> 00:02:17,778
KICK OFF THE MEETING.

57
00:02:17,778 --> 00:02:18,613
>> THANK YOU.

58
00:02:18,613 --> 00:02:20,681
I WANTED TO SAY I'M GLAD TO BE

59
00:02:20,681 --> 00:02:20,882
HERE.

60
00:02:20,882 --> 00:02:23,451
I'M HERE AS A BSA MEMBER.

61
00:02:23,451 --> 00:02:26,187
THIS THE IS MY LAST DAY AS CHAIR

62
00:02:26,187 --> 00:02:28,990
AND TOMORROW I'LL BE A CANCER

63
00:02:28,990 --> 00:02:31,759
BIOLOGY FACULTY MEMBER BEFORE I

64
00:02:31,759 --> 00:02:32,093
MOVE UP HERE.

65
00:02:32,093 --> 00:02:33,961
I'M GLAD TO BE LEARNING FROM

66
00:02:33,961 --> 00:02:36,430
DOUG LOWY AND EVERYONE ELSE AND

67
00:02:36,430 --> 00:02:38,933
I WILL BE VERY QUIET DURING THIS

68
00:02:38,933 --> 00:02:39,166
MEETING.

69
00:02:39,166 --> 00:02:44,005
I'M HERE TO SOAK IT IN TODAY.

70
00:02:44,005 --> 00:02:44,639
SO THANK YOU FOR EVERYTHING THAT

71
00:02:44,639 --> 00:02:45,973
EVERYONE DOES.

72
00:02:45,973 --> 00:02:46,707
>> THAT'S GREAT.

73
00:02:46,707 --> 00:02:51,712
I CONCUR WITH ALL OF KEITH'S

74
00:02:51,712 --> 00:02:54,615
COMMENTS.

75
00:02:54,615 --> 00:02:55,950
SO, REQUIRED ANNOUNCEMENTS.

76
00:02:55,950 --> 00:02:56,751
MEMBERS OF THE PUBLIC WHO MAY

77
00:02:56,751 --> 00:02:59,954
WISH TO EXPRESS VIEWS REGARDING

78
00:02:59,954 --> 00:03:03,724
ANY ITEMS DISCUSSED DURING THE

79
00:03:03,724 --> 00:03:04,358
MEETINGS MAY DO SO BY WRITING TO

80
00:03:04,358 --> 00:03:04,892
DR. PAULA GRAY WHO IS THE

81
00:03:04,892 --> 00:03:06,661
EXECUTIVE SECRETARY OF THE

82
00:03:06,661 --> 00:03:08,729
BOARD, WITHIN 10 DAYS FOLLOWING

83
00:03:08,729 --> 00:03:10,064
THIS MEETING B WRITTEN

84
00:03:10,064 --> 00:03:12,166
STATEMENTS SUBMITTED BY MEMBERS

85
00:03:12,166 --> 00:03:13,868
OF THE PUBLIC WILL RECEIVE

86
00:03:13,868 --> 00:03:15,102
CAREFUL CONSIDERATION.

87
00:03:15,102 --> 00:03:17,405
AS BOARD MEMBERS, I'D LIKE TO

88
00:03:17,405 --> 00:03:20,975
REMIND YOU ALL THAT WE HAVE TO

89
00:03:20,975 --> 00:03:21,976
ABSTAIN OURSELVES VIRTUALLY

90
00:03:21,976 --> 00:03:23,678
DURING SPECIFIC DISCUSSIONS

91
00:03:23,678 --> 00:03:25,813
WITHIN OUR PARTICIPATION AND

92
00:03:25,813 --> 00:03:28,449
DELIBERATIONS ON A PARTICULAR

93
00:03:28,449 --> 00:03:30,117
PRODUCT OR PROGRAM WOULD

94
00:03:30,117 --> 00:03:31,419
CONSTITUTE A CONFLICT OF

95
00:03:31,419 --> 00:03:31,886
INTEREST OR CREATE THE

96
00:03:31,886 --> 00:03:34,021
APPEARANCE OR PERCEPTION OF ONE.

97
00:03:34,021 --> 00:03:36,657
IT IS INCUMBENT UPON OURSELVES

98
00:03:36,657 --> 00:03:40,061
TO ADVISE THE EXECUTIVE

99
00:03:40,061 --> 00:03:41,128
SECRETARY AND ABSTAIN FROM

100
00:03:41,128 --> 00:03:42,096
PARTICIPATION OR DISCUSSION OR

101
00:03:42,096 --> 00:03:45,499
ACTION REGARDING THAT MATTER.

102
00:03:45,499 --> 00:03:46,734
IN LIGHT OF THE CURRENT POLICIES

103
00:03:46,734 --> 00:03:48,169
GOVERNING CONFLICT OF INTEREST

104
00:03:48,169 --> 00:03:50,972
BASED ON FINANCIAL HOLDINGS OF

105
00:03:50,972 --> 00:03:51,739
SPECIAL GOVERNMENT EMPLOYEES AND

106
00:03:51,739 --> 00:03:55,810
AS BOARD MEMBERS, WE HAVE TO

107
00:03:55,810 --> 00:03:58,379
DEPEND ON US TO VOLUNTARILY

108
00:03:58,379 --> 00:03:59,814
ABSTAIN DURING ANY AND ALL

109
00:03:59,814 --> 00:04:01,282
DISCUSSIONS OF MATTERS THAT

110
00:04:01,282 --> 00:04:03,351
COULD CONCEIVABLY IMPACT THE

111
00:04:03,351 --> 00:04:05,219
STATUS OF ANY OF THE HOLDINGS

112
00:04:05,219 --> 00:04:05,486
DISCUSSED.

113
00:04:05,486 --> 00:04:09,624
SO WE HAVE TO TRUST OUR JUDGMENT

114
00:04:09,624 --> 00:04:11,292
IN THESE INSTANCES OF THE DURING

115
00:04:11,292 --> 00:04:12,793
ANY CLOSED SESSION ANY MATERIALS

116
00:04:12,793 --> 00:04:16,831
OR DISCUSSIONS OF A CONFIDENTIAL

117
00:04:16,831 --> 00:04:18,532
NATURE ARE PRIVILEGED

118
00:04:18,532 --> 00:04:20,201
INFORMATION AND ARE MADE

119
00:04:20,201 --> 00:04:21,235
AVAILABLE ON A NEED TO KNOW

120
00:04:21,235 --> 00:04:22,403
BASE, SUCH DELIBERATIONS ARE

121
00:04:22,403 --> 00:04:25,039
PRIVATE AND THEIR CONTENT SHOULD

122
00:04:25,039 --> 00:04:27,041
NOT BE DIVULGED.

123
00:04:27,041 --> 00:04:29,043
SO FUTURE MEETING DATES ARE

124
00:04:29,043 --> 00:04:32,413
LISTED ON THE AGENDA ANDOR THE

125
00:04:32,413 --> 00:04:33,214
CANCER.GOV WEBSITE.

126
00:04:33,214 --> 00:04:37,652
BY LAW, A QUORUM OF BOARD

127
00:04:37,652 --> 00:04:39,787
MEMBERS IS REQUIRED WHETHER IN

128
00:04:39,787 --> 00:04:41,322
OPEN OR CLOSED SESSION.

129
00:04:41,322 --> 00:04:45,326
DURING THIS MEETING A MEMBER OF

130
00:04:45,326 --> 00:04:50,164
24 APPOINTED MEMBERS MUST BE

131
00:04:50,164 --> 00:04:51,465
PRESENT FOR THEIR VOTES.

132
00:04:51,465 --> 00:04:53,534
OUR PRESENCE IN THE VIRTUAL ROOM

133
00:04:53,534 --> 00:04:55,970
FOR ALL SEGMENTS OF THE MEETING

134
00:04:55,970 --> 00:04:57,004
IS A MUST AND REQUIRED.

135
00:04:57,004 --> 00:05:00,074
IT SHOULD BE NOTED THAT WHEN WE

136
00:05:00,074 --> 00:05:02,710
DO THE CONCEPTS LATER TODAY,

137
00:05:02,710 --> 00:05:04,245
WHILE BOTH BOARDS CAN

138
00:05:04,245 --> 00:05:05,913
PARTICIPATE, ONLY BSA MEMBERS

139
00:05:05,913 --> 00:05:08,115
WILL BE COUNTED IN THE VOTE.

140
00:05:08,115 --> 00:05:11,552
THE QUORUM WILL BE 15 MEMBERS

141
00:05:11,552 --> 00:05:11,886
FOR THE BSA.

142
00:05:11,886 --> 00:05:13,154
ADDITIONALLY, FOLLOWING THE

143
00:05:13,154 --> 00:05:17,024
SUBCOMMITTEE REPORTS, ONLY NCATS

144
00:05:17,024 --> 00:05:18,459
MEMBERS WILL BE COUNTED IN THE

145
00:05:18,459 --> 00:05:18,859
VOTE.

146
00:05:18,859 --> 00:05:21,195
ALL BOARD MEMBERS CAN

147
00:05:21,195 --> 00:05:22,730
PARTICIPATE IN DISCUSSION.

148
00:05:22,730 --> 00:05:24,198
AND THE QUORUM WILL BE 10.

149
00:05:24,198 --> 00:05:26,333
DO WE HAVE QUORUM?

150
00:05:26,333 --> 00:05:27,001
>> YES WE DO.

151
00:05:27,001 --> 00:05:30,971
>> SO NEXT WE NEED TO
APPROVE

152
00:05:30,971 --> 00:05:33,174
THE SEPTEMBER 6, 2023 NCATS

153
00:05:33,174 --> 00:05:36,744
VIRTUAL MEETING SUMMARY MINUTES.

154
00:05:36,744 --> 00:05:39,980
SO, WE NEED TO VOTE TO ACCEPT

155
00:05:39,980 --> 00:05:41,115
THOSE MINUTES.

156
00:05:41,115 --> 00:05:44,218
SO IS THERE A MOTION?

157
00:05:44,218 --> 00:05:46,554
>> SO MOVED.

158
00:05:46,554 --> 00:05:50,224
>> SECOND?

159
00:05:50,224 --> 00:05:51,625
>> SECOND.

160
00:05:51,625 --> 00:05:52,259
>> ANY FURTHER DISCUSSION?

161
00:05:52,259 --> 00:05:54,061
IF NOT, WE CAN VOTE.

162
00:05:54,061 --> 00:06:02,470
I'LL ASK IF THERE ARE ANY

163
00:06:02,470 --> 00:06:03,604
NEIGHS, ANY ABSTENTIONS?

164
00:06:03,604 --> 00:06:04,905
-- ANY NAYs -- IF NOT T SEEMS

165
00:06:04,905 --> 00:06:07,975
WE HAVE UNANIMOUS VOTE.

166
00:06:07,975 --> 00:06:10,611
>> GREAT, YES.

167
00:06:10,611 --> 00:06:11,879
>> SO TO BE SURE THERE ARE
NO

168
00:06:11,879 --> 00:06:14,115
INTERRUPTIONS, PLEASE ENSURE YOU

169
00:06:14,115 --> 00:06:18,152
MUTE YOUR MICS UNTIL RECOGNIZED

170
00:06:18,152 --> 00:06:19,220
BY EITHER ME OR PAULET OR THE

171
00:06:19,220 --> 00:06:23,224
ACTING NCI DIRECTOR OR THE

172
00:06:23,224 --> 00:06:25,526
SPEAKER WHO MAY BE ANSWERING

173
00:06:25,526 --> 00:06:27,061
YOUR QUESTIONS.

174
00:06:27,061 --> 00:06:30,064
SO WE'LL NOW BEGIN TODAY'S,A

175
00:06:30,064 --> 00:06:30,765
AGENDA WITH THE DIRECTOR'S

176
00:06:30,765 --> 00:06:33,601
REPORT BROUGHT TO US BY DR. LOWY

177
00:06:33,601 --> 00:06:36,670
WHO IS SERVING AS ACTING AT NCI

178
00:06:36,670 --> 00:06:37,638
DIRECTOR.

179
00:06:37,638 --> 00:06:37,838
DOUG.

180
00:06:37,838 --> 00:06:38,506
>> GOOD MORNING KEITH AND

181
00:06:38,506 --> 00:06:39,273
EVERYONE ELSE.

182
00:06:39,273 --> 00:06:43,177
GOOD MORNING TO THOSE OF YOU ON

183
00:06:43,177 --> 00:06:44,545
MOUNTAIN AND PACIFIC TIME AND

184
00:06:44,545 --> 00:06:46,147
GOOD AFTERNOON TO THE OTHERS WHO

185
00:06:46,147 --> 00:06:47,748
ARE CENTRAL AND EAST.

186
00:06:47,748 --> 00:06:55,389
IT'S ONCE AGAIN MY HONOR TO BE

187
00:06:55,389 --> 00:06:55,956
ACTING NCI DIRECTOR AS MANY

188
00:06:55,956 --> 00:07:01,162
OTHERS KNOW, IT'S A TERRIFIC

189
00:07:01,162 --> 00:07:02,029
POSITION IF I COULD HAVE THE

190
00:07:02,029 --> 00:07:02,596
NEXT SLIDE.

191
00:07:02,596 --> 00:07:07,401
I'M GOING TO TRY TO GET THROUGH

192
00:07:07,401 --> 00:07:09,670
MY PRESENTATION IN 30 MINUTES OR

193
00:07:09,670 --> 00:07:13,674
SO, SO WE HAVE AT LEAST 10

194
00:07:13,674 --> 00:07:15,943
MINUTES FOR DISCUSSION

195
00:07:15,943 --> 00:07:16,577
AFTERWARDS.

196
00:07:16,577 --> 00:07:20,748
AND I'M DIVIDING THE

197
00:07:20,748 --> 00:07:22,449
PRESENTATION INTO FOUR PARTS.

198
00:07:22,449 --> 00:07:24,652
FIRST RECENT NEWS AND UPDATES.

199
00:07:24,652 --> 00:07:28,355
SECOND, SOME RESEARCH AND

200
00:07:28,355 --> 00:07:28,989
PROGRAMMATIC HIGHLIGHTS.

201
00:07:28,989 --> 00:07:33,194
THIRD, THE NCI BUDGET OUTLOOK

202
00:07:33,194 --> 00:07:36,430
AND FOURTHS, THE TIME FOR

203
00:07:36,430 --> 00:07:36,931
DISCUSSION.

204
00:07:36,931 --> 00:07:41,836
SO LET'S GO TO THE RECENT NEWS

205
00:07:41,836 --> 00:07:43,437
AND UPDATES.

206
00:07:43,437 --> 00:07:47,608
GO TWO SLIDES AHEAD, PLEASE.

207
00:07:47,608 --> 00:07:50,077
THIS, AS I HOPE YOU CAN SEE, IS

208
00:07:50,077 --> 00:07:54,682
WE ARE GOING TO HAVE THE THIRD

209
00:07:54,682 --> 00:08:00,287
TRANSITION SINCE 2017 WITH A NEW

210
00:08:00,287 --> 00:08:03,891
NCI DIRECTOR.

211
00:08:03,891 --> 00:08:06,794
AND DR. RATH MEL IS GOING TO

212
00:08:06,794 --> 00:08:08,195
BECOME THE NEXT NCI DIRECTOR IN

213
00:08:08,195 --> 00:08:12,066
THE NEAR FUTURE.

214
00:08:12,066 --> 00:08:13,500
VIRTUALLY ALL OF YOU KNOW HER.

215
00:08:13,500 --> 00:08:15,970
NOT JUST BECAUSE OF HER

216
00:08:15,970 --> 00:08:17,605
LEADERSHIP POSITION AT

217
00:08:17,605 --> 00:08:19,139
VANDERBILT, BUT ALSO SHE HAS

218
00:08:19,139 --> 00:08:23,811
BEEN ON THE BSA AND IMPORTANT

219
00:08:23,811 --> 00:08:25,779
COP CONTRIBUTING MEMBER OF THE

220
00:08:25,779 --> 00:08:29,583
BSA SINCE SHE JOINED IT.

221
00:08:29,583 --> 00:08:32,052
MONICA, I WON'T SEA SHE IS ON TO

222
00:08:32,052 --> 00:08:34,255
A BETTER PLACE, BUT SHE HAS

223
00:08:34,255 --> 00:08:37,124
MOVED ACROSS THE PARKING LOT TO

224
00:08:37,124 --> 00:08:41,295
BUILDING 1 AS THE NIH DIRECTOR.

225
00:08:41,295 --> 00:08:47,301
SHE WAS SWORN IN A COUPLE OF

226
00:08:47,301 --> 00:08:48,402
WEEKS AGO.

227
00:08:48,402 --> 00:08:51,772
AND IT REALLY IS GOING TO BE A

228
00:08:51,772 --> 00:08:56,477
VERY UNUSUAL OPPORTUNITY FOR NCI

229
00:08:56,477 --> 00:09:00,781
TO HAVE THE CURRENT NIH DIRECTOR

230
00:09:00,781 --> 00:09:05,252
TO HAVE JUST BEEN THE NCI

231
00:09:05,252 --> 00:09:05,519
DIRECTOR.

232
00:09:05,519 --> 00:09:10,124
IF I COULD HAVE THE NEXT SLIDE.

233
00:09:10,124 --> 00:09:13,494
THIS IS SOME BAD NEWS.

234
00:09:13,494 --> 00:09:20,134
ALMOST ALL OF YOU KNOW --

235
00:09:20,134 --> 00:09:22,469
UNFORTUNATELY, WORTA DIED TWO

236
00:09:22,469 --> 00:09:22,836
WEEKS AGO.

237
00:09:22,836 --> 00:09:25,773
SHE WAS THE DIRECTOR OF THE

238
00:09:25,773 --> 00:09:28,008
COMMUNITY ONCOLOGY RESEARCH

239
00:09:28,008 --> 00:09:30,945
PROGRAM, WHICH REALLY IS A

240
00:09:30,945 --> 00:09:35,616
LANDMARK VISIONARY PROGRAM THAT

241
00:09:35,616 --> 00:09:46,360
HAS BEEN A GEM FOR NC DEVELOPMER

242
00:09:56,770 --> 00:09:59,406
COMMUNITY ONCOLOGY AND THIS

243
00:09:59,406 --> 00:10:00,307
HAPPENED.

244
00:10:00,307 --> 00:10:03,610
WE ARE GOING TO BE HAVING

245
00:10:03,610 --> 00:10:05,813
FUNDING ANNOUNCEMENTS FOR THIS

246
00:10:05,813 --> 00:10:07,214
CAREER DEVELOPMENT AWARD IN THE

247
00:10:07,214 --> 00:10:17,324
NEAR.

248
00:10:18,692 --> 00:10:20,794
MANY OF YOU HAVE SEEN THIS

249
00:10:20,794 --> 00:10:23,263
SLIDE, BUT THE CANCER MOONSHOT,

250
00:10:23,263 --> 00:10:27,501
PARTICULARLY THE REIGNITED

251
00:10:27,501 --> 00:10:31,605
VERSION, IS A GUIDING LIGHT FOR

252
00:10:31,605 --> 00:10:33,407
US BECAUSE OF THE THREE

253
00:10:33,407 --> 00:10:34,808
PRINCIPLE GOALS.

254
00:10:34,808 --> 00:10:36,510
REDUCING THE DEATH RATE BY AT

255
00:10:36,510 --> 00:10:39,146
LEAST 50% IN THE NEXT 25

256
00:10:39,146 --> 00:10:40,814
YEARS -- AND I PUT IN

257
00:10:40,814 --> 00:10:43,550
PARENTHESES, THIS IS HARD TO DO.

258
00:10:43,550 --> 00:10:44,985
OVERCOMING CANCER DISPARITIES IS

259
00:10:44,985 --> 00:10:45,819
EVEN HARDER.

260
00:10:45,819 --> 00:10:48,322
AND THEN ENDING CANCER AS WE

261
00:10:48,322 --> 00:10:53,327
KNOW IT FOR ALL IS ACTUALLY THE

262
00:10:53,327 --> 00:10:53,827
HARDEST.

263
00:10:53,827 --> 00:10:57,064
AND WE'RE MAKING PROGRESS IN

264
00:10:57,064 --> 00:11:00,334
EACH OF THESE AREAS.

265
00:11:00,334 --> 00:11:03,370
AND MONICA TALKED TO ME ABOUT

266
00:11:03,370 --> 00:11:05,572
THE REIGNITED CANCER MOONSHOT

267
00:11:05,572 --> 00:11:07,441
WITH FUNDS FROM THE INITIAL

268
00:11:07,441 --> 00:11:07,941
MOONSHOT.

269
00:11:07,941 --> 00:11:11,311
AND THEN, TO ENSURE --EUR JOB IS

270
00:11:11,311 --> 00:11:14,448
TO ENSURE THAT THE AS

271
00:11:14,448 --> 00:11:15,883
OPERATIONAL GOALS OF THE

272
00:11:15,883 --> 00:11:19,820
REIGNITED MOONSHOT BECOME

273
00:11:19,820 --> 00:11:20,087
FEASIBLE.

274
00:11:20,087 --> 00:11:25,893
NEXT SLIDE.

275
00:11:25,893 --> 00:11:27,795
IN SHOWS YOU ONE OF THE

276
00:11:27,795 --> 00:11:31,899
ACTIVITIES, THE BIDEN

277
00:11:31,899 --> 00:11:34,301
ADMINISTRATION CREATED THE

278
00:11:34,301 --> 00:11:36,703
CANCER CABINET TO ADVANCE THE

279
00:11:36,703 --> 00:11:38,772
GOALS OF THE CANCER MOONSHOT AND

280
00:11:38,772 --> 00:11:40,541
THE MOST RECENT MEETING OF THE

281
00:11:40,541 --> 00:11:44,178
CANCER CABINET WAS IN SEPTEMBER.

282
00:11:44,178 --> 00:11:48,315
YOU CAN BARELY SEE PRESIDENT

283
00:11:48,315 --> 00:11:52,319
BIDEN AND THE FIRST LADY ON THE

284
00:11:52,319 --> 00:11:54,855
FAR SIDE.

285
00:11:54,855 --> 00:11:59,359
DR. BIDEN IS IN THE RED DRESS

286
00:11:59,359 --> 00:12:00,360
AND PRESIDENT BIDE EP IS NEXT TO

287
00:12:00,360 --> 00:12:00,527
HER.

288
00:12:00,527 --> 00:12:03,864
I WAS PRIVILEGED TO BE THERE AS

289
00:12:03,864 --> 00:12:08,202
THE LOWEST-RANKING MEMBER AT THE

290
00:12:08,202 --> 00:12:08,402
TABLE.

291
00:12:08,402 --> 00:12:17,010
AND THEY TALKED ABOUT A LOT OF

292
00:12:17,010 --> 00:12:27,287
NEW INITIATIVES.

293
00:12:28,388 --> 00:12:31,825
AND THE BIOMEDICAL DATA FABRIC

294
00:12:31,825 --> 00:12:32,893
DUEL BOX FOR CANCER IS ONE OF

295
00:12:32,893 --> 00:12:35,262
THE ACTIVITY WE ARE DOING WITH

296
00:12:35,262 --> 00:12:36,563
ARPA-H THAT WAS ANNOUNCED.

297
00:12:36,563 --> 00:12:41,001
THE VETERANS FOR TOBACCO

298
00:12:41,001 --> 00:12:42,202
CESSATION PROGRAMS JOINTLY WITH

299
00:12:42,202 --> 00:12:43,570
THE V.A. AND NCI.

300
00:12:43,570 --> 00:12:46,073
TWO-WAY DATA EXCHAINS BETWEEN

301
00:12:46,073 --> 00:12:49,743
THE NCI SEAR PROGRAM AND THE

302
00:12:49,743 --> 00:12:51,712
V.A. CANCER REGISTRY TO LEARN

303
00:12:51,712 --> 00:12:52,713
MORE ABOUT THE IMPACT OF CANCER

304
00:12:52,713 --> 00:12:53,447
ON VETERANS.

305
00:12:53,447 --> 00:12:58,318
AND YOU CAN SEE THAT THE PRESS

306
00:12:58,318 --> 00:13:02,556
RELEASE AT THE WEBSITE.

307
00:13:02,556 --> 00:13:04,458
THE NEXT SLIDE IS WHAT MADE IT

308
00:13:04,458 --> 00:13:07,761
SO EASY FOR ME TO BE HERE

309
00:13:07,761 --> 00:13:10,364
BECAUSE ABOUT TWO-THIRDS OF THE

310
00:13:10,364 --> 00:13:13,700
CABINET MEMBERS AGENCY HEADS

311
00:13:13,700 --> 00:13:14,301
ET CETERA, WHO WERE TALKING AT

312
00:13:14,301 --> 00:13:16,503
THE CANCER CABINET, WERE

313
00:13:16,503 --> 00:13:18,405
DISCUSSING COLLABORATIONS THAT

314
00:13:18,405 --> 00:13:20,107
THEY HAVE WITH NCI.

315
00:13:20,107 --> 00:13:22,042
SO IN TERMS OF THE DEPARTMENTS,

316
00:13:22,042 --> 00:13:25,312
THE DEPARTMENT OF DEFENSE AND

317
00:13:25,312 --> 00:13:27,381
ENERGY AND COMMERCE AND WITHIN

318
00:13:27,381 --> 00:13:36,023
THE DHHS, FDA, CDC, HRSA AND

319
00:13:36,023 --> 00:13:38,192
ARPA-H AND OF COURSE MANY OTHER

320
00:13:38,192 --> 00:13:44,031
COMPONENTS WITHIN HHS AND NIH.

321
00:13:44,031 --> 00:13:45,933
NEXT SLIDE.

322
00:13:45,933 --> 00:13:51,605
AND I ALSO REPRESENTED THE NCI

323
00:13:51,605 --> 00:13:53,740
DOWN IN THE FORT LAUDERDALE AREA

324
00:13:53,740 --> 00:13:56,443
FOR THOSE OF YOU WHO DON'T KNOW

325
00:13:56,443 --> 00:14:00,480
WHERE IT IS, IT IS LIKE A SUBURB

326
00:14:00,480 --> 00:14:03,317
OF FORT LATER DADE IN DAVEY.

327
00:14:03,317 --> 00:14:05,385
AND CONGRESSWOMAN, DEBI

328
00:14:05,385 --> 00:14:06,353
WASSERMAN SCHULTZ, A BREAST

329
00:14:06,353 --> 00:14:08,956
CANCER SURVIVOR, ORGANIZED THIS

330
00:14:08,956 --> 00:14:11,325
CANCER SURVIVORSHIP SUMMIT AND

331
00:14:11,325 --> 00:14:13,660
THE KEYNOTE SPEECH WAS GIVEN BY

332
00:14:13,660 --> 00:14:14,761
DR. JOE BIDEN.

333
00:14:14,761 --> 00:14:19,766
AND I TALKED ABOUT SURVIVORSHIP

334
00:14:19,766 --> 00:14:22,369
AND ITS IMPORTANCE AT THE

335
00:14:22,369 --> 00:14:23,270
MEETING.

336
00:14:23,270 --> 00:14:25,439
AND THREE OF THE FLORIDA CANCER

337
00:14:25,439 --> 00:14:28,942
CENTERS, NCI-DESIGNATED CANCER

338
00:14:28,942 --> 00:14:31,578
CENTERS, THE HEADS, WERE THERE

339
00:14:31,578 --> 00:14:36,917
AS WELL AND HAD A VERY

340
00:14:36,917 --> 00:14:37,484
INTERESTING PANEL DISCUSSION

341
00:14:37,484 --> 00:14:38,218
AMONG THEM.

342
00:14:38,218 --> 00:14:39,019
NEXT SLIDE.

343
00:14:39,019 --> 00:14:41,188
SO I WANT TO GO ON AND TALK

344
00:14:41,188 --> 00:14:43,624
ABOUT RESEARCH AND PROGRAMMATIC

345
00:14:43,624 --> 00:14:44,057
HIGHLIGHTS.

346
00:14:44,057 --> 00:14:45,792
THIS IS NOT EVERYTHING WE ARE

347
00:14:45,792 --> 00:14:46,059
DOING.

348
00:14:46,059 --> 00:14:47,961
IT'S NOT NECESSARILY EVEN THE

349
00:14:47,961 --> 00:14:49,463
MOST IMPORTANT THINGS.

350
00:14:49,463 --> 00:14:52,432
BUT I THINK THAT THEY LARGELY

351
00:14:52,432 --> 00:14:55,836
RELATE TO DIFFERENT ASPECTS OF

352
00:14:55,836 --> 00:14:58,905
THE MOONSHOT EITHER DIRECTLY OR

353
00:14:58,905 --> 00:14:59,206
INDIRECTLY.

354
00:14:59,206 --> 00:15:04,344
NEXT SLIDE.

355
00:15:04,344 --> 00:15:14,554
THIS IS A VERY RECENT PAPER

356
00:15:14,554 --> 00:15:17,524
ABOUT THE NUMBER OF

357
00:15:17,524 --> 00:15:18,091
CANCER-SPECIFIC DEATHS THAT

358
00:15:18,091 --> 00:15:21,395
COULD BE AVERTED PER 100,000

359
00:15:21,395 --> 00:15:23,030
ELIGIBLE FOR SCREENING.

360
00:15:23,030 --> 00:15:25,432
WHAT THE NUMBERS SHOW IS PER

361
00:15:25,432 --> 00:15:27,234
100,000, THE NUMBER OF DEATHS

362
00:15:27,234 --> 00:15:29,603
THAT COULD BE AVERTED IF THERE

363
00:15:29,603 --> 00:15:34,174
WERE A 10% INCREASE IN THE

364
00:15:34,174 --> 00:15:36,443
SCREENING FOR LUNG CANCER,

365
00:15:36,443 --> 00:15:39,613
COLORECTAL, BREAST AND CERVICAL

366
00:15:39,613 --> 00:15:44,284
CANCER.

367
00:15:44,284 --> 00:15:47,354
YOU CAN SEE THAT LUNG CANCER HAS

368
00:15:47,354 --> 00:15:47,554
A LOT.

369
00:15:47,554 --> 00:15:49,389
IF YOU ADDED SMOKING CESSATION,

370
00:15:49,389 --> 00:15:52,459
LET'S SAY YOU HAD A 15% SUCCESS

371
00:15:52,459 --> 00:15:56,396
RATE, IT COULD INCREASE THE

372
00:15:56,396 --> 00:15:57,931
NUMBER OF DEATHS PREVENTED FROM

373
00:15:57,931 --> 00:15:58,465
LUNG CANCER.

374
00:15:58,465 --> 00:16:01,735
WHAT'S NOT SHOWN ON THIS SLIDE

375
00:16:01,735 --> 00:16:03,704
IS THAT THERE ALSO WOULD BE MANY

376
00:16:03,704 --> 00:16:07,341
DEATHS PREVENTED IF THERE WAS

377
00:16:07,341 --> 00:16:08,108
SMOKING CESSATION FROM A

378
00:16:08,108 --> 00:16:12,546
DECREASE IN CARDIOVASCULAR AND

379
00:16:12,546 --> 00:16:12,979
PULMONARY DISEASE.

380
00:16:12,979 --> 00:16:17,284
COLORECTAL CANCER IS ALSO HIGH.

381
00:16:17,284 --> 00:16:18,585
BREAST CANCER AND CERVICAL

382
00:16:18,585 --> 00:16:20,854
CANCER CERTAINLY WOULD PREVENT

383
00:16:20,854 --> 00:16:23,824
SOME BUT NOT AS MANY AS LUNG

384
00:16:23,824 --> 00:16:25,926
CANCERS AND COLORECTAL CANCER

385
00:16:25,926 --> 00:16:26,193
SCREENING.

386
00:16:26,193 --> 00:16:29,463
AND I WANT TO ALSO EMPHASIZE

387
00:16:29,463 --> 00:16:32,799
THAT LUNG CANCER SCREENING

388
00:16:32,799 --> 00:16:35,869
ACTUALLY IS FOR UNDER

389
00:16:35,869 --> 00:16:38,405
REPRESENTED MINORITIES AND FOR

390
00:16:38,405 --> 00:16:41,742
WOMEN THAT THEY ARE -- THEY TEND

391
00:16:41,742 --> 00:16:43,744
TO BE UNDERREPRESENTED WITH

392
00:16:43,744 --> 00:16:45,479
CURRENT LUNG CANCER SCREENING

393
00:16:45,479 --> 00:16:45,912
GUIDELINES.

394
00:16:45,912 --> 00:16:47,547
SO THIS -- IF THERE WAS AN

395
00:16:47,547 --> 00:16:50,050
INCREASE IN SCREENING OF

396
00:16:50,050 --> 00:16:52,552
ELIGIBLE PEOPLE, IT COULD HELP

397
00:16:52,552 --> 00:16:56,123
TO NARROW DISPARITIES.

398
00:16:56,123 --> 00:16:58,458
NEXT SLIDE.

399
00:16:58,458 --> 00:17:00,961
AND THE PAPER THAT I WAS JUST

400
00:17:00,961 --> 00:17:03,296
SHOWING WAS REALLY THE SENIOR

401
00:17:03,296 --> 00:17:07,000
AUTHOR IS ROCKY FEUER, WHO IS

402
00:17:07,000 --> 00:17:09,269
GOING TO BE RETIRING NEXT MONTH.

403
00:17:09,269 --> 00:17:14,775
AND ROCKY REALLY IMVENTED SIS

404
00:17:14,775 --> 00:17:16,610
NET, AND THOSE WHO HAVE BEEN ON

405
00:17:16,610 --> 00:17:20,647
THE BSA ESPECIALLY, REMEMBER THE

406
00:17:20,647 --> 00:17:22,315
RE-ISSUANCE OF CISNET.

407
00:17:22,315 --> 00:17:25,619
BUT IT IS A MODELING NETWORK

408
00:17:25,619 --> 00:17:28,288
THAT HAS HAD ENORMOUS IMPACT,

409
00:17:28,288 --> 00:17:30,490
NOT JUST AT THE LEVEL OF NCI AND

410
00:17:30,490 --> 00:17:32,125
CANCER RESEARCH, BUT WITH THE

411
00:17:32,125 --> 00:17:34,461
PREVENTION SERVICES TASK FORCE

412
00:17:34,461 --> 00:17:37,864
FOR THEIR RECOMMENDATIONS.

413
00:17:37,864 --> 00:17:39,733
HE ALSO DEVELOPED THE JOINT

414
00:17:39,733 --> 00:17:41,468
POINT AND NOW SOFTWARE IS

415
00:17:41,468 --> 00:17:43,136
AVAILABLE FOR MEASURING THAT,

416
00:17:43,136 --> 00:17:46,606
WHICH IS THE STANDARD WAY OF

417
00:17:46,606 --> 00:17:49,743
MEASURING CANCER TRENDS IN SEER

418
00:17:49,743 --> 00:17:52,579
AND INCIDENTS-BASED MORTALITY.

419
00:17:52,579 --> 00:17:54,014
FOR EXAMPLE, THIS IS LOOKING

420
00:17:54,014 --> 00:17:56,149
BACK AT WHAT WAS THE PRIMARY

421
00:17:56,149 --> 00:18:00,153
CANCER AND THEN THE METASTASES.

422
00:18:00,153 --> 00:18:01,521
IN THE PAPER THAT ROCKY WAS

423
00:18:01,521 --> 00:18:04,191
INVOLVED WITH BACK IN 2020,

424
00:18:04,191 --> 00:18:05,992
LOOKING AT ADVANCES IN LUNG

425
00:18:05,992 --> 00:18:08,528
CANCER TREATMENT, A SUBSET OF

426
00:18:08,528 --> 00:18:11,698
THOSE PEOPLE WHO WERE PUT DOWN

427
00:18:11,698 --> 00:18:13,934
AS HAVING DIED FROM LUNG CANCER,

428
00:18:13,934 --> 00:18:16,336
THEIR PRIMARY CANCER WAS

429
00:18:16,336 --> 00:18:16,937
ELSEWHERE AND THEY WERE DYING

430
00:18:16,937 --> 00:18:20,841
FROM METASTATIC CANCER TO THE

431
00:18:20,841 --> 00:18:23,677
LUNG BUT IT WAS NOT PRIMARY LUNG

432
00:18:23,677 --> 00:18:23,910
CANCER.

433
00:18:23,910 --> 00:18:29,316
AND THIS WAS USING THIS ASSAY OF

434
00:18:29,316 --> 00:18:31,685
INCIDENCE-BASED MORTALITY AND

435
00:18:31,685 --> 00:18:35,455
DR. FEUER AS BEEN NOMINATED FOR

436
00:18:35,455 --> 00:18:37,657
A SAMMIES AWARD.

437
00:18:37,657 --> 00:18:41,261
HE HAD AN ENORMOUS IMPACT AND

438
00:18:41,261 --> 00:18:43,930
WE'LL BE -- WILL BE MISSED.

439
00:18:43,930 --> 00:18:46,500
SOCIAL DETERMINANTS OF HEALTH.

440
00:18:46,500 --> 00:18:47,767
VERY IMPORTANT FOR MANY

441
00:18:47,767 --> 00:18:50,303
DIFFERENT ASPECTS BUT THIS

442
00:18:50,303 --> 00:18:52,339
PAPER, ONE OF THE THINGS IT

443
00:18:52,339 --> 00:18:56,142
EMPHASIZED IS CANCER SCREENING

444
00:18:56,142 --> 00:18:56,610
INTERVENTIONS.

445
00:18:56,610 --> 00:18:58,011
AND BASICALLY SOCIAL

446
00:18:58,011 --> 00:18:59,713
DETERMINANTS OF HEALTH WHETHER

447
00:18:59,713 --> 00:19:01,248
YOU'RE ON A LOWER END OR UPPER

448
00:19:01,248 --> 00:19:05,118
END, ACTUALLY HAS A SUBSTANTIAL

449
00:19:05,118 --> 00:19:06,553
ASSOCIATION WITH WHETHER YOU'RE

450
00:19:06,553 --> 00:19:08,388
GOING TO BE SCREENED OR NOT.

451
00:19:08,388 --> 00:19:12,092
THIS IS NOT SURPRISING BUT THIS

452
00:19:12,092 --> 00:19:14,361
IS EVIDENCE THAT THE IMPORTANCE

453
00:19:14,361 --> 00:19:16,863
OF SOCIAL DETERMINANTS OF HEALTH

454
00:19:16,863 --> 00:19:21,735
IS CRITICAL PARAMETER.

455
00:19:21,735 --> 00:19:22,602
NEXT SLIDE.

456
00:19:22,602 --> 00:19:25,305
ONE OF THE THINGS THAT WE'RE

457
00:19:25,305 --> 00:19:30,977
TRYING TO DO IS TO THE EXTENT

458
00:19:30,977 --> 00:19:32,245
POSSIBLE, BRING CANCER CARE,

459
00:19:32,245 --> 00:19:35,515
CANCER SCREENING AND CANCER

460
00:19:35,515 --> 00:19:36,650
PREVENTION TO THE PATIENT RATHER

461
00:19:36,650 --> 00:19:42,989
THAN BRINGING THE CANCER CONTROL

462
00:19:42,989 --> 00:19:44,858
AND TREATMENT OF THE PATIENT TO

463
00:19:44,858 --> 00:19:48,828
THOSE INTERVENTIONS.

464
00:19:48,828 --> 00:19:55,135
SO, CERVICAL CANCER IS AN

465
00:19:55,135 --> 00:19:55,735
INTERESTING SITUATION BECAUSE

466
00:19:55,735 --> 00:19:56,369
EVERYTHING THAT'S FDA APPROVED

467
00:19:56,369 --> 00:19:58,371
IS APPROVED WITH HEALTH CARE

468
00:19:58,371 --> 00:20:05,712
WORKERS DOING THE SAMPLING.

469
00:20:05,712 --> 00:20:06,346
BUT MANY COUNTRIES ACTUALLY HAVE

470
00:20:06,346 --> 00:20:09,182
SELF SAMPLING AND IT'S A WAY OF

471
00:20:09,182 --> 00:20:10,483
BRINGING SCREENING TO THE

472
00:20:10,483 --> 00:20:13,186
PATIENT INSTEAD OF BRINGING THE

473
00:20:13,186 --> 00:20:16,856
PATIENT TO THE SCREENING, AT

474
00:20:16,856 --> 00:20:18,592
LEAST INITIALLY.

475
00:20:18,592 --> 00:20:19,426
AND WE KNOW THAT ABOUT HALF OF

476
00:20:19,426 --> 00:20:22,062
THE PATIENTS WHO ARE

477
00:20:22,062 --> 00:20:22,796
UNDERSCREENED, THAT'S WHERE HALF

478
00:20:22,796 --> 00:20:24,831
OF THE PEOPLE WHO GET CERVICAL

479
00:20:24,831 --> 00:20:27,133
CANCER IN THE U.S. COME FROM.

480
00:20:27,133 --> 00:20:31,137
AND WE ALSO KNOW THAT THE

481
00:20:31,137 --> 00:20:33,707
UNDERSCREENED PATIENTS ARE

482
00:20:33,707 --> 00:20:34,140
UNDER-INSURED.

483
00:20:34,140 --> 00:20:38,011
AND MANY OF THEM ARE HISPANIC.

484
00:20:38,011 --> 00:20:39,579
THIS COULD BE YET AUTHOR WAY OF

485
00:20:39,579 --> 00:20:43,316
TRYING TO HELP ADDRESS

486
00:20:43,316 --> 00:20:44,317
PARTIALLY, OVERCOME A HEALTH

487
00:20:44,317 --> 00:20:44,618
DISPARITY.

488
00:20:44,618 --> 00:20:47,020
WE ARE WORKING WITH THE FDA

489
00:20:47,020 --> 00:20:49,823
COMPANIES TO DO THIS LAST MILE

490
00:20:49,823 --> 00:20:52,092
INITIATIVE OF RANDOMIZED CONTROL

491
00:20:52,092 --> 00:20:55,061
TRIAL TO TRY TO PROVIDE

492
00:20:55,061 --> 00:20:56,830
SUFFICIENT EVIDENCE FOR THE FDA

493
00:20:56,830 --> 00:21:01,601
TO WORK THROUGH SELF SAMPLING.

494
00:21:01,601 --> 00:21:03,203
NEXT SLIDE.

495
00:21:03,203 --> 00:21:05,639
AND YOU HAVE ALL HEARD, BECAUSE

496
00:21:05,639 --> 00:21:10,510
YOU WERE INVOLVED IN THE INITIAL

497
00:21:10,510 --> 00:21:11,645
PRESENTATIONS OF THE VANGUARD

498
00:21:11,645 --> 00:21:14,981
STUDY FOR THE MULTI-CANCER

499
00:21:14,981 --> 00:21:15,348
DETECTION TEST.

500
00:21:15,348 --> 00:21:18,685
AND WE'RE LOOKING FORWARD AT THE

501
00:21:18,685 --> 00:21:19,653
BEGINNING OF THE YEAR TO BE ABLE

502
00:21:19,653 --> 00:21:22,389
TO FUND MULTIPLE CANCERS THAT

503
00:21:22,389 --> 00:21:25,892
WILL BE STARTING, THE INITIAL

504
00:21:25,892 --> 00:21:27,927
SCREENING STUDY THAT IS REFERRED

505
00:21:27,927 --> 00:21:32,732
TO AS THE VANGUARD STUDY.

506
00:21:32,732 --> 00:21:35,568
NEXT SLIDE.

507
00:21:35,568 --> 00:21:37,070
SO THIS SLIDE REALLY IS GOING

508
00:21:37,070 --> 00:21:39,372
FROM THE SCREENING ISSUE TO

509
00:21:39,372 --> 00:21:42,909
LOOKING AT MORTALITY RATES.

510
00:21:42,909 --> 00:21:46,446
AND IT'S FROM A PAPER THAT WAS

511
00:21:46,446 --> 00:21:48,848
PUBLISHED LAST YEAR, PRIMARILY

512
00:21:48,848 --> 00:21:54,287
FROM INVESTIGATORS IN DCCPS AND

513
00:21:54,287 --> 00:21:57,457
BOB COIL WAS THE LAST AUTHOR OF

514
00:21:57,457 --> 00:21:57,991
THE PAPER.

515
00:21:57,991 --> 00:22:00,360
IT'S REALLY DIVIDED, IF YOU

516
00:22:00,360 --> 00:22:02,395
WILL, INTO THREE PARTS.

517
00:22:02,395 --> 00:22:04,831
CANCER MORTALITY RATES AND ALL

518
00:22:04,831 --> 00:22:06,933
SITES, LUNG AND BRONCH US IN THE

519
00:22:06,933 --> 00:22:12,739
MIDDLE AND COLORECTAL ON THE

520
00:22:12,739 --> 00:22:15,175
RIGHT.

521
00:22:15,175 --> 00:22:25,685
AND THE WADE -- AND THE WHITE

522
00:22:31,524 --> 00:22:34,794
BARS ARE NON-POSTIE COUNTS, AND

523
00:22:34,794 --> 00:22:37,931
THE BLACK BARS ARE THE

524
00:22:37,931 --> 00:22:39,265
PERSISTENT POVERTY COUNTERRIES.

525
00:22:39,265 --> 00:22:41,367
WHAT I THINK YOU CAN SEE IF YOU

526
00:22:41,367 --> 00:22:46,172
LOOK AT ALL SITES, IS THAT THERE

527
00:22:46,172 --> 00:22:50,710
IS A HIGHER MORTALITY RATE FOR

528
00:22:50,710 --> 00:22:51,611
BLACKS COMPARED TO WHITES.

529
00:22:51,611 --> 00:22:53,947
THERE DOESN'T SEEM TO BE A MAJOR

530
00:22:53,947 --> 00:22:59,686
DIFFERENT FOR THE URBAN PEOPLE

531
00:22:59,686 --> 00:23:02,188
WHETHER THEY ARE UNTIL POOR

532
00:23:02,188 --> 00:23:03,590
COUNTIES OR NOT.

533
00:23:03,590 --> 00:23:07,694
BUT WHEN YOU LOOK AT THE RURAL

534
00:23:07,694 --> 00:23:11,030
COUNTIES UTHAT'S WITH THE RED

535
00:23:11,030 --> 00:23:14,234
OVAL, THEIR MORTALITY RATES ARE

536
00:23:14,234 --> 00:23:16,903
A BIT HIGHER BOTH FOR BLACKS AND

537
00:23:16,903 --> 00:23:18,671
WHITES COMPARED TO THE

538
00:23:18,671 --> 00:23:20,340
COMPARABLE URBAN POPULATION.

539
00:23:20,340 --> 00:23:24,377
BUT IF YOU NOW TURN TO LUNG AND

540
00:23:24,377 --> 00:23:26,913
BRONCHUS IN THE MIDDLE, WHAT I

541
00:23:26,913 --> 00:23:29,282
HOPE YOU CAN APPRECIATE IS THAT

542
00:23:29,282 --> 00:23:33,386
THE RURAL MORTALITY RATES FOR

543
00:23:33,386 --> 00:23:34,387
BOTH BLACK PATIENTS AND WHITE

544
00:23:34,387 --> 00:23:36,055
PATIENTS ARE SUBSTANTIALLY

545
00:23:36,055 --> 00:23:38,925
HIGHER THAN THE MORTALITY RATES

546
00:23:38,925 --> 00:23:41,594
FOR BLACK AND WHITE PATIENTS WHO

547
00:23:41,594 --> 00:23:43,129
ARE URBAN PATIENTS.

548
00:23:43,129 --> 00:23:46,766
AND THIS IS PROBABLY A

549
00:23:46,766 --> 00:23:48,735
COMBINATION OF MORE SMOKING IN

550
00:23:48,735 --> 00:23:53,439
RURAL AREAS AND PROBABLY IN

551
00:23:53,439 --> 00:23:56,476
ADDITION, LESS ACCESS TO THE

552
00:23:56,476 --> 00:23:59,813
ADVANCES IN CANCER -- LUNG

553
00:23:59,813 --> 00:24:00,947
CANCER TREATMENT.

554
00:24:00,947 --> 00:24:03,550
AND THE DIFFERENCE THAT YOU SEE,

555
00:24:03,550 --> 00:24:05,919
ESPECIALLY IN THE RURAL

556
00:24:05,919 --> 00:24:08,121
POPULATIONS WITH THE PERSISTENT

557
00:24:08,121 --> 00:24:11,157
POVERTY VERSUS THE NON-POVERTY

558
00:24:11,157 --> 00:24:12,859
GROUPS, ARE SUBSTANTIAL WITH

559
00:24:12,859 --> 00:24:14,227
LUNG AND BRONCHUS AND YOU CAN

560
00:24:14,227 --> 00:24:16,930
SEE THAT IF YOU LOOK OVER AT

561
00:24:16,930 --> 00:24:19,299
COLORECTAL, AGAIN IN THE RURAL

562
00:24:19,299 --> 00:24:22,602
AREA, PERSISTENT POVERTY IS VERY

563
00:24:22,602 --> 00:24:25,205
IMPORTANT BOTH FOR BLACK RURAL

564
00:24:25,205 --> 00:24:28,975
PATIENTS AND WHITE RURAL

565
00:24:28,975 --> 00:24:29,242
PATIENTS.

566
00:24:29,242 --> 00:24:31,277
NEXT SLIDE.

567
00:24:31,277 --> 00:24:34,848
SO THIS SLIDE SHOWS YOU WHAT HAS

568
00:24:34,848 --> 00:24:38,818
HAPPENED OVER THE LAST COUPLE OF

569
00:24:38,818 --> 00:24:40,753
DECADES WITH REGARD TO INCIDENCE

570
00:24:40,753 --> 00:24:44,257
OF LUNG CANCER AND MORTALITY

571
00:24:44,257 --> 00:24:46,593
RATES FOR LUNG CANCER.

572
00:24:46,593 --> 00:24:50,096
IF YOU LOOK FIRST AT THE TOP

573
00:24:50,096 --> 00:24:52,866
TABLE OR THE TOP PART OF THE

574
00:24:52,866 --> 00:24:54,367
GRAPH, YOU CAN SEE THAT THERE IS

575
00:24:54,367 --> 00:24:56,970
A PROGRESSIVE DECREASE IN THE

576
00:24:56,970 --> 00:24:58,438
INCIDENCE OF LUNG CANCER.

577
00:24:58,438 --> 00:25:02,842
THIS IS PREDOMINANTLY BECAUSE OF

578
00:25:02,842 --> 00:25:03,343
SMOKING CESSATION.

579
00:25:03,343 --> 00:25:05,311
IF YOU LOOK AT THE TABLES,

580
00:25:05,311 --> 00:25:07,013
YOU'LL SEE THAT THE RATE OF DOE

581
00:25:07,013 --> 00:25:14,254
CREASE IS ABOUT 2% PER YEAR IN

582
00:25:14,254 --> 00:25:14,520
INCIDENTS.

583
00:25:14,520 --> 00:25:16,055
BUT IF YOU NOW TURP TO YOUR

584
00:25:16,055 --> 00:25:18,391
ATTENTION TO THE MORTALITY

585
00:25:18,391 --> 00:25:20,059
RATES, WHAT I HOPE YOU CAN

586
00:25:20,059 --> 00:25:21,895
APPRECIATE, ESPECIALLY IN THE

587
00:25:21,895 --> 00:25:22,929
TABLE, IF YOU LOOK ALL THE WAY

588
00:25:22,929 --> 00:25:27,267
ON THE RIGHT, THE ANNUAL

589
00:25:27,267 --> 00:25:28,935
PERCENTAGE CHANGED IN EACH OF

590
00:25:28,935 --> 00:25:32,171
THE LAST SIX YEARS IS OVER 4

591
00:25:32,171 --> 00:25:35,642
1/2%, 4.7% ANNUAL CHANGE.

592
00:25:35,642 --> 00:25:37,644
SO IT'S MORE THAN TWICE THE

593
00:25:37,644 --> 00:25:40,580
MORTALITY RATES ARE GOING DOWN

594
00:25:40,580 --> 00:25:43,716
BY MORE THAN TWICE AS FAST FOR

595
00:25:43,716 --> 00:25:47,020
LUNG CANCER AS FOR THE INCIDENCE

596
00:25:47,020 --> 00:25:47,420
RATES.

597
00:25:47,420 --> 00:25:50,790
AND THIS, WE THINK, IS LARGELY

598
00:25:50,790 --> 00:25:54,027
ATTRIBUTABLE TO ADVANCES IN

599
00:25:54,027 --> 00:25:54,727
CANCER TREATMENT.

600
00:25:54,727 --> 00:26:00,466
SHOWING THE NEXT SLIDE, IT SHOWS

601
00:26:00,466 --> 00:26:03,403
THIS ADVANCE IS LARGELY WHAT

602
00:26:03,403 --> 00:26:04,804
HAPPENED WITH LUNG

603
00:26:04,804 --> 00:26:05,171
ADENOCARCINOMA.

604
00:26:05,171 --> 00:26:11,611
YOU CAN SEE ALL OF THESE

605
00:26:11,611 --> 00:26:14,047
DIFFERENT DRUG APPROVALS JUST IN

606
00:26:14,047 --> 00:26:18,851
THE LAST TWO YEARS FOR LUNG

607
00:26:18,851 --> 00:26:19,085
CANCER.

608
00:26:19,085 --> 00:26:21,921
AND I JUST WANT TO LARK EN BACK

609
00:26:21,921 --> 00:26:25,258
TO WHAT YOU SAW -- HARKEN

610
00:26:25,258 --> 00:26:26,359
BACK -- WITH THE RURAL VERSUS

611
00:26:26,359 --> 00:26:27,393
URBAN PATIENTS.

612
00:26:27,393 --> 00:26:31,965
WE SUSPECT IN TRYING TO DO

613
00:26:31,965 --> 00:26:32,765
NANCYS TO PROVIDE EVIDENCE THAT

614
00:26:32,765 --> 00:26:34,767
THE PEOPLE IN RURAL AREAS JUST

615
00:26:34,767 --> 00:26:38,438
DON'T HAVE AS MUCH ACCESS TO

616
00:26:38,438 --> 00:26:41,941
THESE NEW DRUGS THE WAY THAT

617
00:26:41,941 --> 00:26:44,844
PEOPLE IN URBAN AREAS HAVE.

618
00:26:44,844 --> 00:26:46,479
NEXT SLIDE.

619
00:26:46,479 --> 00:26:52,285
AND FOR THOSE ON THE NCAB,

620
00:26:52,285 --> 00:26:54,620
CARLENE RILEY IN SEPTEMBER, DID

621
00:26:54,620 --> 00:26:57,056
A REALLY TERRIFIC PRESENTATION

622
00:26:57,056 --> 00:26:59,625
ABOUT MY PART, WHICH IS THE

623
00:26:59,625 --> 00:27:04,464
ACRONYM FOR HIGH TIDE AT RICK

624
00:27:04,464 --> 00:27:08,368
AND ADULT RARE TUMOR NETWORK.

625
00:27:08,368 --> 00:27:11,270
THIS IS A MOONSHOT ACTIVITY FROM

626
00:27:11,270 --> 00:27:14,207
MOONSHOT 1.0.

627
00:27:14,207 --> 00:27:16,876
IS IT FOCUSED ON THE CLINICAL

628
00:27:16,876 --> 00:27:21,581
CENTER BUT IT IS NOT JUST AN

629
00:27:21,581 --> 00:27:22,048
EXTRAMURAL-INTRAMURAL

630
00:27:22,048 --> 00:27:24,484
COLLABORATION BUT IT IS ALSO AN

631
00:27:24,484 --> 00:27:25,885
INTERNATIONAL COLLABORATION.

632
00:27:25,885 --> 00:27:28,321
MORE THAN 25 DIFFERENT COUNTRIES

633
00:27:28,321 --> 00:27:30,656
HAVE CONTRIBUTED PATIENTS.

634
00:27:30,656 --> 00:27:36,062
THEY ENROLLED MORE THAN 500

635
00:27:36,062 --> 00:27:37,296
PATIENTS IN THE LAST FOUR YEARS.

636
00:27:37,296 --> 00:27:41,034
AND FOR THOSE OF OFF WHO ARE NOT

637
00:27:41,034 --> 00:27:44,537
ON THE NCAB, I REALLY URGE YOU

638
00:27:44,537 --> 00:27:46,973
TO GO TO THE NCAB WEBSITE AND

639
00:27:46,973 --> 00:27:49,108
LOOK AT THE SLIDES THAT DR. WEED

640
00:27:49,108 --> 00:27:51,911
MAP AND DR. RILEY PRESENTED

641
00:27:51,911 --> 00:27:54,347
BECAUSE IT'S A VERY EXCITING AND

642
00:27:54,347 --> 00:27:54,914
IMPORTANT AREA.

643
00:27:54,914 --> 00:27:57,650
AND FOR THOSE OF YOU WHO DON'T

644
00:27:57,650 --> 00:28:00,653
KNOW WHILE RARE CANCERS ARE BY

645
00:28:00,653 --> 00:28:03,489
DEFINITION, RARE, THEY REPRESENT

646
00:28:03,489 --> 00:28:05,892
ABOUT 27% OF THE CANCER IN THE

647
00:28:05,892 --> 00:28:07,760
UNITED STATES.

648
00:28:07,760 --> 00:28:09,762
SO, IT'S MORE THAN A HALF

649
00:28:09,762 --> 00:28:11,898
MILLION CANCERS PER YEAR IN THE

650
00:28:11,898 --> 00:28:14,000
UNITED STATES ARE RARE TUMORS.

651
00:28:14,000 --> 00:28:16,736
AND THEY REPRESENT ABOUT 25% OF

652
00:28:16,736 --> 00:28:18,604
THE CANCER DEATHS.

653
00:28:18,604 --> 00:28:20,840
SO THAT THE RARE CANCERS ACCOUNT

654
00:28:20,840 --> 00:28:25,445
FOR ABOUT 150,000 PEOPLE DYING

655
00:28:25,445 --> 00:28:27,246
EACH YEAR IN THE UNITED STATES.

656
00:28:27,246 --> 00:28:30,750
SO THIS INITIATIVE REALLY IS

657
00:28:30,750 --> 00:28:32,819
HOPING TO BE ABLE TO CATALOG

658
00:28:32,819 --> 00:28:36,489
THESE PATIENTS BETTER AND ALSO

659
00:28:36,489 --> 00:28:39,525
IN ITS NEW FORM TO BE ABLE TO

660
00:28:39,525 --> 00:28:41,027
DEVELOP INTERVENTIONS WHERE IT

661
00:28:41,027 --> 00:28:44,564
LOOKS LIKE THERE ARE CANDIDATES

662
00:28:44,564 --> 00:28:48,868
THAT COULD BE USEFUL FOR NEW

663
00:28:48,868 --> 00:28:49,502
INTERVENTIONS.

664
00:28:49,502 --> 00:28:50,636
NEXT SLIDE.

665
00:28:50,636 --> 00:28:53,873
AND THIS IS ANOTHER IMPORTANT

666
00:28:53,873 --> 00:29:03,049
ADVANCE ON THE TREATMENT SIDE.

667
00:29:03,049 --> 00:29:07,687
THE PD-L1 IMMUNE CHECKPOINT

668
00:29:07,687 --> 00:29:07,954
INHIBITOR.

669
00:29:07,954 --> 00:29:10,256
THIS WAS LED BY THE INTRAPURELY

670
00:29:10,256 --> 00:29:12,225
PROGRAM, ABOUT 40% OF THE

671
00:29:12,225 --> 00:29:13,926
PATIENTS WERE TREATED

672
00:29:13,926 --> 00:29:16,095
INTRAMURALLY BUT THIS REALLY IS

673
00:29:16,095 --> 00:29:17,897
THE FIRST TIME THAT IS THIS A

674
00:29:17,897 --> 00:29:20,533
RARE CANCER THAT EFFECTS MOSTLY

675
00:29:20,533 --> 00:29:23,336
ADOLESCENCE AND YOUNG ADULTS AND

676
00:29:23,336 --> 00:29:25,238
IT'S THE FIRST TIME THAT THIS

677
00:29:25,238 --> 00:29:27,140
IMMUNE CHECKPOINT INHIBITOR HAS

678
00:29:27,140 --> 00:29:31,511
BEEN APPROVED FOR CHILDREN IN

679
00:29:31,511 --> 00:29:32,345
THE NEW ENGLAND JOURNAL OF

680
00:29:32,345 --> 00:29:34,547
MEDICINE ARTICLE A COUPLE OF

681
00:29:34,547 --> 00:29:37,283
MONTHS AGO REPORTING THIS

682
00:29:37,283 --> 00:29:37,817
ADVANCE.

683
00:29:37,817 --> 00:29:38,417
NEXT SLIDE.

684
00:29:38,417 --> 00:29:41,187
NOW THE BUDGET OUTLOOK.

685
00:29:41,187 --> 00:29:43,022
I JUST, BEFORE WE GET STARTED, I

686
00:29:43,022 --> 00:29:46,726
WANT YOU TO KNOW I HAVE DONE MY

687
00:29:46,726 --> 00:29:49,362
PART BECAUSE I WAS ABLE TO FIND

688
00:29:49,362 --> 00:29:50,563
MY BUSINESS CARDS FROM THE LAST

689
00:29:50,563 --> 00:29:54,200
TIME THAT I WAS ACTIVE DIRECTOR.

690
00:29:54,200 --> 00:29:56,169
AND USING THEM, IT TURNS OUT

691
00:29:56,169 --> 00:29:58,638
THAT ALTHOUGH I HAVE SAVED THE

692
00:29:58,638 --> 00:30:00,606
NCI A LOT OF MONEY, IT'S NOT

693
00:30:00,606 --> 00:30:01,140
ENOUGH.

694
00:30:01,140 --> 00:30:02,608
SO LET ME TELL YOU ABOUT THE

695
00:30:02,608 --> 00:30:07,713
BUDGET SITUATION.

696
00:30:07,713 --> 00:30:11,751
NEXT SLIDE.

697
00:30:11,751 --> 00:30:14,353
AT FIRST LET'S LOOK AT THE TOP

698
00:30:14,353 --> 00:30:14,620
PART.

699
00:30:14,620 --> 00:30:17,323
WE'VE HAD A BIG INCREASE.

700
00:30:17,323 --> 00:30:21,260
IF YOU LOOK AT FY17, COMPARED TO

701
00:30:21,260 --> 00:30:22,762
FY23, WE WENT FROM ABOUT 5.5

702
00:30:22,762 --> 00:30:26,966
BILLION DOLLARS TO OVER 7

703
00:30:26,966 --> 00:30:27,600
MILLION DOLLARS FOR THE TOTAL

704
00:30:27,600 --> 00:30:28,901
APPROPRIATION.

705
00:30:28,901 --> 00:30:30,937
THE MOONSHOT FUNDS REPRESENTED

706
00:30:30,937 --> 00:30:34,640
AN IMPORTANT COMPONENT OF THOSE

707
00:30:34,640 --> 00:30:35,374
APPROPRIATIONS.

708
00:30:35,374 --> 00:30:41,714
300 MILLION IN' 17 AND 216 IN

709
00:30:41,714 --> 00:30:41,914
23.

710
00:30:41,914 --> 00:30:44,116
IN 24, WE DON'T KNOW WHAT IS

711
00:30:44,116 --> 00:30:45,251
GOING TO HAPPEN.

712
00:30:45,251 --> 00:30:49,522
NOW JUST FOCUS ON THE BOTTOM

713
00:30:49,522 --> 00:30:51,857
PART WHERE IT HAS TO DO WITH THE

714
00:30:51,857 --> 00:30:57,597
PAY LINES BETWEEN 2017 AND 2023.

715
00:30:57,597 --> 00:31:03,603
THE TOP PART OF THAT TABLE SHOWS

716
00:31:03,603 --> 00:31:05,238
THE EXPERIENCED INVESTIGATORS,

717
00:31:05,238 --> 00:31:09,408
THEIR PAY LINE.

718
00:31:09,408 --> 00:31:11,143
AND IT HAS BEEN VERY LOW.

719
00:31:11,143 --> 00:31:12,979
WE HAVE BEEN TRYING TO INCREASE

720
00:31:12,979 --> 00:31:15,948
THE PAY LINE EACH YEAR AND HAVE

721
00:31:15,948 --> 00:31:18,351
SUCCEEDED TO SOME DEGROW BUT WE

722
00:31:18,351 --> 00:31:22,054
HAD TO GO DOWN, FOR EXAMPLE, IN

723
00:31:22,054 --> 00:31:24,390
2019, TO THE 8th PERCENTILE,

724
00:31:24,390 --> 00:31:27,994
WHICH IS JUST -- GOING DOWN INTO

725
00:31:27,994 --> 00:31:30,129
SINGLE-DIGITS IS TERRIBLE AND

726
00:31:30,129 --> 00:31:31,030
THAT'S WHERE WE ARE FOR THE

727
00:31:31,030 --> 00:31:32,298
CONTINUED RESOLUTION, AS I'M

728
00:31:32,298 --> 00:31:36,068
SURE YOU KNOW AND I'LL SHOW YOU

729
00:31:36,068 --> 00:31:37,470
IN SUBSEQUENT SLIDE.

730
00:31:37,470 --> 00:31:43,609
STARTING IN FY18, WE ALSO GAVE A

731
00:31:43,609 --> 00:31:44,377
BOOST TO THE EARLY-STAGE

732
00:31:44,377 --> 00:31:47,079
INVESTIGATORS FOR THEIR RO1 OP

733
00:31:47,079 --> 00:31:48,648
INDICATION OF 5 POINTS.

734
00:31:48,648 --> 00:31:50,916
AND I JUST WANT TO POINT OUT

735
00:31:50,916 --> 00:31:54,320
THAT IN 200019, WHEN WE WENT

736
00:31:54,320 --> 00:31:57,456
DOWN TO THE 8th PERCENTILE,

737
00:31:57,456 --> 00:32:00,459
WE KEPT THE BOOST AT 14.

738
00:32:00,459 --> 00:32:03,329
IT WAS A 6 PERCENTILE

739
00:32:03,329 --> 00:32:03,629
DIFFERENCE.

740
00:32:03,629 --> 00:32:05,598
AND TRY AS WE MIGHT, WE

741
00:32:05,598 --> 00:32:07,600
INCREASED THE PERCENTAGE OF THE

742
00:32:07,600 --> 00:32:10,569
NCI BUDGET OVER THE LAST FOUR

743
00:32:10,569 --> 00:32:13,339
YEARS FROM 41% IN THE RPG POOL

744
00:32:13,339 --> 00:32:16,842
TO 44%.

745
00:32:16,842 --> 00:32:18,044
BUT IT UNIVERSITY DOESN'T KEEP

746
00:32:18,044 --> 00:32:20,479
PACE WITH EVERYTHING THAT

747
00:32:20,479 --> 00:32:24,550
WE'RE -- IT DOESN'T KEEP PACE --

748
00:32:24,550 --> 00:32:27,186
NEXT SLIDE.

749
00:32:27,186 --> 00:32:28,287
AND EVERYTHING IS INTERCONNECTED

750
00:32:28,287 --> 00:32:29,955
WITH THE NCI BUDGET.

751
00:32:29,955 --> 00:32:32,625
IF YOU LOOK ON THE TOP RIGHT,

752
00:32:32,625 --> 00:32:35,895
THE ULTIMATE GOAL IS IMPROVED

753
00:32:35,895 --> 00:32:37,396
HEALTH OUTCOMES.

754
00:32:37,396 --> 00:32:39,965
BUT GOING AROUND THE GEARS, WE

755
00:32:39,965 --> 00:32:41,634
NEED TO HAVE THE RESEARCH

756
00:32:41,634 --> 00:32:44,770
FUNDING, TRAINING AND WORKFORCE

757
00:32:44,770 --> 00:32:46,772
DEVELOPMENT, RESOURCES FOR

758
00:32:46,772 --> 00:32:48,808
RESEARCHERS, OPERATING EXPENSES,

759
00:32:48,808 --> 00:32:53,446
CLINICAL CENTERS AND CLINICAL

760
00:32:53,446 --> 00:32:53,679
TRIALS.

761
00:32:53,679 --> 00:32:55,014
JUST TO HIGHLIGHT A FEW OF THE

762
00:32:55,014 --> 00:32:56,282
IMPORTANT COMPONENTS.

763
00:32:56,282 --> 00:33:00,519
THE NEXT SLIDE TELLS YOU THAT

764
00:33:00,519 --> 00:33:03,122
THE NCI BUDGET IS NOT DEVELOPED

765
00:33:03,122 --> 00:33:04,357
IN A VACUUM.

766
00:33:04,357 --> 00:33:05,558
AND IT'S NOT JUST DEVELOPED

767
00:33:05,558 --> 00:33:07,727
WITHIN THE CONTEXT OF NIH.

768
00:33:07,727 --> 00:33:09,695
BUT IT'S REALLY DETERMINED

769
00:33:09,695 --> 00:33:13,299
WITHIN THE FEDERAL BUDGET

770
00:33:13,299 --> 00:33:15,835
ECOSYSTEM ALONG WITH MANY OTHER

771
00:33:15,835 --> 00:33:19,372
NATIONAL PRIORITIES AS DEFINED

772
00:33:19,372 --> 00:33:22,375
BY CONGRESS.

773
00:33:22,375 --> 00:33:28,514
AND SO THAT NEEDS TO -- FOR

774
00:33:28,514 --> 00:33:31,117
FY24, ALTHOUGH WE ARE -- TODAY

775
00:33:31,117 --> 00:33:34,253
IS THE LAST DAY OF THE SECOND

776
00:33:34,253 --> 00:33:37,923
MONTH OF FY24.

777
00:33:37,923 --> 00:33:38,224
NEXT SLIDE.

778
00:33:38,224 --> 00:33:40,025
WHERE ARE WE?

779
00:33:40,025 --> 00:33:46,132
THE POTENTIAL LAPSES IN

780
00:33:46,132 --> 00:33:46,999
APPROPRIATION AVERTED WERE

781
00:33:46,999 --> 00:33:48,300
SEPTEMBER 30 AND NOVEMBER 17.

782
00:33:48,300 --> 00:33:50,903
THAT'S WHEN WE HAD CONTINUING

783
00:33:50,903 --> 00:33:51,203
RESOLUTIONS.

784
00:33:51,203 --> 00:33:55,207
THE FIRST ONE WAS SIGNED

785
00:33:55,207 --> 00:33:55,541
SEPTEMBER 30.

786
00:33:55,541 --> 00:34:00,146
THE LAST ONE WAS TWO WEEKS AGO.

787
00:34:00,146 --> 00:34:03,349
AND THAT CURRENT CONTINUING

788
00:34:03,349 --> 00:34:05,951
RESOLUTION EXPIRES ON FEBRUARY

789
00:34:05,951 --> 00:34:08,487
2, WHICH NOT ONLY IS GROUNDHOG

790
00:34:08,487 --> 00:34:10,256
DAY AND WE ARE HOPING IT WON'T

791
00:34:10,256 --> 00:34:11,524
REPRESENT THE FILM WITH BILL

792
00:34:11,524 --> 00:34:13,058
MURRAY WITH THE SAME THING

793
00:34:13,058 --> 00:34:15,161
HAPPENING AGAIN AND AGAIN, BUT

794
00:34:15,161 --> 00:34:18,564
1/3 OF THE FISCAL YEAR WILL HAVE

795
00:34:18,564 --> 00:34:21,467
PASSED AT THAT POINT.

796
00:34:21,467 --> 00:34:24,770
AND NK HOLOHAN, WAS GOING TO BE

797
00:34:24,770 --> 00:34:27,740
TALKING ABOUT MORE ABOUT THE

798
00:34:27,740 --> 00:34:28,040
KNOWLEDGEET.

799
00:34:28,040 --> 00:34:30,443
INTERIM PAY LINES HAVE BEEN SET.

800
00:34:30,443 --> 00:34:33,078
THEY WON'T BE SET UNTIL THE NCI

801
00:34:33,078 --> 00:34:35,915
RECEIVES A FULL YEAR

802
00:34:35,915 --> 00:34:36,849
APPROPRIATION.

803
00:34:36,849 --> 00:34:40,653
SO THIS IS THE SAD POSITION THAT

804
00:34:40,653 --> 00:34:41,854
WE FIND OURSELVES WITH THE

805
00:34:41,854 --> 00:34:43,989
FUNDING THAT WE CURRENTLY HAVE

806
00:34:43,989 --> 00:34:46,926
FOR THE CONTINUING RESOLUTION.

807
00:34:46,926 --> 00:34:51,497
IT'S VERY SIMILAR NIH-WIDE WITH

808
00:34:51,497 --> 00:34:52,865
9th PERCENTILE WITH

809
00:34:52,865 --> 00:34:53,899
ESTABLISHED INVESTIGATORS.

810
00:34:53,899 --> 00:34:57,169
AND 14th FOR EARLY STAGE

811
00:34:57,169 --> 00:34:59,605
INVESTIGATION AND R21 ALSO

812
00:34:59,605 --> 00:35:00,806
9th.

813
00:35:00,806 --> 00:35:02,308
NONCOMPETING GRANTS BEING FUNDED

814
00:35:02,308 --> 00:35:04,043
AT 90%.

815
00:35:04,043 --> 00:35:08,614
THIS WAS RECOMMENDED BY NIH.

816
00:35:08,614 --> 00:35:10,316
NEXT SLIDE.

817
00:35:10,316 --> 00:35:12,485
SO THE BUDGET OUTLOOK FOR THE

818
00:35:12,485 --> 00:35:15,287
NEXT TWO YEARS.

819
00:35:15,287 --> 00:35:19,091
WE PUT OUT THE PROFESSIONAL

820
00:35:19,091 --> 00:35:23,195
JUDGMENT BUDGET, DIANE AND HER

821
00:35:23,195 --> 00:35:25,130
COLLEAGUES HAVE LED THAT EFFORT.

822
00:35:25,130 --> 00:35:27,032
AND THE PROFESSIONAL JUDGMENT

823
00:35:27,032 --> 00:35:30,135
BUDGET FOR FY24 WHICH WE PUT OUT

824
00:35:30,135 --> 00:35:34,673
LAST YEAR, WAS ESSENTIALLY FOR

825
00:35:34,673 --> 00:35:35,107
10 BILLION DOLLARS.

826
00:35:35,107 --> 00:35:37,109
THE PRESIDENT'S BUDGET PROPOSAL

827
00:35:37,109 --> 00:35:42,314
FOR NCI FOR FY24 WAS 7.8.

828
00:35:42,314 --> 00:35:44,850
IT REPRESENTED ABOUT A 700

829
00:35:44,850 --> 00:35:48,120
MILLION DOLLARS INCREASE OVER

830
00:35:48,120 --> 00:35:50,656
FY23 FOR THE BASE BUDGET BUT IT

831
00:35:50,656 --> 00:35:55,327
WAS REALLY 500 MILLION ABOVE

832
00:35:55,327 --> 00:35:57,329
FY23 AND CONTINUING THE 216

833
00:35:57,329 --> 00:36:01,967
MILLION WE GOT IN FY23 FOR THE

834
00:36:01,967 --> 00:36:05,371
CANCER MOONSHOT.

835
00:36:05,371 --> 00:36:06,272
AND BACK IN SEPTEMBER WHEN WE

836
00:36:06,272 --> 00:36:11,677
PUT OUT THE BUDGET PROPOSAL FOR

837
00:36:11,677 --> 00:36:15,414
FY25, WE PROPOSED CLOSE TO 11.5

838
00:36:15,414 --> 00:36:16,649
BILLION DOLLARS.

839
00:36:16,649 --> 00:36:20,719
AND JUST FOR YOU TO SEE THE

840
00:36:20,719 --> 00:36:21,320
EXCLA POLICE STATION PINTS AT

841
00:36:21,320 --> 00:36:23,322
THE BOTTOM, JUST TO MAINTAIN THE

842
00:36:23,322 --> 00:36:25,925
FY23 PAY LINE -- EXCLAMATION

843
00:36:25,925 --> 00:36:27,760
POINTS -- AND TO FUND THE

844
00:36:27,760 --> 00:36:30,629
CONTINUING GRANTS, THE

845
00:36:30,629 --> 00:36:32,131
NONCOMPETING GRANTS, WE WOULD

846
00:36:32,131 --> 00:36:34,800
NEED TO ADD 250 MILLION DOLLARS

847
00:36:34,800 --> 00:36:39,572
JUST IN FQ24 TO THE RPG POOL.

848
00:36:39,572 --> 00:36:41,807
AND WE IN ADDITION, INCURRED

849
00:36:41,807 --> 00:36:44,076
BETWEEN 75 AND 100 MILLION

850
00:36:44,076 --> 00:36:45,544
DOLLARS EACH YEAR INCREASE

851
00:36:45,544 --> 00:36:48,847
MANDATORY EXPENSES, PHYSICAL

852
00:36:48,847 --> 00:36:49,882
SECURITIESY, CYBERSECURITY,

853
00:36:49,882 --> 00:36:51,684
UTILITIES, CENTERS FOR

854
00:36:51,684 --> 00:36:53,786
SCIENTIFIC REVIEW ET CETERA.

855
00:36:53,786 --> 00:36:56,255
PLANE OF THEM.

856
00:36:56,255 --> 00:36:56,555
NEXT SLIDE.

857
00:36:56,555 --> 00:36:56,956
-- MANY OF THEM.

858
00:36:56,956 --> 00:37:02,227
THIS IS A SLIDE THAT SOME OF YOU

859
00:37:02,227 --> 00:37:05,064
HAVE SEEN BEFORE, WE TALKED BACK

860
00:37:05,064 --> 00:37:08,968
IN JUNE AND WHAT I WANT TO

861
00:37:08,968 --> 00:37:11,337
EMPHASIZE HERE IS THE 10-YEAR

862
00:37:11,337 --> 00:37:15,174
INTERVAL BETWEEN 2003 AND 2014.

863
00:37:15,174 --> 00:37:17,977
AND THE 10-YEAR INTERVAL BETWEEN

864
00:37:17,977 --> 00:37:21,313
2013 AND 2023.

865
00:37:21,313 --> 00:37:25,084
THERE WERE VERY FEW INCREASES IN

866
00:37:25,084 --> 00:37:27,886
THE NIH BUDGET BETWEEN 2003, THE

867
00:37:27,886 --> 00:37:30,656
END OF THE DOUBLING AND 2000

868
00:37:30,656 --> 00:37:30,923
THIRTEEN.

869
00:37:30,923 --> 00:37:33,359
AND OUR PURCHASING POWER WENT

870
00:37:33,359 --> 00:37:36,929
DOWN BY ESSENTIALLY A QUARTER,

871
00:37:36,929 --> 00:37:37,796
24% LESS.

872
00:37:37,796 --> 00:37:44,870
FAST FORWARD TO 2013-2023, AND

873
00:37:44,870 --> 00:37:47,740
WE HAVE GOTTEN INCREASES EACH OF

874
00:37:47,740 --> 00:37:52,444
THE YEARS BETWEEN 2015 AND 2023.

875
00:37:52,444 --> 00:37:56,515
SO NINE OF THOSE 10 YEARS.

876
00:37:56,515 --> 00:38:00,419
WE ARE STILL 13% UNDER WHERE WE

877
00:38:00,419 --> 00:38:02,287
WERE IN 2003.

878
00:38:02,287 --> 00:38:06,058
SO THE DEFICIT AFTER NINE

879
00:38:06,058 --> 00:38:07,393
CONSECUTIVE YEARS OF INCREASED

880
00:38:07,393 --> 00:38:10,796
FUNDING, WAS SIMPLY CUT IN HALF.

881
00:38:10,796 --> 00:38:12,865
AND WHAT DOES THAT REPRESENT IN

882
00:38:12,865 --> 00:38:13,432
TERMS OF PURCHASING POWER OR

883
00:38:13,432 --> 00:38:19,705
BUYING POWER IN FY23 FUNDS?

884
00:38:19,705 --> 00:38:23,142
1.1 BILLION DOLLARS LESS THAN 20

885
00:38:23,142 --> 00:38:23,509
YEARS AGO.

886
00:38:23,509 --> 00:38:27,112
SO THIS IS -- THIS IS PART OF

887
00:38:27,112 --> 00:38:29,948
THE REASON THAT WE'RE TRYING TO

888
00:38:29,948 --> 00:38:31,984
REALLY DO MORE WITH LESS.

889
00:38:31,984 --> 00:38:34,186
AND THE OPPORTUNITIES ARE JUST

890
00:38:34,186 --> 00:38:36,155
EXTRAORDINARY.

891
00:38:36,155 --> 00:38:39,324
NEXT SLIDE.

892
00:38:39,324 --> 00:38:41,694
AND THIS SLIDE SHOWS YOU THAT A

893
00:38:41,694 --> 00:38:48,000
FLAT BUDGET IS NOT TRULY FLAT,

894
00:38:48,000 --> 00:38:48,600
AS WELT IN AND I SAID BACK IN

895
00:38:48,600 --> 00:38:48,867
JUNE.

896
00:38:48,867 --> 00:38:50,836
-- WEST IN: RESEARCH COST

897
00:38:50,836 --> 00:38:52,104
CONTINUED TO INCREASE.

898
00:38:52,104 --> 00:38:54,339
THE CURIOUS FUNDING OVER THE

899
00:38:54,339 --> 00:39:00,145
LAST YEAR WAS FY23 AND AUTO NON

900
00:39:00,145 --> 00:39:00,446
NEGOTIABLE.

901
00:39:00,446 --> 00:39:02,981
AND THEY REQUIRE NCI CUTS ACROSS

902
00:39:02,981 --> 00:39:07,686
VARIOUS PROGRAMS AND THIS GIVES

903
00:39:07,686 --> 00:39:08,287
YOU THE VARIOUS EXAMPLES WHERE

904
00:39:08,287 --> 00:39:11,390
YOU CAN HAVE THESE CONSULT.

905
00:39:11,390 --> 00:39:12,858
NEXT SLIDE.

906
00:39:12,858 --> 00:39:14,493
-- CUTS.

907
00:39:14,493 --> 00:39:16,195
AND THIS IS JUST SORT OF A

908
00:39:16,195 --> 00:39:17,996
SUMMARY SLIDE.

909
00:39:17,996 --> 00:39:19,198
WE HAVE WRITTEN QUITE A ABOUT

910
00:39:19,198 --> 00:39:23,068
ABOUT THE BUDGET AND THE THIS

911
00:39:23,068 --> 00:39:25,604
GIVES YOU THE LINKS TO THESE

912
00:39:25,604 --> 00:39:28,874
VARIOUS KINDS OF ASPECTS AND MK

913
00:39:28,874 --> 00:39:31,443
HOLOHAN WILL BE DISCUSSING IT.

914
00:39:31,443 --> 00:39:34,313
SO I THINK THAT'S MY LAST SLIDE.

915
00:39:34,313 --> 00:39:35,981
CAN WE GO TO THE LAST ONE?

916
00:39:35,981 --> 00:39:39,952
I WANT TO THANK YOU FOR YOUR

917
00:39:39,952 --> 00:39:40,619
ATTENTION.

918
00:39:40,619 --> 00:39:42,988
I'M LOOKING FORWARD TO YOUR

919
00:39:42,988 --> 00:39:45,190
QUESTIONS AND COMMENTS.

920
00:39:45,190 --> 00:39:46,992
I'M HAPPY TO ANSWER ANY EASY

921
00:39:46,992 --> 00:39:48,594
QUESTIONS ABOUT THE BUDGET.

922
00:39:48,594 --> 00:39:50,629
IF YOU ASK ME ANY DIFFICULT

923
00:39:50,629 --> 00:39:52,564
ONES, I'LL TELL YOU THAT MK IS

924
00:39:52,564 --> 00:39:56,135
GOING TO COVER THEM.

925
00:39:56,135 --> 00:39:57,736
>> THAT'S GREAT, THANK YOU
VERY

926
00:39:57,736 --> 00:40:00,305
MUCH FOR THAT FANTASTIC

927
00:40:00,305 --> 00:40:00,572
OVERVIEW.

928
00:40:00,572 --> 00:40:03,609
AND SO WE CAN NOW OPEN UP THE

929
00:40:03,609 --> 00:40:04,543
FLOOR FOR QUESTIONS.

930
00:40:04,543 --> 00:40:07,312
I SEE KARIN'S HAND.

931
00:40:07,312 --> 00:40:08,147
KARIN?

932
00:40:08,147 --> 00:40:10,282
>> KARIN: THANK YOU FOR
THE

933
00:40:10,282 --> 00:40:11,784
LEADERSHIP AND OTHER FOR THE

934
00:40:11,784 --> 00:40:12,951
INCREDIBLE UPDATE.

935
00:40:12,951 --> 00:40:14,119
VERY MUCH APPRECIATED.

936
00:40:14,119 --> 00:40:16,221
I WAS STRUCK BY THE BEAUTIFUL

937
00:40:16,221 --> 00:40:17,856
GRAPHIC FROM THE DATA THAT YOU

938
00:40:17,856 --> 00:40:19,291
REPORTED LOOKING AT THE

939
00:40:19,291 --> 00:40:21,360
POTENTIAL IMPACT OF WHAT IT

940
00:40:21,360 --> 00:40:24,096
WOULD MEAN FOR CAPSER PATIENTS

941
00:40:24,096 --> 00:40:25,464
AND OUTCOMES IF MORE SCREENING

942
00:40:25,464 --> 00:40:26,865
COULD BE HAD.

943
00:40:26,865 --> 00:40:30,803
ONE OF THE ONES YOU FOCUSED ON

944
00:40:30,803 --> 00:40:31,170
WAS LUNG CANCER.

945
00:40:31,170 --> 00:40:33,705
AND AFTER A MULTI-YEAR STUDY WE

946
00:40:33,705 --> 00:40:36,308
RELEASED NEW AT THE AMERICAN

947
00:40:36,308 --> 00:40:37,976
CANCER SOCIETY, A LUNG CANCER

948
00:40:37,976 --> 00:40:39,878
SCREENING GUIDELINES WHICH

949
00:40:39,878 --> 00:40:41,947
SIGNIFICANTLY EXPANDED

950
00:40:41,947 --> 00:40:43,949
ELIGIBILITY FOR LUNG CANCER

951
00:40:43,949 --> 00:40:44,216
SCREENING.

952
00:40:44,216 --> 00:40:46,218
NOW WE'LL SEE WHAT HAPPENS.

953
00:40:46,218 --> 00:40:49,788
TRADITIONALLY U.S. PREVENTION

954
00:40:49,788 --> 00:40:52,090
TASK SEVERANCES FOLLOWS US.

955
00:40:52,090 --> 00:40:53,659
BUT I THINK THESE KINDS OF DATA

956
00:40:53,659 --> 00:40:56,829
CAN BE USED TO CHANGE HEARTS AND

957
00:40:56,829 --> 00:40:58,130
MINDS AND SERVE AS A CALL TO

958
00:40:58,130 --> 00:41:00,966
ACTION FOR PEOPLE TO GET INTO

959
00:41:00,966 --> 00:41:01,233
SCREENING.

960
00:41:01,233 --> 00:41:03,035
I'D LOVE FOR US HO TO THINK

961
00:41:03,035 --> 00:41:05,037
ABOUT HOW TO TAP INTO RESOURCES

962
00:41:05,037 --> 00:41:08,540
SO WHEN THERE IS A NEW GUIDELINE

963
00:41:08,540 --> 00:41:09,641
DROPPED, WE COULD HAVE AN

964
00:41:09,641 --> 00:41:11,643
OPPORTUNITY TO DO THOSE MODELS

965
00:41:11,643 --> 00:41:13,779
AND SAY ACCORDING TO THESE

966
00:41:13,779 --> 00:41:15,614
GUIDELINES, THIS NUMBER OF

967
00:41:15,614 --> 00:41:16,181
PEOPLE MAY BENEFIT AND THIS

968
00:41:16,181 --> 00:41:18,250
COULD BE THE POTENTIAL OUTPUT.

969
00:41:18,250 --> 00:41:20,018
JUST, A THOUGHT ABOUT HOW WE

970
00:41:20,018 --> 00:41:21,920
TAKE THAT, NOT JUST WHOLE OF

971
00:41:21,920 --> 00:41:24,156
GOVERNMENT BUT WHOLE OF CANCER

972
00:41:24,156 --> 00:41:25,290
COMMUNITY APPROACH TO CREATE

973
00:41:25,290 --> 00:41:28,427
CALLS TO ACTION FOR SCREENING.

974
00:41:28,427 --> 00:41:30,796
>> KARIN, THANKS TO ACS
FOR YOUR

975
00:41:30,796 --> 00:41:31,096
LEADERSHIP.

976
00:41:31,096 --> 00:41:32,631
AND I JUST WANT TO POINT OUT,

977
00:41:32,631 --> 00:41:35,868
THAT THE ACS GUIDELINES ARE

978
00:41:35,868 --> 00:41:39,004
SIMILAR TO BUT NOT IDENTICAL TO

979
00:41:39,004 --> 00:41:40,472
THOSE OF THE PREVENTION SERVICES

980
00:41:40,472 --> 00:41:43,542
TASK FORCE WHEN THEY EXPANDED

981
00:41:43,542 --> 00:41:46,445
THE CRITERIA IN 2021.

982
00:41:46,445 --> 00:41:49,248
WHAT ACS IS SAYING IS, IF YOU

983
00:41:49,248 --> 00:41:53,986
ARE A FORMER SMOKER AND YOU WERE

984
00:41:53,986 --> 00:41:55,220
ELIGIBLE, BECAUSE YOU HAD A

985
00:41:55,220 --> 00:41:57,656
20-BACK YEAR OR MORE, YOU

986
00:41:57,656 --> 00:41:59,558
CONTINUE TO BE ELIGIBLE FOREVER

987
00:41:59,558 --> 00:42:02,494
WHETHER IT'S 15 YEARS OR MORE

988
00:42:02,494 --> 00:42:06,899
THAN 15 YEARS SINCE YOU STOPPED.

989
00:42:06,899 --> 00:42:08,767
BUT I WANT TO THE REPEAT

990
00:42:08,767 --> 00:42:11,703
SOMETHING I SAID, WHICH IS THAT

991
00:42:11,703 --> 00:42:14,406
THAT THIS IS A HEALTH DISPARITY.

992
00:42:14,406 --> 00:42:17,242
AND TRYING TO GET MORE PEOPLE

993
00:42:17,242 --> 00:42:19,177
WHO ARE ELIGIBLE TO HAVE LUNG

994
00:42:19,177 --> 00:42:22,080
CANCER SCREENING, COULD BE --

995
00:42:22,080 --> 00:42:24,516
IT'S NOT GOING TO TAKE CARE OF

996
00:42:24,516 --> 00:42:26,018
ALL THE DISPARITIES BUT IT'S A

997
00:42:26,018 --> 00:42:29,488
WAY OF TRYING TO OVERCOME THEM.

998
00:42:29,488 --> 00:42:30,188
KARIN, THANKS.

999
00:42:30,188 --> 00:42:34,159
>> WE ARE GOING TO GO TO
CHEEK

1000
00:42:34,159 --> 00:42:38,096
AND THEN NEILY AND THENOTIS.

1001
00:42:38,096 --> 00:42:40,799
>> THANK YOU VERY MUCH FOR
YOUR

1002
00:42:40,799 --> 00:42:41,099
LEADERSHIP.

1003
00:42:41,099 --> 00:42:43,468
IT WAS INTERESTING TO SEE THE

1004
00:42:43,468 --> 00:42:45,704
WORK AND THE PAIN THAT WE HAVE

1005
00:42:45,704 --> 00:42:52,644
BEEN THROUGH AND ALL OF US FEEL

1006
00:42:52,644 --> 00:42:54,846
WELL PAIN.

1007
00:42:54,846 --> 00:42:55,914
I WANTED TO ALSO CHANNEL BACK TO

1008
00:42:55,914 --> 00:42:58,784
THE POINT YOU MADE ABOUT THE

1009
00:42:58,784 --> 00:43:00,752
MOONSHOT INITIATIVES AND THE

1010
00:43:00,752 --> 00:43:02,554
OBJECTIVES ASPIRATIONS GOING

1011
00:43:02,554 --> 00:43:05,257
FROM THE HARD, HARDER TO

1012
00:43:05,257 --> 00:43:06,425
HARDEST.

1013
00:43:06,425 --> 00:43:09,027
I GUESS IT WILL BE HELPFUL OR

1014
00:43:09,027 --> 00:43:10,095
USEFUL TO HEAR FROM YOU AND

1015
00:43:10,095 --> 00:43:13,699
OTHERS IN TERMS OF WHAT IS NCI

1016
00:43:13,699 --> 00:43:15,500
DOING TO TURN THE HARDER TO

1017
00:43:15,500 --> 00:43:17,502
SOMETHING THAT IS SOLVABLE.

1018
00:43:17,502 --> 00:43:18,670
FOR INSTANCE, DISPARITIES ARE

1019
00:43:18,670 --> 00:43:20,439
HARDER TO SOLVE BUT I DON'T

1020
00:43:20,439 --> 00:43:22,341
THINK THEY ARE IMPOSSIBLE TO

1021
00:43:22,341 --> 00:43:22,541
SOLVE.

1022
00:43:22,541 --> 00:43:25,944
AND I DO THINK THAT SOME

1023
00:43:25,944 --> 00:43:29,014
COORDINATED LONG-TERM STRATEGY

1024
00:43:29,014 --> 00:43:30,248
COULD MAYBE CHANGE THAT THINKING

1025
00:43:30,248 --> 00:43:33,785
AROUND AND HELP US ADDRESS IT.

1026
00:43:33,785 --> 00:43:36,288
ACROSS THE TALENT POOLS, I THINK

1027
00:43:36,288 --> 00:43:37,923
WE HAVE ABILITY AND CAPACITY TO

1028
00:43:37,923 --> 00:43:38,890
DO IT.

1029
00:43:38,890 --> 00:43:40,892
I KNOW NCI IS DOING A LOT OF

1030
00:43:40,892 --> 00:43:42,494
WORK IN THIS AREA AND I'M

1031
00:43:42,494 --> 00:43:45,397
INTERESTED TO HEAR YOUR THOUGHTS

1032
00:43:45,397 --> 00:43:45,998
AROUND THAT.

1033
00:43:45,998 --> 00:43:49,267
>> I WOULD SAY THAT FOR
EXAMPLE,

1034
00:43:49,267 --> 00:43:52,938
I PRESENTED A COUPLE OF THINGS

1035
00:43:52,938 --> 00:43:54,606
WHICH COULD BE DONE.

1036
00:43:54,606 --> 00:43:59,544
TO ME, TRYING TO MORE EQUITABLY

1037
00:43:59,544 --> 00:44:00,779
DISTRIBUTE CURRENT STANDARD OF

1038
00:44:00,779 --> 00:44:03,782
CARE IS A VERY IMPORTANT PART.

1039
00:44:03,782 --> 00:44:06,118
I THINK THAT IT'S NOT JUST A

1040
00:44:06,118 --> 00:44:06,985
QUESTION OF RESEARCH.

1041
00:44:06,985 --> 00:44:11,823
IT ALSO IS A QUESTION OF POLICY.

1042
00:44:11,823 --> 00:44:17,896
AND I LIKE THE IDEA OF NCI NOT

1043
00:44:17,896 --> 00:44:19,765
DETERMINING THE POLICY BUT BEING

1044
00:44:19,765 --> 00:44:24,369
AT THE TABLE TO HELP DISCUSS

1045
00:44:24,369 --> 00:44:27,706
POLICY AND HOW POLICY CHANGES

1046
00:44:27,706 --> 00:44:32,244
COULD REALLY IMPROVE THE

1047
00:44:32,244 --> 00:44:33,645
SITUATION, BECAUSE FROM MY

1048
00:44:33,645 --> 00:44:34,946
PERSPECTIVE, YOU NEED TO DO

1049
00:44:34,946 --> 00:44:36,348
THINGS AT SCALE IN ORDER TO

1050
00:44:36,348 --> 00:44:38,383
REALLY HAVE AN IMPACT.

1051
00:44:38,383 --> 00:44:40,819
WE COULD SPEND A LONG TIME ON

1052
00:44:40,819 --> 00:44:40,986
IT.

1053
00:44:40,986 --> 00:44:43,522
I DON'T WANT TO TAKE MORE THAN

1054
00:44:43,522 --> 00:44:43,722
THAT.

1055
00:44:43,722 --> 00:44:44,723
I APOLOGIZE.

1056
00:44:44,723 --> 00:44:46,591
JOHN, IS THAT OKAY?

1057
00:44:46,591 --> 00:44:47,259
>> ABSOLUTELY.

1058
00:44:47,259 --> 00:44:48,326
AND I AGREE.

1059
00:44:48,326 --> 00:44:50,662
THE QUESTION IS ABOUT STRATEGY,

1060
00:44:50,662 --> 00:44:50,862
RIGHT?

1061
00:44:50,862 --> 00:44:52,364
AND WHEN WE LOOK AT THE BIG

1062
00:44:52,364 --> 00:44:54,499
PICTURES, HOW DO WE MOST

1063
00:44:54,499 --> 00:44:55,567
STRATEGICALLY -- WHERE ARE THE

1064
00:44:55,567 --> 00:44:56,835
BIG HITS, RIGHT?

1065
00:44:56,835 --> 00:44:59,905
THAT CAN REALLY MOVE THAT

1066
00:44:59,905 --> 00:45:02,074
MORTALITY RATE DOWNWARD, RIGHT?

1067
00:45:02,074 --> 00:45:04,476
SO I THINK IT'S A GREAT QUESTION

1068
00:45:04,476 --> 00:45:07,179
AND THANKS FOR YOUR COMMENTARY.

1069
00:45:07,179 --> 00:45:10,348
NEILY AND THENOTIS.

1070
00:45:10,348 --> 00:45:12,851
>> THANK YOU AGAIN FOR
DOUG FOR

1071
00:45:12,851 --> 00:45:15,120
STEPPING UP AND ALWAYS

1072
00:45:15,120 --> 00:45:15,654
THOUGHTFUL PRESENTATIONS.

1073
00:45:15,654 --> 00:45:17,856
I WAS STRUCK BY THE DATA THAT

1074
00:45:17,856 --> 00:45:19,825
YOU SHOWED ON THE HOW WE HAVE

1075
00:45:19,825 --> 00:45:23,595
NOT ONLY RACIAL DISPARITIES BUT

1076
00:45:23,595 --> 00:45:25,931
HOW WE HAVE ALSO MORALITY OR

1077
00:45:25,931 --> 00:45:27,833
DISTANCE AS A DISPARITY PLAYING

1078
00:45:27,833 --> 00:45:29,000
A MAJOR ROLE.

1079
00:45:29,000 --> 00:45:31,336
SO THIS WAS ONE SPECIFIC

1080
00:45:31,336 --> 00:45:33,105
ANALYSIS WHICH MAY GIVE US SOME

1081
00:45:33,105 --> 00:45:35,373
ROOM FOR INTERVENTIONS AND THINK

1082
00:45:35,373 --> 00:45:36,575
CAREFULLY ABOUT IT.

1083
00:45:36,575 --> 00:45:38,810
YOU MENTIONED THERE ARE OTHER

1084
00:45:38,810 --> 00:45:39,211
ANALYSIS UNDERWAY.

1085
00:45:39,211 --> 00:45:41,213
COULD THIS BE DONE MORE BROADLY

1086
00:45:41,213 --> 00:45:45,917
TO UNDERSTAND WHERE WE HAVE

1087
00:45:45,917 --> 00:45:47,018
POSSIBILITIES TO INTERVENE AND

1088
00:45:47,018 --> 00:45:49,754
THINK CAREFULLY ABOUT HOW TO

1089
00:45:49,754 --> 00:45:53,625
ADDRESS DISPARITIES ACROSS THE

1090
00:45:53,625 --> 00:45:54,426
SPECTRUM?

1091
00:45:54,426 --> 00:45:54,693
>> YES.

1092
00:45:54,693 --> 00:45:56,928
WE ARE DOING TWO DIFFERENT KINDS

1093
00:45:56,928 --> 00:45:59,464
OF ANALYSIS, ONE FOCUSED ON LUNG

1094
00:45:59,464 --> 00:46:04,202
CANCER AND THE OTHER ON CANCER

1095
00:46:04,202 --> 00:46:05,036
TOTALITY.

1096
00:46:05,036 --> 00:46:10,775
BUT IN THAT ONE, WE ARE LEADING

1097
00:46:10,775 --> 00:46:15,347
THAT EFFORT AND LOOKING AT

1098
00:46:15,347 --> 00:46:17,215
SURVIVAL RATES FOR DIFFERENT

1099
00:46:17,215 --> 00:46:18,083
GROUPS.

1100
00:46:18,083 --> 00:46:20,785
SO I THINK THAT THAT WILL BE

1101
00:46:20,785 --> 00:46:23,188
QUITE -- THAT WILL BE QUITE

1102
00:46:23,188 --> 00:46:23,855
INTERESTING.

1103
00:46:23,855 --> 00:46:27,225
AND WHEN I TALK WITH NEILY,

1104
00:46:27,225 --> 00:46:29,494
ONE-ON-ONE, SHE ALWAYS TELLS ME,

1105
00:46:29,494 --> 00:46:31,363
WE'RE NOT RURAL, WE'RE FRONTIER,

1106
00:46:31,363 --> 00:46:36,067
AS THOUGH THAT IS -- AND EVEN

1107
00:46:36,067 --> 00:46:39,371
MORE DISBURSED POPULATION.

1108
00:46:39,371 --> 00:46:40,238
>> EVEN ASPECTS RELATED TO

1109
00:46:40,238 --> 00:46:43,074
AMERICAN INDIANS AND

1110
00:46:43,074 --> 00:46:45,911
RESERVATIONS WHERE THEY ARE VERY

1111
00:46:45,911 --> 00:46:46,411
COMPLICATED.

1112
00:46:46,411 --> 00:46:46,611
OTIS?

1113
00:46:46,611 --> 00:46:48,013
>> THANK YOU, DOUG FOR ALL
THAT

1114
00:46:48,013 --> 00:46:49,447
YOU HAVE DONE.

1115
00:46:49,447 --> 00:46:53,718
I WANT TO ASK -- YOU HAVE GIVEN

1116
00:46:53,718 --> 00:46:54,653
A TREMENDOUS ARGUMENT THAT LUNG

1117
00:46:54,653 --> 00:46:57,455
CANCER SCREENING IS VERY, VERY

1118
00:46:57,455 --> 00:46:57,722
EFFECTIVE.

1119
00:46:57,722 --> 00:47:00,091
BUT I WOULD ASK THAT IN OUR

1120
00:47:00,091 --> 00:47:01,092
RHETORIC WE TALK ABOUT THE

1121
00:47:01,092 --> 00:47:01,960
POLICY NEEDS.

1122
00:47:01,960 --> 00:47:06,398
I WAS CHIEF OF ONCOLOGY AT A

1123
00:47:06,398 --> 00:47:08,300
MAJOR CANCER HOSPITAL, GRADY,

1124
00:47:08,300 --> 00:47:11,636
WHERE WE HAD FOUR CT SCANNERS.

1125
00:47:11,636 --> 00:47:13,972
IF I HAD STARTED A LUNG CANCER

1126
00:47:13,972 --> 00:47:15,273
SCREENING PROGRAM, I WOULD HAVE

1127
00:47:15,273 --> 00:47:18,643
USED ONE OF THOSE CT SCANNERS,

1128
00:47:18,643 --> 00:47:20,779
MADE THE LINE FOR CT SCANNERS

1129
00:47:20,779 --> 00:47:25,016
EVEN LONGER AND INCREASED

1130
00:47:25,016 --> 00:47:26,218
DISPARITIES IN OTHER THAN LUNG

1131
00:47:26,218 --> 00:47:28,853
CANCER JUST BY DOING THAT

1132
00:47:28,853 --> 00:47:30,322
SCREENING PROGRAM, NOT TO

1133
00:47:30,322 --> 00:47:32,090
MENTION I'D ALSO HAVE TO SPEND

1134
00:47:32,090 --> 00:47:34,459
SOME MONEY TO BRING IN PEOPLE

1135
00:47:34,459 --> 00:47:36,061
WHO COULD DO A GOOD JOB OF

1136
00:47:36,061 --> 00:47:40,131
READING THE CTs AND TREATING

1137
00:47:40,131 --> 00:47:40,432
THE PATIENT.

1138
00:47:40,432 --> 00:47:41,099
AND I'M NOT SAYING THIS IS WHY

1139
00:47:41,099 --> 00:47:43,802
WE SHOULD NOT SCREEN FOR LUNG

1140
00:47:43,802 --> 00:47:44,035
CANCER.

1141
00:47:44,035 --> 00:47:45,637
I'M SAYING WE NEED TO TALK TO

1142
00:47:45,637 --> 00:47:49,741
THE POLICYMAKERS ABOUT GETTING

1143
00:47:49,741 --> 00:47:51,876
ADDITIONAL RESOURCES INTO THESE

1144
00:47:51,876 --> 00:47:57,082
HOSPITALS SO THAT THIS CAN BE

1145
00:47:57,082 --> 00:47:57,282
DONE.

1146
00:47:57,282 --> 00:47:57,949
TO JUST SAY IT WORKS AND COME UP

1147
00:47:57,949 --> 00:48:00,118
WITH A GUIDELINE, IS NOT GOING

1148
00:48:00,118 --> 00:48:02,387
TO SAVE LIVES.

1149
00:48:02,387 --> 00:48:06,024
THAT'S HALF THE WAY.

1150
00:48:06,024 --> 00:48:06,491
THANK YOU.

1151
00:48:06,491 --> 00:48:07,025
>> AGREED.

1152
00:48:07,025 --> 00:48:08,960
AND IMPROVEMENTS IN TECHNOLOGY

1153
00:48:08,960 --> 00:48:11,296
AS WELL.

1154
00:48:11,296 --> 00:48:12,330
SO THANKS.

1155
00:48:12,330 --> 00:48:14,432
MARK AND THEN KARIN.

1156
00:48:14,432 --> 00:48:18,470
>> HI, THANKS AGAIN DOUG
FOR THE

1157
00:48:18,470 --> 00:48:18,670
TALK.

1158
00:48:18,670 --> 00:48:20,171
CRITICALLY IMPORTANT ISSUES.

1159
00:48:20,171 --> 00:48:21,539
AND THIS MAY BE A LITTLE BIT

1160
00:48:21,539 --> 00:48:23,308
OF -- MAYBE IT'S CRAZY

1161
00:48:23,308 --> 00:48:25,443
SUGGESTION BUT MAYBE NOT.

1162
00:48:25,443 --> 00:48:28,580
YOU MENTION THE CANCER SCREENING

1163
00:48:28,580 --> 00:48:30,315
NETWORK, AND THE DETECTION

1164
00:48:30,315 --> 00:48:30,548
ASSAYS.

1165
00:48:30,548 --> 00:48:31,316
WAT VE EVIDENCE-BASED SCREENING

1166
00:48:31,316 --> 00:48:32,617
OF LUNG CANCER WE HAVE BEEN

1167
00:48:32,617 --> 00:48:33,752
TALKING ABOUT.

1168
00:48:33,752 --> 00:48:35,553
YOU SUGGESTED THAT IT'S A POLICY

1169
00:48:35,553 --> 00:48:35,820
ISSUE.

1170
00:48:35,820 --> 00:48:37,922
WHICH IS TRUE BUT IT ALSO

1171
00:48:37,922 --> 00:48:40,492
SUGGESTS THE NEED -- THERE IS

1172
00:48:40,492 --> 00:48:43,128
NEW CANCER SCREENING RESEARCH

1173
00:48:43,128 --> 00:48:43,795
NETWORK.

1174
00:48:43,795 --> 00:48:45,096
THERE MAY NEED TO BE SOMETHING

1175
00:48:45,096 --> 00:48:47,565
ALONG THE LINES OF

1176
00:48:47,565 --> 00:48:48,199
IMPLEMENTATION SCIENCE NETWORK.

1177
00:48:48,199 --> 00:48:48,933
THROUGH MOONSHOT WE DID SOME OF

1178
00:48:48,933 --> 00:48:50,769
THIS WITH COLORECTAL CANCER

1179
00:48:50,769 --> 00:48:52,370
SCREEN ACROSS SITES BUT IT

1180
00:48:52,370 --> 00:48:54,339
WASN'T THE SAME METHODOLOGY.

1181
00:48:54,339 --> 00:48:56,207
BUT A NATIONAL COORDINATED

1182
00:48:56,207 --> 00:48:57,642
RESEARCH NETWORK AROUND GETTING

1183
00:48:57,642 --> 00:48:59,911
SOME OF THESE THINGS INTO

1184
00:48:59,911 --> 00:49:03,682
HEIGHTENED AREAS LIKE REMOTE

1185
00:49:03,682 --> 00:49:04,015
RURAL AREAS.

1186
00:49:04,015 --> 00:49:05,050
THERE COULD BE NARRATIVE IN

1187
00:49:05,050 --> 00:49:05,250
THAT.

1188
00:49:05,250 --> 00:49:06,484
SO SOMETHING TO THINK ABOUT FOR

1189
00:49:06,484 --> 00:49:08,920
THE FUTURE.

1190
00:49:08,920 --> 00:49:09,354
>> ABSOLUTELY.

1191
00:49:09,354 --> 00:49:10,455
THANK YOU VERY MUCH.

1192
00:49:10,455 --> 00:49:13,491
>> THAT'S A GREAT
QUESTION.

1193
00:49:13,491 --> 00:49:15,760
KARIN AND THEN ISABEL.

1194
00:49:15,760 --> 00:49:18,563
>> VERY NICE PRESENTATION,
DOUG,

1195
00:49:18,563 --> 00:49:19,197
AS ALWAYS.

1196
00:49:19,197 --> 00:49:24,669
I'M GOING TO BRING MY QUESTION

1197
00:49:24,669 --> 00:49:29,074
BACK A LITTLE BIT TO THE FUNDING

1198
00:49:29,074 --> 00:49:31,376
STREAM AND THE ABILITY FOR US TO

1199
00:49:31,376 --> 00:49:35,246
TRAIN AND RECRUIT AND RETAIN OUR

1200
00:49:35,246 --> 00:49:39,317
JUNIOR AND SORT OF RISING

1201
00:49:39,317 --> 00:49:40,952
MID-CAREER INVESTIGATORS WITH P

1202
00:49:40,952 --> 00:49:43,388
LINES WHERE THEY ARE RIGHT NOW

1203
00:49:43,388 --> 00:49:45,557
WITH PAY LINES LIKE THAT, THEY

1204
00:49:45,557 --> 00:49:46,658
ARE ABSOLUTELY COMPETING AGAINST

1205
00:49:46,658 --> 00:49:51,730
ALL OF US FOR THOSE RO1s.

1206
00:49:51,730 --> 00:49:53,465
AND I THINK IN THE SPIRIT OF THE

1207
00:49:53,465 --> 00:49:57,268
FACT THAT NCI ENCOURAGES TEAM

1208
00:49:57,268 --> 00:49:59,971
SCIENCE, IN MANY WAYS THEY GET

1209
00:49:59,971 --> 00:50:01,673
PENALIZED FOR WANTING TO BECOME

1210
00:50:01,673 --> 00:50:05,944
AN NPI WITH A MID-CAREER OR A

1211
00:50:05,944 --> 00:50:07,178
SENIOR INVESTIGATOR AS ONE OF

1212
00:50:07,178 --> 00:50:09,180
THEIR FIRST BIG RO1 GRANTS.

1213
00:50:09,180 --> 00:50:11,616
WE BROUGHT THIS UP AT THE LAST

1214
00:50:11,616 --> 00:50:12,450
MEETING WHEN WE DID THE

1215
00:50:12,450 --> 00:50:16,621
SUBCOMMITTEE MEETING WITH NCAB

1216
00:50:16,621 --> 00:50:18,323
ON THE TRAINING.

1217
00:50:18,323 --> 00:50:20,558
AND I KIND OF WANT TO BRING IT

1218
00:50:20,558 --> 00:50:21,726
BACK TO THIS COMMITTEE BECAUSE

1219
00:50:21,726 --> 00:50:23,828
WE TALKED ABOUT DEVELOPING A

1220
00:50:23,828 --> 00:50:24,896
SUBCOMMITTEE AND REVISITING SOME

1221
00:50:24,896 --> 00:50:27,298
OF THE TRAINING PIPELINE AND

1222
00:50:27,298 --> 00:50:28,767
OVERALLING IT.

1223
00:50:28,767 --> 00:50:31,269
I'M NOT SURE IF AUTO GOING TO

1224
00:50:31,269 --> 00:50:31,569
HAPPEN.

1225
00:50:31,569 --> 00:50:33,705
BUT I DO THINK IN THE FACE OF

1226
00:50:33,705 --> 00:50:35,240
THIS, IT'S REALLY CRITICAL

1227
00:50:35,240 --> 00:50:37,041
BECAUSE AUTO NOT JUST ABOUT

1228
00:50:37,041 --> 00:50:38,943
RETAINING THE PEOPLE WHO ARE

1229
00:50:38,943 --> 00:50:40,512
COMING OFF TRAINING GRANTS AND

1230
00:50:40,512 --> 00:50:42,547
THE TRYING TO GET K AWARDS BUT

1231
00:50:42,547 --> 00:50:43,982
IT'S ABOUT RETAINING PEOPLE

1232
00:50:43,982 --> 00:50:46,951
GETTING THE FIRST AND SECOND

1233
00:50:46,951 --> 00:50:47,452
RO1s.

1234
00:50:47,452 --> 00:50:51,156
YOU'RE GOING TO LOSE YOUR

1235
00:50:51,156 --> 00:50:51,790
MID-CAREER ASSOCIATE PROFESSORS

1236
00:50:51,790 --> 00:50:52,690
TO CLINICS.

1237
00:50:52,690 --> 00:50:54,325
IT HAPPENS TO ME ALL THE TIME

1238
00:50:54,325 --> 00:50:57,195
WITH THE MDs THAT I'M, WORKING

1239
00:50:57,195 --> 00:50:57,395
WITH.

1240
00:50:57,395 --> 00:50:59,097
BECAUSE THEY ARE NOT ABLE TO GET

1241
00:50:59,097 --> 00:51:01,366
THAT FIRST OR SECOND RO1 WITH

1242
00:51:01,366 --> 00:51:03,168
THESE TYPES OF PAY LINES,

1243
00:51:03,168 --> 00:51:04,035
ESPECIALLY THE SECOND.

1244
00:51:04,035 --> 00:51:07,005
AND THEY END UP BACK IN CLINIC.

1245
00:51:07,005 --> 00:51:08,540
AND, WHO ARE NOT GOING INTO

1246
00:51:08,540 --> 00:51:14,012
CLINIC ARE GOING INTO INDUSTRY

1247
00:51:14,012 --> 00:51:15,647
FASTER THAN I CAN SHAKE THEIR

1248
00:51:15,647 --> 00:51:17,882
HAND ON THE WAY OUT OF THE DOOR.

1249
00:51:17,882 --> 00:51:21,286
I THINK WE NEED TO SORT OF

1250
00:51:21,286 --> 00:51:23,021
REVISIT THAT AND THAT I'M NOT

1251
00:51:23,021 --> 00:51:24,322
SEEING ANYTHING ANY TIME SOON

1252
00:51:24,322 --> 00:51:26,424
THAT WILL MAKE A BIG DENT ON THE

1253
00:51:26,424 --> 00:51:26,991
P LINES.

1254
00:51:26,991 --> 00:51:29,227
SO WE HAVE TO THINK ABOUT WAYS

1255
00:51:29,227 --> 00:51:31,029
IN THE CITIZEN TO DO THINGS

1256
00:51:31,029 --> 00:51:32,197
DIFFERENTLY SO THAT PEOPLE CAN

1257
00:51:32,197 --> 00:51:35,767
STILL WORK TOGETHER IN TEAM

1258
00:51:35,767 --> 00:51:37,902
SCIENCE, NOT GET PENALIZED IN

1259
00:51:37,902 --> 00:51:39,504
CAREERS AND DO SOME GOOD WORK.

1260
00:51:39,504 --> 00:51:44,275
WHERE ARE WE WITH THAT?

1261
00:51:44,275 --> 00:51:47,212
>> YOU'RE MUTED, I
BELIEVE,

1262
00:51:47,212 --> 00:51:47,412
DOUG.

1263
00:51:47,412 --> 00:51:48,213
>> TWO RESPONSES.

1264
00:51:48,213 --> 00:51:50,181
SO KARIN, YOU'RE RAISING A VERY

1265
00:51:50,181 --> 00:51:52,784
IMPORTANT QUESTION.

1266
00:51:52,784 --> 00:51:55,820
FIRST, THAT WAS ONE 69 REASONS

1267
00:51:55,820 --> 00:52:02,827
THAT WE INCREASED THE RO1s FOR

1268
00:52:02,827 --> 00:52:03,928
EARLY-STAGE INVESTIGATORS WHO

1269
00:52:03,928 --> 00:52:08,867
WERE GIVEN AWARDS BY PAY LINE TO

1270
00:52:08,867 --> 00:52:11,736
BECOME R37s.

1271
00:52:11,736 --> 00:52:14,072
AND THIS NOW IS A 7-YEAR AWARD

1272
00:52:14,072 --> 00:52:17,575
RATHER THAN A 5-YEAR AWARD.

1273
00:52:17,575 --> 00:52:24,616
AND THE NCAB LOOKS CAREFULLY IN

1274
00:52:24,616 --> 00:52:28,186
CLOSED SESSION IN YEAR 4 OF THE

1275
00:52:28,186 --> 00:52:28,987
EARLY STAGE INVESTIGATORS.

1276
00:52:28,987 --> 00:52:32,857
AND BELL 90 -- ABOUT 90% OR SO

1277
00:52:32,857 --> 00:52:33,725
OF THE EARLY STAGE INVESTIGATORS

1278
00:52:33,725 --> 00:52:37,195
ARE DOING VERY WELL AND THE NCAB

1279
00:52:37,195 --> 00:52:40,865
THEN RECOMMENDS THAT THEY GET AN

1280
00:52:40,865 --> 00:52:42,567
ADDITIONAL TWO YEARS SO THEY ARE

1281
00:52:42,567 --> 00:52:48,773
CONVERTED TO AN R37 AWARD.

1282
00:52:48,773 --> 00:52:49,641
WE RECOGNIZED EXACTLY WHAT

1283
00:52:49,641 --> 00:52:52,577
YOU'RE SAYING ABOUT MPI AWARDS.

1284
00:52:52,577 --> 00:52:57,015
AND I TALKED WITH MIKED LAUER

1285
00:52:57,015 --> 00:52:58,816
SEVERAL YEARS AGO ABOUT NOT

1286
00:52:58,816 --> 00:53:00,852
HAVING THE SAME CREDIT, IF YOU

1287
00:53:00,852 --> 00:53:04,556
WILL, FOR AN MPI AWARD COMPARED

1288
00:53:04,556 --> 00:53:07,458
WITH A INDIVIDUAL AWARD.

1289
00:53:07,458 --> 00:53:10,461
AND HE REFUSED TO DO IT.

1290
00:53:10,461 --> 00:53:13,731
THIS IS AN NIH-WIDE THING.

1291
00:53:13,731 --> 00:53:15,400
AS FAR AS I KNOW, WE DON'T HAVE

1292
00:53:15,400 --> 00:53:16,000
CONTROL OVER IT.

1293
00:53:16,000 --> 00:53:19,404
ON THE OTHER HAND, IF THE NEXT

1294
00:53:19,404 --> 00:53:23,141
NCI DIRECTOR IS INTERESTED, AND

1295
00:53:23,141 --> 00:53:25,276
WOULD LIKE TO APPOINT ME, I

1296
00:53:25,276 --> 00:53:27,612
WOULD BE VERY HAPPY TO GO AND

1297
00:53:27,612 --> 00:53:31,816
LOOK AND DISCUSS THIS AGAIN WITH

1298
00:53:31,816 --> 00:53:32,617
MIKE.

1299
00:53:32,617 --> 00:53:33,585
OKAY?

1300
00:53:33,585 --> 00:53:34,519
>> THANKS.

1301
00:53:34,519 --> 00:53:37,555
ISABEL IF YOU COULD BE SUCCINCT

1302
00:53:37,555 --> 00:53:38,723
THAT WOULD BE HELPFUL TO MOVE ON

1303
00:53:38,723 --> 00:53:40,725
TO THE NEXT PRESENTATION.

1304
00:53:40,725 --> 00:53:43,595
>> I'LL GO TO PART B,
DOUG, AND

1305
00:53:43,595 --> 00:53:45,196
THAT I THINK THAT RESOLVING THE

1306
00:53:45,196 --> 00:53:47,031
ISSUE OR GETTING CLOSER TO THE

1307
00:53:47,031 --> 00:53:51,069
ISSUE OF DIMINISHING AND GETTING

1308
00:53:51,069 --> 00:53:52,337
PEOPLE INTO SCREENING EARLIER IN

1309
00:53:52,337 --> 00:53:55,273
ORDER TO DIMINISH MORTALITY

1310
00:53:55,273 --> 00:53:56,307
RATES IN UNDERSERVED

1311
00:53:56,307 --> 00:53:57,842
COMMUNITIES, YOU NEED TO DEPLOY

1312
00:53:57,842 --> 00:54:00,078
BOOTS ON THE GROUND AS THEY DID

1313
00:54:00,078 --> 00:54:01,245
IN COVID WITH COMMUNITY HEALTH

1314
00:54:01,245 --> 00:54:04,849
WORKERS AND COMMUNITY-BASED

1315
00:54:04,849 --> 00:54:06,618
ORGANIZATIONS WHO WHEN TASKED

1316
00:54:06,618 --> 00:54:08,419
WITH PUBLIC HEALTH WERE ABLE TO

1317
00:54:08,419 --> 00:54:10,989
REALLY INCREASE BOAST TETHING

1318
00:54:10,989 --> 00:54:11,322
AND SCREENING.

1319
00:54:11,322 --> 00:54:13,224
AND I THINK THAT -- AND I KNOW

1320
00:54:13,224 --> 00:54:16,761
THAT THERE IS SO MUCH THAT GOES

1321
00:54:16,761 --> 00:54:18,429
INTO THE RESEARCH BUT IT'S TIME

1322
00:54:18,429 --> 00:54:21,099
TO INVEST IN COMMUNITIED BASED

1323
00:54:21,099 --> 00:54:22,700
ORGANIZATIONS TO GET RESULTS OF

1324
00:54:22,700 --> 00:54:23,468
MOVING PEOPLE FROM COMMUNITY

1325
00:54:23,468 --> 00:54:25,003
INTO THE SCREENINGS.

1326
00:54:25,003 --> 00:54:26,070
AT MULTIPLE LEVELS.

1327
00:54:26,070 --> 00:54:28,439
I THINK IT'S A VERY STRONG

1328
00:54:28,439 --> 00:54:29,340
PARTNERSHIP THAT REALLY COULD BE

1329
00:54:29,340 --> 00:54:31,643
VERY HELPFUL WITH NOT ONLY

1330
00:54:31,643 --> 00:54:33,511
COMPREHENSIVE CANCER CENTERS BUT

1331
00:54:33,511 --> 00:54:34,445
PUBLIC HEALTH AND CLINICS.

1332
00:54:34,445 --> 00:54:37,248
BUT WE NEED INVESTMENT.

1333
00:54:37,248 --> 00:54:39,150
WE CAN TRAIN AND DEPLOY AND

1334
00:54:39,150 --> 00:54:41,285
REALLY GET SOME RESULTS BUT WE

1335
00:54:41,285 --> 00:54:43,021
NEED THE INVESTMENT.

1336
00:54:43,021 --> 00:54:44,455
>> YES, THANK YOU.

1337
00:54:44,455 --> 00:54:44,856
>> GREAT POINT.

1338
00:54:44,856 --> 00:54:46,624
THANK YOU.

1339
00:54:46,624 --> 00:54:49,027
SO IN THE INTEREST ATIME WE'LL

1340
00:54:49,027 --> 00:54:50,728
MOVE ON TO THE LEGISLATIVE

1341
00:54:50,728 --> 00:54:51,796
REPORT THAT WILL BE BROUGHT TO

1342
00:54:51,796 --> 00:54:55,767
US BY MK HOLOHAN.

1343
00:54:55,767 --> 00:55:00,138
ISABEL, CAN YOU LOWER YOUR HAND,

1344
00:55:00,138 --> 00:55:00,872
PLEASE.

1345
00:55:00,872 --> 00:55:02,040
>> THANK YOU, AND THANK
YOU FOR

1346
00:55:02,040 --> 00:55:03,341
THE OPPORTUNITY TO TALK WITH YOU

1347
00:55:03,341 --> 00:55:03,708
TODAY.

1348
00:55:03,708 --> 00:55:07,612
I'M GOING TO PROBABLY SKIP A FEW

1349
00:55:07,612 --> 00:55:08,246
SLIDES IN THE INTEREST OF TIME

1350
00:55:08,246 --> 00:55:10,682
SO WE HAVE THE ABILITY TO ASK

1351
00:55:10,682 --> 00:55:11,015
QUESTIONS.

1352
00:55:11,015 --> 00:55:11,849
NEXT SLIDE.

1353
00:55:11,849 --> 00:55:14,218
I WANT TO REMIND YOU THAT I'M

1354
00:55:14,218 --> 00:55:16,054
ALWAYS HAPPY TO TALK WITH YOU OR

1355
00:55:16,054 --> 00:55:19,057
STAFF IF YOU HAVE ANY QUESTIONS.

1356
00:55:19,057 --> 00:55:20,358
I'M GOING TO TOUCH ON THESE

1357
00:55:20,358 --> 00:55:22,994
TOPICS, FY24 APPROPRIATIONS

1358
00:55:22,994 --> 00:55:26,431
PROCESS, SOME OVERALL

1359
00:55:26,431 --> 00:55:27,365
CONGRESSIONALAL UPDATES.

1360
00:55:27,365 --> 00:55:28,800
I'LL PROBABLY SKIP THE RECENT

1361
00:55:28,800 --> 00:55:31,169
HEARINGS AND VISIT SECTIONS TO

1362
00:55:31,169 --> 00:55:33,204
SAVE TIME FOR QUESTIONS.

1363
00:55:33,204 --> 00:55:35,373
SO, FINALIZING SPENDING BILLS IS

1364
00:55:35,373 --> 00:55:37,341
ALWAYS A CHALLENGE.

1365
00:55:37,341 --> 00:55:38,843
THIS YEAR HAS BEEN MUCH WORSE

1366
00:55:38,843 --> 00:55:39,944
THAN USUAL.

1367
00:55:39,944 --> 00:55:42,013
WHEN THERE ARE PERIODIC DEBT

1368
00:55:42,013 --> 00:55:45,717
LIMIT INCREASES NEEDED, THAT

1369
00:55:45,717 --> 00:55:47,018
USUALLY IS PAIRED WITH SOME SORT

1370
00:55:47,018 --> 00:55:48,853
OF BUDGET DEAL.

1371
00:55:48,853 --> 00:55:50,088
NO EXCEPTION THIS YEAR.

1372
00:55:50,088 --> 00:55:54,058
IT'S ALSO DONE AT THE VERY LAST

1373
00:55:54,058 --> 00:55:54,292
MINUTE.

1374
00:55:54,292 --> 00:55:55,693
THAT'S WHAT HAPPENED.

1375
00:55:55,693 --> 00:55:56,461
I'M SURE YOU REMEMBER IN THE

1376
00:55:56,461 --> 00:55:58,496
BEGINNING OF JUNE AFTER THE

1377
00:55:58,496 --> 00:56:00,598
TREASURY SECRETARY WAS TALKING

1378
00:56:00,598 --> 00:56:02,133
ABOUT THE FULFILL AND CREDIT OF

1379
00:56:02,133 --> 00:56:04,368
THE UNITED STATES AND TAKING

1380
00:56:04,368 --> 00:56:05,103
EXTRAORDINARY MEASURES AND

1381
00:56:05,103 --> 00:56:05,903
CONGRESS DID COME TOGETHER WITH

1382
00:56:05,903 --> 00:56:09,073
A BUDGET DEAL CALLED THE FISCAL

1383
00:56:09,073 --> 00:56:09,507
RESPONSIBILITY ACT.

1384
00:56:09,507 --> 00:56:12,877
SO THIS IS THE DEBT LIMIT UNTIL

1385
00:56:12,877 --> 00:56:16,380
JANUARY 2025.

1386
00:56:16,380 --> 00:56:17,281
IT CAPPED FISCAL YEAR 24

1387
00:56:17,281 --> 00:56:20,451
SPENDING AT FY23 LEVELS AND

1388
00:56:20,451 --> 00:56:24,322
LIMITED FY25 SPENDING TO 1%

1389
00:56:24,322 --> 00:56:27,191
INCREASE.

1390
00:56:27,191 --> 00:56:28,893
SO THIS IS SOMETHING FOR

1391
00:56:28,893 --> 00:56:29,160
EVERYONE.

1392
00:56:29,160 --> 00:56:30,928
IT ALLOWED DEFENSE TO BE

1393
00:56:30,928 --> 00:56:32,663
INCREASED BY 3%, WHICH IS THE

1394
00:56:32,663 --> 00:56:36,667
AMOUNT THAT WAS REQUESTED IN THE

1395
00:56:36,667 --> 00:56:36,968
BUILT'S BID.

1396
00:56:36,968 --> 00:56:38,903
IT ALSO -- THERE WAS SIDE DEALS

1397
00:56:38,903 --> 00:56:41,539
THAT WERE NOT IN THE LEGISLATION

1398
00:56:41,539 --> 00:56:43,174
AND ALLOWED THIS TO RETURN TO

1399
00:56:43,174 --> 00:56:44,709
THAT ISSUE BECAUSE IT'S BECOME A

1400
00:56:44,709 --> 00:56:49,347
BIG POINT OF CONTENTION AS OF

1401
00:56:49,347 --> 00:56:49,547
TODAY.

1402
00:56:49,547 --> 00:56:51,215
THEY INCLUDE WHAD IS SORT OF

1403
00:56:51,215 --> 00:56:54,619
UNUSUAL, A STICK THAT WOULD

1404
00:56:54,619 --> 00:57:00,658
AUTOMATICALLY TRIGGER A CUT, A

1405
00:57:00,658 --> 00:57:00,925
SEQUESTER.

1406
00:57:00,925 --> 00:57:03,361
IF CONGRESS DOESN'T PASS ALL 12

1407
00:57:03,361 --> 00:57:05,563
SPENDING BILLS BY JANUARY 1,

1408
00:57:05,563 --> 00:57:08,266
THERE WILL BE TRIGGERED A 1%

1409
00:57:08,266 --> 00:57:09,000
SEQUESTER.

1410
00:57:09,000 --> 00:57:09,400
ACROSS-THE-BOARD.

1411
00:57:09,400 --> 00:57:10,835
AND THE THAT INCLUDES DEFENSE.

1412
00:57:10,835 --> 00:57:12,804
TO THE DOESN'T EXEMPT DEFENSE AS

1413
00:57:12,804 --> 00:57:16,207
SOMETIMES IS THE CASE WITH THESE

1414
00:57:16,207 --> 00:57:17,575
SORTS OF BUDGET DEALS.

1415
00:57:17,575 --> 00:57:19,210
IF THE 12 BILLS ARE NOT

1416
00:57:19,210 --> 00:57:21,412
COMPLETED BY APRIL 30, THEN THAT

1417
00:57:21,412 --> 00:57:23,614
SEQUESTER, THAT 1% CUT BECOMES

1418
00:57:23,614 --> 00:57:26,050
PERMANENT FOR THE REST OF THE

1419
00:57:26,050 --> 00:57:26,717
FISCAL YEAR.

1420
00:57:26,717 --> 00:57:30,221
SO, THIS IS A VERY BIG DEAL.

1421
00:57:30,221 --> 00:57:31,956
DEFENSE WOULD LOSE A LOT OF

1422
00:57:31,956 --> 00:57:34,091
MONEY IF THEY WERE HIT WITH A 1%

1423
00:57:34,091 --> 00:57:34,759
CUT FOR THE YEAR.

1424
00:57:34,759 --> 00:57:35,993
ONE THING THAT IS REALLY

1425
00:57:35,993 --> 00:57:39,063
INTERESTING HERE, IS THAT IT IS

1426
00:57:39,063 --> 00:57:41,899
UNKNOWN TERRITORY.

1427
00:57:41,899 --> 00:57:44,335
WE HAVEN'T HAD EXACTLY THIS

1428
00:57:44,335 --> 00:57:44,936
SITUATION AS FAR AS I KNOW IN

1429
00:57:44,936 --> 00:57:46,070
THE REPORTING.

1430
00:57:46,070 --> 00:57:50,174
I READ IT IS CONFIRMED.

1431
00:57:50,174 --> 00:57:52,677
IF THE RESOLUTION OF FY24 WAS A

1432
00:57:52,677 --> 00:57:56,280
FULL YEAR CONTINUING RESOLUTION

1433
00:57:56,280 --> 00:57:57,415
HELD KEEP ALL AGENCIES IN THAT

1434
00:57:57,415 --> 00:58:02,119
FULL YEAR-CR FE FY23 FUNDING

1435
00:58:02,119 --> 00:58:02,753
LEVEL, WOULD THAT BE CONSIDERED

1436
00:58:02,753 --> 00:58:05,990
COMPLETING THE APPROPRIATIONS

1437
00:58:05,990 --> 00:58:08,492
AND THEN NOT HAVE THOSE CUTS

1438
00:58:08,492 --> 00:58:08,793
TRIGGERED?

1439
00:58:08,793 --> 00:58:09,927
THAT IS SOMETHING THAT WE ARE

1440
00:58:09,927 --> 00:58:11,996
SEEING A LOT OF WRITING ABOUT

1441
00:58:11,996 --> 00:58:13,264
NOW.

1442
00:58:13,264 --> 00:58:14,765
UNFORTUNATELY, ONE THING THAT

1443
00:58:14,765 --> 00:58:15,800
HAPPENED ALMOST IMMEDIATELY

1444
00:58:15,800 --> 00:58:17,602
THERE WAS A SHORT-LIVED

1445
00:58:17,602 --> 00:58:19,270
CELEBRATION BY SPEAKER

1446
00:58:19,270 --> 00:58:21,105
McCARTHY AND OTHER LEADERS

1447
00:58:21,105 --> 00:58:22,406
WITHIN THE HOUSE AND SENATE,

1448
00:58:22,406 --> 00:58:24,408
ABOUT THE FISCAL RESPONSIBILITY

1449
00:58:24,408 --> 00:58:25,843
ACT BEING COMPLETED.

1450
00:58:25,843 --> 00:58:27,745
WITHIN A NUMBER OF DAYS OR

1451
00:58:27,745 --> 00:58:30,581
PROBABLY OVERNIGHT, WE STARTED

1452
00:58:30,581 --> 00:58:31,983
HEARING A GREAT OBJECTIONS FROM

1453
00:58:31,983 --> 00:58:34,986
THE HOUSE FREEDOM CAUCUS,

1454
00:58:34,986 --> 00:58:36,087
ULTRACONSERVATIVE FASHION OF THE

1455
00:58:36,087 --> 00:58:38,789
HOUSE GOP CAUCUS, AND THEY

1456
00:58:38,789 --> 00:58:41,692
REALLY WERE VERY UPSET ABOUT THE

1457
00:58:41,692 --> 00:58:43,027
FUNDING LEVEL FOR 24 AND NOT

1458
00:58:43,027 --> 00:58:44,262
BEING LOW ENOUGH.

1459
00:58:44,262 --> 00:58:46,464
THEY WANTED TO RETURN TO FY22

1460
00:58:46,464 --> 00:58:47,298
LEVELS.

1461
00:58:47,298 --> 00:58:50,401
AND SO, WE THEN SAW A DIFFERENT

1462
00:58:50,401 --> 00:58:52,503
APPROACH FROM HOUSE REPUBLICAN

1463
00:58:52,503 --> 00:58:52,803
LEADERSHIP.

1464
00:58:52,803 --> 00:58:55,406
THEY BEGAN TALKING ABOUT THE

1465
00:58:55,406 --> 00:58:57,675
FISCAL RESPONSIBILITY LEADERSHIP

1466
00:58:57,675 --> 00:58:59,577
FOR FY24 SETTING A SEALING, NOT

1467
00:58:59,577 --> 00:59:00,611
A FLOOR.

1468
00:59:00,611 --> 00:59:02,313
SO THEY FELT THEY WERE FREE TO

1469
00:59:02,313 --> 00:59:04,415
WRITE THEIR BILLS TO MUCH LOWER

1470
00:59:04,415 --> 00:59:05,349
LEVELS.

1471
00:59:05,349 --> 00:59:07,518
DEMOCRATS DID NOT VIEW IT THAT

1472
00:59:07,518 --> 00:59:09,320
WAY NEITHER DID SENATE

1473
00:59:09,320 --> 00:59:09,787
REPUBLICANS.

1474
00:59:09,787 --> 00:59:11,222
IT'S JUST BEEN HOUSE REPUBLICANS

1475
00:59:11,222 --> 00:59:13,557
THAT HAD THIS APPROACH AND THERE

1476
00:59:13,557 --> 00:59:16,494
WAS SORT OF A MUTINY ABOUT IT.

1477
00:59:16,494 --> 00:59:17,662
THERE WAS NO BUSINESS BEING ABLE

1478
00:59:17,662 --> 00:59:22,366
TO GET DONE ON THE HOUSE FLOOR.

1479
00:59:22,366 --> 00:59:23,367
THERE WAS THIS SIDE AGREEMENTS

1480
00:59:23,367 --> 00:59:26,170
THAT I REFERENCED THAT WOULD ADD

1481
00:59:26,170 --> 00:59:27,872
ABOUT -- ONE OF THE WAYS THEY

1482
00:59:27,872 --> 00:59:29,240
GOT TO YES WITH SOME OF THE

1483
00:59:29,240 --> 00:59:31,809
DEMOCRAT, ALLOWING THE 3%

1484
00:59:31,809 --> 00:59:34,478
INCREASE IN DEFENSE, THEY HAD TO

1485
00:59:34,478 --> 00:59:37,415
ALLOW FOR SIDE DEALS AND THERE

1486
00:59:37,415 --> 00:59:38,582
WAS ABOUT 54 MILLION DOLLARS OF

1487
00:59:38,582 --> 00:59:41,218
THE WHITE HOUSE REFERRED TO AS

1488
00:59:41,218 --> 00:59:42,320
AGREED UPON ADJUSTMENTS.

1489
00:59:42,320 --> 00:59:44,388
THAT'S NOT WRITTEN IN THE LAW,

1490
00:59:44,388 --> 00:59:46,223
IN THE FISCAL RESPONSIBILITY

1491
00:59:46,223 --> 00:59:46,757
ACT.

1492
00:59:46,757 --> 00:59:49,460
RANKING NUMBER DELORE OH, THE

1493
00:59:49,460 --> 00:59:49,894
TOP GEM CRACK IN THE

1494
00:59:49,894 --> 00:59:51,896
APPROPRIATIONS COMMITTEE, WAS

1495
00:59:51,896 --> 00:59:53,831
VERY SKEPTICAL ABOUT THIS AND

1496
00:59:53,831 --> 00:59:56,167
DIDN'T WANT THIS TO BE SORT OF A

1497
00:59:56,167 --> 00:59:57,802
SIDE DEAL AS IT PLAYED OUT.

1498
00:59:57,802 --> 01:00:00,438
SO WE ARE GOING TO COME BACK TO

1499
01:00:00,438 --> 01:00:01,906
THIS AND SEE HOW THIS GOES.

1500
01:00:01,906 --> 01:00:05,209
THERE WAS SOME GOOD NEWS THIS

1501
01:00:05,209 --> 01:00:08,245
MORNING THAT HOUSE FREEDOM

1502
01:00:08,245 --> 01:00:11,349
CAUCUS HAD STUCK WITH THEIR

1503
01:00:11,349 --> 01:00:12,883
LEVEL WHICH WAS FAR LOWER THAN

1504
01:00:12,883 --> 01:00:14,785
WHAT THE SENATE IS WRITING TO.

1505
01:00:14,785 --> 01:00:17,488
AND AS OF TODAY, THEY SEEM TO --

1506
01:00:17,488 --> 01:00:20,191
AT LEAST SOME OF OF THEM

1507
01:00:20,191 --> 01:00:21,258
ACKEISED TO THAT IS WHAT IS IN

1508
01:00:21,258 --> 01:00:22,927
THE LAW AND WHERE WE ARE GOING

1509
01:00:22,927 --> 01:00:24,862
TO END UP BUT THE FOCUSES IS NOW

1510
01:00:24,862 --> 01:00:25,963
ON THE SIDE DEALS.

1511
01:00:25,963 --> 01:00:28,499
IN ACCIDENT SLIDE, PLEASE.

1512
01:00:28,499 --> 01:00:30,401
SO I'M SURE YOU'RE ALL AWARE.

1513
01:00:30,401 --> 01:00:34,205
WE HAVE A NEW SPEAKER OF THE

1514
01:00:34,205 --> 01:00:35,339
HOUSE.

1515
01:00:35,339 --> 01:00:38,175
SO THIS WAS -- HE WAS FOURTH

1516
01:00:38,175 --> 01:00:43,514
NOMINEE TO TRY TO GET THE VOTES

1517
01:00:43,514 --> 01:00:43,814
NECESSARY.

1518
01:00:43,814 --> 01:00:45,316
NOT SOMEONE WHO HAS BEEN IN

1519
01:00:45,316 --> 01:00:46,851
CONGRESS FOR A LONG TIME.

1520
01:00:46,851 --> 01:00:48,552
I THINK A MEMBER OF THE HOUSE

1521
01:00:48,552 --> 01:00:50,187
FOR JUST OVER SIX YEARS.

1522
01:00:50,187 --> 01:00:52,990
AND THE SO HE HAS A LOT OF

1523
01:00:52,990 --> 01:00:54,425
REALLY DIFFICULT JOBS AHEAD OF

1524
01:00:54,425 --> 01:00:54,592
HIM.

1525
01:00:54,592 --> 01:00:58,396
RIGHT NOW, WE ARE FUNDED UNDER A

1526
01:00:58,396 --> 01:01:00,464
STOP GAP FUNDING BILL,

1527
01:01:00,464 --> 01:01:04,402
CONTINUING RESOLUTION, A CR,

1528
01:01:04,402 --> 01:01:07,605
AUTO AN ODD HYBRID.

1529
01:01:07,605 --> 01:01:09,540
IT'S BEING DESCRIBED AS A

1530
01:01:09,540 --> 01:01:11,842
LADDERED CR.

1531
01:01:11,842 --> 01:01:12,877
IT HAS TWO RUNGS.

1532
01:01:12,877 --> 01:01:14,745
SO THEY DIVIDED THE 12 BILLS

1533
01:01:14,745 --> 01:01:21,786
INTO A GROUP OF FOUR, WHICH ARE

1534
01:01:21,786 --> 01:01:23,687
FUNDED THROUGH JANUARY 19.

1535
01:01:23,687 --> 01:01:25,556
SO WE HAVE ALREADY GONE THROUGH

1536
01:01:25,556 --> 01:01:26,290
ONE CR.

1537
01:01:26,290 --> 01:01:26,891
THAT'S FINE.

1538
01:01:26,891 --> 01:01:28,826
NUMBER 17 WE MADE IT THROUGH

1539
01:01:28,826 --> 01:01:29,193
THAT.

1540
01:01:29,193 --> 01:01:31,695
THE SECOND ONE IS THIS ODD

1541
01:01:31,695 --> 01:01:33,564
LADDERED HYBRID.

1542
01:01:33,564 --> 01:01:38,302
SO THE FIRST FOUR ARE MILITARY

1543
01:01:38,302 --> 01:01:41,072
CONSTRUCTION, V.A., AGRICULTURE

1544
01:01:41,072 --> 01:01:41,672
AND TRANSPORTATION AND HOUSING

1545
01:01:41,672 --> 01:01:44,475
AND URBAN DEVELOPMENT.

1546
01:01:44,475 --> 01:01:45,242
SO THESE ARE FUNDED THROUGH

1547
01:01:45,242 --> 01:01:46,110
JANUARY 19.

1548
01:01:46,110 --> 01:01:48,179
ALL OF THE REST OF THE BILLS

1549
01:01:48,179 --> 01:01:50,881
INCLUDING LABOR HHS WHERE NIH

1550
01:01:50,881 --> 01:01:53,684
GETS ITS FUNDING AND THE DEFENSE

1551
01:01:53,684 --> 01:01:56,954
BILL, A VERY POPULAR BILL, ARE

1552
01:01:56,954 --> 01:01:57,421
IN THE SECOND TRENCH.

1553
01:01:57,421 --> 01:02:00,057
THOSE ARE FUNDED THROUGH

1554
01:02:00,057 --> 01:02:00,424
FEBRUARY 2.

1555
01:02:00,424 --> 01:02:02,493
WHAT IS NOT ADDRESSED ARE ANY OF

1556
01:02:02,493 --> 01:02:04,395
THE ISSUES FOR FOREIGN AID, AID

1557
01:02:04,395 --> 01:02:06,430
FOR ISRAEL, UKRAINE.

1558
01:02:06,430 --> 01:02:08,966
THERE IS A BIG PUSH AS I'M SURE

1559
01:02:08,966 --> 01:02:10,668
YOU HAVE READ IN ALL REPORTING

1560
01:02:10,668 --> 01:02:11,836
ABOUT THIS, THERE IS A BIG PUSH

1561
01:02:11,836 --> 01:02:13,571
FOR BORDER SECURITY PROVISIONS

1562
01:02:13,571 --> 01:02:16,674
TO BE ADDED TO THE AID FOR

1563
01:02:16,674 --> 01:02:16,907
UKRAINE.

1564
01:02:16,907 --> 01:02:18,242
THERE IS SOME SUGGESTION IN THE

1565
01:02:18,242 --> 01:02:19,343
HOUSE THAT THERE SHOULD BE SOME

1566
01:02:19,343 --> 01:02:21,645
SORT OF IRS PROVISIONS ADDED TO

1567
01:02:21,645 --> 01:02:23,881
AID FOR ISRAEL.

1568
01:02:23,881 --> 01:02:25,249
I DON'T WHEREIN THIS IS GOING TO

1569
01:02:25,249 --> 01:02:26,951
END EXCEPT BORDER SECURITY IS A

1570
01:02:26,951 --> 01:02:30,087
VERY BIG ISSUE AND IT'S REALLY

1571
01:02:30,087 --> 01:02:31,188
COMPLICATED AND IMMIGRATION

1572
01:02:31,188 --> 01:02:31,956
NEGOTIATIONS HAVE BEEN GOING ON

1573
01:02:31,956 --> 01:02:34,758
FOR YEARS AND YEARS AND REALLY

1574
01:02:34,758 --> 01:02:37,061
NOD BEEN ABLE TO HAVE A LOT OF

1575
01:02:37,061 --> 01:02:37,862
MEANING.

1576
01:02:37,862 --> 01:02:38,596
COMPROMISE AND MOVE THAT

1577
01:02:38,596 --> 01:02:38,829
FORWARD.

1578
01:02:38,829 --> 01:02:41,532
THIS IS CREATING A BIG PROBLEM

1579
01:02:41,532 --> 01:02:43,901
FOR THE NEW SPEAKER AND THE

1580
01:02:43,901 --> 01:02:45,603
LEADERSHIP OF THE SENATE.

1581
01:02:45,603 --> 01:02:48,072
SPEAKER JOHNSON MET WITH

1582
01:02:48,072 --> 01:02:49,840
MINORITY LEADER, MITCH

1583
01:02:49,840 --> 01:02:50,975
McCONNELL YESTERDAY AND IT WAS

1584
01:02:50,975 --> 01:02:52,943
A LARGE PART WHAT HAVE THEY WERE

1585
01:02:52,943 --> 01:02:53,244
DISCUSSING.

1586
01:02:53,244 --> 01:02:56,747
ALSO THE CR THAT WAS DONE THIS

1587
01:02:56,747 --> 01:02:59,016
LADDERED CR, IS A CLEAN CR.

1588
01:02:59,016 --> 01:03:00,851
AND THAT MEANS IS NO POLICY

1589
01:03:00,851 --> 01:03:02,887
RIDERS THAT WOULD BE VERY

1590
01:03:02,887 --> 01:03:06,724
PARTISAN AND THOSE CAN BE REALLY

1591
01:03:06,724 --> 01:03:08,392
KILLED AT THE CHANCE OF A CR

1592
01:03:08,392 --> 01:03:09,793
BECOMING ENACTED.

1593
01:03:09,793 --> 01:03:13,597
AND A LOT OF THE SPEAKER'S

1594
01:03:13,597 --> 01:03:14,965
CONSERVATIVE COLLEAGUES WERE

1595
01:03:14,965 --> 01:03:16,700
CONCERNED THERE WEREN'T POLICY

1596
01:03:16,700 --> 01:03:18,602
WRITERS AND CONTINUING THE

1597
01:03:18,602 --> 01:03:19,270
CURRENT FUNDING LEVEL.

1598
01:03:19,270 --> 01:03:20,971
THAT'S WHAT HE WAS ABLE TO GET

1599
01:03:20,971 --> 01:03:24,308
PASSED AND THE PLAY HE NEEDED TO

1600
01:03:24,308 --> 01:03:25,075
MAKE.

1601
01:03:25,075 --> 01:03:27,611
SO THE REASON I WANTED TO SHOW

1602
01:03:27,611 --> 01:03:29,847
THU TABLE IS TO SHOW YOU AS

1603
01:03:29,847 --> 01:03:32,116
DR. LOWY ALLUDED TO, WE ARE A

1604
01:03:32,116 --> 01:03:34,852
PART OF A LARGER SYSTEM.

1605
01:03:34,852 --> 01:03:40,958
THIS IS REFLECTING DISCRETIONARY

1606
01:03:40,958 --> 01:03:42,126
FUNDING.

1607
01:03:42,126 --> 01:03:44,361
HEALTH INSURANCE PROGRAMS LIKE

1608
01:03:44,361 --> 01:03:46,263
MEDICARE AND MEDICAID, SOCIAL

1609
01:03:46,263 --> 01:03:47,598
SECURITY, CHIP, DOESN'T REFLECT

1610
01:03:47,598 --> 01:03:48,465
ANY OF THIS.

1611
01:03:48,465 --> 01:03:50,434
THIS IS JUST DISCRETIONARY

1612
01:03:50,434 --> 01:03:50,968
FUNDING THAT THE HOUSE AND

1613
01:03:50,968 --> 01:03:52,603
SENATE APPROPRIATIONS COMMITTEES

1614
01:03:52,603 --> 01:03:52,836
CONTROL.

1615
01:03:52,836 --> 01:03:56,140
SO WE ARE IN THIS CATEGORY

1616
01:03:56,140 --> 01:03:59,510
HIGHLIGHTED IN YELLOW, THE LABOR

1617
01:03:59,510 --> 01:04:00,811
HHS FUNDING BILL.

1618
01:04:00,811 --> 01:04:03,714
SO THIS IS THE FY23 FINAL LEVEL.

1619
01:04:03,714 --> 01:04:06,317
THESE ARE DOLLARS IN MILLIONS.

1620
01:04:06,317 --> 01:04:09,386
THEN THE HOUSE LEVEL, THE SENATE

1621
01:04:09,386 --> 01:04:12,556
LEVEL AND THE DIFFERENCE.

1622
01:04:12,556 --> 01:04:14,158
SO HERE YOU'RE SEEING HOW THE

1623
01:04:14,158 --> 01:04:15,693
SENATE WROTE TO THE FISCAL

1624
01:04:15,693 --> 01:04:16,961
RESPONSIBILITY ACT LEVELS, THE

1625
01:04:16,961 --> 01:04:18,062
HOUSE CHOSE NOT TO.

1626
01:04:18,062 --> 01:04:19,563
AND IT'S A PRETTY SIGNIFICANT

1627
01:04:19,563 --> 01:04:20,464
DIFFERENCE FOR OUR BILL.

1628
01:04:20,464 --> 01:04:23,167
YOU GO DOWN TO THE POLT, YOU CAN

1629
01:04:23,167 --> 01:04:24,835
SEE THE DIFFERENCE

1630
01:04:24,835 --> 01:04:25,236
ACROSS-THE-BOARD.

1631
01:04:25,236 --> 01:04:27,871
ONE OF THE THINGS I WANTED TO

1632
01:04:27,871 --> 01:04:29,907
POINT OUT HERE, THESE DON'T

1633
01:04:29,907 --> 01:04:32,209
REFLECT THE SIDE DOLES THAT I

1634
01:04:32,209 --> 01:04:32,776
ALLUDED TO.

1635
01:04:32,776 --> 01:04:35,813
THESE ARE TOP-LINE NUMBERS.

1636
01:04:35,813 --> 01:04:38,048
SO THE CUTS THAT WERE AGREED TO

1637
01:04:38,048 --> 01:04:42,386
AND THE FLAT FUNDING FOR 24 AND

1638
01:04:42,386 --> 01:04:45,189
THE 1% ALLOWED INCREASE FOR '25,

1639
01:04:45,189 --> 01:04:47,224
THOSE ARE TOP LINE T DOESN'T

1640
01:04:47,224 --> 01:04:48,592
MEAN THAT EVERY PROGRAM HAS TO

1641
01:04:48,592 --> 01:04:51,562
BE CUT BY THAT SAME AMOUNT.

1642
01:04:51,562 --> 01:04:54,164
SO, APPROPRIATORS WILL USE THEIR

1643
01:04:54,164 --> 01:04:54,465
DISCRETION.

1644
01:04:54,465 --> 01:04:56,700
WHAT THIS REFLECTS HERE ARE THE

1645
01:04:56,700 --> 01:04:57,701
SUBCOMMITTEE ALLOCATION THAT IS

1646
01:04:57,701 --> 01:05:00,037
THE LEADERSHIP OF THE

1647
01:05:00,037 --> 01:05:01,105
APPROPRIATIONS COMMITTEES MAKE.

1648
01:05:01,105 --> 01:05:03,340
AND THE HOUSE AND SENATE DO NOT

1649
01:05:03,340 --> 01:05:06,477
MAKE THE SAME ALLOCATIONS.

1650
01:05:06,477 --> 01:05:07,111
THIS THE IS THE PROCESS OF THEM

1651
01:05:07,111 --> 01:05:11,382
WORKING OUT THE BILLS, DOLLARS,

1652
01:05:11,382 --> 01:05:12,650
DIRECTIVES, BUT THE JOB WAS MADE

1653
01:05:12,650 --> 01:05:15,319
A LOT HARDER THIS YEAR BU THE

1654
01:05:15,319 --> 01:05:17,521
WALKING AWAY FROM THE FISCAL

1655
01:05:17,521 --> 01:05:19,823
RESPONSIBILITY ACT AGREEMENTS.

1656
01:05:19,823 --> 01:05:23,827
SO, IT'S NOT AN ACROSS-THE-BOARD

1657
01:05:23,827 --> 01:05:24,028
CUT.

1658
01:05:24,028 --> 01:05:25,996
WE CAN'T BE OPTIMISTIC ABOUT THE

1659
01:05:25,996 --> 01:05:28,565
BUDGET FOR FY24 BECAUSE WE

1660
01:05:28,565 --> 01:05:30,100
UNDERSTAND THE MATH THAT

1661
01:05:30,100 --> 01:05:31,468
CONGRESS IS FACING AND THE

1662
01:05:31,468 --> 01:05:32,703
ALLOCATIONS THAT THE

1663
01:05:32,703 --> 01:05:35,806
APPROPRIATORS HAVE TO WORK WITH.

1664
01:05:35,806 --> 01:05:37,408
HOWEVER, I WOULD SAY WE HAVE A

1665
01:05:37,408 --> 01:05:39,476
TREMENDOUS AMOUNT OF BIPARTISAN

1666
01:05:39,476 --> 01:05:41,011
SUPPORT FOR CANCER RESEARCH.

1667
01:05:41,011 --> 01:05:43,280
WE ARE VERY GRATEFUL FOR THAT

1668
01:05:43,280 --> 01:05:46,183
AND WE CONTINUED TO BE AS

1669
01:05:46,183 --> 01:05:47,685
OPTIMISTIC THAT OUR SUPPORTERS

1670
01:05:47,685 --> 01:05:49,520
WILL CONTINUE TO PRIORITIZE SOME

1671
01:05:49,520 --> 01:05:50,888
OF THESE PROGRAMS AS THEY HAVE

1672
01:05:50,888 --> 01:05:51,722
IN THE PAST.

1673
01:05:51,722 --> 01:05:55,559
NEXT SLIDE, PLEASE.

1674
01:05:55,559 --> 01:05:58,395
SO THIS, I'M TRYING TO SHOW

1675
01:05:58,395 --> 01:05:59,763
HERE, THE SPECIFICS WITHIN THE

1676
01:05:59,763 --> 01:06:01,598
LABOR HHS BILL.

1677
01:06:01,598 --> 01:06:04,501
THESE ARE THE NIH, NCI AND

1678
01:06:04,501 --> 01:06:06,136
ARPA-H NUMBERS FOR CONTRAST.

1679
01:06:06,136 --> 01:06:09,406
SO THE FIRST COLUMN IS MA WE HAD

1680
01:06:09,406 --> 01:06:11,742
LAST FISCAL YEAR, WHAT WAS

1681
01:06:11,742 --> 01:06:12,076
ENACTED.

1682
01:06:12,076 --> 01:06:13,477
THE SECOND IS THE PRESIDENT'S

1683
01:06:13,477 --> 01:06:16,980
BUDGET REQUEST FOR FY24 AND THEN

1684
01:06:16,980 --> 01:06:19,249
THE HOUSE AND SENATE NUMBERS.

1685
01:06:19,249 --> 01:06:20,718
THESE ARE ONLY NOT ENACTED INTO

1686
01:06:20,718 --> 01:06:22,319
LAW SO THEY ARE IN GRAY BECAUSE

1687
01:06:22,319 --> 01:06:24,021
THEY ARE IN DEVELOPMENT.

1688
01:06:24,021 --> 01:06:28,058
BUT YOU CAN SEE JUST FOCUSING ON

1689
01:06:28,058 --> 01:06:31,128
2346789CI, THE HOUSE

1690
01:06:31,128 --> 01:06:33,397
SUBCOMMITTEE WOULD BE A

1691
01:06:33,397 --> 01:06:34,164
REDUCTION OF TWO16 MILLION

1692
01:06:34,164 --> 01:06:36,300
DOLLARS FOR NCI.

1693
01:06:36,300 --> 01:06:38,969
THIS IS NOTAISE CUT TO OUR BASE

1694
01:06:38,969 --> 01:06:39,203
BUDGET.

1695
01:06:39,203 --> 01:06:44,241
THIS IS THE -- THIS REFLECTS THE

1696
01:06:44,241 --> 01:06:44,842
FACT THAT THE MOONSHOT FUNDING

1697
01:06:44,842 --> 01:06:46,643
FROM THE CURES LEGISLATION, THAT

1698
01:06:46,643 --> 01:06:49,847
FUNDING LAST YEAR WAS FY23.

1699
01:06:49,847 --> 01:06:52,416
SO, IT LOOKS LIKE A CUT.

1700
01:06:52,416 --> 01:06:55,185
IT FEELS LIKE A CUT BUT FROM THE

1701
01:06:55,185 --> 01:06:55,853
APPROPRIATOR'S PERSPECTIVE, THEY

1702
01:06:55,853 --> 01:06:57,488
KEPT US FLAT.

1703
01:06:57,488 --> 01:06:59,223
THEY DID NOT FIND A WAY TO

1704
01:06:59,223 --> 01:07:00,657
BACKSTOP THAT MONEY THAT CAME

1705
01:07:00,657 --> 01:07:02,259
FROM A MANDATORY STREAM.

1706
01:07:02,259 --> 01:07:05,295
IN CONTRAST, THE SENATE DID

1707
01:07:05,295 --> 01:07:06,730
ALLOW FOR THAT.

1708
01:07:06,730 --> 01:07:08,632
AND THEY DID ACCOMMODATE PUTTING

1709
01:07:08,632 --> 01:07:11,735
IN THE 216 MILLION DOLLAR

1710
01:07:11,735 --> 01:07:12,836
INCREASE TO FILL THAT HOLE.

1711
01:07:12,836 --> 01:07:14,838
THEY ALSO PROPOSED A 60 MILLION

1712
01:07:14,838 --> 01:07:17,508
DOLLAR INCREASE ON TOP OF THAT

1713
01:07:17,508 --> 01:07:19,343
TO OUR BASE BUDGET.

1714
01:07:19,343 --> 01:07:20,310
NEXT SLIDE.

1715
01:07:20,310 --> 01:07:22,880
SO WHAT I WANTED TO SHOW YOU IS

1716
01:07:22,880 --> 01:07:27,584
THE FLUXATIONS IN OUR BASE

1717
01:07:27,584 --> 01:07:27,818
BUDGET.

1718
01:07:27,818 --> 01:07:28,485
DR. LOWY SHOWED YOU DETAIL ABOUT

1719
01:07:28,485 --> 01:07:29,753
THE FUNDING STREAMS AND WE HAVE

1720
01:07:29,753 --> 01:07:31,455
MONEY FOR THE CANCER MOONSHOT

1721
01:07:31,455 --> 01:07:34,925
AND WE HAD MONEY FOR CCDI FOR

1722
01:07:34,925 --> 01:07:36,927
THESE SPECIFIC PROGRAMS.

1723
01:07:36,927 --> 01:07:39,363
THIS SLIDE JUST SHOWS THE BASE

1724
01:07:39,363 --> 01:07:43,634
BUDGET AND YOU CAN SEE THERE IS

1725
01:07:43,634 --> 01:07:44,234
SIGNIFICANT VARIATIONS IN THE

1726
01:07:44,234 --> 01:07:45,169
AMOUNT OF INCREASES WE RECEIVED.

1727
01:07:45,169 --> 01:07:48,305
AND YOU IS CAN SIGH IN FY19 IT

1728
01:07:48,305 --> 01:07:49,873
WAS A 79 MILLION DOLLAR

1729
01:07:49,873 --> 01:07:50,140
INCREASE.

1730
01:07:50,140 --> 01:07:52,409
CONTRASTING THAT FY20 WITH A

1731
01:07:52,409 --> 01:07:53,944
VERY LARGE INCREASE AND WE

1732
01:07:53,944 --> 01:07:56,246
WANTED TO POINT OUT THIS IS WHEN

1733
01:07:56,246 --> 01:07:58,382
THERE WAS THE FIRST CLIP FOR

1734
01:07:58,382 --> 01:08:00,517
CANCER MOONSHOT FUNDING.

1735
01:08:00,517 --> 01:08:02,686
IT DROPPED FROM 400 MILLION THE

1736
01:08:02,686 --> 01:08:07,391
YEAR PRIOR TO 195 MILLION IN

1737
01:08:07,391 --> 01:08:07,658
FY20.

1738
01:08:07,658 --> 01:08:10,093
SO THE APPROPRIATOR FOUND A WAY

1739
01:08:10,093 --> 01:08:13,197
TO RESCUE US FROM THE FUNDING

1740
01:08:13,197 --> 01:08:13,530
CLIFF.

1741
01:08:13,530 --> 01:08:15,065
SO THAT WAS VERY GOOD NEWS FOR

1742
01:08:15,065 --> 01:08:15,532
US.

1743
01:08:15,532 --> 01:08:16,400
OBVIOUSLY THESE WERE GREAT

1744
01:08:16,400 --> 01:08:18,936
PROGRAMS AND WE WANTED TO

1745
01:08:18,936 --> 01:08:19,203
CONTINUE.

1746
01:08:19,203 --> 01:08:21,438
BUT, HAVING DIFFERENT FUNDING

1747
01:08:21,438 --> 01:08:25,442
STREAMS MAKES IT COMPLICATED.

1748
01:08:25,442 --> 01:08:28,378
SO WE WANTED TO POINT THAT OUT

1749
01:08:28,378 --> 01:08:28,579
HERE.

1750
01:08:28,579 --> 01:08:31,915
SO WHAT HAPPENS HERE?

1751
01:08:31,915 --> 01:08:32,115
NEXT?

1752
01:08:32,115 --> 01:08:33,550
FOR THE FIRST TIME WE DO NOT

1753
01:08:33,550 --> 01:08:35,185
HAVE A FUNDING CRISIS LOOMING

1754
01:08:35,185 --> 01:08:37,488
RIGHT BEFORE THE CHRISTMAS

1755
01:08:37,488 --> 01:08:37,888
HOLIDAY.

1756
01:08:37,888 --> 01:08:40,090
AND THAT'S GREAT FOR ALL THE

1757
01:08:40,090 --> 01:08:41,758
REPORTERS THAT COVER CONGRESS

1758
01:08:41,758 --> 01:08:43,227
FOR THE MEMBERS THEMSELVES.

1759
01:08:43,227 --> 01:08:46,129
BUT ALL IT REALLY DOES IS PUNT

1760
01:08:46,129 --> 01:08:47,498
IT TO THE NEXT MONTH.

1761
01:08:47,498 --> 01:08:49,366
AND THERE IS NOT A LOT OF TIME

1762
01:08:49,366 --> 01:08:50,534
LEFT.

1763
01:08:50,534 --> 01:08:52,336
SPEAKER JOHNSON WILL NOT VIEW

1764
01:08:52,336 --> 01:08:53,804
ANOTHER PLEA FUNDING BILL.

1765
01:08:53,804 --> 01:08:56,673
SO IF WE STICKS TO THAT, THAT

1766
01:08:56,673 --> 01:08:58,942
REALLY LIMITS HIS OPTIONS.

1767
01:08:58,942 --> 01:09:01,879
IT'S EITHER GET THESE BILLS DONE

1768
01:09:01,879 --> 01:09:05,182
FOR REAL AND FINALIZED OR DO EYE

1769
01:09:05,182 --> 01:09:06,016
FULL-YEAR CR.

1770
01:09:06,016 --> 01:09:08,318
WE'LL SEE.

1771
01:09:08,318 --> 01:09:09,152
THEY DON'T HAVE A LOT OF TIME TO

1772
01:09:09,152 --> 01:09:10,487
RECONCILE THESE BILLS AND AS YOU

1773
01:09:10,487 --> 01:09:11,755
SEEK FROM THE TABLE WITH ALL OF

1774
01:09:11,755 --> 01:09:15,692
THE REALLY CONTRASTING TOP LINE

1775
01:09:15,692 --> 01:09:16,860
NUMBERS, THEY HAVEN'T CERTAINLY

1776
01:09:16,860 --> 01:09:19,930
BEGUN TO COME TO AGREEMENT ON

1777
01:09:19,930 --> 01:09:20,964
THESE BILLS.

1778
01:09:20,964 --> 01:09:23,967
THE LATTER HYBRID CR WE HAVE HAS

1779
01:09:23,967 --> 01:09:26,703
TWO DATES FOR POSSIBLE

1780
01:09:26,703 --> 01:09:27,604
SHUTDOWNS.

1781
01:09:27,604 --> 01:09:28,105
WE COULD HAVE A PARTIAL

1782
01:09:28,105 --> 01:09:28,839
GOVERNMENT SHUTDOWN ON JANUARY

1783
01:09:28,839 --> 01:09:31,208
19 AND THEN WE COULD HAVE

1784
01:09:31,208 --> 01:09:32,409
ANOTHER PARTIAL GOVERNMENT

1785
01:09:32,409 --> 01:09:35,445
SHUTDOWN ON FEBRUARY 2 BECAUSE

1786
01:09:35,445 --> 01:09:37,981
THERE ARE THESE DIFFERENT

1787
01:09:37,981 --> 01:09:38,549
TIMEFRAMES FOR WHICH FEDERAL

1788
01:09:38,549 --> 01:09:42,486
PROGRAMS ARE FUNDED.

1789
01:09:42,486 --> 01:09:44,988
THE CHASM BETWEEN THE HOUSE AND

1790
01:09:44,988 --> 01:09:46,557
SENATE CEALING, NOT A FLOOR

1791
01:09:46,557 --> 01:09:46,757
ISSUE.

1792
01:09:46,757 --> 01:09:48,458
MAYBE THAT'S COMING CLOSER TO

1793
01:09:48,458 --> 01:09:49,059
RESOLUTION.

1794
01:09:49,059 --> 01:09:51,628
WE DID SEE SOME POSITIVE NEWS ON

1795
01:09:51,628 --> 01:09:51,929
THAT TODAY.

1796
01:09:51,929 --> 01:09:53,730
BUT THEN THERE IS THE SIDE DEAL

1797
01:09:53,730 --> 01:09:53,964
ISSUES.

1798
01:09:53,964 --> 01:09:56,934
AND SO THAT WOULD CERTAINLY BE A

1799
01:09:56,934 --> 01:09:57,167
PROBLEM.

1800
01:09:57,167 --> 01:10:00,137
HOWEVER, THAT PLAYS OUT.

1801
01:10:00,137 --> 01:10:00,771
OTHER BIG PROBLEMS THAT CONGRESS

1802
01:10:00,771 --> 01:10:03,373
HAS TO DEAL WITH ARE FOREIGN AID

1803
01:10:03,373 --> 01:10:03,840
ISSUES.

1804
01:10:03,840 --> 01:10:07,411
PARTICULARLY THE BORDER SECURITY

1805
01:10:07,411 --> 01:10:08,278
DEMANDS ARE GOING TO BE VERY

1806
01:10:08,278 --> 01:10:08,545
DIFFICULT.

1807
01:10:08,545 --> 01:10:10,781
HOUSE AND SENATE REPUBLICANS DO

1808
01:10:10,781 --> 01:10:12,916
SEEM TO BE UNITED ON INSISTING

1809
01:10:12,916 --> 01:10:15,185
THAT THEY WANT BORDER SECURITY

1810
01:10:15,185 --> 01:10:16,420
PROVISIONS TO BE PART OF ANY

1811
01:10:16,420 --> 01:10:19,723
DEAL FOR UKRAINE.

1812
01:10:19,723 --> 01:10:21,091
AND THERE ARE OTHER MACHINES WHO

1813
01:10:21,091 --> 01:10:22,793
ARE DETERMINED THAT AID TO

1814
01:10:22,793 --> 01:10:24,061
UKRAINE WILL BE CONDITIONED ON

1815
01:10:24,061 --> 01:10:26,029
GETTING AID TO ISRAEL FIRST.

1816
01:10:26,029 --> 01:10:28,231
SO, AS I'M SURE YOU KNOW FROM

1817
01:10:28,231 --> 01:10:29,333
ALL OF THE REPORTING ABOUT THOSE

1818
01:10:29,333 --> 01:10:33,704
TWO ISSUES, THIS IS CAUSING A

1819
01:10:33,704 --> 01:10:35,539
LOT OF FASHIONS FOR BOTH SIDES

1820
01:10:35,539 --> 01:10:37,441
SO IT WILL NOT BE RESOLVED

1821
01:10:37,441 --> 01:10:38,775
QUICKLY OR EASILY.

1822
01:10:38,775 --> 01:10:41,078
NEXT SLIDE, PLEASE.

1823
01:10:41,078 --> 01:10:43,914
I WANTED TO POINT OUT, YRs ARE

1824
01:10:43,914 --> 01:10:44,748
VERY COMMON.

1825
01:10:44,748 --> 01:10:46,750
AN AVERAGE OF 5 PER YEAR.

1826
01:10:46,750 --> 01:10:47,584
I LIKE THIS SLIDE BECAUSE IT

1827
01:10:47,584 --> 01:10:49,353
SHOWS THE DURATION OF HOW LONG

1828
01:10:49,353 --> 01:10:52,789
THE CRs ARE AND I WANT TO

1829
01:10:52,789 --> 01:10:55,559
POINT OUT THE 365 DAYS, THAT

1830
01:10:55,559 --> 01:10:59,363
INDICATES THAT THERE WERE AT

1831
01:10:59,363 --> 01:11:00,097
LEAST SOME GOVERNMENT BILLS

1832
01:11:00,097 --> 01:11:02,833
FUNDED IN A FULL-YEAR CR.

1833
01:11:02,833 --> 01:11:03,967
NOT ALL OF THEM.

1834
01:11:03,967 --> 01:11:05,802
DEFENSE HAS ALWAYS FOUND A WAY

1835
01:11:05,802 --> 01:11:08,505
TO BE FUNDED BY A SUBSEQUENT

1836
01:11:08,505 --> 01:11:08,872
APPROPRIATION.

1837
01:11:08,872 --> 01:11:10,707
THAT HAS NOT BEEN THE WAYS FOR

1838
01:11:10,707 --> 01:11:13,043
ALL OF THE SUB COMMITTEE

1839
01:11:13,043 --> 01:11:14,111
ALLOCATIONS OR BILLS.

1840
01:11:14,111 --> 01:11:16,813
AND THIS DOESN'T SHOW YOU 2023.

1841
01:11:16,813 --> 01:11:19,983
THERE WERE THREE CRs THAT WENT

1842
01:11:19,983 --> 01:11:22,319
90 DAYS INTO THE FISCAL YEAR.

1843
01:11:22,319 --> 01:11:24,421
ALL OF YOU KNOW VERY WELL, THE

1844
01:11:24,421 --> 01:11:25,822
LONGER INTO THE FISCAL YEAR WE

1845
01:11:25,822 --> 01:11:27,557
HAVE UNCERTAINTY ABOUT OUR

1846
01:11:27,557 --> 01:11:29,226
FUNDING LEVELS, THE MORE

1847
01:11:29,226 --> 01:11:31,461
DIFFICULT IT IS TO PLAN BOTH FOR

1848
01:11:31,461 --> 01:11:34,364
NCI AND FOR THE GRANTEES AND SO

1849
01:11:34,364 --> 01:11:35,966
THAT IS SOMETHING WE WOULD

1850
01:11:35,966 --> 01:11:37,834
REALLY HOPE DOESN'T EXTEND

1851
01:11:37,834 --> 01:11:38,368
TERRIBLY LONG.

1852
01:11:38,368 --> 01:11:41,471
SINCE WE ARE FUNDED THROUGH A CR

1853
01:11:41,471 --> 01:11:43,373
UNTIL FEBRUARY 2, THAT WOULD BE

1854
01:11:43,373 --> 01:11:45,776
THE EARLIEST WE WOULD POSSIBLY

1855
01:11:45,776 --> 01:11:47,944
GET OUR 24 APPROPRIATION

1856
01:11:47,944 --> 01:11:48,211
SETTLEED.

1857
01:11:48,211 --> 01:11:50,547
AND I DON'T KNOW WHAT THE ODDS

1858
01:11:50,547 --> 01:11:53,216
ARE THAT WILL BE THE FINAL

1859
01:11:53,216 --> 01:11:55,185
RESOLUTION.

1860
01:11:55,185 --> 01:11:57,421
NEXT SLIDE.

1861
01:11:57,421 --> 01:11:59,690
YOU'RE SEEING A LOT OF NEWS

1862
01:11:59,690 --> 01:12:00,991
ABOUT RETIREMENTS.

1863
01:12:00,991 --> 01:12:01,858
THE NUMBER OF THE ACCUMULATIVE

1864
01:12:01,858 --> 01:12:04,695
NUMBERS ARE NOT ALL THAT OUT OF

1865
01:12:04,695 --> 01:12:06,229
THE ORDINARY.

1866
01:12:06,229 --> 01:12:09,399
THERE IS A LOT OF FLUX.

1867
01:12:09,399 --> 01:12:10,167
ONE THING THAT IS OUT OF THE

1868
01:12:10,167 --> 01:12:12,169
ORDINARY IS THE LEVEL OF

1869
01:12:12,169 --> 01:12:15,038
INSTITUTIONAL KNOWLEDGE THAT IS

1870
01:12:15,038 --> 01:12:16,640
LEAVING, THESE INDIVIDUALS THAT

1871
01:12:16,640 --> 01:12:17,174
ARE LEAVING.

1872
01:12:17,174 --> 01:12:21,778
I WANTED TO HIGHLIGHT A FEW

1873
01:12:21,778 --> 01:12:22,112
MEMBERS HERE.

1874
01:12:22,112 --> 01:12:25,949
ON THE TOP RIGHT IS

1875
01:12:25,949 --> 01:12:28,852
CONGRESSWOMANNA OF CALIFORNIA.

1876
01:12:28,852 --> 01:12:30,487
SHE IS A FIERCE CHAMPION OF

1877
01:12:30,487 --> 01:12:31,421
BIOMEDICAL RESEARCH.

1878
01:12:31,421 --> 01:12:34,357
AND THEN THE NEXT TWO

1879
01:12:34,357 --> 01:12:34,758
PHOTOGRAPHS GOING

1880
01:12:34,758 --> 01:12:37,127
COUNTERCLOCKWISE ARE CONGRESSMAN

1881
01:12:37,127 --> 01:12:39,429
BRIAN HIGGINS OF NEW YORK AND

1882
01:12:39,429 --> 01:12:40,063
REPRESENTATIVE DERRICK KILMER OF

1883
01:12:40,063 --> 01:12:43,300
WASHINGTON STATE STANDING WITH

1884
01:12:43,300 --> 01:12:44,401
DR.-- THEY BOTH WERE CHAIRS OF

1885
01:12:44,401 --> 01:12:47,971
THE HOUSE CANCER CAUCUS AND VERY

1886
01:12:47,971 --> 01:12:49,873
SUPPORTIVE OF CANCER RESEARCH

1887
01:12:49,873 --> 01:12:51,208
AND WORKED CLOSELY WITH NCI AND

1888
01:12:51,208 --> 01:12:57,247
LOTS OF THE CANCER GROUPS LIKE

1889
01:12:57,247 --> 01:12:57,748
ACS HAD HAD REALLY GOOD

1890
01:12:57,748 --> 01:12:58,415
RELATIONSHIPS WITH THEM AS WELL.

1891
01:12:58,415 --> 01:13:03,587
IT'S JUST A LOSS FOR US.

1892
01:13:03,587 --> 01:13:04,755
THEN CONGRESSWOMAN KATE

1893
01:13:04,755 --> 01:13:05,322
GRAINGER, CHAIR OF THE FULL

1894
01:13:05,322 --> 01:13:06,056
APPROPRIATIONS COMMITTEE IN THE

1895
01:13:06,056 --> 01:13:09,826
HOUSE IS RETIRING.

1896
01:13:09,826 --> 01:13:12,062
AND SENATOR JOE MANSION

1897
01:13:12,062 --> 01:13:14,798
ANNOUNCED HIS SEAT WILL FLIP

1898
01:13:14,798 --> 01:13:15,732
FROM BLUE TO RED.

1899
01:13:15,732 --> 01:13:17,534
THAT THE IS A SIGNIFICANT ISSUE

1900
01:13:17,534 --> 01:13:19,703
FOR SENATE DEMOCRATS.

1901
01:13:19,703 --> 01:13:22,405
SOME OF THE ASSESSMENTS HAVE

1902
01:13:22,405 --> 01:13:32,949
LOOKED AT OVER TIME IN CONGRESS

1903
01:13:33,150 --> 01:13:36,953
HAD BEEN IN OFFICE FOR LESS THAN

1904
01:13:36,953 --> 01:13:37,988
5 YEARS.

1905
01:13:37,988 --> 01:13:39,422
BY WENT TOY BETWEEN, ALMOST 47%

1906
01:13:39,422 --> 01:13:43,460
OF HOUSE MEMBERS WERE THERE LESS

1907
01:13:43,460 --> 01:13:44,227
THAN 5 YEARS.

1908
01:13:44,227 --> 01:13:46,363
NANCY PELOSI SERVED FOR 20

1909
01:13:46,363 --> 01:13:47,631
BEFORE SHE BECAME SPEAKER.

1910
01:13:47,631 --> 01:13:50,300
PAUL RYAN FOR 17.

1911
01:13:50,300 --> 01:13:51,168
McCARTHY FOR 17.

1912
01:13:51,168 --> 01:13:52,869
IT'S JUST A LOT.

1913
01:13:52,869 --> 01:13:55,372
I GUESS THE HOPE IS THAT PEOPLE

1914
01:13:55,372 --> 01:13:56,873
WHO HAD MORE EXPERIENCE AND ABLE

1915
01:13:56,873 --> 01:14:00,277
TO DO MORE BIPARTISAN WORKING

1916
01:14:00,277 --> 01:14:02,979
KEEP DOING THAT AND KEEP

1917
01:14:02,979 --> 01:14:12,956
AVOIDING SOME OF THE EMERGEN 

1918
01:14:12,956 --> 01:14:14,057
EMERGENCIES.

1919
01:14:14,057 --> 01:14:14,391
NEXT SLIGHTED.

1920
01:14:14,391 --> 01:14:16,326
WE TRY VERY HARD TO POST MEMBERS

1921
01:14:16,326 --> 01:14:18,228
OF CONGRESS TO VISIT AND THEIR

1922
01:14:18,228 --> 01:14:20,864
STAFF TO VISIT NCI TO WORK WITH

1923
01:14:20,864 --> 01:14:23,633
SITES TO HAVE, IF WE COULD BE

1924
01:14:23,633 --> 01:14:26,503
HELPFUL UPONFUL TO HAVE SOLICITS

1925
01:14:26,503 --> 01:14:27,804
TO NCI-FUNDED INSTITUTIONS AND

1926
01:14:27,804 --> 01:14:28,305
THAT'S WHAT THESE SLIDES

1927
01:14:28,305 --> 01:14:28,972
REPRESENT.

1928
01:14:28,972 --> 01:14:32,843
I'M GOING TO LEAVE THESE FOR

1929
01:14:32,843 --> 01:14:33,009
YOU.

1930
01:14:33,009 --> 01:14:35,679
THIS WAS A TERRIFIC BRIEFING

1931
01:14:35,679 --> 01:14:37,948
THAT OUR COLLEAGUES AGAINST

1932
01:14:37,948 --> 01:14:39,950
CANCER, GROUP ORGANIZED THROUGH

1933
01:14:39,950 --> 01:14:41,885
ACS CAN AND THEY PUT TOGETHER A

1934
01:14:41,885 --> 01:14:43,220
TERRIFIC BRIEFING ON CAPITOL

1935
01:14:43,220 --> 01:14:46,489
HILL THAT WAS REALLY WELL

1936
01:14:46,489 --> 01:14:47,757
INTENDED BY CONGRESSIONAL STAFF.

1937
01:14:47,757 --> 01:14:48,191
LAST SLIDE.

1938
01:14:48,191 --> 01:14:52,229
AND IF WE HAVE ANY TIME FOR

1939
01:14:52,229 --> 01:14:54,664
QUESTIONS, I JUST WANTED TO

1940
01:14:54,664 --> 01:14:57,634
THANK ALL OF YOU WHO WORKED TO

1941
01:14:57,634 --> 01:14:59,002
ENGAGE AND INFORM MEMBERS OF

1942
01:14:59,002 --> 01:15:00,770
CONGRESS AND THEIR STAFF AT YOUR

1943
01:15:00,770 --> 01:15:02,572
OWN INSTITUTIONS AND WHEN YOU'RE

1944
01:15:02,572 --> 01:15:06,810
DOING VISITS ON CAPITOL HILL,

1945
01:15:06,810 --> 01:15:08,178
BECAUSE IT IS -- IT REALLY

1946
01:15:08,178 --> 01:15:08,411
MATTERS.

1947
01:15:08,411 --> 01:15:11,648
IT'S VERY HELPFUL FOR THAT

1948
01:15:11,648 --> 01:15:13,016
CONTEXT FOR MEMBERS TO HAVE THAT

1949
01:15:13,016 --> 01:15:14,384
AND THEIR STAFF TO LEARN ABOUT

1950
01:15:14,384 --> 01:15:16,620
THE KIND OF WORK THAT NCI IS

1951
01:15:16,620 --> 01:15:18,622
SUPPORTING AND THE KIND OF WORK

1952
01:15:18,622 --> 01:15:20,924
THAT IS HAPPENING.

1953
01:15:20,924 --> 01:15:21,324
THANK YOU.

1954
01:15:21,324 --> 01:15:22,626
HAPPY TO HEAR FROM ANY OF YOU

1955
01:15:22,626 --> 01:15:24,361
HERE OR WHEN YOU HAVE TIME AFTER

1956
01:15:24,361 --> 01:15:27,898
THE MEETING.

1957
01:15:27,898 --> 01:15:29,132
>> ARE THERE GO BURNING

1958
01:15:29,132 --> 01:15:30,667
QUESTIONS FOR MK?

1959
01:15:30,667 --> 01:15:32,369
FOR ME THE QUESTION WOULD BE, AS

1960
01:15:32,369 --> 01:15:37,240
YOU LOOK BACK ON THOSE FULL 365

1961
01:15:37,240 --> 01:15:41,311
DAY CRs HOW HAS HHS TYPICALLY

1962
01:15:41,311 --> 01:15:41,544
FAIRED?

1963
01:15:41,544 --> 01:15:44,781
WE TALK ABOUT THE VARIOUS BILLS,

1964
01:15:44,781 --> 01:15:47,250
DOD, DEFENSE ALWAYS, BUT HOW

1965
01:15:47,250 --> 01:15:48,618
HAS --

1966
01:15:48,618 --> 01:15:49,719
>> NOT LABOR HHS.

1967
01:15:49,719 --> 01:15:51,788
OUR BILL IS ALWAYS ONE OF THE

1968
01:15:51,788 --> 01:15:52,589
LAST TO GET DONE.

1969
01:15:52,589 --> 01:15:56,192
IT IS THE BIGGEST DISCRETIONARY,

1970
01:15:56,192 --> 01:15:58,295
NON-DEFENSE DISCRETIONARY BILL.

1971
01:15:58,295 --> 01:16:01,698
AND IT IS FULL OF POLICY RIDERS

1972
01:16:01,698 --> 01:16:04,167
THAT ARE CONTROVERSIAL.

1973
01:16:04,167 --> 01:16:05,402
AND THIS YEAR THERE IS LOTS OF

1974
01:16:05,402 --> 01:16:08,571
BILLS THAT HAVE CONTROVERSIAL

1975
01:16:08,571 --> 01:16:09,406
RIDERS, AGRICULTURE BILL IS

1976
01:16:09,406 --> 01:16:10,507
REALLY PROBLEMATIC.

1977
01:16:10,507 --> 01:16:12,509
AND THAT IS THE IN THE FIRST

1978
01:16:12,509 --> 01:16:15,345
TRAUNCH INTENDED TO BE AN EASIER

1979
01:16:15,345 --> 01:16:17,247
GROUP TO GET THROUGH.

1980
01:16:17,247 --> 01:16:23,386
THERE IS RESTRICTIONS ABOUT

1981
01:16:23,386 --> 01:16:28,158
ACCESS TO THE -- I CAN NEVER

1982
01:16:28,158 --> 01:16:30,293
PRONOUNCE THE NAME.

1983
01:16:30,293 --> 01:16:32,963
SO THERE WAS RETAIL RESTRICTIONS

1984
01:16:32,963 --> 01:16:34,064
ABOUT THAT AND SOME MODERATE

1985
01:16:34,064 --> 01:16:35,899
REPUBLICANS VOTED AGAINST IT AND

1986
01:16:35,899 --> 01:16:37,634
SAID THEY WOULD NOT SUPPORT THAT

1987
01:16:37,634 --> 01:16:39,336
AG APPROPRIATIONS BILL AND THAT

1988
01:16:39,336 --> 01:16:42,372
IS HOLDING UP FDA'S

1989
01:16:42,372 --> 01:16:42,939
APPROPRIATION.

1990
01:16:42,939 --> 01:16:46,576
SO, WE ARE NEVER GOING TO BE THE

1991
01:16:46,576 --> 01:16:49,179
FIRST OR EXEMPTED FROM A FULL CR

1992
01:16:49,179 --> 01:16:50,246
BECAUSE OUR BILL IS TOO

1993
01:16:50,246 --> 01:16:52,782
DIFFICULT TO GET DONE

1994
01:16:52,782 --> 01:16:53,083
POLITICALLY.

1995
01:16:53,083 --> 01:16:56,953
>> AND I'LL ALLOW WONG
QUESTION.

1996
01:16:56,953 --> 01:16:57,120
RAY?

1997
01:16:57,120 --> 01:16:59,422
>> SO THANKS FOR THIS
BRIEFING.

1998
01:16:59,422 --> 01:17:02,058
IT'S ALMOST LIKE A SKY IS

1999
01:17:02,058 --> 01:17:03,693
FALLING BRIEFING ALL OVER AGAIN.

2000
01:17:03,693 --> 01:17:04,928
>> THERE WAS SOME GOOD
NEWS

2001
01:17:04,928 --> 01:17:05,195
TODAY.

2002
01:17:05,195 --> 01:17:07,731
NOT A LOT BUT --

2003
01:17:07,731 --> 01:17:11,234
>> SO, MY QUESTION IS,
WHAT IS

2004
01:17:11,234 --> 01:17:12,002
THE DOOMSDAY SCENARIO?

2005
01:17:12,002 --> 01:17:18,308
HOW REALISTIC IS IS IT?

2006
01:17:18,308 --> 01:17:20,243
AND OTHER THAN DOING THE ONE

2007
01:17:20,243 --> 01:17:21,745
VOICE AGAINST CANCER ON CAPITOL

2008
01:17:21,745 --> 01:17:23,646
HILL EVENTS, WHICH PRETTY MUCH

2009
01:17:23,646 --> 01:17:27,684
MOST OF US DO, WHAT CAN WE BE

2010
01:17:27,684 --> 01:17:30,820
DOING TO HELP FOSTER

2011
01:17:30,820 --> 01:17:31,154
UNDERSTANDING?

2012
01:17:31,154 --> 01:17:32,155
MAYBE MOVE DIALOGUE?

2013
01:17:32,155 --> 01:17:34,424
IS THERE ANYTHING OR ARE WE

2014
01:17:34,424 --> 01:17:35,892
TOTALLY HELPLESS WAITING FOR THE

2015
01:17:35,892 --> 01:17:40,030
SKY TO FALL?

2016
01:17:40,030 --> 01:17:44,100
>> SO THE LAST QUESTION
FIRST.

2017
01:17:44,100 --> 01:17:46,503
I THINK THERE ARE GROUPS WHO CAN

2018
01:17:46,503 --> 01:17:48,638
DO WHAT IS ESSENTIALLY LOBBYING,

2019
01:17:48,638 --> 01:17:50,173
THAT IS NOT SOMETHING FEDERAL

2020
01:17:50,173 --> 01:17:53,076
AGENCIES CAN DO BUT WHAT WE --

2021
01:17:53,076 --> 01:17:55,879
WHAT I SEE THE MOST VALUE IN, MY

2022
01:17:55,879 --> 01:17:57,714
PERSONAL OPINION, IS REALLY JUST

2023
01:17:57,714 --> 01:17:58,548
THE ENGAGEMENT.

2024
01:17:58,548 --> 01:18:02,085
WHEN I SEE THE OVAC EVENT,

2025
01:18:02,085 --> 01:18:02,886
DR. LOWY WAS THERE.

2026
01:18:02,886 --> 01:18:05,455
A RESEARCHER FROM NORTHWESTERN

2027
01:18:05,455 --> 01:18:12,262
CANCER CENTER, DR. ADAM, HE

2028
01:18:12,262 --> 01:18:14,130
SHOWED A VIDEO OF THIS REALLY

2029
01:18:14,130 --> 01:18:14,931
INTERESTING RESEARCH HE'S DONE

2030
01:18:14,931 --> 01:18:18,001
ABOUT GETTING THROUGH THE BLOOD

2031
01:18:18,001 --> 01:18:21,171
BRAIN BABIER FOR NEURO-ONCOLOGY

2032
01:18:21,171 --> 01:18:22,672
CASES, PEOPLE -- NON-SCIENTISTS

2033
01:18:22,672 --> 01:18:24,374
IN THE AUDIENCE WERE AMAZED.

2034
01:18:24,374 --> 01:18:26,543
AND THAT'S NOT THE KIND OF THING

2035
01:18:26,543 --> 01:18:28,078
YOU CAN BRING PEOPLE TO THE

2036
01:18:28,078 --> 01:18:29,712
CLINIC TO SHOW THEM.

2037
01:18:29,712 --> 01:18:31,514
THEY HAD A TERRIFIC VIDEO.

2038
01:18:31,514 --> 01:18:34,184
DOING THAT SORT OF -- SAME

2039
01:18:34,184 --> 01:18:36,186
THINGS THAT ARE REAL AND THINGS

2040
01:18:36,186 --> 01:18:37,520
THAT ARE TAVERN AND I BELIEVE

2041
01:18:37,520 --> 01:18:39,489
CONNECTED TO PATIENTS, HAS A LOT

2042
01:18:39,489 --> 01:18:40,390
OF RESONANCE WITH STAFF AND

2043
01:18:40,390 --> 01:18:43,259
MEMBERS FROM WHAT I HAVE SEEN

2044
01:18:43,259 --> 01:18:45,161
OVER THE YEARS I HAVE BEEN

2045
01:18:45,161 --> 01:18:46,796
WORKING AT NCI.

2046
01:18:46,796 --> 01:18:50,934
I DON'T THINK THERE IS A -- I'M

2047
01:18:50,934 --> 01:18:53,236
NOT GOING TO GIVE A DOOMSDAY, A

2048
01:18:53,236 --> 01:18:55,705
FULL-YEAR CR OR STAYING FLAT,

2049
01:18:55,705 --> 01:18:58,775
FLAT IS NOT FLAT.

2050
01:18:58,775 --> 01:19:00,910
EXPENSES CONTINUE AND SO IT IS A

2051
01:19:00,910 --> 01:19:03,813
DECREASE IN RESOURCES.

2052
01:19:03,813 --> 01:19:06,249
BUT I THINK IN SOME WAYS, HAVING

2053
01:19:06,249 --> 01:19:10,753
A SENSE OF THE LONG GAME, CANCER

2054
01:19:10,753 --> 01:19:13,423
RESEARCH TAKES TIME AND WE MAY

2055
01:19:13,423 --> 01:19:15,625
HAVE A YEAR THAT DOESN'T HAVE AS

2056
01:19:15,625 --> 01:19:18,394
MANY OPPORTUNITIES FOR NEW

2057
01:19:18,394 --> 01:19:20,463
STARTS BUT I THINK ONE OF THE

2058
01:19:20,463 --> 01:19:24,334
MOST POWERFUL MESSAGES I HEARD

2059
01:19:24,334 --> 01:19:26,035
SCIENTISTS AND PEOPLE THAT WORK

2060
01:19:26,035 --> 01:19:29,806
IN THEIR LABS AND PATIENTS ON

2061
01:19:29,806 --> 01:19:31,074
CLINICAL TRIALS AND CONGRESS, IS

2062
01:19:31,074 --> 01:19:32,976
AN IDEA THAT STARTS IN THE LAB

2063
01:19:32,976 --> 01:19:36,212
THAT IS DOING VERY BASIC WORK.

2064
01:19:36,212 --> 01:19:39,549
CAN END UP BEING TRANSFORMATIVE

2065
01:19:39,549 --> 01:19:41,518
FOR PATIENTS IN SHORTER AND

2066
01:19:41,518 --> 01:19:46,556
SHORTER INTERVALS AND SOME OF

2067
01:19:46,556 --> 01:19:56,266
THAT IS SO POWERFUL.

2068
01:19:56,266 --> 01:19:57,901
AND THOSE ARE VERY POWERFUL

2069
01:19:57,901 --> 01:19:59,969
EVENTS EACH FOR A JADED CAPITOL

2070
01:19:59,969 --> 01:20:01,671
HILL AUDIENCE, I THINK PEOPLE

2071
01:20:01,671 --> 01:20:03,373
FEEL REALLY GOOD ABOUT

2072
01:20:03,373 --> 01:20:04,641
SUPPORTING CANCER RESEARCH WHEN

2073
01:20:04,641 --> 01:20:09,512
THEY CAN SEE THAT IMPACT.

2074
01:20:09,512 --> 01:20:10,413
>> THANK YOU.

2075
01:20:10,413 --> 01:20:11,948
IT'S ALWAYS SO INFORMATIVE AND

2076
01:20:11,948 --> 01:20:14,817
SO HELPFUL FOR US TO UNDERSTAND

2077
01:20:14,817 --> 01:20:17,153
ABOUT THE PERSPECTIVE AROUND THE

2078
01:20:17,153 --> 01:20:17,687
BUDGET.

2079
01:20:17,687 --> 01:20:20,089
SO, WE'LL MOVE ON TO THE NEXT

2080
01:20:20,089 --> 01:20:21,291
AGENDA ITEMS ITEM, RECOGNITION

2081
01:20:21,291 --> 01:20:25,962
OF RETIRING BOARD MEMBERS.

2082
01:20:25,962 --> 01:20:27,497
THAT WILL BE LED BY DOUG.

2083
01:20:27,497 --> 01:20:29,399
>> THANK YOU, JOHN.

2084
01:20:29,399 --> 01:20:38,141
WE ARE REALLY BLESSED TO HAVE

2085
01:20:38,141 --> 01:20:39,943
AMAZING MEMBERS OF BOTH BOARDS.

2086
01:20:39,943 --> 01:20:41,544
IT'S A BITTER SWEET MOMENT

2087
01:20:41,544 --> 01:20:43,446
BECAUSE YOU CONTRIBUTE SO MUCH

2088
01:20:43,446 --> 01:20:48,117
TO WHAT WE DO.

2089
01:20:48,117 --> 01:20:52,522
BUT OBVIOUSLY DR. FLAHERTY HAS

2090
01:20:52,522 --> 01:20:54,591
BEEN THE LEDDER OF THE BSA AND

2091
01:20:54,591 --> 01:20:57,193
THE HAS DONE AN AMAZING JOB WITH

2092
01:20:57,193 --> 01:21:00,697
THAT POSITION.

2093
01:21:00,697 --> 01:21:02,699
DR. BRAWLEY, TELLING US HIS

2094
01:21:02,699 --> 01:21:04,300
EXPERIENCES, BECAUSE HE HAS SO

2095
01:21:04,300 --> 01:21:07,303
MUCH DIFFERENT KIND OF

2096
01:21:07,303 --> 01:21:09,739
EXPERIENCE.

2097
01:21:09,739 --> 01:21:11,341
DR. KNUDSEN, FIRST AS LEADER OF

2098
01:21:11,341 --> 01:21:14,310
THE JEFFERSON CANCER CENTER AND

2099
01:21:14,310 --> 01:21:20,416
NOW AT ACS AGAIN, WEALTH OF

2100
01:21:20,416 --> 01:21:20,984
EXPERIENCE AND DR. SIDRANSKY

2101
01:21:20,984 --> 01:21:23,019
WITH HIS SPECIAL EXPERTISE IN

2102
01:21:23,019 --> 01:21:28,758
HEAD AND NECK AND OTHER CANCERS.

2103
01:21:28,758 --> 01:21:31,728
DR. SIDRANSKY IS NOT HERE TODAY

2104
01:21:31,728 --> 01:21:34,897
BUT DR. FLAHERTY, BRAWLY AND

2105
01:21:34,897 --> 01:21:37,867
KNUDSEN, ALL WHO HAVE SPOKEN AND

2106
01:21:37,867 --> 01:21:40,169
HAVE BEEN HELPFUL TODAY AND AT

2107
01:21:40,169 --> 01:21:41,671
OTHER TIMES.

2108
01:21:41,671 --> 01:21:43,573
WE REALLY APPRECIATE ALL THAT

2109
01:21:43,573 --> 01:21:48,778
YOU HAVE DONE FOR US AND I'M

2110
01:21:48,778 --> 01:21:50,647
ONLY REGRET THAT THIS HAS TO BE

2111
01:21:50,647 --> 01:21:53,016
A VIRTUAL MEETING RATHER THAN IN

2112
01:21:53,016 --> 01:21:53,249
PERSON.

2113
01:21:53,249 --> 01:21:56,019
THANK YOU.

2114
01:21:56,019 --> 01:21:56,586
>> THANK YOU ALL FOR YOUR

2115
01:21:56,586 --> 01:21:58,121
SERVICE, FOR SURE.

2116
01:21:58,121 --> 01:22:00,990
AND I'M SURE YOU'LL ALL REMAIN

2117
01:22:00,990 --> 01:22:02,792
HIGHLY ENGAGED IN CANCER

2118
01:22:02,792 --> 01:22:03,626
RESEARCH.

2119
01:22:03,626 --> 01:22:07,263
SO THANKS, DOUG.

2120
01:22:07,263 --> 01:22:10,333
SO THE LAST AGENDA ITEM DURING

2121
01:22:10,333 --> 01:22:11,200
THIS SECTION OF THE MEETING WILL

2122
01:22:11,200 --> 01:22:15,071
BE A PRESENTATION, INVESTIGATOR

2123
01:22:15,071 --> 01:22:19,842
ROLE CDK4/6 ACTIVITY DURING CELL

2124
01:22:19,842 --> 01:22:22,645
CYCLE LIVE-CELL IMAGING BY

2125
01:22:22,645 --> 01:22:25,748
STEPHEN CAPPEL WHO IS AN NIH

2126
01:22:25,748 --> 01:22:26,349
INVESTIGATOR WITHIN THE CENTER

2127
01:22:26,349 --> 01:22:32,188
FOR CANCER RESEARCH AT NCI.

2128
01:22:32,188 --> 01:22:33,856
>> THANK YOU FOR THE

2129
01:22:33,856 --> 01:22:34,190
INTRODUCTION.

2130
01:22:34,190 --> 01:22:44,000
I WILL SHARE MY SCREEN.

2131
01:22:44,000 --> 01:22:44,634
SO THANK YOU FOR THE OPPORTUNITY

2132
01:22:44,634 --> 01:22:47,337
TO PRESENT MY LAB'S WORK ON

2133
01:22:47,337 --> 01:22:49,372
UNDERSTANDING THE PRINCIPLES OF

2134
01:22:49,372 --> 01:22:52,942
CELL CYCLE REGULATION.

2135
01:22:52,942 --> 01:22:55,945
IT'S IT'S NEEDED TO REPAIR

2136
01:22:55,945 --> 01:22:58,514
WOUNDS, AND TO MOUND AN

2137
01:22:58,514 --> 01:22:59,716
EFFECTIVE IMMUNE RESPONSE.

2138
01:22:59,716 --> 01:23:01,117
WHEN THIS PROCESS GETS BROKEN IT

2139
01:23:01,117 --> 01:23:03,186
CAN LEAD TO CANCER OR

2140
01:23:03,186 --> 01:23:03,820
DEGENERATIVE DISEASES.

2141
01:23:03,820 --> 01:23:06,055
THE GOALS OF MY LAB AT THE NCI

2142
01:23:06,055 --> 01:23:08,324
ARE TO INVESTIGATE THE

2143
01:23:08,324 --> 01:23:09,625
FUNDAMENTAL MOLECULAR MECHANISM

2144
01:23:09,625 --> 01:23:11,627
THAT REGULAR CELL CYCLE ENTRY

2145
01:23:11,627 --> 01:23:13,296
AND EXIT, TO UNDERSTAND HOW THEY

2146
01:23:13,296 --> 01:23:15,698
GET BROKEN AND CONTRIBUTE TO

2147
01:23:15,698 --> 01:23:18,935
HUMAN DISEASE AND TO HOPEFULLY

2148
01:23:18,935 --> 01:23:20,203
TRANSLATE OUR FINDINGS TO

2149
01:23:20,203 --> 01:23:22,839
DEVELOP NEW OR IMPROVED

2150
01:23:22,839 --> 01:23:32,882
CHEMOTHERAPIES FOR CANCER

2151
01:23:32,882 --> 01:23:34,617
PATIENTS.

2152
01:23:34,617 --> 01:23:35,885
THE CELL CYCLE IS WIDELY KNOWN

2153
01:23:35,885 --> 01:23:37,587
THAT PROPER PROGRESSION IS

2154
01:23:37,587 --> 01:23:39,522
REGULATED BY A SERIES OF

2155
01:23:39,522 --> 01:23:40,823
CHECKPOINTS THAT CONTROL

2156
01:23:40,823 --> 01:23:41,891
PROGRESSION FROM EACH STAGE OF

2157
01:23:41,891 --> 01:23:43,826
THE CELL CYCLE TO THE NEXT.

2158
01:23:43,826 --> 01:23:46,496
THE LAST 20-30 YEARS, A LOT OF

2159
01:23:46,496 --> 01:23:49,365
BIOCHEMICAL AND GENETIC

2160
01:23:49,365 --> 01:23:50,967
APPROACHES HAVE BEEN USED TO

2161
01:23:50,967 --> 01:23:52,402
ELUCIDATE 340 ELECULAR MECHANISM

2162
01:23:52,402 --> 01:23:55,371
THAT APPEAR TO ACCOUNT FOR A LOT

2163
01:23:55,371 --> 01:23:56,572
OF THESE ACCOUNTS.

2164
01:23:56,572 --> 01:23:58,307
NOT SURPRISING THAT MOST OF THE

2165
01:23:58,307 --> 01:24:03,146
CHEMO THERAPEUTIC AND TARGETED

2166
01:24:03,146 --> 01:24:03,746
AGENCY THAT ARE USED IN CANCER

2167
01:24:03,746 --> 01:24:06,582
TREATMENT ARE TARGETING THESE

2168
01:24:06,582 --> 01:24:07,283
CHECKPOINTS.

2169
01:24:07,283 --> 01:24:09,719
BUT ONE OF THE MAIN PROBLEMS IN

2170
01:24:09,719 --> 01:24:12,522
THE CLINIC IS THAT MANY OF THESE

2171
01:24:12,522 --> 01:24:13,456
CHEMOTHERAPEUTICS DESPITE BEING

2172
01:24:13,456 --> 01:24:15,558
VERY SUCCESSFUL IN THE CLINIC,

2173
01:24:15,558 --> 01:24:17,894
OFTEN DON'T WORK EXACTLY AS WE

2174
01:24:17,894 --> 01:24:19,862
PREDICTED BASED ON THESE MODELS.

2175
01:24:19,862 --> 01:24:21,564
FOR EXAMPLE, THERE IS

2176
01:24:21,564 --> 01:24:23,065
HETEROGENOUS RESPONSEES FROM

2177
01:24:23,065 --> 01:24:25,568
CELLS IN THE TUMOR WHERE YOU CAN

2178
01:24:25,568 --> 01:24:26,636
ONLY GET FRACTIONAL KILLING THAT

2179
01:24:26,636 --> 01:24:28,704
CAN LEAD TO REOCCURRENCE OF THE

2180
01:24:28,704 --> 01:24:28,971
TUMOR.

2181
01:24:28,971 --> 01:24:31,774
YOU ALSO GET UNEXPECTED

2182
01:24:31,774 --> 01:24:33,176
COMPENSATORY MECHANISMS THAT CAN

2183
01:24:33,176 --> 01:24:35,311
LEAD TO RESISTANCE.

2184
01:24:35,311 --> 01:24:38,147
AND SO THIS PROBLEM HIGHLIGHTS

2185
01:24:38,147 --> 01:24:41,584
THAT MAYBE THESE MOLECULAR

2186
01:24:41,584 --> 01:24:43,186
MECHANISMS ENSHRINED IN

2187
01:24:43,186 --> 01:24:44,587
TEXTBOOKS AREN'T REALLY GIVING

2188
01:24:44,587 --> 01:24:46,856
US THE PICTURE FOR UNDERSTANDING

2189
01:24:46,856 --> 01:24:48,758
HOW THE CELL CYCLE WORKS.

2190
01:24:48,758 --> 01:24:50,426
ONE OF THE MAIN PROBLEMS

2191
01:24:50,426 --> 01:24:51,661
LIMITING OUR FULL UNDERSTANDING

2192
01:24:51,661 --> 01:24:54,697
OF THESE PROCESSES IS A LOT OF

2193
01:24:54,697 --> 01:24:56,432
THESE MECHANISMS WERE ELUCIDATED

2194
01:24:56,432 --> 01:24:58,167
USING BIOCHEMICAL TECHNIQUES AND

2195
01:24:58,167 --> 01:25:00,536
THESE CHECKPOINTS ARE STUDIED AT

2196
01:25:00,536 --> 01:25:02,038
THE LEVEL OF CELL BIOLOGY.

2197
01:25:02,038 --> 01:25:03,372
ONE OF THE MAJOR CHALLENGES IN

2198
01:25:03,372 --> 01:25:05,775
THE REACH IS HOW TO LINK THESE

2199
01:25:05,775 --> 01:25:07,577
MECHANISMS TO THE CELL

2200
01:25:07,577 --> 01:25:08,945
BIOLOGICAL PROCESSES INVOLVED IN

2201
01:25:08,945 --> 01:25:09,879
THE CELL CYCLE?

2202
01:25:09,879 --> 01:25:12,748
AND SO MY LAB AT THE NCI TRIES

2203
01:25:12,748 --> 01:25:16,619
TO ADDRESS THESE CHALLENGES BY

2204
01:25:16,619 --> 01:25:18,821
ENGINEERING NEW AND USING

2205
01:25:18,821 --> 01:25:22,091
CURRENT FLUORESCENT BIOSENSORS

2206
01:25:22,091 --> 01:25:23,426
FOR THESE ENZYMES IN THE

2207
01:25:23,426 --> 01:25:24,327
PATHWAYS THAT CONTROL

2208
01:25:24,327 --> 01:25:26,028
PROGRESSION THROUGH THE CELL

2209
01:25:26,028 --> 01:25:26,829
CYCLE.

2210
01:25:26,829 --> 01:25:29,332
USING THESE BIOSENSORS, WE CAN

2211
01:25:29,332 --> 01:25:31,801
MONITOR THE ACTIVITY OF THESE

2212
01:25:31,801 --> 01:25:34,337
PATHWAYS IN LIVE SINGLE-CELLS AS

2213
01:25:34,337 --> 01:25:36,472
THEY DYNAMICALLY PROGRESS FROM

2214
01:25:36,472 --> 01:25:37,773
EACH STAGE OF THE CELL CYCLE TO

2215
01:25:37,773 --> 01:25:38,374
THE NEXT.

2216
01:25:38,374 --> 01:25:41,477
AND SO THIS APPROACH ALLOWS US

2217
01:25:41,477 --> 01:25:44,280
TO MEASURE IN THOUSANDS OF CELLS

2218
01:25:44,280 --> 01:25:46,349
AT THE SAME TIME THE ENZYME

2219
01:25:46,349 --> 01:25:48,384
ACTIVITIES THAT ARE KEY FOR CELL

2220
01:25:48,384 --> 01:25:49,685
CYCLE CONTROL.

2221
01:25:49,685 --> 01:25:51,587
THEN WE TREAT THESE CELLS WITH

2222
01:25:51,587 --> 01:25:55,024
SMALL MOLECULE INHIBITORS OR

2223
01:25:55,024 --> 01:25:56,526
THERAPEUTIC AGENTS AND TRY TO

2224
01:25:56,526 --> 01:25:58,060
UNDERSTAND HOW THESE ENZYME

2225
01:25:58,060 --> 01:25:59,962
ACTIVITIES ARE CHANGING

2226
01:25:59,962 --> 01:26:02,899
DYNAMICALLY AND IN REALTIME.

2227
01:26:02,899 --> 01:26:05,768
WE COMBINE WITH AUTOMATED TIME

2228
01:26:05,768 --> 01:26:06,836
LAPSE IMAGING ANALYSIS PIPELINE

2229
01:26:06,836 --> 01:26:09,939
THAT ALLOWS US TO CONVERT THESE

2230
01:26:09,939 --> 01:26:12,341
RAW IMAGES FROM THE MICROSCOPE

2231
01:26:12,341 --> 01:26:14,243
INTO SINGLE CELL TIME SERIES

2232
01:26:14,243 --> 01:26:14,544
DATA.

2233
01:26:14,544 --> 01:26:16,812
THIS GIVES US A QUANTITATIVE AND

2234
01:26:16,812 --> 01:26:18,948
DYNAMIC READ OUT OF THESE

2235
01:26:18,948 --> 01:26:22,752
MOLECULAR MECHANISMS IN CELLS.

2236
01:26:22,752 --> 01:26:24,887
TO GIVE YOU AN IDEA OF HOW THESE

2237
01:26:24,887 --> 01:26:26,155
BIOSENSORS WORK, I CAN EXPLAIN

2238
01:26:26,155 --> 01:26:29,125
HOW ONE OF OUR MAIN BIOSENSORS

2239
01:26:29,125 --> 01:26:29,458
WORK.

2240
01:26:29,458 --> 01:26:33,229
THIS IS FOR PROTEIN CYCLIN

2241
01:26:33,229 --> 01:26:35,398
DEPENDENT KINASE 2, A MAIN

2242
01:26:35,398 --> 01:26:38,467
REGULATOR OF CELL CYCLE

2243
01:26:38,467 --> 01:26:38,834
PROGRESSION.

2244
01:26:38,834 --> 01:26:41,137
CDK2 IS A KINASE AND ONE OF THE

2245
01:26:41,137 --> 01:26:44,774
NO ONE SUBSTRATES OF CDK2 IS DNA

2246
01:26:44,774 --> 01:26:45,741
HELICASE B.

2247
01:26:45,741 --> 01:26:48,277
WE FUSED THE C TERMINIS OF DNA

2248
01:26:48,277 --> 01:26:50,713
HEEL CASE B TO A FLUORESCENT

2249
01:26:50,713 --> 01:26:51,614
PROTEIN.

2250
01:26:51,614 --> 01:26:54,917
AND IN THE C TERMINIS IT HAS

2251
01:26:54,917 --> 01:26:56,619
FOUR POTENTIAL PHOSPHORYLATION

2252
01:26:56,619 --> 01:26:58,354
SITES AS WELL AS NUCLEAR

2253
01:26:58,354 --> 01:27:00,456
LOCALIZATION SEE EXPENSE IS AND

2254
01:27:00,456 --> 01:27:02,124
NUCLEAR EXPORT SEQUENCE.

2255
01:27:02,124 --> 01:27:03,025
IT TURNS OBJECT WHEN THIS

2256
01:27:03,025 --> 01:27:04,527
PEPTIDE IS NOT PHOSPHORYLATED,

2257
01:27:04,527 --> 01:27:07,463
THE NUCLEAR LOCALIZATION

2258
01:27:07,463 --> 01:27:08,264
SEQUENCE DOMINATES AND

2259
01:27:08,264 --> 01:27:10,733
BIOSENSORY SIDES IN THE NUCLEUS.

2260
01:27:10,733 --> 01:27:14,203
WHEN THE KINASE TURNS ON AND

2261
01:27:14,203 --> 01:27:16,205
PHOSPHORYLATES, THE NEGATIVE

2262
01:27:16,205 --> 01:27:18,074
CHARGES TIP THE BALANCE AND THE

2263
01:27:18,074 --> 01:27:21,077
BIOSENSORY GETS EXPORTED INTO

2264
01:27:21,077 --> 01:27:22,979
THE CYTOPLASM.

2265
01:27:22,979 --> 01:27:24,380
SO WE CAN LOOK AT THE

2266
01:27:24,380 --> 01:27:26,782
LOCALIZATION OF THE BEEO SENSOR

2267
01:27:26,782 --> 01:27:27,817
AS IT MOVES FROM THE NUCLEUS

2268
01:27:27,817 --> 01:27:30,286
INTO THE CYTOPLASM AS A READ OUT

2269
01:27:30,286 --> 01:27:32,121
FOR CDK2 ACTIVITY.

2270
01:27:32,121 --> 01:27:36,859
WE CAN QUANTIFY THIS USING IMAGE

2271
01:27:36,859 --> 01:27:37,860
ANALYSIS PINE LINE BY MEASURING

2272
01:27:37,860 --> 01:27:40,930
FLUORESCENCE IN THE CYTOPLASM BY

2273
01:27:40,930 --> 01:27:43,933
TAKING THE RATIO OF THE VALUES

2274
01:27:43,933 --> 01:27:48,838
TO GIVE US A READ OUT OF CDK2

2275
01:27:48,838 --> 01:27:51,440
ACTIVITY.

2276
01:27:51,440 --> 01:27:54,343
I'M SHOW A MOVIE HERE.

2277
01:27:54,343 --> 01:27:56,479
THIS CELL WILL START OUT WITH

2278
01:27:56,479 --> 01:27:57,647
HIGH CDK2 ACTIVITY T WILL GO

2279
01:27:57,647 --> 01:27:59,649
THROUGH MITOSIS WHEN THE

2280
01:27:59,649 --> 01:28:01,250
ACTIVITY RAPIDLY DROPS AND THEN

2281
01:28:01,250 --> 01:28:04,286
CDK2 ACTIVITY WILL SLOWLY RAMP

2282
01:28:04,286 --> 01:28:06,022
UP OVER THE COURSE OF THE CELL

2283
01:28:06,022 --> 01:28:07,657
CYCLE AND THEN REACHES ANOTHER

2284
01:28:07,657 --> 01:28:09,492
MITOSIS AND FALLS AGAIN

2285
01:28:09,492 --> 01:28:12,261
REPEATING THE CYCLE.

2286
01:28:12,261 --> 01:28:14,497
YOU'LL SEE THIS STEREOTYPICAL

2287
01:28:14,497 --> 01:28:15,231
SAW TOOTH PATTERN NORMAL FOR

2288
01:28:15,231 --> 01:28:17,033
PROTEINS THAT ARE REGULATED

2289
01:28:17,033 --> 01:28:18,868
THROUGHOUT THE CELL CYCLE.

2290
01:28:18,868 --> 01:28:20,202
I CAN SHOW YOU THAT CELL AGAIN.

2291
01:28:20,202 --> 01:28:23,005
IT WILL DROP IN MITOSIS.

2292
01:28:23,005 --> 01:28:23,172
WHY.

2293
01:28:23,172 --> 01:28:24,674
DK2 TERPS ON AND WILL RAMP UP

2294
01:28:24,674 --> 01:28:27,243
THROUGHOUT THE CELL CYCLE.

2295
01:28:27,243 --> 01:28:29,045
WE MEASURE MANY CELLS

2296
01:28:29,045 --> 01:28:30,279
SIMULTANEOUSLY AS THEY ARE GOING

2297
01:28:30,279 --> 01:28:31,981
THROUGH THE CELL CYCLE.

2298
01:28:31,981 --> 01:28:34,183
HERE ARE 10 THAT ARE

2299
01:28:34,183 --> 01:28:35,685
HETEROGENOUSLY PROGRESSING

2300
01:28:35,685 --> 01:28:36,419
THROUGH THE CELL CYCLE AT THE

2301
01:28:36,419 --> 01:28:38,120
SAME TIME.

2302
01:28:38,120 --> 01:28:39,922
I HOPE YOU APPRECIATE HOW A

2303
01:28:39,922 --> 01:28:41,023
COMPLICATED MESS LOOKING AT ALL

2304
01:28:41,023 --> 01:28:43,459
10 OF THESE CELLS IS AT A TIME.

2305
01:28:43,459 --> 01:28:44,727
IT'S WORSE WHEN YOU LOOK AT 100

2306
01:28:44,727 --> 01:28:46,128
CELLS.

2307
01:28:46,128 --> 01:28:49,198
YOU SEE THIS HUGE HAIR BALL OF

2308
01:28:49,198 --> 01:28:49,532
HETEROGENEITY.

2309
01:28:49,532 --> 01:28:51,400
WE CAN MAKE SENSE OF THIS

2310
01:28:51,400 --> 01:28:53,302
HETEROGENEITY BY IN SILICO

2311
01:28:53,302 --> 01:28:54,970
SYNCHRONIZING THESE CELLS TO

2312
01:28:54,970 --> 01:28:55,204
MITOSIS.

2313
01:28:55,204 --> 01:28:58,174
WHEN YOU DO THIS, WHAT EMERGES

2314
01:28:58,174 --> 01:29:03,879
FROM THAT HEALTH GENIUS DATA IS

2315
01:29:03,879 --> 01:29:04,513
TWO SUBPOPULATIONS OF CELLS THAT

2316
01:29:04,513 --> 01:29:05,948
BEHAVE QUITE DIFFERENTLY.

2317
01:29:05,948 --> 01:29:08,551
SOME CELLS WILL IMMEDIATELY EXIT

2318
01:29:08,551 --> 01:29:10,753
MITOSIS AND TURN CDK2 ON

2319
01:29:10,753 --> 01:29:12,188
INDICATING THAT I HAVE ENTERED

2320
01:29:12,188 --> 01:29:14,557
THE CELL CYCLE.

2321
01:29:14,557 --> 01:29:23,032
AND SOME SELLS LEAD TURN CDK2

2322
01:29:23,032 --> 01:29:23,199
OFF.

2323
01:29:23,199 --> 01:29:25,434
AND SO THESE BIOSENSOR ARE COOL.

2324
01:29:25,434 --> 01:29:27,236
THEY ALLOW US TO MAKE SENSE OF

2325
01:29:27,236 --> 01:29:29,872
THIS HETEROGENOUS BEHAVIOR AND

2326
01:29:29,872 --> 01:29:32,241
IDENTIFY THE SUB POPULATIONS AND

2327
01:29:32,241 --> 01:29:34,510
ALLOW US TO VISUALIZE WHEN CELLS

2328
01:29:34,510 --> 01:29:36,579
ARE MAKING THESE DECISIONS AND

2329
01:29:36,579 --> 01:29:36,879
TRAPSITIONS.

2330
01:29:36,879 --> 01:29:38,681
YOU CAN SEE AT THE POINT WHEN

2331
01:29:38,681 --> 01:29:40,116
THESE DIFFERENT POPULATIONS

2332
01:29:40,116 --> 01:29:41,984
DIVERGE, THAT'S WHEN THESE CELLS

2333
01:29:41,984 --> 01:29:43,786
WERE MAKING THIS DECISION.

2334
01:29:43,786 --> 01:29:47,490
SO OPENING MY LAB IN 2018, WE

2335
01:29:47,490 --> 01:29:51,227
USED THIS APPROACH TO STUDY

2336
01:29:51,227 --> 01:29:52,695
FUNDAMENTAL PRINCIPLES OF CELL

2337
01:29:52,695 --> 01:29:54,497
CYCLE REGULATION.

2338
01:29:54,497 --> 01:29:59,802
THE G1S CHECKPOINT, CELLS DON'T

2339
01:29:59,802 --> 01:30:03,005
JUST ARREST IN RESPONSE TO DNA

2340
01:30:03,005 --> 01:30:05,708
DAMAGE BUT IN FACT CELLS TAKE

2341
01:30:05,708 --> 01:30:07,143
DIVERGENT PACKS AFTER DNA

2342
01:30:07,143 --> 01:30:07,877
DAMAGE.

2343
01:30:07,877 --> 01:30:08,477
SOME CELLS WILL GO BACKWARDS

2344
01:30:08,477 --> 01:30:09,512
THROUGH THE CELL CYCLE AND

2345
01:30:09,512 --> 01:30:12,281
RETURN TO QUIESCENCE SO THEY CAN

2346
01:30:12,281 --> 01:30:13,649
REPAIR THE DAMAGE.

2347
01:30:13,649 --> 01:30:15,217
OTHER CELLS MOVE FORWARD THROUGH

2348
01:30:15,217 --> 01:30:16,919
THE CYCLE AND ENTER INTO S

2349
01:30:16,919 --> 01:30:17,119
PHASE.

2350
01:30:17,119 --> 01:30:20,389
AND WE THINK THIS IDEA THAT

2351
01:30:20,389 --> 01:30:21,824
CELLS ALL ARRESTED AT THE

2352
01:30:21,824 --> 01:30:24,126
TRANSITION REALLY JUST AN

2353
01:30:24,126 --> 01:30:24,927
ARTIFACT OF BULK CELL ANALYSIS

2354
01:30:24,927 --> 01:30:26,962
WHERE YOU COMBINE THE CELLS WITH

2355
01:30:26,962 --> 01:30:28,531
OPPOSITE PHASE INTO ONE SAMPLE.

2356
01:30:28,531 --> 01:30:30,900
SO LOOKING AT THESE WITH SINGLE

2357
01:30:30,900 --> 01:30:33,869
CELL RESOLUTION IS KEY FOR

2358
01:30:33,869 --> 01:30:34,503
UNDERSTANDING THESE MECHANISMS.

2359
01:30:34,503 --> 01:30:40,109
WE LOOK AT A FORM OF

2360
01:30:40,109 --> 01:30:42,178
IRREVERSIBLE, SINESENCE.

2361
01:30:42,178 --> 01:30:44,914
WE USED A DRUG COMBINATION SHOWN

2362
01:30:44,914 --> 01:30:55,291
TO INDUCE SENESCENCE.

2363
01:31:05,668 --> 01:31:07,837
WE IDENTIFIED A MECHANISM WHERE

2364
01:31:07,837 --> 01:31:10,840
mTOR REGULATES A LIGASE

2365
01:31:10,840 --> 01:31:12,875
CONTROLLING THE CELL CYCLE WHICH

2366
01:31:12,875 --> 01:31:15,878
IN TURN REGULATES GLYCOLYSIS.

2367
01:31:15,878 --> 01:31:16,745
THIS GIVES CELLS A BOOST THEY

2368
01:31:16,745 --> 01:31:18,814
NEED TO GET THROUGH THE FIRST

2369
01:31:18,814 --> 01:31:19,915
CELL CYCLE.

2370
01:31:19,915 --> 01:31:21,784
IN ADDITION TO THESE

2371
01:31:21,784 --> 01:31:23,219
QUESTION-BASED PROJECTS, WE ALSO

2372
01:31:23,219 --> 01:31:24,653
ARE INTERESTED IN TOOL

2373
01:31:24,653 --> 01:31:25,921
DEVELOPMENT THAT CAN BE USED BY

2374
01:31:25,921 --> 01:31:27,623
THE SCIENTIFIC COMMUNITY.

2375
01:31:27,623 --> 01:31:31,126
WE DEVELOPED A NEW BIOSENTENCOR

2376
01:31:31,126 --> 01:31:33,329
FOR THE LIGASE BETA TRCP

2377
01:31:33,329 --> 01:31:34,830
UPREGULATED IN MANY CANCERS AND

2378
01:31:34,830 --> 01:31:36,265
CONSIDERED AN ONCOGENE.

2379
01:31:36,265 --> 01:31:38,801
WE USED THIS BIOSENSOR IN

2380
01:31:38,801 --> 01:31:41,303
COLLABORATION WITH NCATS TO DO

2381
01:31:41,303 --> 01:31:41,937
HIGH-THROUGHPUT SMALL MOLECULE

2382
01:31:41,937 --> 01:31:45,007
SCREENS TO SEE IF WE CAN

2383
01:31:45,007 --> 01:31:46,809
IDENTIFY INHIBITORS THAT COULD

2384
01:31:46,809 --> 01:31:57,186
BE USED IN THE CLINIC.

2385
01:32:00,890 --> 01:32:04,727
SO IN THE 70s AND 80s, IT

2386
01:32:04,727 --> 01:32:06,262
WAS DESCRIBED THE POINT WHEN

2387
01:32:06,262 --> 01:32:07,596
CELLS APPEARED TO BE

2388
01:32:07,596 --> 01:32:09,064
IRREVERSIBLE COMMITTED TO THE

2389
01:32:09,064 --> 01:32:10,099
CELL CYCLE.

2390
01:32:10,099 --> 01:32:11,967
THIS IS THE RESTRICTION POINT.

2391
01:32:11,967 --> 01:32:13,302
THIS MEANS IF A CELL IS BEFORE

2392
01:32:13,302 --> 01:32:15,104
THE RESTRICTION POINT WHEN MIGHT

2393
01:32:15,104 --> 01:32:16,672
JEN SIGNALING IS LOST, THE CELL

2394
01:32:16,672 --> 01:32:19,174
WILL GO QUIESCENT.

2395
01:32:19,174 --> 01:32:20,876
IF A CELL IS AFTER THE

2396
01:32:20,876 --> 01:32:22,044
RESTRICTION POINT WHEN THE

2397
01:32:22,044 --> 01:32:24,179
SIGNALS IS LOST, IT'S THOUGHT TO

2398
01:32:24,179 --> 01:32:27,516
BE IRREVERSIBLY COMMITTED TO THE

2399
01:32:27,516 --> 01:32:29,451
CELL CYCLE AND WILL COMPLETE THE

2400
01:32:29,451 --> 01:32:30,319
CYCLE AND DIVIDE INTO DAUGHTER

2401
01:32:30,319 --> 01:32:31,353
CELLS AND IT'S THE DAUGHTER

2402
01:32:31,353 --> 01:32:34,256
CELLS THAT WILL GO QUIESCENT.

2403
01:32:34,256 --> 01:32:36,091
THE MOLECULAR MECHANISM THOUGHT

2404
01:32:36,091 --> 01:32:37,626
TO UNDERLIE THIS PROCESS HAS

2405
01:32:37,626 --> 01:32:38,928
BEEN WELL CHARACTERIZED OVER THE

2406
01:32:38,928 --> 01:32:40,663
LAST 20-30 YEARS.

2407
01:32:40,663 --> 01:32:44,600
IT INVOLVES A FEED BACK LOOP

2408
01:32:44,600 --> 01:32:46,568
WITH THE TUMOR SUPPRESSOR

2409
01:32:46,568 --> 01:32:47,836
PROTEIN, A FAMILY OF

2410
01:32:47,836 --> 01:32:51,340
TRANSCRIPTION FACTORS AND THE

2411
01:32:51,340 --> 01:32:52,441
AFOREMENTIONED CDK2.

2412
01:32:52,441 --> 01:32:54,677
AND HOW THIS PROCESS WORKS IS

2413
01:32:54,677 --> 01:32:58,213
THAT CDK4 AND 6 ARE REVERSIBLY

2414
01:32:58,213 --> 01:33:01,383
ACTIVATED BY UPSTREAM MAP KINASE

2415
01:33:01,383 --> 01:33:02,217
SIGNALING.

2416
01:33:02,217 --> 01:33:05,387
ONCE CDK4/6 IS ACTIVE IT

2417
01:33:05,387 --> 01:33:07,523
INHIBITS THE RB AND LEADS TO

2418
01:33:07,523 --> 01:33:09,258
TRANSCRIPTIONAL PROGRAM THAT

2419
01:33:09,258 --> 01:33:11,293
ACTIVATES CDK2.

2420
01:33:11,293 --> 01:33:14,029
AND CDK2 ITSELF CAN

2421
01:33:14,029 --> 01:33:15,464
PHOSPHORYLATE THUS COMPLETING

2422
01:33:15,464 --> 01:33:17,032
THE FEEDBACK LOOP.

2423
01:33:17,032 --> 01:33:19,101
ONCE THIS FEEDBACK LOOP IS

2424
01:33:19,101 --> 01:33:21,603
ACTIVE, IT SELF SUSTAINING AND

2425
01:33:21,603 --> 01:33:21,837
ACTIVE.

2426
01:33:21,837 --> 01:33:24,073
THAT'S BECAUSE YOU CAN BLOCK

2427
01:33:24,073 --> 01:33:26,342
UPSTREAM CDK4/6 OR MIGHT JEN

2428
01:33:26,342 --> 01:33:28,777
SIGNALING AND THIS PATHWAY SILL

2429
01:33:28,777 --> 01:33:29,611
REMAINS ACTIVE.

2430
01:33:29,611 --> 01:33:31,380
IT IS IMPORTANT TO NOTE THAT

2431
01:33:31,380 --> 01:33:34,016
THIS MOLECULAR MECHANISM IS THE

2432
01:33:34,016 --> 01:33:36,952
CLINICAL RATIONAL FOR A WIDE

2433
01:33:36,952 --> 01:33:37,586
VARIETY OF TARGETED AGENTS THAT

2434
01:33:37,586 --> 01:33:40,689
ARE USED IN THE CLINIC INCLUDING

2435
01:33:40,689 --> 01:33:44,059
CDK4/6 INHIBITORS, MEK

2436
01:33:44,059 --> 01:33:49,398
INHIBITORS AND TYROSINE KINASE

2437
01:33:49,398 --> 01:33:49,698
INHIBITORS.

2438
01:33:49,698 --> 01:33:51,333
THE POSTDOC IN THE LAB FOUND

2439
01:33:51,333 --> 01:33:54,937
THAT THIS PATHWAY IS NOT IR

2440
01:33:54,937 --> 01:33:55,237
REVERSE IB.

2441
01:33:55,237 --> 01:33:56,171
WE CAN FULLY REVERSE IT AND

2442
01:33:56,171 --> 01:33:59,842
THAT'S BECAUSE CDK4/6 AND MIGHT

2443
01:33:59,842 --> 01:34:00,743
JEN SIGNALING PATHWAYS ARE

2444
01:34:00,743 --> 01:34:02,344
REQUIRED FOR THE ENTIRE CELL

2445
01:34:02,344 --> 01:34:03,178
CYCLE.

2446
01:34:03,178 --> 01:34:05,014
AND BY TREATING WITH INHIBITORS,

2447
01:34:05,014 --> 01:34:06,782
WE CAN FORCE CELLS INTO

2448
01:34:06,782 --> 01:34:08,751
QUIESCENCE FROM ANY POINT IN THE

2449
01:34:08,751 --> 01:34:10,953
CELL CYCLE.

2450
01:34:10,953 --> 01:34:15,090
THIS OBSERVATION WAS USED USING

2451
01:34:15,090 --> 01:34:16,859
LIVE-CELL IMAGING PLATFORM.

2452
01:34:16,859 --> 01:34:19,528
TWO EXAMPLES OF CELLS THAT

2453
01:34:19,528 --> 01:34:20,829
BEHAVE DIFFERENTLY.

2454
01:34:20,829 --> 01:34:23,332
THESE CELLS ARE EXPRESSING CDK

2455
01:34:23,332 --> 01:34:25,534
BIOSENSOR AND APC BIOSENTENCOR

2456
01:34:25,534 --> 01:34:27,503
THAT ALLOWS US TO MONITOR THE

2457
01:34:27,503 --> 01:34:28,971
STATUS OF THIS FEEDBACK LOOP

2458
01:34:28,971 --> 01:34:31,106
THAT IS SUPPOSED TO BE

2459
01:34:31,106 --> 01:34:32,875
UNDERLYING RESTRICTION POINT

2460
01:34:32,875 --> 01:34:33,175
PHENOMENON.

2461
01:34:33,175 --> 01:34:34,410
HERE IS THE CELL T WILL START

2462
01:34:34,410 --> 01:34:38,047
OFF IN G2 PHASE AND GO THROUGH

2463
01:34:38,047 --> 01:34:39,882
MITOSIS AND THANSITION AND THEN

2464
01:34:39,882 --> 01:34:42,785
HITS WITH A CDK4/6 INHIBITOR.

2465
01:34:42,785 --> 01:34:45,687
THIS CELL WILL MAKE IT TO

2466
01:34:45,687 --> 01:34:46,755
MYOSETOSIS AND DIVIDE INTO TWO

2467
01:34:46,755 --> 01:34:48,157
DAUGHTER CELLS AND IT'S THE

2468
01:34:48,157 --> 01:34:49,792
DAUGHTER CELLS THAT HAVE ENTERED

2469
01:34:49,792 --> 01:34:50,959
INTO QUIESCENCE.

2470
01:34:50,959 --> 01:34:53,429
WE KNOW THAT BECAUSE THEY HAVE

2471
01:34:53,429 --> 01:34:58,067
BIOMARKERS FOR QUIESCENCE.

2472
01:34:58,067 --> 01:35:01,470
SO THIS CELL BEHAVED AS YOU

2473
01:35:01,470 --> 01:35:03,138
WOULD PREDICT FROM THE MODEL.

2474
01:35:03,138 --> 01:35:05,641
BUT WE ALSO SEE MANY CELLS THAT

2475
01:35:05,641 --> 01:35:07,776
TAKE A DIFFERENT AND UNEXPECTED

2476
01:35:07,776 --> 01:35:08,777
TRAJECTORY THROUGH THE CELL

2477
01:35:08,777 --> 01:35:08,977
CYCLE.

2478
01:35:08,977 --> 01:35:12,448
SO THIS CELL WILL START OFF VERY

2479
01:35:12,448 --> 01:35:13,082
SIMILAR TO THE OTHER CELL IN G2

2480
01:35:13,082 --> 01:35:15,417
PHASE AND GO THROUGH MITOSIS AND

2481
01:35:15,417 --> 01:35:17,186
THE TRANSITION AND THEN IT WILL

2482
01:35:17,186 --> 01:35:20,022
GET HIT WITH THE CDK64

2483
01:35:20,022 --> 01:35:20,289
INHIBITOR.

2484
01:35:20,289 --> 01:35:22,057
OF THIS CELL DOES SOMETHING

2485
01:35:22,057 --> 01:35:22,324
DIFFERENT.

2486
01:35:22,324 --> 01:35:24,593
RATHER THAN REACH MITOSIS, IT

2487
01:35:24,593 --> 01:35:26,128
SPONTANNUOUSLY LOST THE CDK TWO

2488
01:35:26,128 --> 01:35:28,664
ACTIVITY AND RE-ACTIVATED.

2489
01:35:28,664 --> 01:35:28,831
APC.

2490
01:35:28,831 --> 01:35:33,502
THIS CELL ENTERED A G0 LIKE

2491
01:35:33,502 --> 01:35:33,702
STATE.

2492
01:35:33,702 --> 01:35:35,070
IF YOU JUST LOOK AT THE END OF

2493
01:35:35,070 --> 01:35:37,206
THE MOVIE, BIOCHEMICALLY IT'S

2494
01:35:37,206 --> 01:35:39,108
VERY SIMILAR TO THE OTHER TWO

2495
01:35:39,108 --> 01:35:39,308
CELLS.

2496
01:35:39,308 --> 01:35:43,045
HIGH APC ACTIVITY AND LOW CDK2

2497
01:35:43,045 --> 01:35:43,312
ACTIVITY.

2498
01:35:43,312 --> 01:35:44,480
AND IF WE FIX AND STAIN THESE

2499
01:35:44,480 --> 01:35:47,483
CELLS FOR A THIRD MARKER OF

2500
01:35:47,483 --> 01:35:49,451
QUIESCENCE, WE SEE THAT BOTH

2501
01:35:49,451 --> 01:35:52,421
TRAJECTORIES RESULT IN LOW

2502
01:35:52,421 --> 01:35:52,721
PHOSPHOR B.

2503
01:35:52,721 --> 01:35:56,258
THE CELL THAT TOOK THE WEIRD

2504
01:35:56,258 --> 01:35:56,825
TRAJECTORY THROUGH THE CELL

2505
01:35:56,825 --> 01:35:57,826
CYCLE ENDED UP WEAPON A EXTRA

2506
01:35:57,826 --> 01:36:00,829
COPY OF DNA CONTENT.

2507
01:36:00,829 --> 01:36:02,598
AND THAT'S BECAUSE IT SKIPPED

2508
01:36:02,598 --> 01:36:03,031
MITOSIS.

2509
01:36:03,031 --> 01:36:06,135
AND SO WE WONDERED WHAT SETS THE

2510
01:36:06,135 --> 01:36:08,203
SMALL 10% OF CELLS APART FROM

2511
01:36:08,203 --> 01:36:09,037
THE OTHER CELLS?

2512
01:36:09,037 --> 01:36:11,406
WHY DO THEY TAKE THIS DIFFERENT

2513
01:36:11,406 --> 01:36:12,941
TRAJECTORY AND WHY DIDN'T THEY

2514
01:36:12,941 --> 01:36:16,111
BEHAVE AS EXPECTED BY THE

2515
01:36:16,111 --> 01:36:17,379
RESTRICTION POINT MODEL?

2516
01:36:17,379 --> 01:36:19,114
AND ONE CLUE THAT LED US TO THE

2517
01:36:19,114 --> 01:36:20,048
ANSWER THO THIS QUESTION WAS

2518
01:36:20,048 --> 01:36:22,017
JUST LOOKING AT THE RELATIVE

2519
01:36:22,017 --> 01:36:23,886
TIMING IT TAKES CELLS TO EITHER

2520
01:36:23,886 --> 01:36:27,222
REACH MITOSIS OR EXIT THE CELL

2521
01:36:27,222 --> 01:36:27,589
CYCLE.

2522
01:36:27,589 --> 01:36:30,159
WE DID LIVE-CELL IMAGING

2523
01:36:30,159 --> 01:36:32,361
EXPERIMENTS WHERE WE MEASURED

2524
01:36:32,361 --> 01:36:33,729
CDK2 ACTIVITY AND MEASURED THE

2525
01:36:33,729 --> 01:36:34,963
TIME IT TAKES CELLS TO GO FROM S

2526
01:36:34,963 --> 01:36:36,899
PHASE TO REACH THE NEXT MITOSIS.

2527
01:36:36,899 --> 01:36:39,835
YOU CAN SEE THAT THE MITOSIS

2528
01:36:39,835 --> 01:36:43,071
WHEN YOU SEE THE RAPID DROP IN

2529
01:36:43,071 --> 01:36:44,072
CDK2 ACTIVITY WE COVERED WITH A

2530
01:36:44,072 --> 01:36:44,706
BLACK DOT.

2531
01:36:44,706 --> 01:36:46,241
WE FOUND ON AVERAGE IT TAKES

2532
01:36:46,241 --> 01:36:49,211
CELLS ABOUT 12 HOURS TO REACH

2533
01:36:49,211 --> 01:36:49,444
MITOSIS.

2534
01:36:49,444 --> 01:36:51,747
AND THEN WE TREATED CELLS WITH

2535
01:36:51,747 --> 01:36:54,116
THE CDK4/6 INHIBITOR AND ASKED

2536
01:36:54,116 --> 01:36:55,784
HOW LONG DOES IT TAKE THESE PINK

2537
01:36:55,784 --> 01:36:59,321
CELLS TO LOSE CDK2 ACTIVITY AND

2538
01:36:59,321 --> 01:37:04,426
EXIT THE CELL CYCLE.

2539
01:37:04,426 --> 01:37:06,595
THE TIME OVERLAPPED WITH THE

2540
01:37:06,595 --> 01:37:08,597
TIME IT TOOK THE OTHER CELLS TO

2541
01:37:08,597 --> 01:37:11,400
REACH MITOSIS.

2542
01:37:11,400 --> 01:37:12,201
WE THOUGHT ABOUT THIS PROBLEM

2543
01:37:12,201 --> 01:37:14,136
AND REALIZED THAT THESE TWO

2544
01:37:14,136 --> 01:37:16,838
FATES WE OBSERVED ARE MUTUALLY

2545
01:37:16,838 --> 01:37:17,105
EXCLUSIVE.

2546
01:37:17,105 --> 01:37:19,775
IF YOU EXIT THE CELL CYCLE THEN

2547
01:37:19,775 --> 01:37:21,777
YOU CAN'T BY DEFINITION GO

2548
01:37:21,777 --> 01:37:23,879
THROUGH MITOSIS AND VICE VERSA.

2549
01:37:23,879 --> 01:37:25,647
BECAUSE THESE TWO FATES ARE

2550
01:37:25,647 --> 01:37:27,616
HAPPENING ON VERY SIMILAR TIME

2551
01:37:27,616 --> 01:37:29,751
SCALES, THEY ARE IN COMPETITION

2552
01:37:29,751 --> 01:37:30,252
WITH EACH OTHER.

2553
01:37:30,252 --> 01:37:33,088
SO WE HYPOTHESIZED THAT PERHAPS

2554
01:37:33,088 --> 01:37:34,556
IF WE WERE ABLE TO BLOCK THE

2555
01:37:34,556 --> 01:37:37,960
CELLS FROM UNDERGOING MITOSIS,

2556
01:37:37,960 --> 01:37:40,629
MAYBE WE WOULD OBSERVE ALL CELLS

2557
01:37:40,629 --> 01:37:42,197
EXISTING INTO THIS STATE AND NOT

2558
01:37:42,197 --> 01:37:45,100
JUST THESE FEW OUTLIER CELLS.

2559
01:37:45,100 --> 01:37:46,868
SO TO BLOCK MITOSIS, WE TREATED

2560
01:37:46,868 --> 01:37:49,171
WITH A CDK1 INHIBITOR AND

2561
01:37:49,171 --> 01:37:51,773
COMBINED WITH THE CDK4/6

2562
01:37:51,773 --> 01:37:54,876
INHIBITOR AND NOW ALL CELLS CAN

2563
01:37:54,876 --> 01:37:58,647
EXPECT THE CELL CYCLE INTO THIS

2564
01:37:58,647 --> 01:38:00,449
G0-LIKE STATE AND TAKE THIS

2565
01:38:00,449 --> 01:38:00,816
ALTERNATE PATH.

2566
01:38:00,816 --> 01:38:01,550
IT'S NOT THAT THERE WAS

2567
01:38:01,550 --> 01:38:03,785
SOMETHING BIOCHEMICAL OR

2568
01:38:03,785 --> 01:38:05,621
GENETICALLY DIFFERENT ABOUT

2569
01:38:05,621 --> 01:38:06,822
THESE FEW OUTLIER CELLS, THE

2570
01:38:06,822 --> 01:38:08,490
RELATIVE TIMING BETWEEN EITHER

2571
01:38:08,490 --> 01:38:11,159
EXITING THE CELL CYCLE OR

2572
01:38:11,159 --> 01:38:12,761
MITOSIS THAT DICTATES THE FATE

2573
01:38:12,761 --> 01:38:16,098
OF THESE CELLS.

2574
01:38:16,098 --> 01:38:16,732
MECHANISTICALLY, THE REASON WHY

2575
01:38:16,732 --> 01:38:18,333
THIS ALL IMPORTANT FEEDBACK LOOP

2576
01:38:18,333 --> 01:38:21,503
IS REVERSIBLE IS BECAUSE WE

2577
01:38:21,503 --> 01:38:22,904
FOUND THAT CYCLIN A mRNA IS

2578
01:38:22,904 --> 01:38:26,241
THE UNIQUELY REGULATED BY CDK4/6

2579
01:38:26,241 --> 01:38:28,043
IN THE ENTIRE CELL CYCLE.

2580
01:38:28,043 --> 01:38:30,979
IF YOU TREAT CELLS WITH THE

2581
01:38:30,979 --> 01:38:33,882
CDK4/6 INHIBITOR AND MEASURE

2582
01:38:33,882 --> 01:38:36,551
COMPONENTS, CYCLIN A mRNA WAS

2583
01:38:36,551 --> 01:38:39,955
LOST UPON TREATMENT WITH THE

2584
01:38:39,955 --> 01:38:40,155
DRUG.

2585
01:38:40,155 --> 01:38:41,123
WHILE THE REST OF THE COMPONENTS

2586
01:38:41,123 --> 01:38:42,090
APPEARED TO BE SUSTAINED FOR

2587
01:38:42,090 --> 01:38:44,393
MANY HOURS.

2588
01:38:44,393 --> 01:38:45,961
WE FOUND THAT THIS IS BECAUSE OF

2589
01:38:45,961 --> 01:38:47,095
A NEW SIGNALING COMPONENT TO

2590
01:38:47,095 --> 01:38:49,064
THIS PATHWAY.

2591
01:38:49,064 --> 01:38:51,867
CDK4/6 REGULATES CYCLIN A mRNA

2592
01:38:51,867 --> 01:38:56,438
THROUGH TWO RB-LIKE PROTEINS AND

2593
01:38:56,438 --> 01:39:00,976
A FAMILY OF REPRESS TORY E2Fs.

2594
01:39:00,976 --> 01:39:02,144
AND THIS MEANS THAT WHEN YOU

2595
01:39:02,144 --> 01:39:06,181
TREAT CELLS WITH THE CDK4/6

2596
01:39:06,181 --> 01:39:10,719
INHIBITOR ICYCLIN A mRNA IS

2597
01:39:10,719 --> 01:39:11,953
RAPIDLY LOST AND THESE PROTEINS

2598
01:39:11,953 --> 01:39:13,221
CAN BE MAINTAINED AS LONG AS

2599
01:39:13,221 --> 01:39:14,389
THOSE PROTEINS ARE AROUND

2600
01:39:14,389 --> 01:39:15,590
BECAUSE THEY CAN BE STABLE.

2601
01:39:15,590 --> 01:39:17,759
AND THAT MEANS THAT CDK2 WILL

2602
01:39:17,759 --> 01:39:20,529
STAY ACTIVE AS LONG AS THERE IS

2603
01:39:20,529 --> 01:39:21,496
CYCLIN A PROTEIN AROUND.

2604
01:39:21,496 --> 01:39:22,831
WE WERE ABLE TO SUPPORT THIS BY

2605
01:39:22,831 --> 01:39:25,467
SHOWING A STRONG CORRELATION

2606
01:39:25,467 --> 01:39:27,002
BETWEEN THE HALF-LIFE OF CYCLIN

2607
01:39:27,002 --> 01:39:29,338
A PROTEIN ACROSS DIFFERENT CELL

2608
01:39:29,338 --> 01:39:30,539
LINES AND THE TIME IT TAKES

2609
01:39:30,539 --> 01:39:33,508
CELLS TO EXIT THE CELL CYCLE.

2610
01:39:33,508 --> 01:39:36,011
WE CAN MANIPULATE THIS BY FUSING

2611
01:39:36,011 --> 01:39:40,882
CYCLIN A TO IN -- DESTABILIZE

2612
01:39:40,882 --> 01:39:41,249
IT.

2613
01:39:41,249 --> 01:39:43,318
NOW CELLS EXIT THE CELL CYCLE

2614
01:39:43,318 --> 01:39:45,354
FASTER UPON TREATMENT WITH THE

2615
01:39:45,354 --> 01:39:47,255
CDK4/6 INHIBITOR.

2616
01:39:47,255 --> 01:39:49,725
SO THAT MEANS THAT INSTEAD OF

2617
01:39:49,725 --> 01:39:51,827
THIS RESTRICTION POINT

2618
01:39:51,827 --> 01:39:53,762
PHENOMENON BEING REGULATED BY

2619
01:39:53,762 --> 01:39:55,864
SELF SUSTAINING FEEDBACK LOOK,

2620
01:39:55,864 --> 01:39:57,866
WHAT WE HAVE SHOWN IS THAT THE

2621
01:39:57,866 --> 01:39:59,735
RESTRICTION POINT PHENOMENON IS

2622
01:39:59,735 --> 01:40:01,036
EXPLAINED BY TEMPORAL

2623
01:40:01,036 --> 01:40:04,539
COMPETITION BETWEEN THESE TWO

2624
01:40:04,539 --> 01:40:05,107
MUTUALLY EXCLUSIVE FATES OF

2625
01:40:05,107 --> 01:40:08,076
MITOSIS OR CELL CYCLE EXIT.

2626
01:40:08,076 --> 01:40:09,644
THAT'S BECAUSE CDK4/6 AND

2627
01:40:09,644 --> 01:40:11,747
UPSTREAM SIGNALING IS NEEDED FOR

2628
01:40:11,747 --> 01:40:14,449
THE ENTIRE CELL CYCLE.

2629
01:40:14,449 --> 01:40:17,586
AND THE IMPLICATIONS OF THIS ARE

2630
01:40:17,586 --> 01:40:21,523
THAT INHIBITING CDK ACTIVITY CAN

2631
01:40:21,523 --> 01:40:25,160
SEND CELLS TO THIS G0-LIKE

2632
01:40:25,160 --> 01:40:25,794
STAYED WHERE THEY HAVE AN EXTRA

2633
01:40:25,794 --> 01:40:26,895
COPY OF DNA.

2634
01:40:26,895 --> 01:40:29,131
WE THINK THAT THIS STUDY REALLY

2635
01:40:29,131 --> 01:40:31,466
ANSWERS A LONG-STANDING

2636
01:40:31,466 --> 01:40:32,834
DECADES-OLD PROBLEM OF THE

2637
01:40:32,834 --> 01:40:34,503
RESTRICTION POINT PHENOMENON BUT

2638
01:40:34,503 --> 01:40:36,204
I THINK THESE FINDINGS GO BEYOND

2639
01:40:36,204 --> 01:40:38,673
JUST OUR BASIC UNDERSTANDING OF

2640
01:40:38,673 --> 01:40:40,275
CELL BIOLOGY.

2641
01:40:40,275 --> 01:40:44,212
GIVEN THE CLINICAL USE OF CDK

2642
01:40:44,212 --> 01:40:46,047
INHIBITORS IN THE CLINICAL

2643
01:40:46,047 --> 01:40:47,783
TRIALS, WE THINK THAT THIS STUDY

2644
01:40:47,783 --> 01:40:49,317
HAS BROAD IMPLICATIONS.

2645
01:40:49,317 --> 01:40:50,485
THAT'S WHAT WE ARE TAKING THIS

2646
01:40:50,485 --> 01:40:51,486
NOW IN THE FUTURE.

2647
01:40:51,486 --> 01:40:54,289
WE ARE STARTING TO UNDERSTAND

2648
01:40:54,289 --> 01:40:56,258
HOW THESE -- HOW NEW MECHANISM

2649
01:40:56,258 --> 01:40:59,795
MIGHT BE WORKING IN ALL ANIMALS

2650
01:40:59,795 --> 01:41:00,862
AND IN THE CLINIC.

2651
01:41:00,862 --> 01:41:03,698
SO FOR EXAMPLE, CDK4/6

2652
01:41:03,698 --> 01:41:05,000
INHIBITORS ARE USED IN THE

2653
01:41:05,000 --> 01:41:06,368
CLINIC BECAUSE THEY ARE THE

2654
01:41:06,368 --> 01:41:09,371
FRONT-LINE THERAPY FOR HORMONE

2655
01:41:09,371 --> 01:41:11,006
RECEPTIVE POSITIVE BREAST CANCER

2656
01:41:11,006 --> 01:41:13,508
AND CLINICAL TRIALS FOR OTHER

2657
01:41:13,508 --> 01:41:15,744
CANCER TYPES, OF.

2658
01:41:15,744 --> 01:41:18,313
IN ADDITION CDK TWO INHIBITORS

2659
01:41:18,313 --> 01:41:19,548
ARE IN DEVELOPMENT BY A NUMBER

2660
01:41:19,548 --> 01:41:21,116
OF PHARMACEUTICAL COMPANIES TO

2661
01:41:21,116 --> 01:41:23,051
BEIDES ALONE OR IN COMBINATION

2662
01:41:23,051 --> 01:41:25,887
WITH CDK4/6 INHIBITORS.

2663
01:41:25,887 --> 01:41:30,292
BECAUSE WE HAVE SHOWN DRUGS CAN

2664
01:41:30,292 --> 01:41:33,562
INDUCE THIS PATH, IT'S CRITICAL

2665
01:41:33,562 --> 01:41:34,996
TO UNDERSTAND WHAT THE LONG-TERM

2666
01:41:34,996 --> 01:41:37,265
CONSEQUENCES OF CELLS IN THIS

2667
01:41:37,265 --> 01:41:38,300
STATE ARE.

2668
01:41:38,300 --> 01:41:39,968
FOR EXAMPLE, WHAT HAPPENS WHEN

2669
01:41:39,968 --> 01:41:41,036
YOU PUTTER THESE CELLS IN DRUG

2670
01:41:41,036 --> 01:41:41,303
HOLIDAYS?

2671
01:41:41,303 --> 01:41:45,173
YOU STOP GIVING THEM THE DRUGS.

2672
01:41:45,173 --> 01:41:45,540
WILL THEISMS RE.

2673
01:41:45,540 --> 01:41:46,842
THE CELL CYCLE?

2674
01:41:46,842 --> 01:41:50,879
IF THEY DO, WHAT PATH WILL THEY

2675
01:41:50,879 --> 01:41:51,313
TAKE?

2676
01:41:51,313 --> 01:41:52,981
WILL THEISMS THAT EXITED FROM G2

2677
01:41:52,981 --> 01:41:53,815
REMEMBER THAT'S WHERE THEY USED

2678
01:41:53,815 --> 01:41:55,984
TO BE IN THE CELL CYCLE AND

2679
01:41:55,984 --> 01:41:57,552
REENTER THE CELL CYCLE FROM G2

2680
01:41:57,552 --> 01:41:58,119
PHASE?

2681
01:41:58,119 --> 01:41:59,754
OR WILL THESE CELLS THINK THEY

2682
01:41:59,754 --> 01:42:02,491
ARE REALLY A G0 CELL AND REENTER

2683
01:42:02,491 --> 01:42:04,693
THE CELL CYCLE IN G1 PHASE?

2684
01:42:04,693 --> 01:42:06,294
WE ARE DOING PRELIMINARY STUDIES

2685
01:42:06,294 --> 01:42:08,730
WITH THIS BY TREATING WITH CDK

2686
01:42:08,730 --> 01:42:10,866
INHIBITORS AND WASHING THEM OFF.

2687
01:42:10,866 --> 01:42:14,636
OUR PRELIMINARY RESULTS GIVE US

2688
01:42:14,636 --> 01:42:16,905
A QUITE CLEAR ANSWER TO THIS

2689
01:42:16,905 --> 01:42:17,172
QUESTION.

2690
01:42:17,172 --> 01:42:18,173
WHEN YOU TREAT WITH THE DRUGS

2691
01:42:18,173 --> 01:42:20,775
THEY GO INTO A G0-LIKE STATE.

2692
01:42:20,775 --> 01:42:23,278
WHEN YOU WASH THEM OFF, THE

2693
01:42:23,278 --> 01:42:25,247
CELLS REENTER THE CELL CYCLE IN

2694
01:42:25,247 --> 01:42:26,481
G1 PHASE AND THEY'LL GO THROUGH

2695
01:42:26,481 --> 01:42:28,917
ANOTHER ROUND OF DNA SYNTHESIS

2696
01:42:28,917 --> 01:42:32,821
AND THEY END UP WITH 8 END DNA

2697
01:42:32,821 --> 01:42:34,656
CONTENT, THEY HAVE GONE THROUGH

2698
01:42:34,656 --> 01:42:36,558
A WHOLE GENOME DUPLICATION.

2699
01:42:36,558 --> 01:42:38,426
THEY WILL UNDERGO ANOTHER

2700
01:42:38,426 --> 01:42:40,929
MITOSIS AND IF WE WATCH THEM,

2701
01:42:40,929 --> 01:42:43,665
THEY'LL DIVIDE INTO FOUR

2702
01:42:43,665 --> 01:42:44,032
DAUGHTER CELLS.

2703
01:42:44,032 --> 01:42:45,734
AND IF WE GROW THEISMS FOR LONG

2704
01:42:45,734 --> 01:42:48,069
PERIOD OF TIME, WE SEE A

2705
01:42:48,069 --> 01:42:50,171
TREATMENT PLUS WASHING OFF THE

2706
01:42:50,171 --> 01:42:54,042
DRUGS INDUCES A HUGE VARIETY OF

2707
01:42:54,042 --> 01:42:55,076
DIFFERENT TYPES OF ANEUPLOIDY

2708
01:42:55,076 --> 01:42:56,545
WHICH COULD HAVE DRASTIC

2709
01:42:56,545 --> 01:42:57,979
CONSEQUENCES FOR THE CANCER

2710
01:42:57,979 --> 01:43:00,282
CELLS BEING TREATED AND

2711
01:43:00,282 --> 01:43:01,550
POTENTIALLY FOR NORMAL

2712
01:43:01,550 --> 01:43:02,684
PROLIFERATIVE CELLS AND

2713
01:43:02,684 --> 01:43:03,885
DIFFERENT TISSUES IN THE BODY.

2714
01:43:03,885 --> 01:43:06,121
SO OUR FUTURE STUDIES WILL BE TO

2715
01:43:06,121 --> 01:43:07,722
INVESTIGATE THIS FURTHER.

2716
01:43:07,722 --> 01:43:09,991
I THINK IT'S DEMONSTRATE HOW

2717
01:43:09,991 --> 01:43:13,161
REALLY A BASIC BIOLOGICAL

2718
01:43:13,161 --> 01:43:15,330
QUESTION CAN TRANSLATE AND HAVE

2719
01:43:15,330 --> 01:43:18,166
IMPORTANT CLINICAL IMPLICATIONS.

2720
01:43:18,166 --> 01:43:20,368
WITH THAT, I'D LIKE TO THANK MY

2721
01:43:20,368 --> 01:43:21,970
TEAM HERE AT THE NCI.

2722
01:43:21,970 --> 01:43:24,839
WE ARE RELATIVELY SMALL TEAM BUT

2723
01:43:24,839 --> 01:43:27,409
THROUGH HARD WORK AND DEDICATION

2724
01:43:27,409 --> 01:43:27,976
THEY HAVE BEEN PRODUCTIVE.

2725
01:43:27,976 --> 01:43:30,145
AND ALSO WE HAD A NUMBER OF

2726
01:43:30,145 --> 01:43:32,681
COLLABORATIONS BOTH WITHIN THE

2727
01:43:32,681 --> 01:43:34,749
NIH AND OUTSIDE OF THE NIH.

2728
01:43:34,749 --> 01:43:37,252
AND I THANK YOU FOR YOUR

2729
01:43:37,252 --> 01:43:37,886
ATTENTION AND I'M HAPPY TO TAKE

2730
01:43:37,886 --> 01:43:41,122
ANY QUESTIONS.

2731
01:43:41,122 --> 01:43:44,626
>> BEAUTIFUL WORK,
STEPHEN.

2732
01:43:44,626 --> 01:43:47,963
I THINK YOU HAVE YOUR HAND UP.

2733
01:43:47,963 --> 01:43:52,167
>> I'M LOOKING FOR THE THE
HAND.

2734
01:43:52,167 --> 01:43:52,834
THANK YOU.

2735
01:43:52,834 --> 01:43:55,170
STEPHEN, GREAT TALK.

2736
01:43:55,170 --> 01:43:57,238
I WONDER IF YOU COULD COMMENT ON

2737
01:43:57,238 --> 01:43:59,808
IMPLICATIONS FOR DEVELOPMENT OF

2738
01:43:59,808 --> 01:44:01,776
PAL BOW RESISTANCE?

2739
01:44:01,776 --> 01:44:03,678
IT SEEMS LIKE MAYBE THERE COULD

2740
01:44:03,678 --> 01:44:06,715
NOW BE ANOTHER PATHWAY IN

2741
01:44:06,715 --> 01:44:08,516
CHUCKED DEVELOP RESISTANT

2742
01:44:08,516 --> 01:44:11,486
MUTATIONS THAT'S NOT, RB RELATED

2743
01:44:11,486 --> 01:44:12,554
OR MYC RELATED.

2744
01:44:12,554 --> 01:44:17,325
BUT IT'S A G2 RELATED, SG2

2745
01:44:17,325 --> 01:44:20,128
RELATED PATHWAY --

2746
01:44:20,128 --> 01:44:21,029
>> FOR SURE.

2747
01:44:21,029 --> 01:44:22,097
THAT'S WHAT WE ARE THINKING

2748
01:44:22,097 --> 01:44:23,098
ABOUT NOW.

2749
01:44:23,098 --> 01:44:24,332
WITH THESE DRUG WASH OFF

2750
01:44:24,332 --> 01:44:24,633
EXPERIMENT.

2751
01:44:24,633 --> 01:44:30,005
BECAUSE IT INDUCES ANDYPLOYEDY.

2752
01:44:30,005 --> 01:44:30,605
YOU'RE SHUFFLING OFF THE GENES

2753
01:44:30,605 --> 01:44:33,508
OF THESE CELLS AND MAYBE THAT

2754
01:44:33,508 --> 01:44:36,144
COULD LEAD TO SOME SMALL

2755
01:44:36,144 --> 01:44:38,647
POPULATION WHERE EVEN MYC IS UP

2756
01:44:38,647 --> 01:44:38,913
REGULATED.

2757
01:44:38,913 --> 01:44:40,515
THAT COULD BE THE GENETIC

2758
01:44:40,515 --> 01:44:43,685
PERTBAITION THAT LEADS TO THESE

2759
01:44:43,685 --> 01:44:47,989
RESISTANCE MECHANISMS T.

2760
01:44:47,989 --> 01:44:48,289
>> KARIN?

2761
01:44:48,289 --> 01:44:49,724
>> I HAD A VERY SIMILAR
QUESTION

2762
01:44:49,724 --> 01:45:00,435
BUT I ALSO WONDER IF YOU MIGHT E

2763
01:45:22,757 --> 01:45:26,594
BEAUTIFUL BUT A COLLABORATION

2764
01:45:26,594 --> 01:45:27,128
WHERE WE MIGHT BE ABLE TO

2765
01:45:27,128 --> 01:45:28,963
FURTHER UNDERSTAND HOW THESE

2766
01:45:28,963 --> 01:45:31,299
PATHWAYS ARE BEING TWEAKED IN

2767
01:45:31,299 --> 01:45:32,867
THE RESISTANCE MODELS THAT

2768
01:45:32,867 --> 01:45:34,135
ALREADY DEVELOPED, COULD BE

2769
01:45:34,135 --> 01:45:34,436
INTERESTING.

2770
01:45:34,436 --> 01:45:36,604
>> WE ARE TRYING TO REACH
OUT TO

2771
01:45:36,604 --> 01:45:39,441
FIND CLINICAL SAMPLES OR LAB

2772
01:45:39,441 --> 01:45:42,110
THAT IS HAVE PATIENT DATA TO SEE

2773
01:45:42,110 --> 01:45:43,378
IF SOME OF THE STUFF THEY ARE

2774
01:45:43,378 --> 01:45:47,916
SEEISEEING IS MATCH WHAT WE ARE

2775
01:45:47,916 --> 01:45:50,118
SEEING AS WELL.

2776
01:45:50,118 --> 01:45:51,786
>> SO WHAT ARE THE
IMPLICATIONS

2777
01:45:51,786 --> 01:45:55,190
TO MY TO THETIC CATASTROPHE AND

2778
01:45:55,190 --> 01:45:56,991
STANDARD CHEMO TREATMENT?

2779
01:45:56,991 --> 01:45:59,994
IS THIS A POTENTIAL MECHANISM OF

2780
01:45:59,994 --> 01:46:03,031
RESISTANCE FOR CHEMO?

2781
01:46:03,031 --> 01:46:04,265
ESPECIALLY DNA DAMAGING AGENTS?

2782
01:46:04,265 --> 01:46:06,401
>> WE PLAYED AROUND A LOT
WITH

2783
01:46:06,401 --> 01:46:08,636
DNA DAMAGE AND THAT'S HOW THIS

2784
01:46:08,636 --> 01:46:09,003
PROJECT STARTED.

2785
01:46:09,003 --> 01:46:11,840
WE WERE INDUCING DNA DAMAGE AND

2786
01:46:11,840 --> 01:46:13,808
SEEN THIS EXACT SAME TRAJECTORY.

2787
01:46:13,808 --> 01:46:15,210
AND WE THOUGHT IT HAD SOMETHING

2788
01:46:15,210 --> 01:46:17,245
TO DO WITH DNA DAMAGE.

2789
01:46:17,245 --> 01:46:18,546
WE STARTED INVESTIGATING ALL

2790
01:46:18,546 --> 01:46:19,748
THESE PATHWAYS.

2791
01:46:19,748 --> 01:46:22,083
AND THEN WE REALIZED THAT WHAT

2792
01:46:22,083 --> 01:46:23,918
DNA DAMAGE WAS DOING WAS

2793
01:46:23,918 --> 01:46:26,488
TRIGGERING THE G2M CHECKPOINT

2794
01:46:26,488 --> 01:46:28,223
AND IT WAS DELAYING THE TIME TO

2795
01:46:28,223 --> 01:46:29,991
REACH MITOSIS.

2796
01:46:29,991 --> 01:46:31,493
AND THAT'S WHEN WE STARTED

2797
01:46:31,493 --> 01:46:33,428
SAYING, IF THAT'S THE CASE, THEN

2798
01:46:33,428 --> 01:46:34,829
WE SHOULD BE ABLE TO REPEAT THE

2799
01:46:34,829 --> 01:46:36,865
PHENOTYPE WITH THE CDK1

2800
01:46:36,865 --> 01:46:39,868
INHIBITOR WHEN WE COMBINED WITH
THE CDK4/6 INHIBITOR.

2801
01:46:39,868 --> 01:46:42,971
COMBINING DNA DAMAGE AND THE
CDK4/6 INHIBITOR COULD BE

2802
01:46:42,971 --> 01:46:45,907
INDUCING THIS ALTERNATE
TRAJECTORY THROUGH THE CELL

2803
01:46:45,907 --> 01:46:46,964
CYCLE QUITE A BIT.

2804
01:46:46,964 --> 01:46:48,299
THERE IS SOME INTERESTING

2805
01:46:48,299 --> 01:46:51,802
FINDINGS IN OUR SINGLE-CELL

2806
01:46:51,802 --> 01:46:52,803
WHOLE GENOME OVARIAN CANCER WORK

2807
01:46:52,803 --> 01:46:53,871
THAT TIES INTO THIS.

2808
01:46:53,871 --> 01:46:56,507
I CAN'T WAIT TO SEE THIS COME

2809
01:46:56,507 --> 01:47:00,344
OUT IN THE LITERATURE.

2810
01:47:00,344 --> 01:47:03,214
GOOD WORK.

2811
01:47:03,214 --> 01:47:07,718
ANY ADDITIONAL QUESTIONS FOR

2812
01:47:07,718 --> 01:47:12,456
STEPHEN BEFORE WE BREAK?

2813
01:47:12,456 --> 01:47:15,326
IF NOT, WELL, THANK YOU VERY

2814
01:47:15,326 --> 01:47:15,860
MUCH.

2815
01:47:15,860 --> 01:47:16,494
CONGRATULATIONS, BEAUTIFUL WORK

2816
01:47:16,494 --> 01:47:18,796
AND AGAIN WE LOOK FORWARD TO

2817
01:47:18,796 --> 01:47:24,702
SEEING ADVANCES IN THIS AREA.

2818
01:47:24,702 --> 01:47:26,003
THANKS.

2819
01:47:26,003 --> 01:47:28,939
OKAY, SO, WE MADE UP A COUPLE OF

2820
01:47:28,939 --> 01:47:30,107
MINUTES HERE.

2821
01:47:30,107 --> 01:47:32,777
SO WE'LL NOW TAKE A BREAK.

2822
01:47:32,777 --> 01:47:35,446
DO NOT DISCONNECT.

2823
01:47:35,446 --> 01:47:37,014
CLOSE YOUR VIDEOS AND MUTE YOUR

2824
01:47:37,014 --> 01:47:38,883
MICS IF YOU WOULD LIKE.

2825
01:47:38,883 --> 01:47:41,385
THE FOLKS IN THE VIRTUAL TABLE,

2826
01:47:41,385 --> 01:47:44,255
DOUG, DEAN AND JIM AND THE BOARD

2827
01:47:44,255 --> 01:47:47,191
MEMBERS, TAKE AN EIGHT MINUTE

2828
01:47:47,191 --> 01:47:48,292
BREAK AND RETURN IN 10 MINUTES

2829
01:47:48,292 --> 01:47:50,394
AFTER THE HOUR.

2830
01:47:50,394 --> 01:47:53,431
TURN YOUR VIDEO CAMERAS BACK ON.

2831
01:47:53,431 --> 01:47:54,198
ALL OTHERS SHOULD RETURNED AT

2832
01:47:54,198 --> 01:47:58,836
ROUGHLY 20 MINUTES AFTER SO WE

2833
01:47:58,836 --> 01:48:00,971
CAN -- SO THAT KEITH CAN BEGIN

2834
01:48:00,971 --> 01:48:02,339
PROMPTLY AT 25 AFTER THE HOUR.

2835
01:48:02,339 --> 01:48:04,742
SO VIRTUAL TABLE, DOUG, DEANA

2836
01:48:04,742 --> 01:48:06,510
AND JIM AND THE BOARD MEMBERS

2837
01:48:06,510 --> 01:48:07,845
TAKE ABOUT A 7-MINUTE BREAK AND

2838
01:48:07,845 --> 01:49:11,609
RETURN AT 10 MINUTES AFTER THE
HOUR.

2839
01:49:11,609 --> 01:49:12,910
>> I'LL BE ASKING YOU TO
RAISE

2840
01:49:12,910 --> 01:49:17,348
YOUR HAND OR STRAIGHT YOUR NAME

2841
01:49:17,348 --> 01:49:19,884
TO INDICATE DISAPPROVAL OR NON

2842
01:49:19,884 --> 01:49:21,719
CONCURRENCE SO PAULET CAN COUNT

2843
01:49:21,719 --> 01:49:26,724
AND RECORD THE VOTE.

2844
01:49:26,724 --> 01:49:31,496
WE HAVE A NEW RFP.

2845
01:49:31,496 --> 01:49:33,464
DR. DAN WILL BE THE PRESENTER.

2846
01:49:33,464 --> 01:49:35,800
THIS SUBCOMMITTEE IS CHAIRED BY

2847
01:49:35,800 --> 01:49:39,070
NELSON AND SUPPORTED BY NELLY

2848
01:49:39,070 --> 01:49:39,704
AND RICH ZELLER.

2849
01:49:39,704 --> 01:49:43,541
SO WITH THAT, DR. ZI, TAKE IT

2850
01:49:43,541 --> 01:49:43,741
AWAY.

2851
01:49:43,741 --> 01:49:48,312
>> THANK YOU FOR THE
OPPORTUNITY

2852
01:49:48,312 --> 01:49:50,314
TO PRESENT THIS NEW DON

2853
01:49:50,314 --> 01:49:51,015
SEPTEMBER.

2854
01:49:51,015 --> 01:49:54,352
MICROBIOME TARGETED INTERVENTION

2855
01:49:54,352 --> 01:49:58,656
TO CANCER NETWORK.

2856
01:49:58,656 --> 01:50:01,292
ON BEHALF OF THE WORKING GROUP.

2857
01:50:01,292 --> 01:50:07,331
THIS CONCEPT IS SPONSORED BY THE

2858
01:50:07,331 --> 01:50:08,065
DCTD.

2859
01:50:08,065 --> 01:50:10,568
NEXT SLIDE.

2860
01:50:10,568 --> 01:50:12,036
THE RESEARCH AND HUMAN STUDIES

2861
01:50:12,036 --> 01:50:16,240
SHOW THE MICROBIOME CAN MODULATE

2862
01:50:16,240 --> 01:50:17,475
THE CANCER CELL.

2863
01:50:17,475 --> 01:50:19,277
SO THIS CONCEPT WILL BE FOCUSING

2864
01:50:19,277 --> 01:50:28,953
ON THE CLINICAL RESEARCH OF THE

2865
01:50:28,953 --> 01:50:32,423
FECAL MICROBIOTA WITH

2866
01:50:32,423 --> 01:50:32,890
IMMUNOTHERAPY.

2867
01:50:32,890 --> 01:50:34,692
THE HIGHLIGHT OF THE CHALLENGES,

2868
01:50:34,692 --> 01:50:38,796
PHASE I AND PHASE II CLINICAL

2869
01:50:38,796 --> 01:50:41,199
TRIAL UNDERWAY IN THE U.S. AND

2870
01:50:41,199 --> 01:50:42,967
INTERNATIONALLY WITH THE VARIOUS

2871
01:50:42,967 --> 01:50:43,267
DESIGN.

2872
01:50:43,267 --> 01:50:46,571
BUT LACK OF THE COORDINATION.

2873
01:50:46,571 --> 01:50:51,175
FOR THE FMT, LONG TERM SAFETY

2874
01:50:51,175 --> 01:50:53,945
AND THE PATIENT STRATIFICATION.

2875
01:50:53,945 --> 01:51:01,586
FOR THE MICROBIAL CONSORTIUM,

2876
01:51:01,586 --> 01:51:03,688
FOR SELECTIONS, BENEFICIAL

2877
01:51:03,688 --> 01:51:09,994
BACTERIA SPECIES CULMINATE WITH

2878
01:51:09,994 --> 01:51:10,595
THERAPEUTIC OUTCOME DIFFERENT

2879
01:51:10,595 --> 01:51:11,329
AMONG THE LABS AND COHORTS.

2880
01:51:11,329 --> 01:51:13,197
THE OPPORTUNITIES AND CLINICAL

2881
01:51:13,197 --> 01:51:17,568
AND PILOT FMT TILES SHOWED THE

2882
01:51:17,568 --> 01:51:20,771
RESULT OF THE SAFETY AND

2883
01:51:20,771 --> 01:51:26,444
IMPROVED IMMUNOTHERAPY RESPONSE

2884
01:51:26,444 --> 01:51:31,048
AND TOXICITY.

2885
01:51:31,048 --> 01:51:35,119
CLINICAL TRIAL NEED TO BUILD

2886
01:51:35,119 --> 01:51:39,657
FECAL MICROBIOME FOR THERAPY AND

2887
01:51:39,657 --> 01:51:43,895
THE REGISTRY IS LONG TERM SAFETY

2888
01:51:43,895 --> 01:51:46,130
NEEDED FOR THE RESEARCH FOR

2889
01:51:46,130 --> 01:51:48,032
VARIABLES.

2890
01:51:48,032 --> 01:51:57,742
NEXT SLIDE.

2891
01:51:57,742 --> 01:52:02,446
SO THESE ARE THE ONLY CANCER

2892
01:52:02,446 --> 01:52:05,249
THERAPEUTIC CLINICAL TRIALS.

2893
01:52:05,249 --> 01:52:07,685
THEY PUBLISHED ENCOURAGING

2894
01:52:07,685 --> 01:52:12,523
RESULT IN THE 2021 OF THE FIRST

2895
01:52:12,523 --> 01:52:19,897
IN-HUMAN PILOT TRIAL TO IMPROVE

2896
01:52:19,897 --> 01:52:20,831
RESPONSE.

2897
01:52:20,831 --> 01:52:23,034
SO THE GAP AND THE NEED.

2898
01:52:23,034 --> 01:52:25,903
THE LACK OF THE CLINICAL TRIAL,

2899
01:52:25,903 --> 01:52:29,106
THE ASSAY AND MICROBIOME'S

2900
01:52:29,106 --> 01:52:34,545
MEASUREMENT AND DATA ANALYSIS.

2901
01:52:34,545 --> 01:52:44,722
AND THE MOST CORRELATIVE

2902
01:52:44,722 --> 01:52:50,561
ANALYSIS T TESTING IN THE MICE

2903
01:52:50,561 --> 01:52:52,797
AND FMT.

2904
01:52:52,797 --> 01:52:54,865
THE LIMITATION OF THE

2905
01:52:54,865 --> 01:52:58,436
PRE-CLINICAL MODELS AND CLINICAL

2906
01:52:58,436 --> 01:52:58,669
CENTER.

2907
01:52:58,669 --> 01:53:04,008
FOR THE NCI, NEEDS TO STIMULATE,

2908
01:53:04,008 --> 01:53:06,677
COORDINATE THE CLINICAL TESTING

2909
01:53:06,677 --> 01:53:10,915
OF CAUSAL EFFECT OF MICROBIOME

2910
01:53:10,915 --> 01:53:14,385
ON CANCER THERAPY AND STUDYING

2911
01:53:14,385 --> 01:53:17,788
RELEVANT MECHANISMS.

2912
01:53:17,788 --> 01:53:19,490
ENSURE PROPER DIVERSITY IN THE

2913
01:53:19,490 --> 01:53:23,694
HUMAN MICROBIOME RESEARCH.

2914
01:53:23,694 --> 01:53:24,295
COORDINATE THE STANDARDIZATION

2915
01:53:24,295 --> 01:53:28,299
AND STUDY VARIABLES.

2916
01:53:28,299 --> 01:53:32,770
NEXT SLIDE.

2917
01:53:32,770 --> 01:53:34,939
THE PURCHASE OF THIS RFA AND

2918
01:53:34,939 --> 01:53:38,743
RFP -- PURPOSE -- TO TIMELY

2919
01:53:38,743 --> 01:53:42,813
EARLY STAGE CLINICAL TESTING OF

2920
01:53:42,813 --> 01:53:45,483
MICROBIOME TARGET CANCER

2921
01:53:45,483 --> 01:53:47,985
INTERVENTION TO IMPROVE

2922
01:53:47,985 --> 01:53:51,756
IMMUNOTHERAPY IN MICROBIOME

2923
01:53:51,756 --> 01:54:02,299
INTERVENTION CANCER NETWORK AND

2924
01:54:03,167 --> 01:54:08,773
THE CLINICAL CENTER AND CLINICAL

2925
01:54:08,773 --> 01:54:10,207
NETWORK CENTER.

2926
01:54:10,207 --> 01:54:13,444
SO OVERALL GOALS.

2927
01:54:13,444 --> 01:54:16,147
U19 TO DEVELOP OPTIMAL FMT OR

2928
01:54:16,147 --> 01:54:18,349
DEFINE MICROBIAL CONSORTIA FOR

2929
01:54:18,349 --> 01:54:20,451
EARLY PHASE OF CLINICAL TRIAL OF

2930
01:54:20,451 --> 01:54:24,121
SAFETY AND EFFICACY TO OVERCOME

2931
01:54:24,121 --> 01:54:27,725
IMMUNOTHERAPY RESISTANCES AND

2932
01:54:27,725 --> 01:54:32,029
REDUCE ADVERSE EVENTS.

2933
01:54:32,029 --> 01:54:34,565
CONDUCT BIDIRECTIONAL HUMAN

2934
01:54:34,565 --> 01:54:40,104
RELEVANT MECHANISTIC STUDIES.

2935
01:54:40,104 --> 01:54:43,340
N01, SUPPORT TWO CORES.

2936
01:54:43,340 --> 01:54:47,645
ADMINISTRATION CORE COORDINATE

2937
01:54:47,645 --> 01:54:50,748
ACROSS THE CENTERS AND ALSO THE

2938
01:54:50,748 --> 01:54:51,348
MICROBIOME CORE, HARMONIZE AND

2939
01:54:51,348 --> 01:54:52,883
STANDARDIZE THE FMT AND DEFINE

2940
01:54:52,883 --> 01:54:55,486
THE MICROBIAL CONSORTIA AND

2941
01:54:55,486 --> 01:54:56,754
CLINICAL TRIAL.

2942
01:54:56,754 --> 01:54:58,823
AND ALSO COORDINATE AND

2943
01:54:58,823 --> 01:55:00,591
STANDARDIZE THE BIOINFORMATIC

2944
01:55:00,591 --> 01:55:04,795
AND DATA FOR INFRASTRUCTURE AND

2945
01:55:04,795 --> 01:55:07,731
ESTABLISH ONE HUMAN CANCER

2946
01:55:07,731 --> 01:55:12,503
IMMUNOTHERAPY IN MICROBIOTA

2947
01:55:12,503 --> 01:55:16,140
ATLAS AND FMT REGISTRY.

2948
01:55:16,140 --> 01:55:23,414
AND ALSO TO DEVELOP ONE FECAL

2949
01:55:23,414 --> 01:55:24,548
RESOURCE TO THE COMMUNITY.

2950
01:55:24,548 --> 01:55:30,588
THE PRIORITY OF INTERVENTION IS

2951
01:55:30,588 --> 01:55:33,691
FMT OR DEFINE MICROBIAL

2952
01:55:33,691 --> 01:55:34,191
CONASSERTIA WITH IMMUNE

2953
01:55:34,191 --> 01:55:37,995
CHECKPOINT INHIBITOR OF THE CART

2954
01:55:37,995 --> 01:55:39,597
T THERAPIES.

2955
01:55:39,597 --> 01:55:41,966
NEXT SLIDE.

2956
01:55:41,966 --> 01:55:45,436
SO THIS SLIDE OUTLINES STRUCTURE

2957
01:55:45,436 --> 01:55:47,138
OF NETWORK.

2958
01:55:47,138 --> 01:55:50,141
HUMAN STUDY AND AT LEAST TWO

2959
01:55:50,141 --> 01:55:54,478
WILL DO THE CLINICAL TRIAL.

2960
01:55:54,478 --> 01:55:57,181
SO U19 NEEDS COPERCEIVE PI.

2961
01:55:57,181 --> 01:55:59,984
ONE FOR PRE-CLINICAL AND ONE FOR

2962
01:55:59,984 --> 01:56:01,919
CLINICAL.

2963
01:56:01,919 --> 01:56:03,521
NEXT SLIDE.

2964
01:56:03,521 --> 01:56:06,957
SO THE EXAMPLE OF THE PROJECT,

2965
01:56:06,957 --> 01:56:10,394
ALL U19s MUCH DEVELOP

2966
01:56:10,394 --> 01:56:11,862
INTERVENTION AND OBTAIN R&D
AND

2967
01:56:11,862 --> 01:56:16,167
ALL CONDUCT CLINICAL TRIAL.

2968
01:56:16,167 --> 01:56:20,437
AND MICROBIAL COMPOSITION AND

2969
01:56:20,437 --> 01:56:25,576
FUNCTIONS THROUGH MULTI-OAKICS,

2970
01:56:25,576 --> 01:56:27,945
MEASURE BIOMARKERS AND SHOW WITH

2971
01:56:27,945 --> 01:56:33,284
THERAPY OUTCOMES AND INVESTIGATE

2972
01:56:33,284 --> 01:56:33,651
THE VARIABLES.

2973
01:56:33,651 --> 01:56:40,157
PRE AND PROBIOTIC PROJECT IS

2974
01:56:40,157 --> 01:56:46,564
ENCOURAGED AND HUMAN RELEVANT --

2975
01:56:46,564 --> 01:56:48,699
STUDIES.

2976
01:56:48,699 --> 01:56:49,433
SCIENTIFIC BASIS FOR THE HUMAN

2977
01:56:49,433 --> 01:56:54,038
CORE STUDY, WE ARE TO REQUIRE

2978
01:56:54,038 --> 01:56:58,142
TWO RACES AND REQUIRE TWO

2979
01:56:58,142 --> 01:56:58,442
LOCATIONS --

2980
01:56:58,442 --> 01:57:08,786
[ BACKGROUND NOISE ]

2981
01:57:10,654 --> 01:57:14,592
>> NEXT SLIDE, PLEASE.

2982
01:57:14,592 --> 01:57:20,497
SO JUSTIFICATION OF RFA AND RFP,

2983
01:57:20,497 --> 01:57:23,334
SCIENTIFIC NEEDS FOR OPTIMIZED

2984
01:57:23,334 --> 01:57:28,072
APPROACH OF CONCEPT OF CLINICAL

2985
01:57:28,072 --> 01:57:30,274
TRIAL.

2986
01:57:30,274 --> 01:57:32,610
AND ALSO MULTIDISCIPLINED TEAMS

2987
01:57:32,610 --> 01:57:34,311
TO THE COLLABORATIVE NETWORK

2988
01:57:34,311 --> 01:57:38,449
WITH A SINGLE RECIPIENT DATE AND

2989
01:57:38,449 --> 01:57:39,617
SPECIFIC REVIEW CRITERIA.

2990
01:57:39,617 --> 01:57:40,684
THE R IF.

2991
01:57:40,684 --> 01:57:42,820
P WOULD BETTER SERVE THE NETWORK

2992
01:57:42,820 --> 01:57:45,322
AND COMMUNITY IN THE LONG RUN.

2993
01:57:45,322 --> 01:57:49,827
FOR THE U MECHANISM, THE NETWORK

2994
01:57:49,827 --> 01:57:50,427
AND SYNERGY.

2995
01:57:50,427 --> 01:57:52,129
THE NCI APPROVAL STAFF

2996
01:57:52,129 --> 01:57:54,365
INVOLVEMENT IN THE STEERING

2997
01:57:54,365 --> 01:57:56,667
COMMITTEE TIMELY PROVIDE

2998
01:57:56,667 --> 01:58:00,137
PROGRAMMATIC FOR THE INPUT AND

2999
01:58:00,137 --> 01:58:03,073
ALSO OTHER RESOURCES AND

3000
01:58:03,073 --> 01:58:03,507
INFORMATION.

3001
01:58:03,507 --> 01:58:06,510
THE COLLABORATION CAN BE FURTHER

3002
01:58:06,510 --> 01:58:09,179
ESTABLISHED FOR THE POST AWARD.

3003
01:58:09,179 --> 01:58:13,684
NEXT SLIDE, PLEASE.

3004
01:58:13,684 --> 01:58:18,389
THE BUDGET IS 7.5 TOTAL COST PER

3005
01:58:18,389 --> 01:58:21,558
YEAR AND 37.5 FURTHER COST FOR

3006
01:58:21,558 --> 01:58:24,461
FIVE YEARS.

3007
01:58:24,461 --> 01:58:26,497
NEXT SLIDE.

3008
01:58:26,497 --> 01:58:30,634
THE EVALUATION CRITERIA FOR THE

3009
01:58:30,634 --> 01:58:33,304
U19, TO CONDUCT CLINICAL TRIAL

3010
01:58:33,304 --> 01:58:37,508
OR DEVELOP THE INTERVENTION
R&D.

3011
01:58:37,508 --> 01:58:40,611
PROCEDURE FOR CLINICAL TRIAL AND

3012
01:58:40,611 --> 01:58:42,813
INTERVENTIONS AND ALSO ADVANCE

3013
01:58:42,813 --> 01:58:44,682
THE SCIENTIFIC KNOWLEDGE OF THE

3014
01:58:44,682 --> 01:58:47,851
VARIABLES AND THE MECHANISMS AND

3015
01:58:47,851 --> 01:58:51,455
ALSO TO TRANSFORM THE GUT

3016
01:58:51,455 --> 01:58:55,492
MICROBIOME AND IMPACT ON THE

3017
01:58:55,492 --> 01:58:56,627
IMMUNOTHERAPY.

3018
01:58:56,627 --> 01:59:00,698
THE RESULTS INFORM THE TRIAL AND

3019
01:59:00,698 --> 01:59:02,700
TEAM TO CONDUCT CLINICAL TRIAL.

3020
01:59:02,700 --> 01:59:05,169
AND ALSO TO IMPROVE THE HEALTH

3021
01:59:05,169 --> 01:59:08,439
DISPARITY IN THE CANCER

3022
01:59:08,439 --> 01:59:10,274
MICROBIOME RESEARCH.

3023
01:59:10,274 --> 01:59:15,746
FOR THE N01, THE CANCER

3024
01:59:15,746 --> 01:59:19,650
IMMUNOTHERAPY AND MICROBIOME

3025
01:59:19,650 --> 01:59:20,284
RESEARCH FOR THE COMMUNITY TO

3026
01:59:20,284 --> 01:59:22,653
ENSURE DATABASE AND FECAL

3027
01:59:22,653 --> 01:59:22,920
RESOURCE.

3028
01:59:22,920 --> 01:59:24,988
ALSO TO STANDARDIZE THE

3029
01:59:24,988 --> 01:59:28,859
MEASUREMENT AND ALSO ADVANCE THE

3030
01:59:28,859 --> 01:59:31,729
COMPUTATION BIOLOGY.

3031
01:59:31,729 --> 01:59:33,564
NEXT SLIDE IS THE LAST SLIDE.

3032
01:59:33,564 --> 01:59:37,901
I HAVE INCORPORATED ALL THE BSA

3033
01:59:37,901 --> 01:59:41,338
REVIEW COMMENTS ON THIS SLIDE.

3034
01:59:41,338 --> 01:59:47,644
THE REVIEWERS ARE --

3035
01:59:47,644 --> 01:59:49,480
[ READING ]

3036
01:59:49,480 --> 01:59:51,548
ALL THANK YOU FOR YOUR VALUABLE

3037
01:59:51,548 --> 01:59:51,849
SUGGESTIONS.

3038
01:59:51,849 --> 01:59:57,121
MOST ARE REALLY INCLUDED IN THE

3039
01:59:57,121 --> 01:59:57,921
SLIDES HERE.

3040
01:59:57,921 --> 02:00:03,360
I JUST WANT TO HAVE ADDITIONAL

3041
02:00:03,360 --> 02:00:05,162
MENTIONS HERE.

3042
02:00:05,162 --> 02:00:07,297
INCLUDING EPIDEMIOLOGIST ALSO

3043
02:00:07,297 --> 02:00:11,969
WOULD BE APPROPRIATE TO GIVE

3044
02:00:11,969 --> 02:00:15,172
EXPANSIVE CLINICAL TRIALS AND

3045
02:00:15,172 --> 02:00:18,342
PROVIDE MEASUREMENT FOR SRNA AND

3046
02:00:18,342 --> 02:00:21,945
OMICS UP TO CERTAIN AMOUNT, FOR

3047
02:00:21,945 --> 02:00:24,348
EXAMPLE 300 SAMPLES PER YEAR FOR

3048
02:00:24,348 --> 02:00:29,119
CLINICAL TRIALS U19 WITH NCI

3049
02:00:29,119 --> 02:00:29,553
PRE-APPROVAL.

3050
02:00:29,553 --> 02:00:32,122
THE PRO OMICS IS NOT REQUIRED

3051
02:00:32,122 --> 02:00:36,059
BUT NCI WORKING GROUP WILL MAKE

3052
02:00:36,059 --> 02:00:39,296
THE PLAN WITH INPUT FROM THE

3053
02:00:39,296 --> 02:00:44,134
STEERING COMMITTEE TO USE THAT.

3054
02:00:44,134 --> 02:00:48,272
IN TIME FOR THE DISPARITY AND

3055
02:00:48,272 --> 02:00:52,309
DIVERSITY REQUIREMENT ON

3056
02:00:52,309 --> 02:00:53,710
SCIENTIFIC BASIS WITH TRIAL WITH

3057
02:00:53,710 --> 02:00:58,415
MORE THAN ONE STATISTICAL

3058
02:00:58,415 --> 02:00:59,950
POWERED RACE WILL BE CONSIDERED

3059
02:00:59,950 --> 02:01:01,952
PRIORITY FOR FUNDING BUT NO

3060
02:01:01,952 --> 02:01:03,454
REQUIREMENT FOR MORE THAN ONE

3061
02:01:03,454 --> 02:01:04,221
SITE.

3062
02:01:04,221 --> 02:01:06,723
I STOP HERE.

3063
02:01:06,723 --> 02:01:07,925
OPEN WITH QUESTION AND LOOK FOR

3064
02:01:07,925 --> 02:01:10,227
YOUR INPUT.

3065
02:01:10,227 --> 02:01:11,462
THANK YOU.

3066
02:01:11,462 --> 02:01:12,329
>> THANK YOU VERY MUCH.

3067
02:01:12,329 --> 02:01:13,630
NELSON WOULD YOU LIKE TO GET US

3068
02:01:13,630 --> 02:01:17,701
STARTED IN DISCUSSION?

3069
02:01:17,701 --> 02:01:19,102
>> THANK YOU.

3070
02:01:19,102 --> 02:01:19,736
I THINK WE HAD A PRETTY ROBUST

3071
02:01:19,736 --> 02:01:20,938
DISCUSSION AROUND THIS.

3072
02:01:20,938 --> 02:01:22,239
I THINK THIS IS A PRETTY TIMELY

3073
02:01:22,239 --> 02:01:22,439
ISSUE.

3074
02:01:22,439 --> 02:01:23,974
I THINK THERE IS A LOT OF WORK

3075
02:01:23,974 --> 02:01:32,349
GOING ON IN THIS AREA AND I

3076
02:01:32,349 --> 02:01:34,318
THINK WHAT WAS SHOWED WITH JUST

3077
02:01:34,318 --> 02:01:37,588
TWO GRANTS, THE PORTFOLIO IS A

3078
02:01:37,588 --> 02:01:38,589
LITTLE LOW.

3079
02:01:38,589 --> 02:01:40,724
WE HAD A LOT OF DISCUSSION

3080
02:01:40,724 --> 02:01:43,060
AROUND HOW TO OPTIMIZE THIS AND

3081
02:01:43,060 --> 02:01:46,163
I THINK AT THE LAST SLIDE THAT

3082
02:01:46,163 --> 02:01:48,499
WAS SHOWN, I THINK A LOT OF OUR

3083
02:01:48,499 --> 02:01:54,071
COMMENTS WERE TAKEN INTO THE

3084
02:01:54,071 --> 02:01:54,605
PROPOSAL.

3085
02:01:54,605 --> 02:01:57,841
SO THE COMMITTEE WAS PRETTY

3086
02:01:57,841 --> 02:02:06,750
ENTHUSIASTIC ABOUT THIS WORK.

3087
02:02:06,750 --> 02:02:07,885
>> IT WAS EXPRESSED WELL.

3088
02:02:07,885 --> 02:02:08,986
THERE WAS A LOT OF DISCUSSION

3089
02:02:08,986 --> 02:02:14,358
ABOUT HOW TO MAKE A VERY COMPLEX

3090
02:02:14,358 --> 02:02:17,728
AND IMPORTANT PROPOSAL BECAUSE

3091
02:02:17,728 --> 02:02:19,396
THERE IS A LOT OF OPPORTUNITIES

3092
02:02:19,396 --> 02:02:20,631
TO DO IMPORTANT RESEARCH HERE.

3093
02:02:20,631 --> 02:02:23,233
SO THANK YOU FOR TAKING OUR

3094
02:02:23,233 --> 02:02:28,338
COMMENTS INTO CONSIDERATION.

3095
02:02:28,338 --> 02:02:31,675
>> I HAVE NOTHING MORE TO
ADD TO

3096
02:02:31,675 --> 02:02:34,378
WHAT MY COLLEAGUES SAID.

3097
02:02:34,378 --> 02:02:38,248
MY ONLY MINOR, MINOR, MINOR

3098
02:02:38,248 --> 02:02:40,684
CONCERN WAS THAT THERE WAS SUCH

3099
02:02:40,684 --> 02:02:43,287
AN EMPHASIS ON DOING THE

3100
02:02:43,287 --> 02:02:46,523
CLINICAL TRIAL AND A LITTLE LESS

3101
02:02:46,523 --> 02:02:49,326
EMPHASIS ON PRE-CLINICAL WORK TO

3102
02:02:49,326 --> 02:02:51,662
GO ALONG WITH IT.

3103
02:02:51,662 --> 02:02:53,730
BUT I THINK DR. ZI ADDRESSED

3104
02:02:53,730 --> 02:02:56,700
SOME OF THAT.

3105
02:02:56,700 --> 02:03:04,741
>> OPEN FOR DISCUSSION.

3106
02:03:04,741 --> 02:03:04,975
TRENT.

3107
02:03:04,975 --> 02:03:07,177
>> THANK YOU, KEITH.

3108
02:03:07,177 --> 02:03:10,881
I'M WONDERING IF ANYONE WHO JUST

3109
02:03:10,881 --> 02:03:12,449
SPOKE CAN COMMENT ON THE

3110
02:03:12,449 --> 02:03:12,983
RELEVANCE.

3111
02:03:12,983 --> 02:03:14,985
IT SEEMS LIKE THERE MIGHT BE

3112
02:03:14,985 --> 02:03:18,021
SOME ON THIS CONTROVERSY THAT

3113
02:03:18,021 --> 02:03:20,591
HAS BEEN GOING ON OVER WHETHER

3114
02:03:20,591 --> 02:03:23,927
AND THE EXTENT TO WHICH THE

3115
02:03:23,927 --> 02:03:26,597
MICROBIOME IS A CANCER AT ALL

3116
02:03:26,597 --> 02:03:28,465
AND IF YOU HAVEN'T FOLLOWED

3117
02:03:28,465 --> 02:03:33,337
THIS, YOU CAN GOOGLE STEPHEN

3118
02:03:33,337 --> 02:03:35,672
STALLED BERG AND MICROBIOME AND

3119
02:03:35,672 --> 02:03:37,107
CANCER.

3120
02:03:37,107 --> 02:03:40,544
AND NOT GO DRAMA HERE BUT IT

3121
02:03:40,544 --> 02:03:43,480
SEEMS LIKE THAT -- IT'S TWO VERY

3122
02:03:43,480 --> 02:03:45,015
WELL RESPECTED GROUPS WHO SIMPLY

3123
02:03:45,015 --> 02:03:46,750
HAVE A SCIENTIFIC DISAGREEMENT

3124
02:03:46,750 --> 02:03:49,853
ABOUT ACCURACY OF WHETHER OR NOT

3125
02:03:49,853 --> 02:03:52,089
A COUPLE OF PROMINENT PAPERS

3126
02:03:52,089 --> 02:03:54,758
THAT CLAIM TO FIND MICROBIOME

3127
02:03:54,758 --> 02:03:56,994
ASSOCIATIONS IN TUMORS WEREN'T

3128
02:03:56,994 --> 02:03:58,996
ACTUALLY MISTAKENLY FINDING

3129
02:03:58,996 --> 02:04:03,033
HUMAN DNA THAT WERE MISLABELED

3130
02:04:03,033 --> 02:04:04,668
IN DATABASES.

3131
02:04:04,668 --> 02:04:06,103
IT'S AN ONGOING DISCUSSION.

3132
02:04:06,103 --> 02:04:07,871
MAYBE SOMEONE ELSE HAS MORE

3133
02:04:07,871 --> 02:04:09,206
CURRENT KNOWLEDGE THAN ME AS TO

3134
02:04:09,206 --> 02:04:12,109
WHETHER IT'S BEEN RESOLVED BUT

3135
02:04:12,109 --> 02:04:13,443
IT SEEMS IMPORTANT, AT LEAST TO

3136
02:04:13,443 --> 02:04:14,811
THE PARTS OF WHAT ARE BEING

3137
02:04:14,811 --> 02:04:19,883
DISCUSSED WITH THIS RFA.

3138
02:04:19,883 --> 02:04:27,858
>> I CAN RESPOND, BUT I'D
LIKE A

3139
02:04:27,858 --> 02:04:30,394
BSA MEMBER.

3140
02:04:30,394 --> 02:04:32,295
>> I JUST WANT TO RAISE
IT.

3141
02:04:32,295 --> 02:04:33,797
I MEAN --

3142
02:04:33,797 --> 02:04:34,264
>> OKAY.

3143
02:04:34,264 --> 02:04:35,866
I CAN SAY A COUPLE OF THINGS.

3144
02:04:35,866 --> 02:04:39,102
ONE THING IS IN THE CONCEPT WE

3145
02:04:39,102 --> 02:04:42,172
DO MENTION WHENEVER THE TISSUE

3146
02:04:42,172 --> 02:04:44,508
IS AVAILABLE WE ALSO ENCOURAGE

3147
02:04:44,508 --> 02:04:46,977
TO DO THE MICROBIOME MEASUREMENT

3148
02:04:46,977 --> 02:04:51,548
WITH THE TISSUE.

3149
02:04:51,548 --> 02:04:53,350
SO -- I THINK I READ THAT PAPER

3150
02:04:53,350 --> 02:04:57,788
AND A LOT OF WHAT YOU

3151
02:04:57,788 --> 02:04:58,822
DISCUSSED -- I THINK FURTHERMORE

3152
02:04:58,822 --> 02:05:02,693
MAINLY A TERM FOR AI, THE

3153
02:05:02,693 --> 02:05:03,860
COMPUTATION FOR THE METHOD.

3154
02:05:03,860 --> 02:05:07,164
SO ACTUALLY THE FIELD IN THE

3155
02:05:07,164 --> 02:05:12,169
MICROBIOME HOW TO DO THE

3156
02:05:12,169 --> 02:05:14,604
COMPUTATION, CORRECTION, IS NOT

3157
02:05:14,604 --> 02:05:16,373
VERY STANDARDIZED.

3158
02:05:16,373 --> 02:05:19,009
SO THIS IS LARGE AREA WE ALSO

3159
02:05:19,009 --> 02:05:19,976
CAN INCLUDE.

3160
02:05:19,976 --> 02:05:23,847
I ALSO MENTIONED ON THE SLIDE

3161
02:05:23,847 --> 02:05:26,116
AND IF YOU NOTICE FOR THE

3162
02:05:26,116 --> 02:05:28,118
EXAMPLE, THE AI IS ENCOURAGED.

3163
02:05:28,118 --> 02:05:37,461
SO AI RIGHT NOW STILL IS NOT

3164
02:05:37,461 --> 02:05:38,428
STANDARDIZATION -- BEST

3165
02:05:38,428 --> 02:05:41,565
CORRECTION SO THAT IS

3166
02:05:41,565 --> 02:05:41,865
COMPUTATION.

3167
02:05:41,865 --> 02:05:43,567
>> MY IMPRESSION WAS IT
WAS MORE

3168
02:05:43,567 --> 02:05:45,235
THAN THE COMPUTATION.

3169
02:05:45,235 --> 02:05:45,869
IT WAS REALLY ABOUT ANNOTATION

3170
02:05:45,869 --> 02:05:47,738
OF SEQUENCES IN DATABASES.

3171
02:05:47,738 --> 02:05:51,208
YES, THERE IS SOME, OF COURSE,

3172
02:05:51,208 --> 02:05:53,810
SEQUENCE ALIGNMENT METHODOLOGY

3173
02:05:53,810 --> 02:05:54,678
BEHIND THAT.

3174
02:05:54,678 --> 02:05:56,880
I KNOW AI IS A POPULAR WORD

3175
02:05:56,880 --> 02:05:58,849
THESE DAYS BUT I DON'T THINK

3176
02:05:58,849 --> 02:06:02,819
THIS IS LIKE CHAT GBT LEVEL AI.

3177
02:06:02,819 --> 02:06:05,589
I THINK THIS IS A CLASSICAL --ED

3178
02:06:05,589 --> 02:06:06,957
IF THEY ARE RIGHT, IT'S A

3179
02:06:06,957 --> 02:06:08,658
CLASSICAL DATABASE ISSUE AND THE

3180
02:06:08,658 --> 02:06:11,595
DATABASE IS JUST MISS ANITATED.

3181
02:06:11,595 --> 02:06:14,731
AND AGAIN, IT'S TWO VERY

3182
02:06:14,731 --> 02:06:16,099
WELL-RESPECTED GROUPS.

3183
02:06:16,099 --> 02:06:18,435
THERE IS NO DISHONESTY GOING ON

3184
02:06:18,435 --> 02:06:18,635
HERE.

3185
02:06:18,635 --> 02:06:23,440
IT'S SIMPLY WHO IS RIGHT.

3186
02:06:23,440 --> 02:06:24,374
ANYWAY, SOMETHING TO BE AWARE

3187
02:06:24,374 --> 02:06:26,877
OF.

3188
02:06:26,877 --> 02:06:30,247
>> OKAY, THANK YOU VERY
MUCH.

3189
02:06:30,247 --> 02:06:31,648
FOCUS ON WHETHER CONTAMINATION

3190
02:06:31,648 --> 02:06:33,283
OF THE HUMAN SEQUENCE --

3191
02:06:33,283 --> 02:06:38,555
>> IT'S A CONTAMINATION.

3192
02:06:38,555 --> 02:06:40,657
IT'S A COUPLE OF VERY LARGE

3193
02:06:40,657 --> 02:06:42,993
PAPERS THAT WOULD HAVE TO BE

3194
02:06:42,993 --> 02:06:45,796
RETRACTED THAT HAVE REALLY

3195
02:06:45,796 --> 02:06:46,196
DRIVEN THIS FIELD.

3196
02:06:46,196 --> 02:06:47,964
THAT'S THE REASON FOR THE RED

3197
02:06:47,964 --> 02:06:50,734
FLAG, I THINK.

3198
02:06:50,734 --> 02:06:55,005
>> KARIN AND THEN SHELLY.

3199
02:06:55,005 --> 02:06:55,305
>> THANKS.

3200
02:06:55,305 --> 02:06:59,543
A REALLY INTERESTING CONCEPT.

3201
02:06:59,543 --> 02:07:00,443
I MISSED IN YOUR LAST SLIDE --

3202
02:07:00,443 --> 02:07:03,113
SO THERE IS A BIG EMPHASIS ON

3203
02:07:03,113 --> 02:07:04,247
FMS AND INTERVENTION.

3204
02:07:04,247 --> 02:07:05,382
ON THE LAST SLIDE IN YOUR

3205
02:07:05,382 --> 02:07:08,518
RESPONSES YOU CLARIFIED THAT

3206
02:07:08,518 --> 02:07:12,055
PRETTY AND PROBIOTICS COULD ALSO

3207
02:07:12,055 --> 02:07:12,689
BE INTERVENTIONS.

3208
02:07:12,689 --> 02:07:19,396
DOES THAT INCLUDE DIETARY

3209
02:07:19,396 --> 02:07:19,729
INTERVENTIONS?

3210
02:07:19,729 --> 02:07:19,996
>> YES.

3211
02:07:19,996 --> 02:07:20,263
>> OKAY.

3212
02:07:20,263 --> 02:07:22,232
VERY INTERESTING, THANK YOU.

3213
02:07:22,232 --> 02:07:23,500
>> SHELLY?

3214
02:07:23,500 --> 02:07:26,536
>> I THINK THIS IS REALLY

3215
02:07:26,536 --> 02:07:29,206
IMPORTANT FOR THE REASON THAT

3216
02:07:29,206 --> 02:07:29,639
TRAY RAISED.

3217
02:07:29,639 --> 02:07:30,774
AND THERE MAY NOT BE ENOUGH

3218
02:07:30,774 --> 02:07:33,276
MONEY IN IT TO REALLY RESOLVE

3219
02:07:33,276 --> 02:07:35,145
THIS BUT FROM THE BEGINNING OF

3220
02:07:35,145 --> 02:07:37,147
THE THREE PAPERS IT ALL SHOWED

3221
02:07:37,147 --> 02:07:39,616
THIS REALLY INTERESTING EFFECT

3222
02:07:39,616 --> 02:07:41,151
BUT ALL HAD DIFFERENT BUGS

3223
02:07:41,151 --> 02:07:43,553
DEPENDING ON WHERE THEY ARE.

3224
02:07:43,553 --> 02:07:46,456
THIS IS NOW BECOME A COTTAGE

3225
02:07:46,456 --> 02:07:47,357
INDUSTRY.

3226
02:07:47,357 --> 02:07:49,359
YOU SEE THIS ADVERTISED.

3227
02:07:49,359 --> 02:07:50,093
I MEAN, THIS IS SOMETHING THAT

3228
02:07:50,093 --> 02:07:53,230
REALLY HAS GOTTEN INTO THE

3229
02:07:53,230 --> 02:07:55,332
PUBLIC'S EYE AND IT NEEDS TO GET

3230
02:07:55,332 --> 02:07:55,599
RESOLVED.

3231
02:07:55,599 --> 02:07:58,969
AND I THINK THAT THIS IS

3232
02:07:58,969 --> 02:08:02,105
PROBABLY A GOOD WAY TO START.

3233
02:08:02,105 --> 02:08:03,340
WHAT IS ABSOLUTELY CRUCIAL IS

3234
02:08:03,340 --> 02:08:05,542
THAT ALL OF THE DATA AND FRANKLY

3235
02:08:05,542 --> 02:08:07,711
BIOLOGIC SAMPLES THAT COME OUT

3236
02:08:07,711 --> 02:08:12,182
OF THIS BE SHAREABLE.

3237
02:08:12,182 --> 02:08:13,316
BECAUSE IT'S GOING TO NEED A

3238
02:08:13,316 --> 02:08:15,619
NUMBER OF PEOPLE, SEQUENCING AND

3239
02:08:15,619 --> 02:08:16,152
CRUNCHING NUMBERS.

3240
02:08:16,152 --> 02:08:19,823
SO IT REALLY SETS UP A

3241
02:08:19,823 --> 02:08:21,424
REPOSITORY WHERE A NUMBER OF

3242
02:08:21,424 --> 02:08:23,727
PEOPLE CAN LOOK AT THIS IN

3243
02:08:23,727 --> 02:08:24,294
DIFFERENT WAYS.

3244
02:08:24,294 --> 02:08:27,364
I THINK IT'S VERY WORTHWHILE IN

3245
02:08:27,364 --> 02:08:31,301
DOING SIMPLY BECAUSE IT IS A BIG

3246
02:08:31,301 --> 02:08:36,773
CONTROVERSY.

3247
02:08:36,773 --> 02:08:37,707
>> GOOD DISCUSSION.

3248
02:08:37,707 --> 02:08:40,844
I DON'T SEE ANY REMAINING HANDS.

3249
02:08:40,844 --> 02:08:47,317
>> I HAVE MY HAND UP.

3250
02:08:47,317 --> 02:08:50,654
>> YOU'RE ON THE BACK
SCREEN.

3251
02:08:50,654 --> 02:08:53,323
FRED, I THINK --

3252
02:08:53,323 --> 02:08:54,491
>> IZ JUST RAISED MY HAND
UP

3253
02:08:54,491 --> 02:08:54,658
NOW.

3254
02:08:54,658 --> 02:08:57,594
I THINK ANDY'S HAND HAS BEEN UP

3255
02:08:57,594 --> 02:08:58,261
FOR QUITE A WHILE.

3256
02:08:58,261 --> 02:09:00,964
I WILL LET ANDY GO.

3257
02:09:00,964 --> 02:09:01,264
>> THANKS.

3258
02:09:01,264 --> 02:09:01,564
>> THANKS.

3259
02:09:01,564 --> 02:09:02,399
I THINK THIS IS VERY INTERESTING

3260
02:09:02,399 --> 02:09:05,135
AND I AGREE WITH WHAT SHELLY

3261
02:09:05,135 --> 02:09:05,335
SAID.

3262
02:09:05,335 --> 02:09:07,070
I THINK PART OF THE REASON TO

3263
02:09:07,070 --> 02:09:08,171
REALLY SUPPORT THIS IS TO KIND

3264
02:09:08,171 --> 02:09:10,407
OF RESOLVE SOME OF THESE

3265
02:09:10,407 --> 02:09:11,241
QUESTIONS IN THE FIELD WITH

3266
02:09:11,241 --> 02:09:12,709
TRIAL DATA.

3267
02:09:12,709 --> 02:09:13,777
I THINK ONE OF THE QUESTIONS I

3268
02:09:13,777 --> 02:09:15,312
WAS WONDERING ABOUT IS THE

3269
02:09:15,312 --> 02:09:17,380
REQUIREMENT ABOUT THE FDA

3270
02:09:17,380 --> 02:09:19,149
APPROVAL.

3271
02:09:19,149 --> 02:09:19,749
SPECIFICALLY WITH FMT, I THINK

3272
02:09:19,749 --> 02:09:21,985
THERE IS A HISTORY OF THE FDA

3273
02:09:21,985 --> 02:09:23,720
HAVING SHIFTING STANDARDS IN

3274
02:09:23,720 --> 02:09:25,221
TERMS OF HOW THEY HAVE PROVED

3275
02:09:25,221 --> 02:09:28,158
FMT AND HOW THEY CONSIDER FMT AS

3276
02:09:28,158 --> 02:09:28,858
A THERAPY.

3277
02:09:28,858 --> 02:09:30,760
I CAN IMAGINE A LOT OF PROPOSALS

3278
02:09:30,760 --> 02:09:34,197
MIGHT GET HUNG UP WITH THAT

3279
02:09:34,197 --> 02:09:34,497
REQUIREMENT.

3280
02:09:34,497 --> 02:09:35,198
IS THERE ANY EFFORT TO

3281
02:09:35,198 --> 02:09:37,934
COORDINATE WITH FDA WHEN THESE

3282
02:09:37,934 --> 02:09:40,503
PROPOSALS GET EVENTUALLY

3283
02:09:40,503 --> 02:09:41,705
SUPPORTED?

3284
02:09:41,705 --> 02:09:44,741
>> VERY GOOD QUESTION.

3285
02:09:44,741 --> 02:09:47,110
ACTUALLY, NCI LEAD THE

3286
02:09:47,110 --> 02:09:51,114
CONFERENCE OF WORKSHOP 2019

3287
02:09:51,114 --> 02:09:53,249
RIGHT AFTER I SEE THE PAPER

3288
02:09:53,249 --> 02:09:58,822
PUBLISHED IN 2018.

3289
02:09:58,822 --> 02:10:01,591
SO ALSO -- TO INCLUDE FDA.

3290
02:10:01,591 --> 02:10:04,294
THEY ARE PART OF THE PLAN.

3291
02:10:04,294 --> 02:10:07,964
AND OF THE MEETINGS AND

3292
02:10:07,964 --> 02:10:09,799
PUBLISHING THE WEBSITE.

3293
02:10:09,799 --> 02:10:12,235
THEY ARE HIGHLY SUPPORTIVE.

3294
02:10:12,235 --> 02:10:16,139
BEFORE WE SEE THE POSITIVE

3295
02:10:16,139 --> 02:10:23,046
RESULTS IN THE -- [ INAUDIBLE ]

3296
02:10:23,046 --> 02:10:26,883
SO WE HAVE COMMUNICATION

3297
02:10:26,883 --> 02:10:30,720
CONSTANTLY.

3298
02:10:30,720 --> 02:10:31,721
>> THANKS.

3299
02:10:31,721 --> 02:10:33,690
REALLY GREAT PROPOSAL AND VERY

3300
02:10:33,690 --> 02:10:35,191
MUCH APPRECIATE THE PERSPECTIVE

3301
02:10:35,191 --> 02:10:38,094
OF BRINGING IN THESE MULTIPLE

3302
02:10:38,094 --> 02:10:40,997
ASPECTS OF DIVERSITY.

3303
02:10:40,997 --> 02:10:43,333
AND ALSO OBVIOUSLY THE

3304
02:10:43,333 --> 02:10:45,301
MICROBIOME IS SO DEPENDENT ON

3305
02:10:45,301 --> 02:10:47,070
WHAT WE EAT.

3306
02:10:47,070 --> 02:10:47,937
AND I KNOW THAT THERE IS A LOT

3307
02:10:47,937 --> 02:10:50,607
TO LOOK AT BUT TO JUST BE SURE

3308
02:10:50,607 --> 02:10:53,743
AS I THINK SOME FOLKS WERE

3309
02:10:53,743 --> 02:11:01,351
ALLUDING TO THAT ACCESS TO FOOD,

3310
02:11:01,351 --> 02:11:02,485
GEOGRAPHIC LOCATION, PROCESSING

3311
02:11:02,485 --> 02:11:06,623
OF FOOD CAN DIFFER AS WE AGE.

3312
02:11:06,623 --> 02:11:10,260
AND SO ALL OF THOSE COMPONENTS

3313
02:11:10,260 --> 02:11:13,363
MAY ALSO BE IMPORTANT TO ENHANCE

3314
02:11:13,363 --> 02:11:15,732
OUR UNDERSTANDING.

3315
02:11:15,732 --> 02:11:18,635
THANK YOU.

3316
02:11:18,635 --> 02:11:29,312
>> YES, THANK YOU VERY
MUCH.

3317
02:11:29,312 --> 02:11:31,081
>> THERE IS ISSUE OF
DIFFERENCES

3318
02:11:31,081 --> 02:11:33,049
IN ANNOTATION AND I THINK THIS

3319
02:11:33,049 --> 02:11:34,984
IS REALLY AN IMPORTANT ISSUE

3320
02:11:34,984 --> 02:11:38,955
THAT WE CONTINUE TO PRODUCE

3321
02:11:38,955 --> 02:11:40,590
RESULTS, MICROBIOME RESULTS WITH

3322
02:11:40,590 --> 02:11:44,427
THESE DIFFERENT LINES AND HAVE

3323
02:11:44,427 --> 02:11:48,331
KNOWN AGREEMENT ON WHICH ONE IS

3324
02:11:48,331 --> 02:11:48,932
ACCURATE.

3325
02:11:48,932 --> 02:11:51,601
I DOUBT HOW USEFUL OR

3326
02:11:51,601 --> 02:11:52,569
TRANSLATABLE THE FINDINGS ARE

3327
02:11:52,569 --> 02:11:56,773
GOING TO BE.

3328
02:11:56,773 --> 02:11:59,509
SO, I DON'T KNOW WHETHER THE NCI

3329
02:11:59,509 --> 02:12:02,312
CAN TAKE LEADERSHIP ROLE AND

3330
02:12:02,312 --> 02:12:03,713
BRING THE EXPERTS TOGETHER TO

3331
02:12:03,713 --> 02:12:06,449
TRY TO RESOLVE THIS ISSUE OF

3332
02:12:06,449 --> 02:12:08,051
ANNOTATION, ESPECIALLY WHEN IT

3333
02:12:08,051 --> 02:12:16,159
COMES TO TISSUE-LEVEL MICROBIOME

3334
02:12:16,159 --> 02:12:19,629
WHERE THE BOOKS ARE GOING TO BE

3335
02:12:19,629 --> 02:12:21,331
DOMINATED BY HUMAN IMMUNE CELLS.

3336
02:12:21,331 --> 02:12:23,066
I HAVE A COLLEAGUE I COLLABORATE

3337
02:12:23,066 --> 02:12:28,037
WITH MICROBIOME PROJECTS THAT --

3338
02:12:28,037 --> 02:12:29,305
USING SECONDARY DATA FROM

3339
02:12:29,305 --> 02:12:32,542
ANOTHER LAB, WE HAVE TO REQUEST

3340
02:12:32,542 --> 02:12:36,045
THE ORIGINAL READS AND REALIGN

3341
02:12:36,045 --> 02:12:39,349
WITH THE PIPELINE THAT HE TRUSTS

3342
02:12:39,349 --> 02:12:40,650
TO TRY TO GET OUR OWN

3343
02:12:40,650 --> 02:12:41,284
ANNOTATION.

3344
02:12:41,284 --> 02:12:42,051
SO I THINK THIS IS REALLY

3345
02:12:42,051 --> 02:12:45,388
IMPORTANT TO TRY TO RESOLVE SO

3346
02:12:45,388 --> 02:12:49,859
WE CAN GET SOME LEVEL OF

3347
02:12:49,859 --> 02:12:51,094
HOMOGENEITY.

3348
02:12:51,094 --> 02:12:57,800
>> I THINK THIS IS VERY
TIMELY,

3349
02:12:57,800 --> 02:12:59,702
AND CONFERENCE IN MARCH.

3350
02:12:59,702 --> 02:13:02,005
I PROBABLY CAN ALSO BRING TO

3351
02:13:02,005 --> 02:13:04,474
THIS GROUP TOGETHER AND ALSO

3352
02:13:04,474 --> 02:13:09,512
INVITE THEM TO BE PART OF THIS

3353
02:13:09,512 --> 02:13:19,189
CONFERENCE AND WORKSHOP.

3354
02:13:19,189 --> 02:13:20,290
>> JOELING ACROSS THREE
PAGES OF

3355
02:13:20,290 --> 02:13:22,458
GRID VIEW, I DON'T SEE ANY MORE

3356
02:13:22,458 --> 02:13:22,792
HANDS.

3357
02:13:22,792 --> 02:13:26,596
I THINK WE CAN MOVE TO VOTING.

3358
02:13:26,596 --> 02:13:28,464
SO NELSON T SOUNDS LIKE THE

3359
02:13:28,464 --> 02:13:30,333
COMMITTEE WAS SUPPORTIVE OF THIS

3360
02:13:30,333 --> 02:13:30,800
PROPOSAL.

3361
02:13:30,800 --> 02:13:33,503
I WOULD YOU LIKE TO MAKE A

3362
02:13:33,503 --> 02:13:35,038
MOTION.

3363
02:13:35,038 --> 02:13:36,105
>> MOVE TO APPROVE.

3364
02:13:36,105 --> 02:13:36,906
WHAT'S THE MOTION?

3365
02:13:36,906 --> 02:13:37,774
>> THAT'S IT.

3366
02:13:37,774 --> 02:13:40,276
YOU GOT IT.

3367
02:13:40,276 --> 02:13:43,546
CAN I GET A SECOND?

3368
02:13:43,546 --> 02:13:43,846
>> SECOND.

3369
02:13:43,846 --> 02:13:45,048
>> THANK YOU.

3370
02:13:45,048 --> 02:13:55,458
ANY FURTHER DISCUSSION?

3371
02:13:58,194 --> 02:14:01,898
I'M LOOKING SPECIFICALLY FOR

3372
02:14:01,898 --> 02:14:05,068
VOLTS OF DISAPPROVAL BY RAISE OF

3373
02:14:05,068 --> 02:14:15,378
HANDS OR VERBALLY.

3374
02:14:16,179 --> 02:14:18,681
PAULET?

3375
02:14:18,681 --> 02:14:20,149
NO PRE RECORDED ABSTENTIONS BUT

3376
02:14:20,149 --> 02:14:29,092
ANY LAST-MINUTE ONES?

3377
02:14:29,092 --> 02:14:29,525
>> NO.

3378
02:14:29,525 --> 02:14:33,363
SO IT'S UNANIMOUS APPROVAL.

3379
02:14:33,363 --> 02:14:33,630
>> OKAY.

3380
02:14:33,630 --> 02:14:36,099
THANK YOU, ALL.

3381
02:14:36,099 --> 02:14:43,940
THE NEXT CONCEPT IS REISSUE RFP,

3382
02:14:43,940 --> 02:14:48,478
NCISBIR INNOVATIVE CONCEPT FOR

3383
02:14:48,478 --> 02:14:50,747
PROGRAM.

3384
02:14:50,747 --> 02:14:52,915
DR. BOASA WILL BE THE PRESENTER.

3385
02:14:52,915 --> 02:14:54,951
THE SUBCOMMITTEE REVIEWED THIS

3386
02:14:54,951 --> 02:14:56,653
RE-ISSUANCE AND RECOMMENDED

3387
02:14:56,653 --> 02:15:00,623
DISCUSSION OR PRESENTATION, I

3388
02:15:00,623 --> 02:15:06,829
SHOULD SAY.

3389
02:15:06,829 --> 02:15:07,897
RAY IS THE CHAIR OF THIS

3390
02:15:07,897 --> 02:15:08,865
COMMITTEE, JENNIFER, WHO I

3391
02:15:08,865 --> 02:15:11,401
BELIEVE IS UNABLE TO JOIN US

3392
02:15:11,401 --> 02:15:14,504
THIS AFTERNOON, WAS ALSO ON THE

3393
02:15:14,504 --> 02:15:15,805
COMMITTEE AND CHANDRA.

3394
02:15:15,805 --> 02:15:20,376
SO THE TWO OF YOU HOPEFULLY CAN

3395
02:15:20,376 --> 02:15:21,644
DRIVE THE DISCUSSION.

3396
02:15:21,644 --> 02:15:25,114
SO WITH THAT SAID, DR. BOASA

3397
02:15:25,114 --> 02:15:27,550
TAKE IT AWAY WITH THE

3398
02:15:27,550 --> 02:15:30,687
PRESENTATION.

3399
02:15:30,687 --> 02:15:32,755
>> THANK YOU.

3400
02:15:32,755 --> 02:15:35,358
I'M PROGRAM DIRECTOR AT SBIR

3401
02:15:35,358 --> 02:15:35,792
DEVELOPMENT CENTER.

3402
02:15:35,792 --> 02:15:37,393
I'M EXCITED TO GO OVER THE

3403
02:15:37,393 --> 02:15:39,962
CONCEPT AWARD AND OUR PROPOSED

3404
02:15:39,962 --> 02:15:42,999
RE-ISSUANCE OF THIS REQUEST FOR

3405
02:15:42,999 --> 02:15:43,266
PROPOSAL.

3406
02:15:43,266 --> 02:15:46,202
THE SBIR STANDS FOR SMALL

3407
02:15:46,202 --> 02:15:47,370
BUSINESS INNOVATION RESEARCH.

3408
02:15:47,370 --> 02:15:50,373
IT'S ONE OF THE LARGEST SOURCES

3409
02:15:50,373 --> 02:15:53,509
OF NON-DILUTED SEED FUNDING.

3410
02:15:53,509 --> 02:15:54,077
SO CONGRESSIONALLY MANDATED

3411
02:15:54,077 --> 02:15:55,545
PROGRAM SO IT DOESN'T TAP INTO

3412
02:15:55,545 --> 02:15:56,779
THE RPG.

3413
02:15:56,779 --> 02:15:59,515
SO WE HAVE GUARANTEED SET ASIDES

3414
02:15:59,515 --> 02:16:01,851
EACH FISCAL YEAR FOR FY2023.

3415
02:16:01,851 --> 02:16:04,487
WE HAD 1.3 BILLION AT NIH AND

3416
02:16:04,487 --> 02:16:07,256
OVER 200 MILLION AT NCI.

3417
02:16:07,256 --> 02:16:09,525
SO LARGE SIZEABLE PROGRAM THAT

3418
02:16:09,525 --> 02:16:10,960
SMALL BUSINESS CAN TAKE

3419
02:16:10,960 --> 02:16:11,728
ADVANTAGE OF.

3420
02:16:11,728 --> 02:16:13,329
SO THE CONCEPT AWARD WAS

3421
02:16:13,329 --> 02:16:15,264
DEVELOPED IN RESPONSE TO AN

3422
02:16:15,264 --> 02:16:16,532
EXTERNAL WORKING GROUP THAT WAS

3423
02:16:16,532 --> 02:16:18,501
CONVENED BY THE NCAB.

3424
02:16:18,501 --> 02:16:21,270
IT WAS TO EVALUATE THE SBIR

3425
02:16:21,270 --> 02:16:22,271
PROGRAM AS A LOCAL.

3426
02:16:22,271 --> 02:16:23,840
ONE OF THEIR TOP RECOMMENDATIONS

3427
02:16:23,840 --> 02:16:25,875
WAS TO DEVELOP A HIGH RISK,

3428
02:16:25,875 --> 02:16:27,443
HIGH-REWARD CONCEPT PROGRAM TO

3429
02:16:27,443 --> 02:16:29,645
HELP PROMOTE PARADIGM SHIFTING

3430
02:16:29,645 --> 02:16:29,946
INNOVATION.

3431
02:16:29,946 --> 02:16:32,048
SO WITH THIS, WE PILOTED THE

3432
02:16:32,048 --> 02:16:35,752
PROGRAM AS A 3-YEAR PROGRAM IN

3433
02:16:35,752 --> 02:16:36,419
2021.

3434
02:16:36,419 --> 02:16:38,087
AND THE BIG PICTURE GOAL IS TO

3435
02:16:38,087 --> 02:16:39,822
FIND HIGH RISK, HIGH-REWARD

3436
02:16:39,822 --> 02:16:41,691
PROJECTS AT AN EARLY STAGE.

3437
02:16:41,691 --> 02:16:45,228
A HIGH BAR ON INNOVATION AND THE

3438
02:16:45,228 --> 02:16:46,662
PEER-REVIEWED SCORING HAS BEEN

3439
02:16:46,662 --> 02:16:48,097
ADJUSTED WITH THE 50% WEIGHT

3440
02:16:48,097 --> 02:16:50,166
FOCUSED ON INNOVATION AND THE

3441
02:16:50,166 --> 02:16:52,335
SECOND COMPONENT IS WHERE

3442
02:16:52,335 --> 02:16:53,202
FOCUSING ON THIS SPECIFICALLY

3443
02:16:53,202 --> 02:16:55,405
FOR RARE AND PEDIATRIC CANCER

3444
02:16:55,405 --> 02:16:55,738
TECHNOLOGIES.

3445
02:16:55,738 --> 02:16:57,740
WE THINK THERE IS A NICE NATURAL

3446
02:16:57,740 --> 02:16:59,041
FIT WITH FEDERAL FUNDING AND

3447
02:16:59,041 --> 02:17:01,043
STIMULATION OF EARLY STAGE

3448
02:17:01,043 --> 02:17:02,812
INNOVATION AND SOME OF THESE LOW

3449
02:17:02,812 --> 02:17:04,080
POPULATION CANCER INDICATIONS

3450
02:17:04,080 --> 02:17:06,616
WHERE IT IS QUITE CHALLENGING

3451
02:17:06,616 --> 02:17:08,484
AND DIFFICULT FOR COMPANIES TO

3452
02:17:08,484 --> 02:17:09,318
COMMERCIALIZE TECHNOLOGIES IN

3453
02:17:09,318 --> 02:17:10,987
THE SPACE AND TRYING TO LOWER

3454
02:17:10,987 --> 02:17:11,821
THE BAR A BIT.

3455
02:17:11,821 --> 02:17:14,524
SO THE CONCEPT AWARDS IS 300,000

3456
02:17:14,524 --> 02:17:15,958
CONTRACT FUNDING OPPORTUNITY FOR

3457
02:17:15,958 --> 02:17:18,060
ONE YEAR PROJECTS.

3458
02:17:18,060 --> 02:17:18,694
THE OTHER BIG PIECE OF THIS IS

3459
02:17:18,694 --> 02:17:19,996
NO PRELIMINARY DATA IS REQUIRED

3460
02:17:19,996 --> 02:17:21,898
SO WE ARE AND HAVE BEEN

3461
02:17:21,898 --> 02:17:23,366
SUCCESSFUL IN FUNDING PROJECTS

3462
02:17:23,366 --> 02:17:24,867
THAT HAVE LIMITED AND IN SOME

3463
02:17:24,867 --> 02:17:26,602
CASES NO PRELIMINARY DATA.

3464
02:17:26,602 --> 02:17:28,037
THIS IS QUITE DIFFERENT FROM THE

3465
02:17:28,037 --> 02:17:29,205
REST OF OUR FUNDING

3466
02:17:29,205 --> 02:17:31,607
OPPORTUNITIES WITHIN THE SBIR

3467
02:17:31,607 --> 02:17:31,841
PROGRAM.

3468
02:17:31,841 --> 02:17:34,510
AND OUR GOAL IS TO GET THIS

3469
02:17:34,510 --> 02:17:36,379
FEDERAL FUNDING TO COMPANIES TO

3470
02:17:36,379 --> 02:17:38,448
PERFORM THE EXPERIMENTS AND TO

3471
02:17:38,448 --> 02:17:40,249
OBTAIN THIS INITIAL DERISKING.

3472
02:17:40,249 --> 02:17:41,584
I'LL USE THAT LANGUAGE A FEW

3473
02:17:41,584 --> 02:17:44,353
TIMES IN THE PRESENTATION.

3474
02:17:44,353 --> 02:17:46,255
THAT MEANS THE COMPANIES

3475
02:17:46,255 --> 02:17:47,790
GENERATING SOME OF THIS

3476
02:17:47,790 --> 02:17:49,625
FEASIBILITY PROOF-OF-CONCEPT

3477
02:17:49,625 --> 02:17:51,127
DATA THAT DERISKSING TECHNOLOGY

3478
02:17:51,127 --> 02:17:53,830
TOW MAKE IT MOREAL ATABLE FOR

3479
02:17:53,830 --> 02:17:55,531
FUTURE FUNDING CONSIDERATIONS

3480
02:17:55,531 --> 02:17:57,667
WHETHER THE PROGRAM OR OTHER

3481
02:17:57,667 --> 02:17:58,334
FEDERAL FUNDING OPPORTUNITIES OR

3482
02:17:58,334 --> 02:18:03,739
OUTSIDE OF FEDERAL FUNDING.

3483
02:18:03,739 --> 02:18:07,910
THE PROGRAM HAS BEEN A 3-PHASE

3484
02:18:07,910 --> 02:18:08,144
PROGRAM.

3485
02:18:08,144 --> 02:18:08,744
THESE ARE SBIR PHASES NOT

3486
02:18:08,744 --> 02:18:09,345
CLINICAL.

3487
02:18:09,345 --> 02:18:11,280
SINCE THAT, WE DEVELOPED A

3488
02:18:11,280 --> 02:18:12,815
CONCEPT AND WE VIEW IT AS

3489
02:18:12,815 --> 02:18:14,083
SITTING AT THE FOREFRONT OF OUR

3490
02:18:14,083 --> 02:18:14,350
PIPELINE.

3491
02:18:14,350 --> 02:18:17,220
SO IT ALLOWS US TO FUND HIGH

3492
02:18:17,220 --> 02:18:18,654
RISK, HIGH-REWARD PROJECTS AND

3493
02:18:18,654 --> 02:18:21,257
SERVES AS A PIPELINE OF UP

3494
02:18:21,257 --> 02:18:23,226
OVATION TO MAKE SURE OUR

3495
02:18:23,226 --> 02:18:24,427
PORTFOLIO KEEPS THESE EARLY

3496
02:18:24,427 --> 02:18:26,896
STAGE PROJECTS COMING IN.

3497
02:18:26,896 --> 02:18:28,598
SO THERE IS FOUR MAJOR PURPOSE

3498
02:18:28,598 --> 02:18:30,566
AND OBJECTIVES OF THE CONCEPT

3499
02:18:30,566 --> 02:18:31,868
AWARD I WANTED TO HIGHLIGHT FOR

3500
02:18:31,868 --> 02:18:33,202
YOU ALL.

3501
02:18:33,202 --> 02:18:34,537
THE FIRST IS PORTFOLIO

3502
02:18:34,537 --> 02:18:34,837
INNOVATION.

3503
02:18:34,837 --> 02:18:36,272
SO WE TOUCHED ON THIS AND

3504
02:18:36,272 --> 02:18:38,674
LOOKING TO FUND EARLY STAGE

3505
02:18:38,674 --> 02:18:39,308
HIGH-RISK, HIGH-REWARD PROJECTS

3506
02:18:39,308 --> 02:18:41,344
THAT HAVE THE POTENTIAL TO BE

3507
02:18:41,344 --> 02:18:41,711
TRANSFORMATIVE.

3508
02:18:41,711 --> 02:18:42,979
THE SECOND WE WANT TO UTILIZE

3509
02:18:42,979 --> 02:18:45,648
THIS MECHANISM TO ADDRESS

3510
02:18:45,648 --> 02:18:47,183
CURRENT PORTFOLIO GAPS WE HAVE

3511
02:18:47,183 --> 02:18:48,284
SPECIFICALLY FOR RARE AND

3512
02:18:48,284 --> 02:18:50,553
PEDIATRIC CANCERS AND BECAUSE

3513
02:18:50,553 --> 02:18:51,387
THESE ARE OFTEN QUITE

3514
02:18:51,387 --> 02:18:53,456
CHALLENGING TO COMMERCIALIZE WE

3515
02:18:53,456 --> 02:18:55,725
RECEIVE FEWER OF THESE

3516
02:18:55,725 --> 02:18:56,225
APPLICATIONS.

3517
02:18:56,225 --> 02:18:57,393
SO BY FOCUSING THROUGH THE

3518
02:18:57,393 --> 02:18:59,562
CONCEPT AWARD WE ARE HOPING TO

3519
02:18:59,562 --> 02:19:01,697
ADDRESS THESE PORTFOLIO GAPS.

3520
02:19:01,697 --> 02:19:03,432
THE THIRD IS, WE THINK IT IS

3521
02:19:03,432 --> 02:19:05,034
CRITICAL TO HAVE HIGH RESPONSE

3522
02:19:05,034 --> 02:19:06,869
RATES AND TAP INTO NEW

3523
02:19:06,869 --> 02:19:07,203
STAKEHOLDERS.

3524
02:19:07,203 --> 02:19:08,304
LOOKING FOR THE MOST INNOVATIVE

3525
02:19:08,304 --> 02:19:11,007
IDEAS, WE NEED TO SEE A LARGE

3526
02:19:11,007 --> 02:19:12,842
NUMBERS OF PROPOSALS TO SELECT

3527
02:19:12,842 --> 02:19:15,177
THE MOST INNOVATIVE PROJECTS AND

3528
02:19:15,177 --> 02:19:16,579
TAP INTO THE STAKEHOLDERS AT

3529
02:19:16,579 --> 02:19:19,215
THIS EARLY STAGE INNOVATION

3530
02:19:19,215 --> 02:19:21,784
STATION WHO HAVE BEEN RELUCTANT

3531
02:19:21,784 --> 02:19:22,752
TO APPLY BECAUSE OF LIMITED

3532
02:19:22,752 --> 02:19:25,021
PRELIMINARY DATA OR PREVIOUSLY

3533
02:19:25,021 --> 02:19:26,355
APPLIED BUT HAVE BEEN

3534
02:19:26,355 --> 02:19:28,624
UNSUCCESSFUL IN RECEIVING AN

3535
02:19:28,624 --> 02:19:28,824
AWARD.

3536
02:19:28,824 --> 02:19:31,527
AND THE LAST IS THIS PROJECT

3537
02:19:31,527 --> 02:19:34,664
DE-RISKING THIS TECHNOLOGY,

3538
02:19:34,664 --> 02:19:36,032
FINDING OUT IF WHATEVER IS BEING

3539
02:19:36,032 --> 02:19:37,433
PROPOSED WORKS OR NOT AND MOVING

3540
02:19:37,433 --> 02:19:38,534
IT FORWARD.

3541
02:19:38,534 --> 02:19:41,270
AND THE BIG PICTURE IMPACT IS WE

3542
02:19:41,270 --> 02:19:42,505
ARE TRYING TO ACCELERATE

3543
02:19:42,505 --> 02:19:43,406
OUT-OF-THE-BOX HIGH PATIENT

3544
02:19:43,406 --> 02:19:47,176
NEEDS FOR RARE AND PEDE 8 RICK

3545
02:19:47,176 --> 02:19:48,210
TECHNOLOGIES FROM CONCEPT TO

3546
02:19:48,210 --> 02:19:48,544
CLINIC.

3547
02:19:48,544 --> 02:19:50,112
HERE IS AN OVERVIEW OF OUR

3548
02:19:50,112 --> 02:19:51,013
AWARDS TO DATE.

3549
02:19:51,013 --> 02:19:54,917
THIS IS THROUGH TWO FUNDING

3550
02:19:54,917 --> 02:19:58,020
ROUTE, THE THIRD IS IN THE LAST

3551
02:19:58,020 --> 02:19:59,288
R IT WILL HAPPEN IN FEBRUARY OF

3552
02:19:59,288 --> 02:20:00,022
NEXT YEAR.

3553
02:20:00,022 --> 02:20:02,291
BUT THROUGH THE FIRST TWO ROUNDS

3554
02:20:02,291 --> 02:20:03,793
WE MADE 13 AWARDS TO DATE JUST

3555
02:20:03,793 --> 02:20:07,430
UNDER 4 MILLION IN NCI FUNDING.

3556
02:20:07,430 --> 02:20:08,831
THE NEXT METRIC WE DISCOVERED IS

3557
02:20:08,831 --> 02:20:11,601
38% OF AWARDS WERE MADE TO WOMEN

3558
02:20:11,601 --> 02:20:13,202
AND UNDERREPRESENTED MINORITIES

3559
02:20:13,202 --> 02:20:16,272
SO THAT MEANS THE SMALL BUSINESS

3560
02:20:16,272 --> 02:20:17,807
CONCERNS -- THESE DEMOGRAPHICS

3561
02:20:17,807 --> 02:20:19,175
AND THEIR LEADERSHIP POSITIONS.

3562
02:20:19,175 --> 02:20:22,578
AND IN TERMS OF PROJECT TYPES,

3563
02:20:22,578 --> 02:20:23,813
WE FUNDED A GOOD CHUNK OF

3564
02:20:23,813 --> 02:20:25,414
THERAPEUTICS AND ALSO SUCCESSFUL

3565
02:20:25,414 --> 02:20:27,650
IN FUNDING DIAGNOSTIC AND

3566
02:20:27,650 --> 02:20:28,651
LABORATORY TESTS.

3567
02:20:28,651 --> 02:20:32,555
IN TERMS OF INDICATIONS, WE ARE

3568
02:20:32,555 --> 02:20:33,823
FUNDING PEDIATRIC INDICATIONS

3569
02:20:33,823 --> 02:20:34,624
AND RARE INDICATIONS.

3570
02:20:34,624 --> 02:20:37,193
WE HAVE THINGS THAT ARE

3571
02:20:37,193 --> 02:20:38,527
ULTRARARE AND THINGS THAT ARE

3572
02:20:38,527 --> 02:20:40,363
LESS RAY RARE.

3573
02:20:40,363 --> 02:20:42,565
SO OUR DEFINITION IS BROAD

3574
02:20:42,565 --> 02:20:44,900
BECAUSE THE FOCUS IS ON

3575
02:20:44,900 --> 02:20:45,534
INNOVATION.

3576
02:20:45,534 --> 02:20:47,536
SO PANCREATIC CANCER IS LESS

3577
02:20:47,536 --> 02:20:49,538
RARE BUT STILL HAVE EXTREMELY

3578
02:20:49,538 --> 02:20:51,474
LOW SURVIVAL RATES, REALLY ARE

3579
02:20:51,474 --> 02:20:54,110
IN NEED OF IMPROVEMENTS OF

3580
02:20:54,110 --> 02:20:56,278
STANDARD OF CARE.

3581
02:20:56,278 --> 02:20:58,881
SO AN EXTERNAL EVALUATION

3582
02:20:58,881 --> 02:21:00,716
COMMITTEE WAS BROUGHT INTO

3583
02:21:00,716 --> 02:21:02,685
EVALUATE WHERE WE ARE WITH THE

3584
02:21:02,685 --> 02:21:04,620
CONCEPT AWARD PROGRAM.

3585
02:21:04,620 --> 02:21:08,257
IT'S CHAIRED BY DR. MEL

3586
02:21:08,257 --> 02:21:12,061
BILLINGSLY, PRESIDENT AND CEO OF

3587
02:21:12,061 --> 02:21:13,029
A LIFE SCIENCESES AND GREENHOUSE

3588
02:21:13,029 --> 02:21:13,996
IN PENNSYLVANIA.

3589
02:21:13,996 --> 02:21:16,832
HE CHAIRED THE ORIGINAL WORKING

3590
02:21:16,832 --> 02:21:18,668
GROUP WHO IS CONVENED AND

3591
02:21:18,668 --> 02:21:20,002
DEVELOPED THE IDEA FOR THE

3592
02:21:20,002 --> 02:21:20,670
CONCEPT AWARD.

3593
02:21:20,670 --> 02:21:22,071
WE THOUGHT IT WAS IMPORTANT TO

3594
02:21:22,071 --> 02:21:24,573
BRING HIM BACK FOR THIS

3595
02:21:24,573 --> 02:21:24,874
EVALUATION.

3596
02:21:24,874 --> 02:21:25,741
NEXT COUPLE SLIDES ARE SOME OF

3597
02:21:25,741 --> 02:21:28,577
THE KEY DATA WE PRESENTED TO THE

3598
02:21:28,577 --> 02:21:30,479
EXTERM WORKING GROUP AND WANTED

3599
02:21:30,479 --> 02:21:31,547
TO HIGHLIGHT FOR BSA.

3600
02:21:31,547 --> 02:21:33,416
THIS IS TO ILLUSTRATE WE ARE

3601
02:21:33,416 --> 02:21:34,350
DEFINITELY RECEIVING HIGH

3602
02:21:34,350 --> 02:21:35,584
RESPONSE RATES AND ARE TAPPING

3603
02:21:35,584 --> 02:21:36,986
INTO NEW STAKEHOLDERS.

3604
02:21:36,986 --> 02:21:39,055
SO THE CONCEPT AWARD UTILIZING A

3605
02:21:39,055 --> 02:21:40,256
WHITE PAPER PROCESS.

3606
02:21:40,256 --> 02:21:42,158
THE WHITE PAPER IS A SHORT 2-3

3607
02:21:42,158 --> 02:21:44,293
PAGE SUMMARY OF THE TECHNOLOGY

3608
02:21:44,293 --> 02:21:46,128
THAT OFFERS TO SUBMIT AND GET

3609
02:21:46,128 --> 02:21:48,831
QUICK FEEDBACK FROM NCI ON WHAT

3610
02:21:48,831 --> 02:21:50,299
IS BEING PROPOSED IS WITHIN

3611
02:21:50,299 --> 02:21:52,134
SCOPE OF THINGS WE WANT TO FUND

3612
02:21:52,134 --> 02:21:52,535
FOR THIS.

3613
02:21:52,535 --> 02:21:54,336
AND YOU CAN SEE FOR THE PAST

3614
02:21:54,336 --> 02:21:56,472
THREE FISCAL YEARS, WE RECEIVED

3615
02:21:56,472 --> 02:21:58,374
ANYWHERE BETWEEN 70-100 WHITE

3616
02:21:58,374 --> 02:21:58,607
PAPERS.

3617
02:21:58,607 --> 02:22:00,409
THIS LEADS TO A GOOD NUMBER OF

3618
02:22:00,409 --> 02:22:01,877
FULL PROPOSALS AND AWARDS THAT

3619
02:22:01,877 --> 02:22:03,079
ARE ABLE TO BE MADE.

3620
02:22:03,079 --> 02:22:05,715
THE OTHER COMPONENT IS 80% OF

3621
02:22:05,715 --> 02:22:08,551
WHITE PAPERS AND JUST UNDER 70%

3622
02:22:08,551 --> 02:22:11,087
OF AWARDS REPRESENT COMPANIES

3623
02:22:11,087 --> 02:22:12,388
NEW TO THESE FUNDS.

3624
02:22:12,388 --> 02:22:14,623
LIKELY THEY ARE INVOLVED IN THIS

3625
02:22:14,623 --> 02:22:16,225
EARLY SPACE AND THIS MECHANISM

3626
02:22:16,225 --> 02:22:19,729
THEY ARE ABLE TO GAIN ACCESS TO

3627
02:22:19,729 --> 02:22:20,296
THE PROGRAM.

3628
02:22:20,296 --> 02:22:23,132
THIS SLIDE TO TO ILLUSTRATE THE

3629
02:22:23,132 --> 02:22:24,967
AWARDS ADDRESS OUR PORTFOLIO

3630
02:22:24,967 --> 02:22:28,104
GAPS FOR RARE AND PEDIATRIC

3631
02:22:28,104 --> 02:22:28,337
CANCER.

3632
02:22:28,337 --> 02:22:30,439
THE TECHNOLOGY CLASS AND THEN

3633
02:22:30,439 --> 02:22:32,341
THE SPECIFIC INDICATION FOR EACH

3634
02:22:32,341 --> 02:22:34,143
AWARD AND THE FAR COLUMN ON THE

3635
02:22:34,143 --> 02:22:35,845
RIGHT INDICATES OUR VIEW POINTED

3636
02:22:35,845 --> 02:22:37,546
OF WHETHER THAT IS CURRENTLY

3637
02:22:37,546 --> 02:22:39,014
UNDER REPRESENTED IN OUR

3638
02:22:39,014 --> 02:22:40,349
PORTFOLIO.

3639
02:22:40,349 --> 02:22:41,317
SO THE CHECKMARK ILLUSTRATES

3640
02:22:41,317 --> 02:22:42,051
THAT AND EVEN FURTHER TO THE

3641
02:22:42,051 --> 02:22:43,652
RIGHT IT GIVES A NUMBER OF

3642
02:22:43,652 --> 02:22:43,886
AWARDS.

3643
02:22:43,886 --> 02:22:46,188
SO THESE ARE BASE PROJECTS AND

3644
02:22:46,188 --> 02:22:48,858
THIS INDICATES SPACE FOR OUR

3645
02:22:48,858 --> 02:22:50,459
FUNDING HISTORY.

3646
02:22:50,459 --> 02:22:53,863
IN SOME CASES, THESE INDICATIONS

3647
02:22:53,863 --> 02:22:54,330
ONLY HAVE ONE AWARD.

3648
02:22:54,330 --> 02:22:57,333
SO DEFINITELY ADDRESSING THESE

3649
02:22:57,333 --> 02:22:58,300
PORTFOLIO GAPS.

3650
02:22:58,300 --> 02:23:02,338
85% OF AWARDS WERE MADE ON THE

3651
02:23:02,338 --> 02:23:02,805
INDICATION SPACE.

3652
02:23:02,805 --> 02:23:05,040
IN TERMS OF PORTFOLIO

3653
02:23:05,040 --> 02:23:06,776
INNOVATION, WE ARE GETTING

3654
02:23:06,776 --> 02:23:08,210
REALLY INNOVATIVE PROJECTS,

3655
02:23:08,210 --> 02:23:11,247
NOVEL TECHNOLOGY CLASSES SUCH AS

3656
02:23:11,247 --> 02:23:13,916
NEXT GENERATION CAR T

3657
02:23:13,916 --> 02:23:14,984
TECHNOLOGIES.

3658
02:23:14,984 --> 02:23:17,453
FIRST-IN-CLASS THERAPEUTIC

3659
02:23:17,453 --> 02:23:19,722
TARGETS, NOVEL DRUG DELIVERY

3660
02:23:19,722 --> 02:23:20,022
METHODS.

3661
02:23:20,022 --> 02:23:23,292
DIAGNOSTIC AND DEVICES AS WELL.

3662
02:23:23,292 --> 02:23:24,660
IN TERMS OF PROJECT DE-RISKING,

3663
02:23:24,660 --> 02:23:27,630
WE HAVE ABOUT SIX COMPANIES THAT

3664
02:23:27,630 --> 02:23:28,497
ARE FULLY VALUABLE AT THIS STAGE

3665
02:23:28,497 --> 02:23:30,166
GIVEN ENOUGH TIME POST AWARD.

3666
02:23:30,166 --> 02:23:32,268
OF THESE SIX TWO HAVE BEEN

3667
02:23:32,268 --> 02:23:33,302
EXTREMELY SUCCESSFUL AND

3668
02:23:33,302 --> 02:23:36,672
SHOWCASING ONE HERE, A COMPANY

3669
02:23:36,672 --> 02:23:37,273
COORDINATION PHARMACEUTICALS.

3670
02:23:37,273 --> 02:23:39,508
SO THEY ARE DEVELOPING AN

3671
02:23:39,508 --> 02:23:40,810
ACTIVATABLE CANCER VACCINE FOR

3672
02:23:40,810 --> 02:23:42,144
TREATMENT OF ORAL CANCER.

3673
02:23:42,144 --> 02:23:44,146
AND THROUGH THE CONCEPT AWARD

3674
02:23:44,146 --> 02:23:45,347
THEY WERE GIVEN FUNDS TO

3675
02:23:45,347 --> 02:23:46,415
ESTABLISH THEIR FEASIBILITY.

3676
02:23:46,415 --> 02:23:48,984
THEY GENERATED A NUMBER OF

3677
02:23:48,984 --> 02:23:51,554
ROBUST IN-VIVO EFFICACY DATASETS

3678
02:23:51,554 --> 02:23:53,522
FOR RARE CANCER MODELS.

3679
02:23:53,522 --> 02:23:55,558
AND SINCE THEN THE COMPANY HAS

3680
02:23:55,558 --> 02:23:57,493
BEEN SUCCESSFUL, ABOUT 18 MONTHS

3681
02:23:57,493 --> 02:23:59,461
POST AWARD USING THEIR COMPANY

3682
02:23:59,461 --> 02:24:02,164
MONEY THEY COMPLETED THEIR IND

3683
02:24:02,164 --> 02:24:04,133
AND FILED WITH FDA.

3684
02:24:04,133 --> 02:24:07,303
AND SCHEDULED TO START

3685
02:24:07,303 --> 02:24:09,772
FIRST-IN-HUMAN STUDIES IN 2024.

3686
02:24:09,772 --> 02:24:12,007
THIS IS A GOOD EXAMPLES HOW THIS

3687
02:24:12,007 --> 02:24:13,108
CAN BE LEVERAGED TO DERISK

3688
02:24:13,108 --> 02:24:14,710
TECHNOLOGY AND ACCELERATE

3689
02:24:14,710 --> 02:24:21,317
TOWARDS THE NEXT INFLECTION

3690
02:24:21,317 --> 02:24:21,617
POINT.

3691
02:24:21,617 --> 02:24:23,385
THESE ARE SOME OF THE FINDINGS

3692
02:24:23,385 --> 02:24:26,155
FROM THE EXTERNAL EVALUATION

3693
02:24:26,155 --> 02:24:26,722
COMMITTEE AND COMMENTED THE

3694
02:24:26,722 --> 02:24:27,857
CONCEPT AWARD HAS SUCCESSFULLY

3695
02:24:27,857 --> 02:24:29,925
MET ALL ORIGINAL EVALUATION

3696
02:24:29,925 --> 02:24:31,093
METRICS PROPOSED AT THE INITIAL

3697
02:24:31,093 --> 02:24:34,063
DEVELOPMENT OF THE CONCEPT.

3698
02:24:34,063 --> 02:24:36,866
INDEED DISRUPTED INNOVATIVE

3699
02:24:36,866 --> 02:24:38,033
APPROACHES BEING DEVELOPED FOR

3700
02:24:38,033 --> 02:24:39,335
PEDIATRIC AND RARE CANCERS.

3701
02:24:39,335 --> 02:24:42,104
THERE ARE HIGH RESPONSE RATES

3702
02:24:42,104 --> 02:24:42,771
AND THAT WE TAPPED INTO A NEW

3703
02:24:42,771 --> 02:24:45,841
POOL OF SMALL BUSINESSES FOR NEW

3704
02:24:45,841 --> 02:24:47,076
SBIR FUNDING.

3705
02:24:47,076 --> 02:24:49,879
THEY ALSO COMMENTED ABOUT THERE

3706
02:24:49,879 --> 02:24:52,014
IS PROMISING INDICATORS OF

3707
02:24:52,014 --> 02:24:53,449
FOLLOW ON FUNDING TIEING INTO

3708
02:24:53,449 --> 02:24:54,683
THE PROJECT DE-RISKING WE HAVE

3709
02:24:54,683 --> 02:24:55,651
BEEN SPEAKING ABOUT.

3710
02:24:55,651 --> 02:24:56,886
AND THEY FELT THE WHITE PAPER

3711
02:24:56,886 --> 02:24:58,888
REVIEW WAS A KEY FEATURE OF THE

3712
02:24:58,888 --> 02:25:00,890
PROGRAM AND THE WHITE PAPER

3713
02:25:00,890 --> 02:25:02,958
PROCESS ITSELF IS A NICE WIN FOR

3714
02:25:02,958 --> 02:25:03,726
NIH.

3715
02:25:03,726 --> 02:25:06,195
EACH YEAR WE ARE ABLE TO RECRUIT

3716
02:25:06,195 --> 02:25:07,196
70 DIFFERENT WHITE PAPER

3717
02:25:07,196 --> 02:25:10,532
REVIEWERS INTERNAL TO NIH TO

3718
02:25:10,532 --> 02:25:11,600
REVIEW WHAT THE PAPERS AND SPAN

3719
02:25:11,600 --> 02:25:12,301
MULTIPLE INSTITUTES.

3720
02:25:12,301 --> 02:25:14,503
MANY FROM NCI AND FOLKS FROM

3721
02:25:14,503 --> 02:25:17,640
NCATS AND IGMS AND NINDS AND

3722
02:25:17,640 --> 02:25:20,142
THIS WHITE PAPER PROCESS HELPS

3723
02:25:20,142 --> 02:25:21,076
US TO TRIAGE AND SELECT THE

3724
02:25:21,076 --> 02:25:22,745
INNOVATIVE PROJECTS TO MOVE

3725
02:25:22,745 --> 02:25:24,079
FORWARD FOR FULL PROPOSAL

3726
02:25:24,079 --> 02:25:25,314
SUBMISSION AND HELPS US TO MEET

3727
02:25:25,314 --> 02:25:27,082
ONE OF OUR ORIGINAL CONCEPT

3728
02:25:27,082 --> 02:25:28,083
EVALUATION METRICS WHICH WAS TO

3729
02:25:28,083 --> 02:25:30,019
MAKE AWARDS RAPIDLY WITHIN SIX

3730
02:25:30,019 --> 02:25:30,953
MONTHS.

3731
02:25:30,953 --> 02:25:32,454
SO WE THINK IT IS CRITICAL IF

3732
02:25:32,454 --> 02:25:34,456
YOU HAVE AN INNOVATIVE IDEA BUT

3733
02:25:34,456 --> 02:25:36,258
MAYBE NOT MUCH PRELIMINARY

3734
02:25:36,258 --> 02:25:37,693
DATAUX YOU WANT THE REVIEW AND

3735
02:25:37,693 --> 02:25:40,195
AWARD PROCESS TO BE AS QUICK AS

3736
02:25:40,195 --> 02:25:40,462
POSSIBLE.

3737
02:25:40,462 --> 02:25:44,800
SO FOR NIH 6 MONTHS IT'S QUITE

3738
02:25:44,800 --> 02:25:45,000
FAST.

3739
02:25:45,000 --> 02:25:46,602
TWO MAIN RECOMMENDATIONS MADE BY

3740
02:25:46,602 --> 02:25:49,138
THE EVALUATION COMMITTEE.

3741
02:25:49,138 --> 02:25:51,740
FIRST, UNANIMOUSLY RECOMMENDED

3742
02:25:51,740 --> 02:25:54,343
THE PROGRAM CONTINUE AND TWO

3743
02:25:54,343 --> 02:25:56,879
POTENTIAL IMPROVEMENTS WERE TO

3744
02:25:56,879 --> 02:25:58,514
DEVELOP ADDITIONAL FEDERAL

3745
02:25:58,514 --> 02:26:02,017
FUNDING TO SUPPORT SOME OF

3746
02:26:02,017 --> 02:26:02,217
THESE.

3747
02:26:02,217 --> 02:26:04,119
AND THE SECOND IS TO DEVELOP A

3748
02:26:04,119 --> 02:26:06,088
PITCH DAY EVENT WHERE AGAIN TO

3749
02:26:06,088 --> 02:26:08,190
HELP COMMERCIAL TRANSLATION OF

3750
02:26:08,190 --> 02:26:08,624
THESE TECHNOLOGIES.

3751
02:26:08,624 --> 02:26:11,160
SO HAVING CONCEPT AWARDS PITCH

3752
02:26:11,160 --> 02:26:15,464
THEIR TECHNOLOGY TO DIFFERENT

3753
02:26:15,464 --> 02:26:16,732
INVESTORS, FOLKS FROM NONPROFIT

3754
02:26:16,732 --> 02:26:19,201
DISEASE FOUNDATIONS, ANYONE THAT

3755
02:26:19,201 --> 02:26:23,172
HAS THE ABILITY TO HELP

3756
02:26:23,172 --> 02:26:23,939
COMMERCIALIZATION AND

3757
02:26:23,939 --> 02:26:24,306
TRANSLATION.

3758
02:26:24,306 --> 02:26:25,774
SO BASED OFF OF THAT, HERE IS

3759
02:26:25,774 --> 02:26:27,876
OUR PROPOSED RE-ISSUANCE REQUEST

3760
02:26:27,876 --> 02:26:29,578
AND BUDGET RECOMMENDATIONS.

3761
02:26:29,578 --> 02:26:31,647
SO REQUESTING 5-YEAR APPROVAL.

3762
02:26:31,647 --> 02:26:33,282
WE THINK IT'S A GOOD IDEA TO

3763
02:26:33,282 --> 02:26:34,550
MAINTAIN THE CURRENT CONCEPT

3764
02:26:34,550 --> 02:26:38,587
AWARD SIZE AT 300,000 FOR PHASE

3765
02:26:38,587 --> 02:26:38,821
I.

3766
02:26:38,821 --> 02:26:40,656
NOW PROPOSING TO DEVELOP FOLLOW

3767
02:26:40,656 --> 02:26:43,559
ON FEES, NOTICES OF FUNDING

3768
02:26:43,559 --> 02:26:43,926
OPPORTUNITIES.

3769
02:26:43,926 --> 02:26:45,694
AND THIS CAN BE A PHASE II OR

3770
02:26:45,694 --> 02:26:48,263
FAST TRACK OF 3 MILLION TO 3.5

3771
02:26:48,263 --> 02:26:48,497
MILLION.

3772
02:26:48,497 --> 02:26:50,499
AND THE REASON FOR THIS IS, WE

3773
02:26:50,499 --> 02:26:53,569
THINK ONCE THESE HAVE

3774
02:26:53,569 --> 02:26:54,203
OUT-OF-THE-BOX IDEAS, THESE

3775
02:26:54,203 --> 02:26:55,904
PROJECTS ARE DERISKED, IT'S

3776
02:26:55,904 --> 02:26:58,240
CRITICAL TO CREATE A STREAMLINED

3777
02:26:58,240 --> 02:27:00,142
PHASE II FUNDING PATH WHERE THEY

3778
02:27:00,142 --> 02:27:01,577
CAN MOVE THESE TECHNOLOGIES

3779
02:27:01,577 --> 02:27:05,514
FORWARD TO THE NEXT INFLECTION

3780
02:27:05,514 --> 02:27:05,714
POINT.

3781
02:27:05,714 --> 02:27:06,348
ANOTHER NICE THING WITH THESE

3782
02:27:06,348 --> 02:27:07,983
PHASE IIs IS WE HAD A LOT OF

3783
02:27:07,983 --> 02:27:10,486
MEETINGS AND DISCUSSIONS WITH

3784
02:27:10,486 --> 02:27:14,590
ANNUALA H SO THEY ARE

3785
02:27:14,590 --> 02:27:15,057
INTERESTED -- ARPA-H.

3786
02:27:15,057 --> 02:27:16,325
AND WE DO HAVE PREVIOUS

3787
02:27:16,325 --> 02:27:20,029
COFUNDING HISTORY WITH ARPA-H

3788
02:27:20,029 --> 02:27:23,599
LAST YEAR AND WE COFUNDED 5.7

3789
02:27:23,599 --> 02:27:26,001
MILLION IN SBIR PROJECTS.

3790
02:27:26,001 --> 02:27:27,202
THIS IS MY LAST SLIDE.

3791
02:27:27,202 --> 02:27:29,338
I WANTED TO ILLUSTRATE THAT THE

3792
02:27:29,338 --> 02:27:30,439
RFP PROCESS IS DEFINITELY

3793
02:27:30,439 --> 02:27:33,208
CRITICAL FOR CONCEPT AWARD AND

3794
02:27:33,208 --> 02:27:34,710
ALLOWS US TO DEVELOP THE SPECIAL

3795
02:27:34,710 --> 02:27:36,912
REVIEW CRITERIA WITH THIS

3796
02:27:36,912 --> 02:27:38,814
ENHANCED SCORE ON INNOVATION AND

3797
02:27:38,814 --> 02:27:41,250
ALLOWS US TO GENERATE THIS PANEL

3798
02:27:41,250 --> 02:27:44,053
WITH REVIEWERS WITH EXPERTISE IN

3799
02:27:44,053 --> 02:27:45,354
EVALUATING EARLY STAGE

3800
02:27:45,354 --> 02:27:45,721
INNOVATION.

3801
02:27:45,721 --> 02:27:48,690
IT ALLOWS US TO DEVELOP A

3802
02:27:48,690 --> 02:27:50,492
STREAMLINED PROPOSAL PROCESS.

3803
02:27:50,492 --> 02:27:52,161
THE WHITE PAPER PROCESS AND ALSO

3804
02:27:52,161 --> 02:27:53,962
GENERATED A FILLABLE FULL

3805
02:27:53,962 --> 02:27:56,465
PROPOSAL TEMPLATE QUITE NEW AND

3806
02:27:56,465 --> 02:27:59,101
IT ALLOWS TO ENTER STREAMLINED

3807
02:27:59,101 --> 02:28:00,235
INFORMATION IN A SIMPLIFIED

3808
02:28:00,235 --> 02:28:02,771
MANNER AND ALLOWS FOR PEER

3809
02:28:02,771 --> 02:28:05,607
REVIEW AND IT ALLOWS US TO GET

3810
02:28:05,607 --> 02:28:07,743
THAT CONCEPT METRIC OF MAKING

3811
02:28:07,743 --> 02:28:11,080
AWARDS RAPIDLY WITHIN SIX

3812
02:28:11,080 --> 02:28:11,313
MONTHS.

3813
02:28:11,313 --> 02:28:12,014
SO I'LL STOP HERE.

3814
02:28:12,014 --> 02:28:13,248
THANK YOU AND I'M HAPPY TO

3815
02:28:13,248 --> 02:28:19,521
ANSWER ANY QUESTIONS.

3816
02:28:19,521 --> 02:28:19,888
>> THANK YOU.

3817
02:28:19,888 --> 02:28:21,290
WOULD YOU LIKE TO GET THE

3818
02:28:21,290 --> 02:28:24,960
CONVERSATION GOING?

3819
02:28:24,960 --> 02:28:25,494
>> THANKS.

3820
02:28:25,494 --> 02:28:26,662
WE HAD THE OPPORTUNITY TO

3821
02:28:26,662 --> 02:28:30,866
GET-TOGETHER A FEW WEEKS AGO.

3822
02:28:30,866 --> 02:28:33,368
I THINK DR. CHANDRA AND OTHERS,

3823
02:28:33,368 --> 02:28:36,972
WE HAD A PRETTY GOOD DISCUSSION.

3824
02:28:36,972 --> 02:28:39,741
ESSENTIALLY HE PRESENTED TO US

3825
02:28:39,741 --> 02:28:40,709
MOSTLY WHAT YOU HEARD.

3826
02:28:40,709 --> 02:28:44,379
WE ALL CAME AWAY VERY

3827
02:28:44,379 --> 02:28:44,713
ENTHUSIASTIC.

3828
02:28:44,713 --> 02:28:46,615
WE THOUGHT THIS WAS AN IMPORTANT

3829
02:28:46,615 --> 02:28:50,552
PROGRAM AND THAT THEY HAD

3830
02:28:50,552 --> 02:28:52,187
ACHIEVED EVERYTHING THEY SET OUT

3831
02:28:52,187 --> 02:28:55,924
AS THE OBJECTIVES AND THAT THE

3832
02:28:55,924 --> 02:29:00,896
RESPONSE HAD BEEN VERY ENCOUR 

3833
02:29:00,896 --> 02:29:02,598
ENCOURAGING THERE WERE SOME

3834
02:29:02,598 --> 02:29:04,933
QUESTIONS ABOUT WHY IS PAN

3835
02:29:04,933 --> 02:29:06,835
COUNTRY ATTIC CANCER A RARE

3836
02:29:06,835 --> 02:29:07,369
CANCER?

3837
02:29:07,369 --> 02:29:08,804
BUT YOU HEARD THE ANSWER THAT

3838
02:29:08,804 --> 02:29:10,973
WAS GIVEN.

3839
02:29:10,973 --> 02:29:13,342
IT SEEMED QUITEERABLY.

3840
02:29:13,342 --> 02:29:15,310
AND THERE WERE SOME SUGGESTIONS

3841
02:29:15,310 --> 02:29:16,411
ABOUT -- QUITE REASONABLE --

3842
02:29:16,411 --> 02:29:17,813
RAISE CAN AWARENESS OF THIS

3843
02:29:17,813 --> 02:29:19,348
PROGRAM AMONG THE PEOPLE WHO ARE

3844
02:29:19,348 --> 02:29:24,286
LIKELY TO BE INTERESTED IN IT.

3845
02:29:24,286 --> 02:29:25,587
I THINK THERE WERE

3846
02:29:25,587 --> 02:29:27,122
RECOMMENDATIONS COME YOU ALREADY

3847
02:29:27,122 --> 02:29:27,322
HEARD.

3848
02:29:27,322 --> 02:29:29,725
SO HOWEVER ALL, WE FEEL LIKE

3849
02:29:29,725 --> 02:29:33,328
THIS IS A TH TH THIS IS A PROPAT

3850
02:29:33,328 --> 02:29:33,996
SHOULD MOVE FORWARD.

3851
02:29:33,996 --> 02:29:36,298
WE WERE UNANIMOUS ON THAT.

3852
02:29:36,298 --> 02:29:37,799
DR. ARI, DO YOU HAVE ANY

3853
02:29:37,799 --> 02:29:39,401
COMMENTS?

3854
02:29:39,401 --> 02:29:40,068
>> SURE.

3855
02:29:40,068 --> 02:29:40,869
I CAN DIME IN.

3856
02:29:40,869 --> 02:29:43,772
AND AGAIN -- CHIME IN.

3857
02:29:43,772 --> 02:29:47,643
I RECALL WHAT WAS JUST MENTIONED

3858
02:29:47,643 --> 02:29:48,510
AND DR. BOSSA, CONGRATULATIONS.

3859
02:29:48,510 --> 02:29:50,846
WE ENJOYED YOUR TALK THEN AND

3860
02:29:50,846 --> 02:29:51,680
NOW AS WELL.

3861
02:29:51,680 --> 02:29:53,048
AND THIS IS VERY IMPORTANT.

3862
02:29:53,048 --> 02:29:57,786
AND I SPEAK FROM PERSONAL

3863
02:29:57,786 --> 02:29:59,788
EXPERIENCE BECAUSE SOME OF THESE

3864
02:29:59,788 --> 02:30:01,356
OUT-OF-THE-BOX IDEAS, THERE IS A

3865
02:30:01,356 --> 02:30:02,991
VALLEY OF DEBT.

3866
02:30:02,991 --> 02:30:05,327
YOU DON'T HAVE ENOUGH DATA.

3867
02:30:05,327 --> 02:30:07,196
TO GET DATA YOU NEED FUNDING BUT

3868
02:30:07,196 --> 02:30:08,597
YOU DON'T HAVE FUNDING TO

3869
02:30:08,597 --> 02:30:10,132
GENERATE THAT DATA.

3870
02:30:10,132 --> 02:30:13,802
SO A GOOD NUMBER OF NEW

3871
02:30:13,802 --> 02:30:14,603
INVENTIONS START IN THAT VALLEY

3872
02:30:14,603 --> 02:30:15,704
OF DEBT.

3873
02:30:15,704 --> 02:30:18,006
I THINK THIS IS QUITE -- AND

3874
02:30:18,006 --> 02:30:20,242
THERE IS A FEW THINGS LIKE WE

3875
02:30:20,242 --> 02:30:21,443
DISCUSSED, ONE IS HOW TO

3876
02:30:21,443 --> 02:30:21,743
ADVERTISE.

3877
02:30:21,743 --> 02:30:26,215
AND THANK YOU FOR SHARING THAT

3878
02:30:26,215 --> 02:30:28,250
ONE-PAGE PAMPHLET OR BROCHURE.

3879
02:30:28,250 --> 02:30:29,751
BECAUSE IN ADDITION TO GO TO

3880
02:30:29,751 --> 02:30:32,254
ACR, WE COULD TAKE THAT TO ASCO,

3881
02:30:32,254 --> 02:30:36,124
SOCIETY OF ONCOLOGY, ASTRO AND

3882
02:30:36,124 --> 02:30:40,696
ALL THE OTHER CANCER SOCIETIES.

3883
02:30:40,696 --> 02:30:42,965
THEN ONE OR TWO OTHER COMMENTS,

3884
02:30:42,965 --> 02:30:45,434
IT IS IMPRESSIVE THAT THE

3885
02:30:45,434 --> 02:30:47,736
TURN-AROUND TIME REMAINS AT SIX

3886
02:30:47,736 --> 02:30:50,472
MONTHS AND TWO, AS A SURGEON, I

3887
02:30:50,472 --> 02:30:51,873
HAVE TO SAY THIS, WHILE DEVICES

3888
02:30:51,873 --> 02:30:54,209
ACCOUNT FOR ABOUT 15%, IT WOULD

3889
02:30:54,209 --> 02:30:57,079
BE NICE TO SEE MORE DEVICES

3890
02:30:57,079 --> 02:31:00,415
BEING INCLUDED IN THIS BECAUSE

3891
02:31:00,415 --> 02:31:02,951
IT CONSISTENTLY SEEMS TO BE THE

3892
02:31:02,951 --> 02:31:05,587
STEPCHILD OF FUNDING.

3893
02:31:05,587 --> 02:31:06,922
BUT OTHERWISE, I THINK IT'S A

3894
02:31:06,922 --> 02:31:09,157
GREAT CONCEPT THAT'S BEING GONE

3895
02:31:09,157 --> 02:31:10,158
ON.

3896
02:31:10,158 --> 02:31:11,727
WE WHOLEHEARTEDLY SUPPORT IT.

3897
02:31:11,727 --> 02:31:12,661
>> THANK YOU.

3898
02:31:12,661 --> 02:31:16,531
HOWARD AND THEN JULIE?

3899
02:31:16,531 --> 02:31:16,832
>> SURE.

3900
02:31:16,832 --> 02:31:19,368
I ALSO SUPPORT AND SHARE WITH

3901
02:31:19,368 --> 02:31:19,601
OTHERS.

3902
02:31:19,601 --> 02:31:23,505
BUT I'D LIKE TO ASK ABOUT THE

3903
02:31:23,505 --> 02:31:25,440
FOLLOW-UP AND YOUR EVALUATION

3904
02:31:25,440 --> 02:31:27,409
METRICS GOING FORWARD.

3905
02:31:27,409 --> 02:31:29,511
YOU MENTIONED GETTING INTO AN

3906
02:31:29,511 --> 02:31:34,049
IND BUT CAN THERE BE ANY KIND OF

3907
02:31:34,049 --> 02:31:37,486
HISTORY OF SUCCESSFUL SUSTAINED

3908
02:31:37,486 --> 02:31:38,487
COMMERCIAL ACCESS?

3909
02:31:38,487 --> 02:31:41,023
THERE IS A LOT OF FAILURES THAT

3910
02:31:41,023 --> 02:31:45,060
END IN IND OR PHASE I AND NEVER

3911
02:31:45,060 --> 02:31:46,128
GET A PARTNERSHIP GOING FORWARD.

3912
02:31:46,128 --> 02:31:48,597
BECAUSE I MEAN, I DO THINK THAT

3913
02:31:48,597 --> 02:31:51,333
THERE IS VALUE IN UNDERSTANDING

3914
02:31:51,333 --> 02:31:53,235
THAT PROCESS AND MAYBE FINDING

3915
02:31:53,235 --> 02:31:55,270
WAYS TO SUPPORT IT GOING

3916
02:31:55,270 --> 02:31:55,637
FORWARD.

3917
02:31:55,637 --> 02:31:58,073
SO THERE IS COMMERCIAL ACCESS.

3918
02:31:58,073 --> 02:32:01,076
AND ANOTHER METRIC FOR

3919
02:32:01,076 --> 02:32:04,579
EVALUATION WILL BE THE NUMBER OF

3920
02:32:04,579 --> 02:32:05,814
PATIENTS IN THE UNITED STATES

3921
02:32:05,814 --> 02:32:09,384
THAT GET TO EXPERIENCE THE FINAL

3922
02:32:09,384 --> 02:32:11,086
PLAN OR THE GOAL OF WHAT THE

3923
02:32:11,086 --> 02:32:16,892
PROGRAM AND THE PROTOCOL IS

3924
02:32:16,892 --> 02:32:17,092
ABOUT.

3925
02:32:17,092 --> 02:32:19,494
AND ANYWAY, JUST COMMENTS GOING

3926
02:32:19,494 --> 02:32:20,929
FORWARD AND MAYBE YOU COULD

3927
02:32:20,929 --> 02:32:22,597
COMMENT ON JUST PLANS GOING

3928
02:32:22,597 --> 02:32:24,132
FORWARD THAT WE MIGHT GET MORE

3929
02:32:24,132 --> 02:32:27,736
LARGER FEEDBACK AND LEARN FROM

3930
02:32:27,736 --> 02:32:29,905
AS THIS PROCEEDS.

3931
02:32:29,905 --> 02:32:30,706
>> THANK YOU.

3932
02:32:30,706 --> 02:32:31,006
ABSOLUTELY.

3933
02:32:31,006 --> 02:32:34,276
THOSE ARE METRICS THAT WE

3934
02:32:34,276 --> 02:32:36,945
UTILIZE TO EVALUATE THAT PROGRAM

3935
02:32:36,945 --> 02:32:37,846
AS A WHOLE.

3936
02:32:37,846 --> 02:32:38,480
OBVIOUSLY COMMERCIALIZATION IS

3937
02:32:38,480 --> 02:32:41,516
THE NUMBER 1 THICK WE WANT TO

3938
02:32:41,516 --> 02:32:41,817
SEE HAPPEN.

3939
02:32:41,817 --> 02:32:43,719
I THINK IT'S CRITICAL.

3940
02:32:43,719 --> 02:32:45,287
SO IT'S BEEN PILOTED SO FAR FOR

3941
02:32:45,287 --> 02:32:47,289
THREE YEARS EXTENDING IT FURTHER

3942
02:32:47,289 --> 02:32:48,156
FOR FIVE YEARS.

3943
02:32:48,156 --> 02:32:49,958
IT'S GOING TO GET US TO A POINT

3944
02:32:49,958 --> 02:32:51,493
WHERE WE CAN START TO SEE

3945
02:32:51,493 --> 02:32:52,894
WHETHER THESE METRICS ARE BEING

3946
02:32:52,894 --> 02:32:53,562
MET.

3947
02:32:53,562 --> 02:32:57,766
SO EARLY SIGNS ARE POSITIVE.

3948
02:32:57,766 --> 02:32:59,234
IND IS NOT -- A COUPLE OF YEARS

3949
02:32:59,234 --> 02:33:02,504
TO GO BEFORE YOU GET TO BLA OR

3950
02:33:02,504 --> 02:33:04,406
GET TO COMMERCIALIZATION.

3951
02:33:04,406 --> 02:33:06,475
BUT WE DO HAVE ONE OTHER

3952
02:33:06,475 --> 02:33:06,708
EXAMPLE.

3953
02:33:06,708 --> 02:33:07,442
IT'S A DEVICE COMPANY.

3954
02:33:07,442 --> 02:33:08,677
THEY HAVE COMMERCIAL SALES

3955
02:33:08,677 --> 02:33:11,146
ALREADY WHICH WAS QUITE

3956
02:33:11,146 --> 02:33:11,446
IMPRESSIVE.

3957
02:33:11,446 --> 02:33:13,682
THEY HAVE 7 MILLION IN DEVICE

3958
02:33:13,682 --> 02:33:16,752
SALES WITHIN THE 18 MONTHS

3959
02:33:16,752 --> 02:33:18,286
POST-AWARD PROCESS.

3960
02:33:18,286 --> 02:33:19,721
SO THAT IS SOMETHING THAT IS ON

3961
02:33:19,721 --> 02:33:24,493
OUR RADAR AND PLAN TOO CONTINUE

3962
02:33:24,493 --> 02:33:27,195
MONITORING.

3963
02:33:27,195 --> 02:33:30,365
>> I WANTED TO COMPLIMENT
YOU.

3964
02:33:30,365 --> 02:33:32,701
I THINK THIS IS AN INCREDIBLE

3965
02:33:32,701 --> 02:33:35,704
EXAMPLE OF THE NCI'S AGILITY.

3966
02:33:35,704 --> 02:33:39,374
I WAS PART OF THE GROUP THAT

3967
02:33:39,374 --> 02:33:42,744
WROTE THE CONCEPT GOALS.

3968
02:33:42,744 --> 02:33:45,514
AND THAT CAME FROM AN NCAB

3969
02:33:45,514 --> 02:33:48,350
REVIEW FOR SBIR SPONSORED BY NED

3970
02:33:48,350 --> 02:33:51,386
SHARPLESS AND IT WAS THE --

3971
02:33:51,386 --> 02:33:52,320
JAFFEE WAS THE CHAIR OF THAT

3972
02:33:52,320 --> 02:33:52,521
GROUP.

3973
02:33:52,521 --> 02:33:54,322
I THINK THIS IS AN EXAMPLE OF A

3974
02:33:54,322 --> 02:33:57,592
FULL CIRCUIT OF THE SBIR PROGRAM

3975
02:33:57,592 --> 02:34:01,463
REVIEW AND THE OBJECTIVE WAS TO

3976
02:34:01,463 --> 02:34:02,264
BRING IN MORE DIVERSE

3977
02:34:02,264 --> 02:34:04,299
APPLICATIONS NOT ONLY FRESMALL

3978
02:34:04,299 --> 02:34:06,468
COMPANIES BUT ALSO TO AREAS THAT

3979
02:34:06,468 --> 02:34:07,636
WERE NOT COVERED THROUGH OTHER

3980
02:34:07,636 --> 02:34:10,272
GRANTING MECHANISMS AND TO

3981
02:34:10,272 --> 02:34:10,972
PROVIDE FAST TURN AROUND.

3982
02:34:10,972 --> 02:34:12,674
I WOULD LOVE TO APPLAUD YOU ON

3983
02:34:12,674 --> 02:34:14,242
SEEING THE RESULTS OF THESE

3984
02:34:14,242 --> 02:34:16,144
ACTIONS IN FULL CIRCLE IN LESS

3985
02:34:16,144 --> 02:34:17,612
THAN FIVE YEARS AND SEE THREE

3986
02:34:17,612 --> 02:34:19,581
YEARS OF RESULTS.

3987
02:34:19,581 --> 02:34:21,983
THAT IS EXTRAORDINARY.

3988
02:34:21,983 --> 02:34:23,552
AND I JUST THINK IT'S REALLY

3989
02:34:23,552 --> 02:34:25,120
IMPORTANT TO HIGHLIGHT THAT

3990
02:34:25,120 --> 02:34:27,055
AGILITY WITHIN THE NCI.

3991
02:34:27,055 --> 02:34:30,759
I CONTINUE TO BELIEVE THAT THE

3992
02:34:30,759 --> 02:34:31,359
SIX MONTH TURN AROUND AND THE

3993
02:34:31,359 --> 02:34:32,360
SPEED OF THAT QUALITY REVIEW IS

3994
02:34:32,360 --> 02:34:34,329
ESSENTIAL FOR SMALL BUSINESSES.

3995
02:34:34,329 --> 02:34:35,997
IT IS ONE OF THE REASONS WHY

3996
02:34:35,997 --> 02:34:38,433
PEOPLE HISTORICALLY HAVE NOT

3997
02:34:38,433 --> 02:34:40,068
APPLIED FOR SBIRs AND SO I

3998
02:34:40,068 --> 02:34:42,237
WOULD LOVE TO CONTINUE TO

3999
02:34:42,237 --> 02:34:44,639
ENCOURAGE THE NCI TO LEVERAGE

4000
02:34:44,639 --> 02:34:46,875
ITS ABILITY TO BE AGILE IN ORDER

4001
02:34:46,875 --> 02:34:50,111
TO MEET THOSE GAPS AND I WONDER

4002
02:34:50,111 --> 02:34:51,279
IF MORE CONCEPT AWARDS CAN

4003
02:34:51,279 --> 02:34:53,849
ENABLE THE NCI TO DO THAT AT

4004
02:34:53,849 --> 02:34:55,851
BROADER SCALE.

4005
02:34:55,851 --> 02:34:56,885
>> I REALLY APPRECIATE
THOSE

4006
02:34:56,885 --> 02:34:57,152
WORDS.

4007
02:34:57,152 --> 02:34:59,020
THAT'S SOMETHING WE CONTINUALLY

4008
02:34:59,020 --> 02:35:01,556
FIGHT AND MAKE SURE BECAUSE IT

4009
02:35:01,556 --> 02:35:02,891
INVOLVES MULTIPLE OFFICE EFFORT

4010
02:35:02,891 --> 02:35:04,392
WITHIN NCI TO MAKE THAT HAPPEN.

4011
02:35:04,392 --> 02:35:07,295
IT'S SOMETHING THAT IS ON OUR

4012
02:35:07,295 --> 02:35:07,829
RADAR AND WE WORK HARD TO

4013
02:35:07,829 --> 02:35:08,563
ACHIEVE THOSE NUMBERS.

4014
02:35:08,563 --> 02:35:10,265
SO SOMETHING WE PLAN TO KEEP

4015
02:35:10,265 --> 02:35:14,102
DOING, FOR SURE.

4016
02:35:14,102 --> 02:35:15,737
>> GREAT JOB.

4017
02:35:15,737 --> 02:35:17,873
>> HI, AGAIN, I THINK THIS
IS A

4018
02:35:17,873 --> 02:35:20,442
GREAT ECHOING JULIE'S COMMENTS.

4019
02:35:20,442 --> 02:35:23,512
WHAT I WONDERED, IF THERE MIGHT

4020
02:35:23,512 --> 02:35:31,386
BE OPPORTUNITY TO LIST AS AN

4021
02:35:31,386 --> 02:35:33,522
AREA OF INTEREST THE

4022
02:35:33,522 --> 02:35:34,189
ENVIRONMENT.

4023
02:35:34,189 --> 02:35:36,024
THAT'S AN AREA THAT I THINK WE

4024
02:35:36,024 --> 02:35:39,094
DO NOT -- THERE IS SO MUCH WE

4025
02:35:39,094 --> 02:35:41,897
COULD LEARN MORE ABOUT.

4026
02:35:41,897 --> 02:35:47,002
AND ITS IMPACT ON CANCER.

4027
02:35:47,002 --> 02:35:50,605
SO, AND COMPANIES MAY HAVE

4028
02:35:50,605 --> 02:35:52,574
INTEREST AND THAT MAY BE A WAY

4029
02:35:52,574 --> 02:35:54,142
TO ACCELERATE KNOWLEDGE IN THIS

4030
02:35:54,142 --> 02:35:54,876
AREA.

4031
02:35:54,876 --> 02:35:56,811
BUT I THINK THE ENVIRONMENT IS

4032
02:35:56,811 --> 02:35:58,847
SOMETHING THAT IS VERY UNDER

4033
02:35:58,847 --> 02:35:59,080
STUDIED.

4034
02:35:59,080 --> 02:36:03,552
SO IT MAY BE AN OPPORTUNITY.

4035
02:36:03,552 --> 02:36:03,885
THANK YOU.

4036
02:36:03,885 --> 02:36:08,089
>> THANK YOU DR. LOPEZ.

4037
02:36:08,089 --> 02:36:10,592
>> I JUST WANTED TO ECHO
THE

4038
02:36:10,592 --> 02:36:13,194
COMMENTS THAT WE DO NEED TO GO

4039
02:36:13,194 --> 02:36:16,531
AFTER ANY OPPORTUNITY, INCLUDING

4040
02:36:16,531 --> 02:36:17,933
ANY STANDING ON THIS ONE, FOR

4041
02:36:17,933 --> 02:36:21,770
MORE FUNDING TO SUPPORT SURGICAL

4042
02:36:21,770 --> 02:36:24,039
INNOVATION.

4043
02:36:24,039 --> 02:36:24,406
>> ABSOLUTELY.

4044
02:36:24,406 --> 02:36:26,474
WE HAVE DONE SOME EFFORTS ON OUR

4045
02:36:26,474 --> 02:36:28,543
RADAR SO WE SEPARATED THE PEER

4046
02:36:28,543 --> 02:36:30,812
REVIEW TO HAVE ONE FOCUSED ON

4047
02:36:30,812 --> 02:36:32,480
THERAPEUTICS AND ANOTHER FOR

4048
02:36:32,480 --> 02:36:35,317
TECHNOLOGIES AND DEVICES,

4049
02:36:35,317 --> 02:36:36,217
DIAGNOSTICS, EVERYTHING NON

4050
02:36:36,217 --> 02:36:37,352
THERAPEUTICS TO MAKE SURE THAT

4051
02:36:37,352 --> 02:36:39,955
EVERYONE IS GETTING AN EQUAL AND

4052
02:36:39,955 --> 02:36:40,722
FAIR SHOT.

4053
02:36:40,722 --> 02:36:42,791
AND WE ALSO HAVE BEEN INCREASING

4054
02:36:42,791 --> 02:36:45,627
OUR OUTREACH AT CONFERENCES

4055
02:36:45,627 --> 02:36:46,761
OUTSIDE OF THE THERAPEUTIC SPACE

4056
02:36:46,761 --> 02:36:50,098
AND THAT IS TRANSLATING WELL.

4057
02:36:50,098 --> 02:36:52,534
I CAN'T SPEAK TOO MUCH BUT THE

4058
02:36:52,534 --> 02:36:55,637
CURRENT OOH AWARDS FOR FY24 SEEM

4059
02:36:55,637 --> 02:36:56,771
QUITE PROMISING FOR THE NON

4060
02:36:56,771 --> 02:37:03,912
THERAPEUTIC TECHNOLOGIES AS WE 

4061
02:37:03,912 --> 02:37:04,112
WELL.

4062
02:37:04,112 --> 02:37:04,412
>> THANKS.

4063
02:37:04,412 --> 02:37:06,247
>> I SEE NOW FURTHER
HANDS.

4064
02:37:06,247 --> 02:37:09,751
SO, I THINK WE'LL MOVE TO

4065
02:37:09,751 --> 02:37:10,452
VOTING.

4066
02:37:10,452 --> 02:37:13,054
SO IT SOUNDS LIKE FROM THE

4067
02:37:13,054 --> 02:37:13,989
SUBCOMMITTEE'S PRIOR

4068
02:37:13,989 --> 02:37:15,724
DELIBERATIONS THAT THEY CAME

4069
02:37:15,724 --> 02:37:19,728
INTO THE MEETING WITH ENTHUSIASM

4070
02:37:19,728 --> 02:37:20,362
FOR CONCURRENCE.

4071
02:37:20,362 --> 02:37:22,130
RAY WOULD YOU LIKE TO MAKE A

4072
02:37:22,130 --> 02:37:23,031
MOTION?

4073
02:37:23,031 --> 02:37:26,768
>> I MOVE WE VOTE IN
FAVOR.

4074
02:37:26,768 --> 02:37:30,005
>> CAN I GET A SECOND?

4075
02:37:30,005 --> 02:37:30,739
>> SECOND.

4076
02:37:30,739 --> 02:37:31,272
>> THANK YOU.

4077
02:37:31,272 --> 02:37:41,449
ANY FURTHER DISCUSSION?

4078
02:37:41,449 --> 02:37:44,919
HEARING NONE, THE MOTION IS FOR

4079
02:37:44,919 --> 02:37:45,954
CONCURRENCE.

4080
02:37:45,954 --> 02:37:50,225
SEEKING ANY NEW VOTES OF NON

4081
02:37:50,225 --> 02:37:50,525
CONCURRENCE?

4082
02:37:50,525 --> 02:37:59,668
VERBALLY OR BY RAISING YOUR

4083
02:37:59,668 --> 02:38:02,671
HANDS.

4084
02:38:02,671 --> 02:38:04,639
>> UNANIMOUS CONCURRENCE.

4085
02:38:04,639 --> 02:38:06,374
>> THANK YOU.

4086
02:38:06,374 --> 02:38:07,642
>> THANK YOU ALL.

4087
02:38:07,642 --> 02:38:10,445
SO NOW THE FINAL CONCEPT IS ALSO

4088
02:38:10,445 --> 02:38:12,514
A REISSUE RFA.

4089
02:38:12,514 --> 02:38:15,450
SMALL BUSINESS TRANSITION GRANT

4090
02:38:15,450 --> 02:38:18,653
FOR EARLY-STAGE INVESTIGATORS.

4091
02:38:18,653 --> 02:38:21,189
THIS WAS REVIEWED BY

4092
02:38:21,189 --> 02:38:23,058
SUBCOMMITTEE AND CHAIRED BY EARL

4093
02:38:23,058 --> 02:38:24,492
ROBERTSON WHO UNFORTUNATELY

4094
02:38:24,492 --> 02:38:25,894
COULDN'T JOIN US TODAY BECAUSE

4095
02:38:25,894 --> 02:38:30,065
OF A PERSONAL MATTER.

4096
02:38:30,065 --> 02:38:31,666
HOWEVER, ARE WITH US TODAY AND

4097
02:38:31,666 --> 02:38:32,967
WE'LL ASK THEM TO LEAD THE

4098
02:38:32,967 --> 02:38:35,036
DISCUSSION WHEN WE GET TO THAT

4099
02:38:35,036 --> 02:38:35,270
POINT.

4100
02:38:35,270 --> 02:38:37,305
THEY ALSO RECOMMEND THE

4101
02:38:37,305 --> 02:38:37,639
PRESENTATION.

4102
02:38:37,639 --> 02:38:43,712
WITH THAT, PLEASE TAKE IT AWAY.

4103
02:38:43,712 --> 02:38:45,480
>> SO PRESENTING THE SMALL

4104
02:38:45,480 --> 02:38:46,715
BUSINESS TRANSITION GRANT

4105
02:38:46,715 --> 02:38:49,984
RENEWAL INITIALLY LAUNCHED IN

4106
02:38:49,984 --> 02:38:50,185
2021.

4107
02:38:50,185 --> 02:38:57,092
FOR THREE-YEAR PILOT PHASE.

4108
02:38:57,092 --> 02:38:59,561
SO I WILL HIGHLIGHT TWO THINGS.

4109
02:38:59,561 --> 02:39:00,795
SO SMALL BUSINESS PROGRAM COMES

4110
02:39:00,795 --> 02:39:03,932
IN TWO FLAVORS, SBI ARE AND TTR.

4111
02:39:03,932 --> 02:39:05,900
AND SOME OF THE KEY DIFFERENCES

4112
02:39:05,900 --> 02:39:09,237
ARE THAT WITH SBIR MECHANISM THE

4113
02:39:09,237 --> 02:39:10,872
PRINCIPLE INVESTIGATOR NEEDS TO

4114
02:39:10,872 --> 02:39:12,440
BE MAJORITY EMPLOYED AT THE

4115
02:39:12,440 --> 02:39:14,242
COMPANY AND WHILE IT DOES ALLOW

4116
02:39:14,242 --> 02:39:17,445
FOR COMPANIES TO PARTNER WITH

4117
02:39:17,445 --> 02:39:19,147
UNIVERSITIES, THAT IS NOT A

4118
02:39:19,147 --> 02:39:19,447
REQUIREMENT.

4119
02:39:19,447 --> 02:39:21,516
IN CONTRAST, STTR MECHANISM

4120
02:39:21,516 --> 02:39:23,818
ALLOWS FLEXIBILITY WHERE THE PI

4121
02:39:23,818 --> 02:39:26,154
IS EMPLOYED, MAYBE EITHER AT

4122
02:39:26,154 --> 02:39:26,955
UNIVERSITY OR BUSINESS.

4123
02:39:26,955 --> 02:39:30,058
BUT IT DOES REQUIRE THAT THE

4124
02:39:30,058 --> 02:39:31,526
BUSINESS PARTNERS WITH A

4125
02:39:31,526 --> 02:39:34,329
UNIVERSITY OR NONPROFIT RESEARCH

4126
02:39:34,329 --> 02:39:34,629
INSTITUTION.

4127
02:39:34,629 --> 02:39:36,464
SO THE GOAL OF THE STTR PROGRAM

4128
02:39:36,464 --> 02:39:39,334
IS TO HELP ASSIST THAT

4129
02:39:39,334 --> 02:39:42,437
TECHNOLOGY FROM ACADEMIA TO

4130
02:39:42,437 --> 02:39:42,737
INDUSTRY.

4131
02:39:42,737 --> 02:39:47,175
AND JUST ALSO REITERATE THAT

4132
02:39:47,175 --> 02:39:49,077
BOTH PROGRAMS USE A

4133
02:39:49,077 --> 02:39:50,345
CONGRESSIONAL SET ASIDE SO IT

4134
02:39:50,345 --> 02:39:52,547
DOESN'T IMPACT RPG FUNDING.

4135
02:39:52,547 --> 02:39:55,116
SO THE MOTIVATION FOR THE SMALL

4136
02:39:55,116 --> 02:39:56,217
BUSINESS TRANSITION GRANT CAME

4137
02:39:56,217 --> 02:40:00,088
FROM A WORKSHOP THAT WE HELD

4138
02:40:00,088 --> 02:40:02,023
WITH CANCER CENTER TECH TRANSFER

4139
02:40:02,023 --> 02:40:05,160
AND INNOVATION OFFICES.

4140
02:40:05,160 --> 02:40:07,362
ONE OF THE KEY FINDINGS WAS THAT

4141
02:40:07,362 --> 02:40:10,698
IN MANY CASES, POSTDOCS AND

4142
02:40:10,698 --> 02:40:11,733
OTHER EARLY CAREER SCIENTISTS

4143
02:40:11,733 --> 02:40:13,234
ARE KEY TO HELP SPIN OUT

4144
02:40:13,234 --> 02:40:14,936
UNIVERSITTI TEKNOLOGI BECAUSE

4145
02:40:14,936 --> 02:40:15,737
THEY OFTEN MOVE WITH THE

4146
02:40:15,737 --> 02:40:19,407
TECHNOLOGY TO A SMALL SUBS TO

4147
02:40:19,407 --> 02:40:20,175
HELP FURTHER THE

4148
02:40:20,175 --> 02:40:21,075
COMMERCIALIZATION.

4149
02:40:21,075 --> 02:40:21,843
-- SMALL BUSINESS.

4150
02:40:21,843 --> 02:40:25,814
IN MANY CASES EARLY CAREER

4151
02:40:25,814 --> 02:40:28,216
SCIENTISTS LACK BUSINESS

4152
02:40:28,216 --> 02:40:29,250
EXPERIENCE AND THIS IS ALSO

4153
02:40:29,250 --> 02:40:30,985
REFLECTED IN THE SUCCESS RATES

4154
02:40:30,985 --> 02:40:33,955
WHEN YOU COMPARE EARLY-STAGE

4155
02:40:33,955 --> 02:40:34,989
INVESTIGATORS WITH MORE

4156
02:40:34,989 --> 02:40:36,257
EXPERIENCED INVESTIGATORS.

4157
02:40:36,257 --> 02:40:38,793
THEY TEND TO HAVE A LOWER

4158
02:40:38,793 --> 02:40:44,465
SUCCESS RATE FOR SBIR FUNDING

4159
02:40:44,465 --> 02:40:44,766
MECHANISMS.

4160
02:40:44,766 --> 02:40:47,535
SO, WE DEVELOPED A PROGRAM TO

4161
02:40:47,535 --> 02:40:49,404
SEE HOW WE COULD BETTER ADDRESS

4162
02:40:49,404 --> 02:40:51,573
THIS NEED BY CREATING A GRANT

4163
02:40:51,573 --> 02:40:55,176
MECHANISM THAT FOCUSED ON

4164
02:40:55,176 --> 02:40:55,710
EARLY-STAGE INVESTIGATORS.

4165
02:40:55,710 --> 02:40:58,246
SO THE PROGRAM WE CAME UP WITH

4166
02:40:58,246 --> 02:41:01,049
REQUIRED MENTORING FROM BOTH THE

4167
02:41:01,049 --> 02:41:02,116
RESEARCH SIDE AS WELL AS

4168
02:41:02,116 --> 02:41:04,953
BUSINESS AND ENTREPRENEURIAL

4169
02:41:04,953 --> 02:41:05,186
SIDE.

4170
02:41:05,186 --> 02:41:07,222
AND ALSO PROVIDES

4171
02:41:07,222 --> 02:41:08,623
ENTREPRENEURIAL STRAINING IN THE

4172
02:41:08,623 --> 02:41:10,425
FORM OF THE ICORE PROGRAM THAT

4173
02:41:10,425 --> 02:41:11,726
COMPANIES NEED TO TAKE PART IN.

4174
02:41:11,726 --> 02:41:14,195
AND THROUGH THE FUNDING PROVIDES

4175
02:41:14,195 --> 02:41:16,431
THEM WITH THE RESOURCES TO SPIN

4176
02:41:16,431 --> 02:41:19,133
OUT THE TECHNOLOGY AND WE ALSO

4177
02:41:19,133 --> 02:41:20,101
DEVELOPED A MECHANISM THAT

4178
02:41:20,101 --> 02:41:22,537
ALLOWS THEM TO USE STTR IN THE

4179
02:41:22,537 --> 02:41:24,706
FIRST YEAR SO THEY HAVE THE

4180
02:41:24,706 --> 02:41:27,442
FLEXIBILITY TO REMAIN AT THE

4181
02:41:27,442 --> 02:41:28,076
UNIVERSITY WHILE THE PROJECT AND

4182
02:41:28,076 --> 02:41:30,712
COMPANY GETS UP AND RUNNING.

4183
02:41:30,712 --> 02:41:33,948
SO THIS SLIDE SHOWS AN SO FAR

4184
02:41:33,948 --> 02:41:35,717
VIEW OF THE PROGRAM.

4185
02:41:35,717 --> 02:41:36,451
SBIR PROGRAM.

4186
02:41:36,451 --> 02:41:37,085
-- OVERVIEW.

4187
02:41:37,085 --> 02:41:41,189
GRANTS COME FIRST AS A PHASE I,

4188
02:41:41,189 --> 02:41:44,525
WHICH PROVIDES FUNDING FOR

4189
02:41:44,525 --> 02:41:45,460
PROOF-OF-CONCEPT WORK.

4190
02:41:45,460 --> 02:41:47,962
AND THEN FOLLOWING THAT, PHASE

4191
02:41:47,962 --> 02:41:50,665
II FUNDING IS FOR FURTHER

4192
02:41:50,665 --> 02:41:51,199
RESEARCH AND DEVELOPMENT.

4193
02:41:51,199 --> 02:41:54,936
THE SBTT PROGRAM USES A FAST

4194
02:41:54,936 --> 02:41:56,471
TRACK MECHANISM WHERE THE

4195
02:41:56,471 --> 02:41:57,438
APPLICANTS APPLY AT THE SAME

4196
02:41:57,438 --> 02:41:59,874
TIME FOR BOTH PHASE I AND PHASE

4197
02:41:59,874 --> 02:42:01,976
II FUNDING AND THEN IF THEY ARE

4198
02:42:01,976 --> 02:42:03,311
SUCCESSFUL, THEY WILL RECEIVE

4199
02:42:03,311 --> 02:42:06,915
PHASE I AWARD AND THEN ON

4200
02:42:06,915 --> 02:42:07,982
MEETING THE MILESTONES,

4201
02:42:07,982 --> 02:42:08,616
TRANSITION TO THE PHASE II

4202
02:42:08,616 --> 02:42:10,685
PROJECT WITHOUT HAVING TO GO

4203
02:42:10,685 --> 02:42:11,286
THROUGH REVIEW AGAIN.

4204
02:42:11,286 --> 02:42:13,488
SO IT'S A MECHANISM THAT ALLOWS

4205
02:42:13,488 --> 02:42:14,689
FOR MORE CONSISTENT LONG TERM

4206
02:42:14,689 --> 02:42:17,091
FUNDING OF A PROJECT, WHICH IS

4207
02:42:17,091 --> 02:42:19,727
REALLY IMPORTANT FOR HELPING

4208
02:42:19,727 --> 02:42:20,762
EARLY-STAGE INVESTIGATORS GET

4209
02:42:20,762 --> 02:42:26,534
THEIR TECHNOLOGY UP AND RUNNING.

4210
02:42:26,534 --> 02:42:29,570
SO THE ROOM IS MODELED ON THE

4211
02:42:29,570 --> 02:42:32,206
K99R00 PROGRAM WHICH IS DESIGNED

4212
02:42:32,206 --> 02:42:35,944
TO HELP RESEARCHERS GO DOWN THE

4213
02:42:35,944 --> 02:42:38,846
ACADEMIC INVESTIGATOR PATH.

4214
02:42:38,846 --> 02:42:41,516
SO IT'S DESIGNED TO HELP THE

4215
02:42:41,516 --> 02:42:42,917
INVESTIGATORS TAKE THE PATH OF

4216
02:42:42,917 --> 02:42:44,886
AN ENTREPRENEUR AND

4217
02:42:44,886 --> 02:42:45,920
COMMERCIALIZE THEIR

4218
02:42:45,920 --> 02:42:46,321
TECHNOLOGIES.

4219
02:42:46,321 --> 02:42:51,225
SO THE WAY IT WORKS, IT USES

4220
02:42:51,225 --> 02:42:52,527
FAST TRACK MECHANISM.

4221
02:42:52,527 --> 02:42:54,162
OTHER REQUIREMENTS ARE THE

4222
02:42:54,162 --> 02:42:56,764
DEFINITION OF EARLY STAGE

4223
02:42:56,764 --> 02:42:58,700
INVESTIGATOR IS THE PI IS WITHIN

4224
02:42:58,700 --> 02:43:01,135
10 YEARS OF THEIR PH.D. OR MD

4225
02:43:01,135 --> 02:43:01,369
DEGREE.

4226
02:43:01,369 --> 02:43:04,238
AND THAT THEY CAN PROVIDE TWO

4227
02:43:04,238 --> 02:43:04,906
MENTORS WHO ARE COMMITTED TO

4228
02:43:04,906 --> 02:43:07,575
THEIR PROJECT BOTH TECHNICAL AND

4229
02:43:07,575 --> 02:43:08,209
BUSINESSMEN TOR.

4230
02:43:08,209 --> 02:43:12,013
AND THE PILOT PROGRAM REQUIRED

4231
02:43:12,013 --> 02:43:14,449
THAT THEIR PIs ARE PERMANENT

4232
02:43:14,449 --> 02:43:15,717
RESIDENTS OR U.S. CITIZENS.

4233
02:43:15,717 --> 02:43:21,556
IN THE PHASE I COMPONENT, THE PI

4234
02:43:21,556 --> 02:43:23,658
TYPICALLY APOSTDOC WOULD LEAD

4235
02:43:23,658 --> 02:43:30,098
THE PROJECT AND THEY NEED TO

4236
02:43:30,098 --> 02:43:33,267
MEET THEIR COMMERCIAL -- PROJECT

4237
02:43:33,267 --> 02:43:34,702
MILESTONES IN ORDER TO

4238
02:43:34,702 --> 02:43:35,303
TRANSITION.

4239
02:43:35,303 --> 02:43:36,471
IN ADDITION TO THE RESEARCH

4240
02:43:36,471 --> 02:43:38,973
WORK, THEY NEED TO COMPLETE THE

4241
02:43:38,973 --> 02:43:41,075
NIH ICORE PROGRAM,

4242
02:43:41,075 --> 02:43:42,844
ENTREPRENEURIAL TRAINING PROGRAM

4243
02:43:42,844 --> 02:43:43,311
THAT I MENTIONED.

4244
02:43:43,311 --> 02:43:46,214
AND WE ALSO ALLOW FOR THE PHASE

4245
02:43:46,214 --> 02:43:50,251
I TO BE EXTENDED FOR THE SBTT

4246
02:43:50,251 --> 02:43:51,619
PROGRAM GIVEN THE EARLY-STAGE

4247
02:43:51,619 --> 02:43:53,021
INVESTIGATORS AND THEY NEED TO

4248
02:43:53,021 --> 02:43:54,756
TAKE PART IN THE ICORE.

4249
02:43:54,756 --> 02:43:56,524
WE ALLOW FOR THE PHASE I TO BE

4250
02:43:56,524 --> 02:43:58,226
ABLE TO TWO YEARS.

4251
02:43:58,226 --> 02:43:59,494
TYPICALLY PHASE I GRANTS ARE

4252
02:43:59,494 --> 02:44:02,296
JUST ONE YEAR.

4253
02:44:02,296 --> 02:44:03,464
FOLLOWING COMPLETION OF THE

4254
02:44:03,464 --> 02:44:06,367
PHASE I PROJECT, THEY NEED TO

4255
02:44:06,367 --> 02:44:07,402
TRANSITION FROM THE UNIVERSITY

4256
02:44:07,402 --> 02:44:08,603
TO THE BUSINESS IF THEY HAVE NOT

4257
02:44:08,603 --> 02:44:10,838
ALREADY DONE SO.

4258
02:44:10,838 --> 02:44:12,206
SO PHASE II NEEDS TO BE EMPLOYED

4259
02:44:12,206 --> 02:44:14,108
BY THE COMPANY, WHICH IS -- AND

4260
02:44:14,108 --> 02:44:17,011
THE PHASE II IS AN SBIR WHICH

4261
02:44:17,011 --> 02:44:18,679
ALLOWS US TO TAP INTO THE LARGER

4262
02:44:18,679 --> 02:44:22,650
SET ASIDE POOL.

4263
02:44:22,650 --> 02:44:26,654
THE PI CANNOT BE TRANSFERRED SO

4264
02:44:26,654 --> 02:44:30,758
THE GRANT FOLLOWS THE PI AND WE

4265
02:44:30,758 --> 02:44:38,933
DO ALLOW FOR SOME SMALL

4266
02:44:38,933 --> 02:44:39,500
BUSINESS -- SOME CHANGES IN

4267
02:44:39,500 --> 02:44:40,234
SCOPE WHERE NEEDED IF THEY ARE

4268
02:44:40,234 --> 02:44:41,769
JUSTIFIED BASED ON THE ICORE

4269
02:44:41,769 --> 02:44:43,671
RESEARCH AND PHASE I RESULTS.

4270
02:44:43,671 --> 02:44:46,107
SO THE PHASE I PROJECT BUDGET

4271
02:44:46,107 --> 02:44:47,942
AND THE CAP OF $400,000 AND THE

4272
02:44:47,942 --> 02:44:50,511
PHASE II OF TWO MILLION DOLLARS

4273
02:44:50,511 --> 02:44:54,749
OVER TWO YEARS.

4274
02:44:54,749 --> 02:44:58,419
WE FOUND ICORE PROGRAM TO BE A

4275
02:44:58,419 --> 02:45:01,155
REALLY GREAT PROGRAM IN HELPING

4276
02:45:01,155 --> 02:45:02,590
TO PROVIDE TRAINING.

4277
02:45:02,590 --> 02:45:06,861
THIS IS A SURVEY OF PARTICIPANTS

4278
02:45:06,861 --> 02:45:07,261
BEFORE AND AFTER.

4279
02:45:07,261 --> 02:45:10,031
SO YOU CAN SEE PRIOR TO STARTING

4280
02:45:10,031 --> 02:45:11,699
THE PROGRAM THEY HAD LACK OF

4281
02:45:11,699 --> 02:45:14,368
KNOWLEDGE IN SOME KEY

4282
02:45:14,368 --> 02:45:15,169
COMMERCIALIZATION KNOWLEDGE SUCH

4283
02:45:15,169 --> 02:45:19,006
AS REIMBURSEMENT AND REGULATORY

4284
02:45:19,006 --> 02:45:21,642
STRATEGY, PRE CLINICAL

4285
02:45:21,642 --> 02:45:24,645
DEVELOPMENT AND CLINICAL TRIALS.

4286
02:45:24,645 --> 02:45:26,647
AND ENTREPRENEUR TRAINING HELPED

4287
02:45:26,647 --> 02:45:29,317
TO ENHANCE AND ADDRESS THE

4288
02:45:29,317 --> 02:45:32,687
KNOWLEDGE GAPS.

4289
02:45:32,687 --> 02:45:35,923
THE PROGRAM WAS LAUNCHED IN 2021

4290
02:45:35,923 --> 02:45:38,392
AND IT HAD RELATIVELY STRONG

4291
02:45:38,392 --> 02:45:38,759
INTEREST.

4292
02:45:38,759 --> 02:45:41,429
A LOT OF INTEREST IN TERMS OF

4293
02:45:41,429 --> 02:45:42,797
POTENTIAL APPLICANTS.

4294
02:45:42,797 --> 02:45:45,700
WE RECEIVED BASED ON

4295
02:45:45,700 --> 02:45:47,702
CONVERSATIONS AND MEETINGS AT

4296
02:45:47,702 --> 02:45:50,638
CONFERENCES AND DISCUSSIONS WITH

4297
02:45:50,638 --> 02:45:52,607
ACADEMICS AND CANCER CENTERS AND

4298
02:45:52,607 --> 02:45:54,008
A LOT OF PUBLIC FEEDBACK FROM

4299
02:45:54,008 --> 02:45:55,877
BOTH ACADEMICS AT CANCER CENTERS

4300
02:45:55,877 --> 02:45:58,446
AND SMALL BUSINESSES.

4301
02:45:58,446 --> 02:46:00,982
LOOKING AT THE FIGURES, YOU CAN

4302
02:46:00,982 --> 02:46:05,186
SEE PRIOR TO THE SBTT PROGRAM WE

4303
02:46:05,186 --> 02:46:08,589
TYPICALLY RECEIVED ABOUT BETWEEN

4304
02:46:08,589 --> 02:46:11,626
30-40 PHASE II -- FAST TRACK

4305
02:46:11,626 --> 02:46:15,696
STTR APPLICATIONS PER YEAR.

4306
02:46:15,696 --> 02:46:17,798
AND ADDING THE PROGRAM HAS

4307
02:46:17,798 --> 02:46:18,799
HELPED BUMP UP THOSE NUMBERS

4308
02:46:18,799 --> 02:46:22,103
WITHOUT CANNIBALIZING THE

4309
02:46:22,103 --> 02:46:25,573
CURRENT LEVEL OF PHASE II

4310
02:46:25,573 --> 02:46:26,274
APPLICATIONS.

4311
02:46:26,274 --> 02:46:28,142
IN THE FIRST ROUND OF FUNDING

4312
02:46:28,142 --> 02:46:31,479
THERE WERE 15 PROPOSALS AND FOUR

4313
02:46:31,479 --> 02:46:32,547
AWARDS WERE MADE.

4314
02:46:32,547 --> 02:46:34,815
THE FOLLOWING YEAR 11

4315
02:46:34,815 --> 02:46:35,783
APPLICATIONS RECEIVED.

4316
02:46:35,783 --> 02:46:37,652
ONLY ONE WAS ABLE TO BE FUNDED

4317
02:46:37,652 --> 02:46:39,220
AT THE END.

4318
02:46:39,220 --> 02:46:42,723
AND THIS YEAR, THERE WERE 15

4319
02:46:42,723 --> 02:46:43,658
APPLICATIONS.

4320
02:46:43,658 --> 02:46:47,595
THOSE APPLICATIONS ARE STILL

4321
02:46:47,595 --> 02:46:48,963
UNDER REVIEW.

4322
02:46:48,963 --> 02:46:50,865
SO I'LLIVE TWO EXAMPLES OF

4323
02:46:50,865 --> 02:46:53,801
PROJECTS FROM THE FIRST COHORT.

4324
02:46:53,801 --> 02:46:56,337
THE FIRST IS TO A COMPANY CALLED

4325
02:46:56,337 --> 02:46:59,507
COVINA, THE PI WAS A POSTDOC IN

4326
02:46:59,507 --> 02:47:03,411
THE LAB OF ELLIOT AND THE

4327
02:47:03,411 --> 02:47:05,079
TECHNOLOGY WAS DEVELOPING A

4328
02:47:05,079 --> 02:47:09,951
SMALL MOLECULE INHIBITOR OF

4329
02:47:09,951 --> 02:47:12,420
HPV-16E6 ONCOPROTEIN.

4330
02:47:12,420 --> 02:47:14,021
THE GOAL OF BEING ABLE TO STOP

4331
02:47:14,021 --> 02:47:15,790
HPV INFECTIONS BEFORE CANCER

4332
02:47:15,790 --> 02:47:19,794
DEVELOPS AND TO TREAT

4333
02:47:19,794 --> 02:47:20,328
HPV-RELATED CANCERS AFTER

4334
02:47:20,328 --> 02:47:20,795
DETECTION.

4335
02:47:20,795 --> 02:47:22,330
THE PROJECT WAS SUCCESSFUL IN

4336
02:47:22,330 --> 02:47:23,664
PHASE I AND MOVED TO PHASE II.

4337
02:47:23,664 --> 02:47:28,236
AND IN THE SUMMER OF 20 -- OF

4338
02:47:28,236 --> 02:47:30,004
THIS YEAR.

4339
02:47:30,004 --> 02:47:33,074
AND THE PHASE II PROJECT WILL BE

4340
02:47:33,074 --> 02:47:34,208
FURTHER ENABLE STUDIES AND THE

4341
02:47:34,208 --> 02:47:35,910
COMPANY RECENTLY WAS ABLE TO

4342
02:47:35,910 --> 02:47:39,747
CLOSE A SEED ROUND AND IS

4343
02:47:39,747 --> 02:47:42,149
RAISING SERIES A FUNDING.

4344
02:47:42,149 --> 02:47:44,318
SECOND EXAMPLE IS A COMPANY

4345
02:47:44,318 --> 02:47:50,658
WHICH IS A SPIN OUT OF NATHAN'S

4346
02:47:50,658 --> 02:47:52,393
LAB FROM THE MEDICAL UNIVERSITY

4347
02:47:52,393 --> 02:47:53,094
OF SOUTH CAROLINA DEVELOPING A

4348
02:47:53,094 --> 02:47:56,664
CANCER VACCINE AND A MUTATED

4349
02:47:56,664 --> 02:48:04,639
FORM OF A PROTEIN FUSED TO AGR2,

4350
02:48:04,639 --> 02:48:07,208
NORMALLY ER-ASSOCIATED PROTEIN

4351
02:48:07,208 --> 02:48:09,010
BUT IS EXPRESSED ON THE CELL

4352
02:48:09,010 --> 02:48:11,178
SURFACE IN SOME TYPES OF CANCER.

4353
02:48:11,178 --> 02:48:13,347
THE PHASE I PROJECT WAS

4354
02:48:13,347 --> 02:48:17,251
SUCCESSFUL AND SHOWED IN-VIVO

4355
02:48:17,251 --> 02:48:18,953
EFFICACY OF THEIR MOUSE MODEL.

4356
02:48:18,953 --> 02:48:20,721
THE PROJECT TRANSITIONED TO

4357
02:48:20,721 --> 02:48:24,558
PHASE II THIS SUMMER AND PHASE

4358
02:48:24,558 --> 02:48:25,626
II PROJECT WILL DO FURTHER

4359
02:48:25,626 --> 02:48:28,396
EFFICACY STUDIES ON ALSO LOOK AT

4360
02:48:28,396 --> 02:48:30,197
COMBINATION WITH CHECKPOINT

4361
02:48:30,197 --> 02:48:32,566
INHIBITORS AND OTHER

4362
02:48:32,566 --> 02:48:35,303
IND-ENABLING STUDIES.

4363
02:48:35,303 --> 02:48:38,039
SO AS WITH THE AWARD, THIS

4364
02:48:38,039 --> 02:48:40,708
PROGRAM ALSO WAS EVALUATED WITH

4365
02:48:40,708 --> 02:48:41,542
EXTERNAL EVALUATION COMMITTEE

4366
02:48:41,542 --> 02:48:44,178
WITH MEMBERS FROM ACADEMIA,

4367
02:48:44,178 --> 02:48:46,380
INDUSTRY AND ALSO UNIVERSITY

4368
02:48:46,380 --> 02:48:49,417
TECH TRANSFER OFFICES.

4369
02:48:49,417 --> 02:48:51,252
THE COMMITTEE HAD STRONG

4370
02:48:51,252 --> 02:48:52,887
ENTHUSIASM FOR THE PROGRAM BUT

4371
02:48:52,887 --> 02:48:56,457
RECOMMENDED SOME CHANGES, WHICH

4372
02:48:56,457 --> 02:48:59,327
I'LL OUTLINE, PARTICULARLY

4373
02:48:59,327 --> 02:49:00,027
RELATED HOW TO BOOST APPLICATION

4374
02:49:00,027 --> 02:49:06,467
NUMBERS AND ELIGIBILITY.

4375
02:49:06,467 --> 02:49:07,735
ONE OF THE FIRST POINTS THAT

4376
02:49:07,735 --> 02:49:11,238
CAME UP WAS THAT BY RESTRICTING

4377
02:49:11,238 --> 02:49:13,507
APPLICANTS TO THE JUST PERMANENT

4378
02:49:13,507 --> 02:49:15,209
RESIDENTS AND CITIZENS, THAT

4379
02:49:15,209 --> 02:49:16,777
EXCLUDES A LOT OF THE

4380
02:49:16,777 --> 02:49:19,013
POSTDOCTORAL POPULATION WHICH

4381
02:49:19,013 --> 02:49:20,648
HAS A LOT OF FOREIGN TRAINEES.

4382
02:49:20,648 --> 02:49:24,085
SO THE PROPOSAL THAT WE ARE

4383
02:49:24,085 --> 02:49:25,653
RECOMMENDING IS TO EXPAND THE

4384
02:49:25,653 --> 02:49:26,754
ELIGIBILITY TO BE ALIGNED WITH

4385
02:49:26,754 --> 02:49:30,591
CURRENT SBIR AND STTR GRANTS

4386
02:49:30,591 --> 02:49:32,593
WHICH REQUIRED JUST THAT PI HAS

4387
02:49:32,593 --> 02:49:35,329
THE RIGHT TO WORK IN THE U.S.

4388
02:49:35,329 --> 02:49:37,631
AND THERE ARE MANY EXAMPLES OF

4389
02:49:37,631 --> 02:49:39,433
PIs THAT WANTED TO APPLY BUT

4390
02:49:39,433 --> 02:49:41,936
STILL WAITING FOR THAT GREEN

4391
02:49:41,936 --> 02:49:43,637
CARD AND THINGS LIKE THAT.

4392
02:49:43,637 --> 02:49:45,539
THIS WILL BE ONE WAY TO ADDRESS

4393
02:49:45,539 --> 02:49:48,342
THIS ISSUE.

4394
02:49:48,342 --> 02:49:48,976
ANOTHER CHALLENGE IDENTIFIED WAS

4395
02:49:48,976 --> 02:49:52,213
THAT A LOT OF INTERESTED

4396
02:49:52,213 --> 02:49:53,814
APPLICANTS HAD EXCITING

4397
02:49:53,814 --> 02:49:54,515
TECHNOLOGIES BUT PERHAPS WERE

4398
02:49:54,515 --> 02:49:57,651
NOT QUITE READY FOR A FAST TRACK

4399
02:49:57,651 --> 02:50:01,055
APPLICATION WHICH THE PILOT

4400
02:50:01,055 --> 02:50:01,322
REQUIRED.

4401
02:50:01,322 --> 02:50:02,757
SO THE RECOMMENDATION FROM THE

4402
02:50:02,757 --> 02:50:05,593
EVALUATION COMMITTEE WAS TO

4403
02:50:05,593 --> 02:50:14,835
ALLOW FOR ALSO JUST PHASE IN ADO

4404
02:50:14,835 --> 02:50:16,270
APPLICANTS TO THE GET THEIR FOOT

4405
02:50:16,270 --> 02:50:17,772
IN THE DOOR WITH A PHASE I

4406
02:50:17,772 --> 02:50:20,040
PROGRAM AND ALSO TAKE ADVANTAGE

4407
02:50:20,040 --> 02:50:25,146
OF OTHER NCISBIR RESOURCES SUCH

4408
02:50:25,146 --> 02:50:27,748
AS ADDITIONAL ACCESS TO

4409
02:50:27,748 --> 02:50:31,519
ENTREPRENEURS AND RESIDENTS TO

4410
02:50:31,519 --> 02:50:33,988
MENTORING PROGRAMS AND OTHER

4411
02:50:33,988 --> 02:50:35,289
NETWORKING PROGRAMS THAT WILL

4412
02:50:35,289 --> 02:50:37,825
HELP THEM FURTHER ADVANCE THEIR

4413
02:50:37,825 --> 02:50:39,760
STUDIES AND ALSO RAISE AWARENESS

4414
02:50:39,760 --> 02:50:44,365
OF POTENTIALLY FUNDRAISING.

4415
02:50:44,365 --> 02:50:46,901
AND THE THIRD RECOMMENDATION

4416
02:50:46,901 --> 02:50:52,706
WHICH ALSO WE DISCUSSED WITH THE

4417
02:50:52,706 --> 02:50:55,009
BSA EVALUATORS ON THE RFA WAS

4418
02:50:55,009 --> 02:50:57,344
HOW TO REACH OR IMPROVE OUTREACH

4419
02:50:57,344 --> 02:50:59,680
OF THE PROGRAM.

4420
02:50:59,680 --> 02:51:02,616
AND THINGS THAT WE WILL BE DOING

4421
02:51:02,616 --> 02:51:04,051
GOING FORWARD IS TO INCREASE OUR

4422
02:51:04,051 --> 02:51:08,756
OUTREACH TO PIs AT CONFERENCES

4423
02:51:08,756 --> 02:51:10,157
AND CANCER CENTERS AND

4424
02:51:10,157 --> 02:51:13,394
UNIVERSITIES, MEETINGS WITH

4425
02:51:13,394 --> 02:51:16,230
TRAINEES AND OTHER POSTDOC

4426
02:51:16,230 --> 02:51:17,765
GROUPS WHICH IS A RECOMMENDATION

4427
02:51:17,765 --> 02:51:21,569
FROM THE REVIEWERS.

4428
02:51:21,569 --> 02:51:24,472
TOW ALSO TARGET POTENTIAL

4429
02:51:24,472 --> 02:51:26,073
MENTORS WHO, THROUGH THINGS LIKE

4430
02:51:26,073 --> 02:51:30,711
THE TECH TRANSFER OFFICES AND

4431
02:51:30,711 --> 02:51:33,747
THE STRUCTURES AND INVESTORS AND

4432
02:51:33,747 --> 02:51:35,983
UTILIZE THE NETWORK OF THE STATE

4433
02:51:35,983 --> 02:51:37,985
ASSOCIATIONS AND OTHER INDUSTRY

4434
02:51:37,985 --> 02:51:38,252
GROUPS.

4435
02:51:38,252 --> 02:51:42,022
AND WE HAVE BEEN MAKING PROGRESS

4436
02:51:42,022 --> 02:51:45,092
IN THAT RECENTLY.

4437
02:51:45,092 --> 02:51:51,465
SO I WANT TO EMPHASIZE THAT THE

4438
02:51:51,465 --> 02:51:53,300
STTR PROGRAM IS REALLY JUST PART

4439
02:51:53,300 --> 02:51:57,071
OF OUR LARGER STRATEGY TO HELP

4440
02:51:57,071 --> 02:51:57,838
IMPROVE DIVERSITY AND ACCESS TO

4441
02:51:57,838 --> 02:51:59,740
THE SBIR FUNDING.

4442
02:51:59,740 --> 02:52:02,209
THE GOAL IS ABOUT HOW WE CAN

4443
02:52:02,209 --> 02:52:05,379
FOSTER AN ECOSYSTEM THAT

4444
02:52:05,379 --> 02:52:09,750
ENCOURAGES COMMERCIALIZATION AND

4445
02:52:09,750 --> 02:52:11,018
SO THIS IS PART OF OUR STRATEGY.

4446
02:52:11,018 --> 02:52:13,554
SOME OTHER THINGS WE ARE DOING

4447
02:52:13,554 --> 02:52:16,257
TO HELP BUILD THIS PIPELINE AND

4448
02:52:16,257 --> 02:52:19,093
IMPROVE THE ECOSYSTEM IS WORK

4449
02:52:19,093 --> 02:52:20,628
THAT WE HAVE UNDER DEVELOPMENT

4450
02:52:20,628 --> 02:52:24,965
SO WE RECENTLY RELEASED WITH THE

4451
02:52:24,965 --> 02:52:27,034
CANCER TRAINING A NOTICE OF

4452
02:52:27,034 --> 02:52:28,769
SPECIAL INTEREST TO DEVELOP

4453
02:52:28,769 --> 02:52:30,905
TRAINING PROGRAMS FOCUSED ON

4454
02:52:30,905 --> 02:52:31,739
ENTREPRENEURSHIP AND THE GOAL IS

4455
02:52:31,739 --> 02:52:35,276
TO HELP IMPROVE EDUCATION AND

4456
02:52:35,276 --> 02:52:36,744
UNDERSTANDING OF HOW TO

4457
02:52:36,744 --> 02:52:38,178
COMMERCIALIZE TECHNOLOGIES FOR

4458
02:52:38,178 --> 02:52:40,481
EARLY STAGE TRAINEES.

4459
02:52:40,481 --> 02:52:46,820
WE ALSO PARTNERING WITH THE

4460
02:52:46,820 --> 02:52:49,890
OFFICE TO DEVELOP A PROGRAM TO

4461
02:52:49,890 --> 02:52:51,058
TARGET ENTREPRENEURS PRIOR TO

4462
02:52:51,058 --> 02:52:53,193
HAVING AN SBIR GRANT AND THAT IS

4463
02:52:53,193 --> 02:52:54,762
SOMETHING WE THINK WILL REALLY

4464
02:52:54,762 --> 02:52:57,631
HELP IMPROVE AWARENESS AND THE

4465
02:52:57,631 --> 02:53:02,136
PIPELINE OF ENTREPRENEUR-MINDED

4466
02:53:02,136 --> 02:53:02,469
INVESTIGATORS.

4467
02:53:02,469 --> 02:53:04,238
WE ARE ALSO LOOKING AT WAYS TO

4468
02:53:04,238 --> 02:53:08,008
PROVIDE FURTHER APPLICATION

4469
02:53:08,008 --> 02:53:08,842
ASSISTANCE.

4470
02:53:08,842 --> 02:53:13,013
SO WE ARE LOOKING AT ENHANCING

4471
02:53:13,013 --> 02:53:14,515
THE APPLICATION ASSISTANCE

4472
02:53:14,515 --> 02:53:20,421
PROGRAM WHICH WE HAVE RUN OVER

4473
02:53:20,421 --> 02:53:22,222
THE LAST NUMBER OF YEARS AND

4474
02:53:22,222 --> 02:53:24,491
LOOKING TO ADD TO THAT

4475
02:53:24,491 --> 02:53:27,428
ASSISTANCE IN HELPING THE

4476
02:53:27,428 --> 02:53:28,495
APPLICANTS WORK AND DISCOVERY

4477
02:53:28,495 --> 02:53:29,330
IMPROVING GRANT WRITING AND

4478
02:53:29,330 --> 02:53:31,165
NAVIGATING THE POST AWARD

4479
02:53:31,165 --> 02:53:34,702
PROCESS SUCH AS RESUBMISSION AND

4480
02:53:34,702 --> 02:53:35,169
THE INTRODUCTION PAGE.

4481
02:53:35,169 --> 02:53:38,205
AND ALSO LOOKING AT WAYS WE CAN

4482
02:53:38,205 --> 02:53:40,407
HELP INVESTIGATORS THINK ABOUT

4483
02:53:40,407 --> 02:53:41,875
CREATION AND IP EVALUATION, A

4484
02:53:41,875 --> 02:53:44,545
LOT OF THE OTHERY STEPS THAT GO

4485
02:53:44,545 --> 02:53:48,649
INTO DEVELOPING A COMPANY EXCUSE

4486
02:53:48,649 --> 02:53:51,752
ME TAKING THAT TECHNOLOGY OUT TO

4487
02:53:51,752 --> 02:53:53,320
HELP UNIVERSITY-BASED

4488
02:53:53,320 --> 02:53:54,822
RESEARCHERS WITH THIS.

4489
02:53:54,822 --> 02:54:00,227
SO THE REQUEST IS FOR A 5-YEAR

4490
02:54:00,227 --> 02:54:01,795
REISSUE OF THE PROGRAM WITH THE

4491
02:54:01,795 --> 02:54:04,565
CHANGES I OUTLINED ALLOWING

4492
02:54:04,565 --> 02:54:06,467
PHASE I AND EXPANDING

4493
02:54:06,467 --> 02:54:07,801
ELIGIBILITY TO FOREIGN TRAINEES

4494
02:54:07,801 --> 02:54:09,603
THAT HAVE THE RIGHT TO WORK IN

4495
02:54:09,603 --> 02:54:11,772
THE U.S.

4496
02:54:11,772 --> 02:54:12,973
SO SOME OF THE REASONS TO

4497
02:54:12,973 --> 02:54:13,474
REISSUE THE PROGRAM.

4498
02:54:13,474 --> 02:54:15,609
WE THINK THIS IS REALLY AN

4499
02:54:15,609 --> 02:54:17,411
EFFECTIVE WAY OF HELPING AND

4500
02:54:17,411 --> 02:54:20,881
ENHANCING THE SPIN OUT OF

4501
02:54:20,881 --> 02:54:24,351
TECHNOLOGIES FROM NCI-FUNDED

4502
02:54:24,351 --> 02:54:30,190
PROJECTS.

4503
02:54:30,190 --> 02:54:33,127
IT NICELY ALLIANCE WITH NATIONAL

4504
02:54:33,127 --> 02:54:35,562
CANCER PLAN GOALS, 3, 6 AND 8,

4505
02:54:35,562 --> 02:54:37,531
TO DEVELOP EFFECTIVE TREATMENT

4506
02:54:37,531 --> 02:54:40,234
AND ENGAGE EVERY PERSON AND OPT

4507
02:54:40,234 --> 02:54:41,268
MICE THE WORKFORCE.

4508
02:54:41,268 --> 02:54:43,070
PROVIDES A UNIQUE PROGRAM THAT

4509
02:54:43,070 --> 02:54:45,606
ALLOWS FOR TRAINING AND

4510
02:54:45,606 --> 02:54:48,008
MENTORSHIP THAT IS ABSENT

4511
02:54:48,008 --> 02:54:52,613
THROUGH THE REGULAR SBIR FUND 

4512
02:54:52,613 --> 02:54:52,846
FUNDING.

4513
02:54:52,846 --> 02:54:55,082
AND IT USES THE SET ASIDE FUNDS

4514
02:54:55,082 --> 02:54:58,018
SO IT DOESN'T IMPACT RPG.

4515
02:54:58,018 --> 02:55:00,187
WE RECOMMEND THE RFA MECHANISM

4516
02:55:00,187 --> 02:55:04,792
BECAUSE IT ALLOWS FOR NCI TO

4517
02:55:04,792 --> 02:55:07,261
HAVE FURTHER OVERSIGHT OF THE

4518
02:55:07,261 --> 02:55:07,828
PEER REVIEW PROCESS WHICH IS

4519
02:55:07,828 --> 02:55:09,229
IMPORTANT IN HELPING TO MAKE

4520
02:55:09,229 --> 02:55:16,704
SURE WE GET REVIEWERS THAT ARE

4521
02:55:16,704 --> 02:55:18,005
FAMILIAR WITH BOTH

4522
02:55:18,005 --> 02:55:20,007
COMMERCIALIZATION AND ALSO

4523
02:55:20,007 --> 02:55:20,574
CAREER DEVELOPMENT PROGRAMS.

4524
02:55:20,574 --> 02:55:24,778
AND THE SET ASIDE IS THE

4525
02:55:24,778 --> 02:55:25,312
COMMITMENT TO THE PROGRAM.

4526
02:55:25,312 --> 02:55:26,580
I'LL END MY PRESENTATION THERE

4527
02:55:26,580 --> 02:55:35,856
AND TAKE ANY QUESTIONS.

4528
02:55:35,856 --> 02:55:37,224
>> THANK YOU VERY MUCH.

4529
02:55:37,224 --> 02:55:41,095
SO, PERHAPS WE COULD HAVE THE

4530
02:55:41,095 --> 02:55:44,832
COMMITTEE MEMBERS START THE

4531
02:55:44,832 --> 02:55:45,265
DISCUSSION.

4532
02:55:45,265 --> 02:55:46,233
>> OTIS, DO YOU WANT TO
START OR

4533
02:55:46,233 --> 02:55:47,634
DO YOU WANT ME TO?

4534
02:55:47,634 --> 02:55:50,003
>> I WAS GOING TO SAY WE
HAD A

4535
02:55:50,003 --> 02:55:58,645
WONDERFUL, GOOD CONVERSATION

4536
02:55:58,645 --> 02:55:59,847
SOME OF HIS COLLEAGUES AND OUR

4537
02:55:59,847 --> 02:56:02,583
GREATEST CONCERN IS THIS IS A

4538
02:56:02,583 --> 02:56:03,617
PROGRAM THAT IS WORTHWHILE AND

4539
02:56:03,617 --> 02:56:06,954
IS NOT BEING USED.

4540
02:56:06,954 --> 02:56:09,256
AND THEY RESPONDED TO ALL OF MY

4541
02:56:09,256 --> 02:56:09,590
CONCERNS.

4542
02:56:09,590 --> 02:56:11,592
I THINK ALL OF THE CONCERNS OF

4543
02:56:11,592 --> 02:56:15,062
THE SUB COMMITTEE.

4544
02:56:15,062 --> 02:56:18,132
AM I CORRECT?

4545
02:56:18,132 --> 02:56:18,766
>> YES.

4546
02:56:18,766 --> 02:56:20,968
IT'S EXCITING.

4547
02:56:20,968 --> 02:56:25,205
ANDRE SPOKE MULTIPLE TIMES ABOUT

4548
02:56:25,205 --> 02:56:30,444
IT, OF GETTING THEM INTO THE

4549
02:56:30,444 --> 02:56:30,711
PIPELINE.

4550
02:56:30,711 --> 02:56:32,012
I THINK WHAT I WASN'T AWARE OF

4551
02:56:32,012 --> 02:56:33,580
IS THE INTENSITY OF THE

4552
02:56:33,580 --> 02:56:35,215
MENTORSHIP IN THIS PROGRAM,

4553
02:56:35,215 --> 02:56:37,718
WHICH IS QUITE APPRAISING.

4554
02:56:37,718 --> 02:56:41,455
THESE APPLICANTS DO 100

4555
02:56:41,455 --> 02:56:44,191
INTERVIEWS AS PART OF THEIR

4556
02:56:44,191 --> 02:56:44,458
TRAINING.

4557
02:56:44,458 --> 02:56:46,660
IT IS RIGOROUS IN TERMS OF THE

4558
02:56:46,660 --> 02:56:47,027
MENTORSHIP.

4559
02:56:47,027 --> 02:56:48,462
THEY HAVE A BUSINESS MACHINE

4560
02:56:48,462 --> 02:56:48,996
TOR.

4561
02:56:48,996 --> 02:56:51,665
THE EXTENSIONS -- MENTOR -- THE

4562
02:56:51,665 --> 02:56:54,601
EXTENSION IS TWO YEARS IS

4563
02:56:54,601 --> 02:56:55,569
CRUCIAL BECAUSE THEY SPEND SO

4564
02:56:55,569 --> 02:56:57,371
MUCH TIME IN MENTORSHIP.

4565
02:56:57,371 --> 02:56:59,773
AND I THINK THE PHASE I ONLY IS

4566
02:56:59,773 --> 02:57:02,910
A GREAT IDEA BECAUSE IT CREATES

4567
02:57:02,910 --> 02:57:09,316
AN OPPORTUNITY.

4568
02:57:09,316 --> 02:57:12,619
I WOULD ADD WOON THING I JUST

4569
02:57:12,619 --> 02:57:12,953
LEARNED ABOUT.

4570
02:57:12,953 --> 02:57:14,054
WE HAD A LOT OF TALK ABOUT HOW

4571
02:57:14,054 --> 02:57:15,222
TO INCREASE THE VISIBILITY OF

4572
02:57:15,222 --> 02:57:16,690
THE PROGRAM.

4573
02:57:16,690 --> 02:57:18,725
AND I THINK IN AN INTERESTING

4574
02:57:18,725 --> 02:57:20,894
WAY, THE WHITE PAPER PROGRAM

4575
02:57:20,894 --> 02:57:22,663
WOULD ENCOURAGE PEOPLE TO

4576
02:57:22,663 --> 02:57:24,398
UNDERSTAND ABOUT THIS BECAUSE WE

4577
02:57:24,398 --> 02:57:28,969
HAVE TO WRITE -- WRITING TWO OR

4578
02:57:28,969 --> 02:57:31,772
THREE00 PAGES IS KIND OF FUN AND

4579
02:57:31,772 --> 02:57:32,973
I THINK YOU WOULD GET MORE

4580
02:57:32,973 --> 02:57:34,041
PEOPLE INTERESTED AND IT WOULD

4581
02:57:34,041 --> 02:57:38,111
BE MORE WORK BUT I THINK THAT IS

4582
02:57:38,111 --> 02:57:38,645
SOMETHING THAT YOU COULD

4583
02:57:38,645 --> 02:57:39,246
POTENTIALLY ADD TO THE PROGRAM

4584
02:57:39,246 --> 02:57:39,746
THAT WOULD HELP IT.

4585
02:57:39,746 --> 02:57:43,016
AND THE LAST THING WE DID TALK

4586
02:57:43,016 --> 02:57:45,519
ABOUT, MAKING SURE WE WERE

4587
02:57:45,519 --> 02:57:48,322
TRYING TO TAP INTO MINORITY

4588
02:57:48,322 --> 02:57:49,089
INVESTIGATORS.

4589
02:57:49,089 --> 02:57:51,525
AND I THINK ONE OF THE SPECIFIC

4590
02:57:51,525 --> 02:57:53,794
COMMENTS WAS THAT WHEN WE TALKED

4591
02:57:53,794 --> 02:57:55,462
ABOUT THE CANCER CENTERS AND

4592
02:57:55,462 --> 02:57:58,932
ALSO USE THE U54 NETWORK WHICH

4593
02:57:58,932 --> 02:58:04,538
IS ONE IN WHICH YOU HAVE

4594
02:58:04,538 --> 02:58:05,138
MINORITY-SERVING INSTITUTIONS

4595
02:58:05,138 --> 02:58:05,539
AND PARTNERSHIPS.

4596
02:58:05,539 --> 02:58:07,341
THOSE ARE ALREADY DONE AND WOULD

4597
02:58:07,341 --> 02:58:10,844
BE A GOOD WAY OF DELIVERING

4598
02:58:10,844 --> 02:58:12,179
MINORITY INSTITUTIONS.

4599
02:58:12,179 --> 02:58:13,714
>> THANK YOU FOR BRINGING
THAT

4600
02:58:13,714 --> 02:58:13,947
UP.

4601
02:58:13,947 --> 02:58:15,916
I FORGOT TO MENTION THAT.

4602
02:58:15,916 --> 02:58:18,085
GREAT SUGGESTIONS AND WE'LL

4603
02:58:18,085 --> 02:58:19,887
DEFINITELY TAKE THAT INTO HEART

4604
02:58:19,887 --> 02:58:20,821
AND ALSO THE SUGGESTION ABOUT

4605
02:58:20,821 --> 02:58:23,624
WORKING WITH THE TRAINING

4606
02:58:23,624 --> 02:58:28,295
OFFICE, CO-BRANDING K99R00 WITH

4607
02:58:28,295 --> 02:58:30,530
SBTT PROGRAM TO HELP ENHANCE

4608
02:58:30,530 --> 02:58:32,299
AWARENESS.

4609
02:58:32,299 --> 02:58:34,001
REGARDING THE IDEA OF WHITE

4610
02:58:34,001 --> 02:58:35,202
PAPERS, WITH THE CONCEPT WE HAVE

4611
02:58:35,202 --> 02:58:39,306
IS FORMAL WHITE PAPER PROCESS

4612
02:58:39,306 --> 02:58:40,540
BECAUSE OF THE FEDERAL LAW

4613
02:58:40,540 --> 02:58:43,977
CONTRACTS HAVE A LOT OF STRICTER

4614
02:58:43,977 --> 02:58:45,412
RULES ABOUT HOW TO COMMUNICATE

4615
02:58:45,412 --> 02:58:46,880
WITH PEOPLE THAT ARE INTERESTED

4616
02:58:46,880 --> 02:58:48,615
IN APPLYING.

4617
02:58:48,615 --> 02:58:52,653
BECAUSE THE SBTT USES A GRANT

4618
02:58:52,653 --> 02:58:54,755
MECHANISM WE ENCOURAGE ALL THE

4619
02:58:54,755 --> 02:58:55,622
APPLICANTS TO CONTACT USES AND

4620
02:58:55,622 --> 02:58:56,890
SHOW SPECIFIC AIMS AND WE DO

4621
02:58:56,890 --> 02:59:00,127
HAVE A DISCUSSION WITH THEM, AND

4622
02:59:00,127 --> 02:59:02,329
GIVE THEM ADVICE HOW TO

4623
02:59:02,329 --> 02:59:04,231
STREAMLINE THEIR PROPOSALS PRIOR

4624
02:59:04,231 --> 02:59:05,132
TO THEM APPLYING.

4625
02:59:05,132 --> 02:59:07,067
WE DO MAKE THEM WORK.

4626
02:59:07,067 --> 02:59:14,775
IT IS A GOOD IDEA.

4627
02:59:14,775 --> 02:59:18,111
>> SO AGAIN, THE SPECIFIC
AIMS

4628
02:59:18,111 --> 02:59:22,849
YOU MENTIONED, AGAIN, I WANT TO

4629
02:59:22,849 --> 02:59:24,017
ASK A SIMILAR QUESTION.

4630
02:59:24,017 --> 02:59:25,385
THE FOLLOW-UP OF HOW THE FUNDS

4631
02:59:25,385 --> 02:59:33,894
ARE SPENT OR WHERE THE PROGRAM

4632
02:59:33,894 --> 02:59:35,062
GOES INCORPORATE JUSTIFICATION

4633
02:59:35,062 --> 02:59:37,564
GIVEN BECAUSE OF SPECIFIC AIMS.

4634
02:59:37,564 --> 02:59:40,267
I MEAN THERE HAVE BEEN TIMES

4635
02:59:40,267 --> 02:59:41,868
WHERE THESE GRANTS ARE TAKEN AND

4636
02:59:41,868 --> 02:59:43,837
THEN THE COMPANY GOES IN A

4637
02:59:43,837 --> 02:59:46,340
DIFFERENT DIRECTION OR SELLS

4638
02:59:46,340 --> 02:59:47,207
ITSELF.

4639
02:59:47,207 --> 02:59:48,108
THINGS THAT ARE UNRELATED TO

4640
02:59:48,108 --> 02:59:48,442
SPECIFIC AIMS.

4641
02:59:48,442 --> 02:59:51,611
AND I THINK FOR US TOO, TO

4642
02:59:51,611 --> 02:59:56,917
UNDERSTAND THE -- WHAT THE

4643
02:59:56,917 --> 03:00:05,592
SCIENTIFIC BASIS WAS THE

4644
03:00:05,592 --> 03:00:08,362
TRAINING, CORE TRAINING -- IN

4645
03:00:08,362 --> 03:00:10,263
PAST PRESENTATIONS, THEY

4646
03:00:10,263 --> 03:00:13,033
MENTIONED THE GARLAND VENDOR AND

4647
03:00:13,033 --> 03:00:18,105
THEIR TEXTBOOK THAT WAS WRITTEN

4648
03:00:18,105 --> 03:00:19,806
BEFORE 1998.

4649
03:00:19,806 --> 03:00:26,079
-- I'M SORRY, BEFORE 2018, LIKE

4650
03:00:26,079 --> 03:00:26,279
2016.

4651
03:00:26,279 --> 03:00:29,616
I THINK YOU KNOW THE REGULATORY

4652
03:00:29,616 --> 03:00:35,088
SCIENCE FIELD HAS REALLY JUMPS A

4653
03:00:35,088 --> 03:00:35,655
LOT IN THE PAST FEW YEARS IN

4654
03:00:35,655 --> 03:00:37,124
TERMS OF WHAT IS REALLY NEEDED

4655
03:00:37,124 --> 03:00:41,595
AND HOW TO MAKE TRIALS MORE

4656
03:00:41,595 --> 03:00:42,629
EFFICIENT WITH NEW GUIDANCES

4657
03:00:42,629 --> 03:00:46,066
ABOUT EVERY FEW MONTHS.

4658
03:00:46,066 --> 03:00:48,568
CAN YOU HELP US UNDERSTAND?

4659
03:00:48,568 --> 03:00:50,570
IS THE CORE TRAINING THAT IS

4660
03:00:50,570 --> 03:00:52,539
PROVIDED AND ORGANIZED, DOES IT

4661
03:00:52,539 --> 03:00:55,008
ALSO ALIGN WITH SOME OF THESE

4662
03:00:55,008 --> 03:00:59,613
MORE MODERN UPDATED 2023, 24

4663
03:00:59,613 --> 03:01:01,214
GUIDANCES?

4664
03:01:01,214 --> 03:01:02,315
>> SO THE ICORE TRAINING
PROGRAM

4665
03:01:02,315 --> 03:01:07,687
HAS BEEN RUNNING AT NIH FOR --

4666
03:01:07,687 --> 03:01:09,823
LIKE A LIVING PROCESS AND IT IS

4667
03:01:09,823 --> 03:01:10,724
CONSTANTLY UPDATED.

4668
03:01:10,724 --> 03:01:14,861
AND THE GOAL OF THE TRAINING IS

4669
03:01:14,861 --> 03:01:16,296
NOT SPOON FEEDING THE

4670
03:01:16,296 --> 03:01:17,297
PARTICIPANTS ANSWERS.

4671
03:01:17,297 --> 03:01:20,667
IT'S TRAINING THEM TO DO THESE

4672
03:01:20,667 --> 03:01:22,969
INTERVIEWS AND COVER WHERE THE

4673
03:01:22,969 --> 03:01:24,638
ANSWERS ARE AND HELP THEM TO GO

4674
03:01:24,638 --> 03:01:29,076
IN THE RIGHT DIRECTIONS.

4675
03:01:29,076 --> 03:01:34,114
I THINK THEY ARE GETTING UPDATED

4676
03:01:34,114 --> 03:01:35,082
INFORMATION BUT IT DOESN'T AIM

4677
03:01:35,082 --> 03:01:36,750
TO PROVIDE THEM WITH ALL THE

4678
03:01:36,750 --> 03:01:37,050
ANSWERS.

4679
03:01:37,050 --> 03:01:38,251
WE HELP THEM GO IN THE RIGHT

4680
03:01:38,251 --> 03:01:41,755
DIRECTION AND THEN YOUR EARLIER

4681
03:01:41,755 --> 03:01:42,856
COMMENT ABOUT CONCERN ABOUT

4682
03:01:42,856 --> 03:01:44,591
COMPANIES RECEIVING FUNDING AND

4683
03:01:44,591 --> 03:01:52,299
GOING IN DIFFERENT DIRECTIONS --

4684
03:01:52,299 --> 03:01:53,133
WITH THE FAST TRACK, IN ORDER TO

4685
03:01:53,133 --> 03:01:54,267
TRANSITION TO THE PHASE II

4686
03:01:54,267 --> 03:01:57,003
PROJECT TO GET THAT LARGER TWO

4687
03:01:57,003 --> 03:01:57,671
MILLION DOLLAR LEVEL OF FUNDING,

4688
03:01:57,671 --> 03:01:59,239
THEY NEED TO SHOW THEY MET THE

4689
03:01:59,239 --> 03:02:00,140
ORIGINAL GOALS.

4690
03:02:00,140 --> 03:02:02,742
ANY CHANGES IN SCOPE TO THE

4691
03:02:02,742 --> 03:02:06,680
PHASE I NEED TO BE AGREED IN

4692
03:02:06,680 --> 03:02:10,984
WRITING PRIOR TO THEM EXECUTING

4693
03:02:10,984 --> 03:02:13,286
ON THAT AND THEN IN ORDER --

4694
03:02:13,286 --> 03:02:14,754
THEY JUST RECEIVED PHASE I, AND

4695
03:02:14,754 --> 03:02:16,656
IN ORDER TO RECEIVE PHASE II

4696
03:02:16,656 --> 03:02:17,757
FUNDING, THEY NEED TO

4697
03:02:17,757 --> 03:02:19,326
DEMONSTRATE THEY HAD

4698
03:02:19,326 --> 03:02:23,196
ACCOMPLISHED THE PHASE I PROJECT

4699
03:02:23,196 --> 03:02:30,904
SUCCESSFULLY.

4700
03:02:30,904 --> 03:02:32,272
>> I JUST HAD A SUGGESTION
ABOUT

4701
03:02:32,272 --> 03:02:35,208
THE TRAINING PART.

4702
03:02:35,208 --> 03:02:36,476
THERE ARE SEVERAL UNIVERSITIES

4703
03:02:36,476 --> 03:02:38,812
THAT HAVE VERY ROBUST TRAINING

4704
03:02:38,812 --> 03:02:41,548
FOR ENTREPRENEURSHIP AND

4705
03:02:41,548 --> 03:02:43,750
INNOVATION LIKE STANFORD AND

4706
03:02:43,750 --> 03:02:44,484
MICHIGAN.

4707
03:02:44,484 --> 03:02:45,118
HAVE YOU PARTNERED WITH ANY OF

4708
03:02:45,118 --> 03:02:47,954
THOSE INSTITUTIONS FOR THEIR

4709
03:02:47,954 --> 03:02:50,123
EXPERIENCE IN EDUCATION AND

4710
03:02:50,123 --> 03:02:52,592
GETTING YOUR PRODUCT?

4711
03:02:52,592 --> 03:02:57,797
IT MIGHT BE HELPFUL TO DO --

4712
03:02:57,797 --> 03:02:58,698
>> WE DO HAVE CONTACTS
WITH A

4713
03:02:58,698 --> 03:02:59,232
NUMBER OF THOSE PROGRAMS.

4714
03:02:59,232 --> 03:03:00,634
WITH THE SBTT WE'RE NOT PUSHING

4715
03:03:00,634 --> 03:03:01,835
ANY ONE MODEL.

4716
03:03:01,835 --> 03:03:03,270
WE PROVIDE THE ICORE TRAINING

4717
03:03:03,270 --> 03:03:06,139
BUT WE ARE LOOKING AS PART OF

4718
03:03:06,139 --> 03:03:07,207
THE APPLICATION, WE NEED TO

4719
03:03:07,207 --> 03:03:09,976
PROVIDE A ROBUST TRAINING ON TOP

4720
03:03:09,976 --> 03:03:12,946
OF THE MENTORING AND IT WILL

4721
03:03:12,946 --> 03:03:14,214
EXPLAIN WHAT OTHER RESOURCES

4722
03:03:14,214 --> 03:03:16,416
THEY ARE ABLE TO ACCESS.

4723
03:03:16,416 --> 03:03:17,250
SO --

4724
03:03:17,250 --> 03:03:18,451
>> BECAUSE THOSE PLACES
HAVE

4725
03:03:18,451 --> 03:03:20,120
REALLY ROBUST TRAINING PROGRAMS

4726
03:03:20,120 --> 03:03:21,855
THAT THEY MIGHT BE ABLE TO

4727
03:03:21,855 --> 03:03:23,557
CONNECT WITH JUST AS A COMMENT.

4728
03:03:23,557 --> 03:03:30,897
>> THAT IS GREAT.

4729
03:03:30,897 --> 03:03:31,498
THANK YOU.

4730
03:03:31,498 --> 03:03:32,499
>> I DON'T SEE ANY FURTHER

4731
03:03:32,499 --> 03:03:32,732
HANDS.

4732
03:03:32,732 --> 03:03:36,503
I THINK WE CAN MOVE.

4733
03:03:36,503 --> 03:03:38,538
>> CAN I MAKE A MOTION?

4734
03:03:38,538 --> 03:03:41,341
>> YES, PLEASE DO.

4735
03:03:41,341 --> 03:03:41,641
>> SECOND.

4736
03:03:41,641 --> 03:03:43,710
>> AND THE MOTION WAS FOR

4737
03:03:43,710 --> 03:03:45,145
CONCURRENCE TO BE CLEAR.

4738
03:03:45,145 --> 03:03:45,512
>> YES.

4739
03:03:45,512 --> 03:03:45,779
>> OKAY.

4740
03:03:45,779 --> 03:03:55,188
ANY FURTHER DISCUSSION?

4741
03:03:55,188 --> 03:04:01,461
LOOKING FOR ANY VOTES OF NON

4742
03:04:01,461 --> 03:04:01,828
CONCURRENCE.

4743
03:04:01,828 --> 03:04:06,466
>> IT APPEARS TO BE
UNANIMOUS.

4744
03:04:06,466 --> 03:04:07,934
>> THANK YOU ALL AND THAT
WRAPS

4745
03:04:07,934 --> 03:04:09,736
UP OUR BSA BUSINESS.

4746
03:04:09,736 --> 03:04:12,872
JOHN, BACK OVER TO YOU.

4747
03:04:12,872 --> 03:04:14,841
>> THE BOARD WILL NOW
CONSIDER

4748
03:04:14,841 --> 03:04:18,378
ONGOING NEW BUSINESS.

4749
03:04:18,378 --> 03:04:20,747
THERE WERE TWO NATURAL CANCER

4750
03:04:20,747 --> 03:04:22,983
ADVISORY BOARD SUBCOMMITTEE

4751
03:04:22,983 --> 03:04:24,584
MEETINGS YESTERDAY.

4752
03:04:24,584 --> 03:04:27,721
THE SUBCOMMITTEE CHAIRS WILL

4753
03:04:27,721 --> 03:04:28,989
GIVE THEIR REPORTS.

4754
03:04:28,989 --> 03:04:32,959
FIRST REPORT WILL BE GIVEN BY

4755
03:04:32,959 --> 03:04:34,361
DR. SUZANNE WHO IS CHAIR OF THE

4756
03:04:34,361 --> 03:04:39,833
SUB COMMITTEE ON CANCER CENTERS.

4757
03:04:39,833 --> 03:04:40,033
SUSAN?

4758
03:04:40,033 --> 03:04:40,967
>> THANK YOU VERY MUCH.

4759
03:04:40,967 --> 03:04:44,137
WE MET YESTERDAY FROM 1-2 P.M.

4760
03:04:44,137 --> 03:04:46,239
EASTERN STANDARD TIME BASED ON

4761
03:04:46,239 --> 03:04:47,073
THE DISCUSSIONS WE HAD AT THE

4762
03:04:47,073 --> 03:04:52,345
LAST MEETING, WE HAD OTHERS

4763
03:04:52,345 --> 03:04:53,747
ADDRESS SEVERAL OF THE ISSUES

4764
03:04:53,747 --> 03:04:54,914
THAT I THINK WERE RAISED.

4765
03:04:54,914 --> 03:04:57,584
HE DID A FANTASTIC JOB.

4766
03:04:57,584 --> 03:04:59,286
THE ATTENDANCE WAS GREAT AND

4767
03:04:59,286 --> 03:05:01,154
GAVE TWO PRESENTATIONS.

4768
03:05:01,154 --> 03:05:04,691
ONE WAS AN UPDATE ON THE CANCER

4769
03:05:04,691 --> 03:05:05,258
CENTER PROGRAM SO TAKING US

4770
03:05:05,258 --> 03:05:09,529
THROUGH THE HISTORY OF SORT OF

4771
03:05:09,529 --> 03:05:12,565
HOW HE HELPED TO IMPLEMENT A

4772
03:05:12,565 --> 03:05:17,304
FUNDING STRATEGY THAT WOULD HELP

4773
03:05:17,304 --> 03:05:18,438
SUPPORT EQUITABLE REVIEW BASED

4774
03:05:18,438 --> 03:05:20,273
ON MERIT AND SLIDES OF CANCER

4775
03:05:20,273 --> 03:05:21,708
CENTER ON 3 PHASES THAT STARTED

4776
03:05:21,708 --> 03:05:25,111
IN 2016 AND BROUGHT US ALL THE

4777
03:05:25,111 --> 03:05:27,380
WAY UP TO TODAY WHERE HE'S NOW

4778
03:05:27,380 --> 03:05:33,153
FOCUSED OR WE ARE FOCUSED ON

4779
03:05:33,153 --> 03:05:35,355
THOSE NEW AREAS AND HISTORICALLY

4780
03:05:35,355 --> 03:05:39,192
BEEN UNDER FUNDED.

4781
03:05:39,192 --> 03:05:41,394
HE ALSO COVERED ANOTHER OFFICE

4782
03:05:41,394 --> 03:05:43,630
OF CANCER CENTER PRIORITY, WHICH

4783
03:05:43,630 --> 03:05:45,298
IS INCREASING THE NUMBER OF NEW

4784
03:05:45,298 --> 03:05:46,266
CANCER CENTERS.

4785
03:05:46,266 --> 03:05:50,603
THERE WAS REALLY A ROBUST

4786
03:05:50,603 --> 03:05:51,438
DISCUSSION BUT EQUALITY AND

4787
03:05:51,438 --> 03:05:53,173
QUANTITY AND MAKING SURE WE

4788
03:05:53,173 --> 03:05:55,709
PRESERVED THAT TO REFLECT THE

4789
03:05:55,709 --> 03:05:58,378
HIGH QUALITY OF WHAT GOES ON AT

4790
03:05:58,378 --> 03:06:04,984
NCI CENTERS AND REAFFIRMED THAT

4791
03:06:04,984 --> 03:06:05,285
COMMITMENT.

4792
03:06:05,285 --> 03:06:07,587
AND TALKED ABOUT THE REVIEW

4793
03:06:07,587 --> 03:06:08,221
PROCESS AND WHAT THE TRADEOFF IS

4794
03:06:08,221 --> 03:06:09,956
FOR THE INTENSITY OF THE REVIEW

4795
03:06:09,956 --> 03:06:13,193
PROCESS VERSUS MAKING SURE THAT

4796
03:06:13,193 --> 03:06:15,128
CANCER CENTERS GET TO SHOW THEIR

4797
03:06:15,128 --> 03:06:17,297
CANCER CENTER NATURE, ET CETERA

4798
03:06:17,297 --> 03:06:20,500
AND WHY WE'RE KIND OF USING

4799
03:06:20,500 --> 03:06:23,036
REVIEW PROCESS WE CURRENTLY

4800
03:06:23,036 --> 03:06:24,637
HAVE.

4801
03:06:24,637 --> 03:06:25,839
AND THEN WE TOUCHED ON

4802
03:06:25,839 --> 03:06:28,441
SUPPLEMENT AND THE VALUE THAT

4803
03:06:28,441 --> 03:06:30,744
THIS RELATIVELY LOW COST

4804
03:06:30,744 --> 03:06:32,479
INVESTMENT HAS HAD IN TERMS OF

4805
03:06:32,479 --> 03:06:34,647
BEING ABLE TO SHIFT CANCER

4806
03:06:34,647 --> 03:06:36,916
CENTERS TO ALSO ALIGN WITH NCI'S

4807
03:06:36,916 --> 03:06:37,550
PRIORITIES.

4808
03:06:37,550 --> 03:06:40,754
THAT'S TYPICALLY DONE IN

4809
03:06:40,754 --> 03:06:41,855
COLLABORATION WITH SOME OF THE

4810
03:06:41,855 --> 03:06:43,823
DIVISIONS OFFICES AND CENTERS AT

4811
03:06:43,823 --> 03:06:45,425
NCI AND HE WOULD LOVE TO SEE

4812
03:06:45,425 --> 03:06:48,228
THAT CONTINUE, BUT ALSO

4813
03:06:48,228 --> 03:06:50,029
POTENTIALLY TO HAVE THE OFFICE

4814
03:06:50,029 --> 03:06:51,564
OF CANS CENTERS HAVE A POOL OF

4815
03:06:51,564 --> 03:06:54,801
FUNDS TO BE ABLE TO ISSUE

4816
03:06:54,801 --> 03:06:55,568
SUPPLEMENTS ON THEIR OWN.

4817
03:06:55,568 --> 03:06:57,604
SO THAT WAS THE FIRST

4818
03:06:57,604 --> 03:06:57,937
PRESENTATION.

4819
03:06:57,937 --> 03:07:01,741
THE SECOND PRESENTATION WE

4820
03:07:01,741 --> 03:07:02,642
TALKED ABOUT, REVISION OF THE

4821
03:07:02,642 --> 03:07:04,611
UPCOMING CCSG GUIDELINES AND

4822
03:07:04,611 --> 03:07:07,313
FOCUS ON A FEW KEY AREAS.

4823
03:07:07,313 --> 03:07:10,283
ONE IS PED, THE NEWEST AREA.

4824
03:07:10,283 --> 03:07:13,086
HE REVIEWED HOW THE FIRST 20

4825
03:07:13,086 --> 03:07:16,055
HAVE GONE AND SOME OF THE

4826
03:07:16,055 --> 03:07:17,857
LESSONS LEARNED AND BASED ON THE

4827
03:07:17,857 --> 03:07:18,992
FEEDBACK AND DISCUSSION WE HAD

4828
03:07:18,992 --> 03:07:22,962
IN HIS OWN THINKING, HE TALKED

4829
03:07:22,962 --> 03:07:25,698
ABOUT AREAS WHERE HE IS GOING

4830
03:07:25,698 --> 03:07:28,234
TO -- WHERE THE GUIDELINES WILL

4831
03:07:28,234 --> 03:07:29,636
CLARIFY A LITTLE BIT MORE SOME

4832
03:07:29,636 --> 03:07:31,104
OF THE EXPECTATIONS, INCLUDING

4833
03:07:31,104 --> 03:07:34,607
BASELINE DIVERSITY OF DATA FOR

4834
03:07:34,607 --> 03:07:38,044
CANCER CENTERS AND TALKING ABOUT

4835
03:07:38,044 --> 03:07:40,547
THE INTERSECTION OF [ INAUDIBLE

4836
03:07:40,547 --> 03:07:42,081
AND HOW WE ARE INVOLVING STAFF

4837
03:07:42,081 --> 03:07:45,785
IN THE DIVERSITY ASSESSMENT OF

4838
03:07:45,785 --> 03:07:46,352
THE CENTER.

4839
03:07:46,352 --> 03:07:50,323
AND INCORPORATE PED INITIATIVES

4840
03:07:50,323 --> 03:07:51,758
INTO THE STRATEGIC PLAN.

4841
03:07:51,758 --> 03:07:54,627
AND TALKED ABOUT CLARIFYING

4842
03:07:54,627 --> 03:07:58,865
TERMINOLOGY, BOTH FOR CANCER

4843
03:07:58,865 --> 03:08:00,333
CENTERS AND HOW WE COMMUNICATE

4844
03:08:00,333 --> 03:08:02,402
TO THE PUBLIC ABOUT DIFFERENT

4845
03:08:02,402 --> 03:08:04,270
AREAS WITHIN CCSG APPLICATIONS

4846
03:08:04,270 --> 03:08:06,739
THAT MAY SOUND SIMILAR LIKE PED

4847
03:08:06,739 --> 03:08:09,509
AND COE.

4848
03:08:09,509 --> 03:08:10,810
FOR ANSWER TECH THERE WAS A

4849
03:08:10,810 --> 03:08:12,645
DISCUSSION ABOUT ARE WE READ TOW

4850
03:08:12,645 --> 03:08:18,017
EXPAND TO A 12-PAGE SECTION?

4851
03:08:18,017 --> 03:08:20,520
THERE WAS NOW THE GENERAL

4852
03:08:20,520 --> 03:08:20,787
CONSENSUS.

4853
03:08:20,787 --> 03:08:23,289
OUR GROUP WAS NO, WE HAVE ENOUGH

4854
03:08:23,289 --> 03:08:23,656
PAGES.

4855
03:08:23,656 --> 03:08:26,493
SO THAT'S KIND OF WHERE WE LEFT

4856
03:08:26,493 --> 03:08:26,693
THAT.

4857
03:08:26,693 --> 03:08:28,228
THERE WAS DISCUSSION REGARDING

4858
03:08:28,228 --> 03:08:31,231
COE AND REALLY ACKNOWLEDGING

4859
03:08:31,231 --> 03:08:33,366
THAT A CURRENT STATE IS UNDER

4860
03:08:33,366 --> 03:08:37,704
FUNDED AND HOW WE CAN SORT OF

4861
03:08:37,704 --> 03:08:39,506
BETTER SUPPORT WHAT IS REALLY A

4862
03:08:39,506 --> 03:08:40,340
CROSSCUTTING INITIATIVE ACROSS

4863
03:08:40,340 --> 03:08:42,642
ALL THE CANCER CENTERS.

4864
03:08:42,642 --> 03:08:45,778
WE HAD A LITTLE BIT OF -- WE HAD

4865
03:08:45,778 --> 03:08:47,780
A GOOD DISCUSSION ABOUT CANCER

4866
03:08:47,780 --> 03:08:48,948
CENTERS AND THE ISSUES THAT CAME

4867
03:08:48,948 --> 03:08:54,053
UP LAST TIME IN OUR MEETING

4868
03:08:54,053 --> 03:08:55,121
ACCEPTING MEDICAID AND IT WAS

4869
03:08:55,121 --> 03:08:57,891
NICE TO HAVE PEOPLE'S INPUT FROM

4870
03:08:57,891 --> 03:09:00,860
ALL DIRECTIONS, WHICH IS OF

4871
03:09:00,860 --> 03:09:02,295
COURSE WE WANT TO SERVE THE

4872
03:09:02,295 --> 03:09:04,397
UNDERSERVED BUT ALSO HAVE TO

4873
03:09:04,397 --> 03:09:08,801
THINK ABOUT THAT THE CCSC ASK A

4874
03:09:08,801 --> 03:09:09,802
RESEARCH-FOCUSED GRANT WHICH MAY

4875
03:09:09,802 --> 03:09:12,972
LIMIT WHAT WE ARE ABLE TO

4876
03:09:12,972 --> 03:09:14,841
MANDATE PLUS THE CONSIDERATIONS

4877
03:09:14,841 --> 03:09:16,476
THAT SEVERAL CENTER DIRECTORS

4878
03:09:16,476 --> 03:09:18,077
BROUGHT UP OF UNIQUE

4879
03:09:18,077 --> 03:09:19,212
CIRCUMSTANCES IN THEIR STATE.

4880
03:09:19,212 --> 03:09:20,813
AND ONE PLACE WHERE WE LANDED

4881
03:09:20,813 --> 03:09:25,285
THAT WE THOUGHT WAS KIND OF A

4882
03:09:25,285 --> 03:09:27,954
GOOD INTERSECTION WAS CLINICAL

4883
03:09:27,954 --> 03:09:31,824
TRIALS AND HOW DO WE SUPPORT

4884
03:09:31,824 --> 03:09:33,826
PATIENTS WHO ARE INSURED BY

4885
03:09:33,826 --> 03:09:37,063
MEDICAID WITHIN CLINICAL TRIALS

4886
03:09:37,063 --> 03:09:38,331
WHICH FELT A LITTLE MORE IN

4887
03:09:38,331 --> 03:09:42,936
SCOPE OF CCSC GIVEN OUR FOCUS ON

4888
03:09:42,936 --> 03:09:44,938
RESEARCH THAT IS THERAPEUTIC

4889
03:09:44,938 --> 03:09:45,705
CLINICAL TRIALS.

4890
03:09:45,705 --> 03:09:50,643
AND THEN, JUST TO CONCLUDE, THE

4891
03:09:50,643 --> 03:09:51,277
NCAB OFFERED SUPPORT IN WHATEVER

4892
03:09:51,277 --> 03:09:53,179
WAY IS HELPFUL AND ALLOWABLE.

4893
03:09:53,179 --> 03:09:55,949
WE ALL HAVE OPINIONS ABOUT THE

4894
03:09:55,949 --> 03:09:58,751
UPDATES FOR THE GUIDELINES AND

4895
03:09:58,751 --> 03:09:59,586
WORKING WITHIN WHATEVER

4896
03:09:59,586 --> 03:09:59,919
PARAMETERS.

4897
03:09:59,919 --> 03:10:01,387
THAT IS SOMETHING WE WOULD LIKE

4898
03:10:01,387 --> 03:10:03,089
TO CONTINUE TO DO AND THEN THERE

4899
03:10:03,089 --> 03:10:06,059
WAS ALSO A GOOD SUGGESTION WHICH

4900
03:10:06,059 --> 03:10:07,427
HENRY SAID HE WOULD LOOK INTO,

4901
03:10:07,427 --> 03:10:10,396
WHICH IS POTENTIALLY, COULD WE

4902
03:10:10,396 --> 03:10:12,966
GET FURTHER COMMENTS LIKE PUBLIC

4903
03:10:12,966 --> 03:10:14,634
COMMENT ISN'T THE RIGHT WORD BUT

4904
03:10:14,634 --> 03:10:16,135
A PROCESS WHERE SOME OF THE NEW

4905
03:10:16,135 --> 03:10:18,938
CONCEPTS ARE VETTED IN A BROADER

4906
03:10:18,938 --> 03:10:20,707
SETTING FOR PEOPLE WHO ARE

4907
03:10:20,707 --> 03:10:21,040
STAKEHOLDERS.

4908
03:10:21,040 --> 03:10:26,646
AND THAT WAS IT.

4909
03:10:26,646 --> 03:10:30,416
>> THANK YOU, SUSAN.

4910
03:10:30,416 --> 03:10:40,426
IT WAS A GREAT MEETING.

4911
03:10:40,426 --> 03:10:41,894
SO NOW THE MEMBERS WILL NOW VOTE

4912
03:10:41,894 --> 03:10:43,396
TO ACCEPT SUSAN'S REPORT.

4913
03:10:43,396 --> 03:10:44,797
IS THERE A MOTION?

4914
03:10:44,797 --> 03:10:45,431
>> SO MOVED.

4915
03:10:45,431 --> 03:10:47,767
>> SO MOVED.

4916
03:10:47,767 --> 03:10:49,469
>> SECOND.

4917
03:10:49,469 --> 03:10:50,503
>> SECOND.

4918
03:10:50,503 --> 03:10:50,803
>> GREAT.

4919
03:10:50,803 --> 03:10:53,906
SHOULD WE NOW NEED A VOTE?

4920
03:10:53,906 --> 03:10:56,309
I'LL FIRST ASK ARE THERE ANY

4921
03:10:56,309 --> 03:10:56,676
NAYs?

4922
03:10:56,676 --> 03:10:59,545
OR ABSTENTIONS?

4923
03:10:59,545 --> 03:11:02,949
THERE BEING NONE, I THINK IT'S

4924
03:11:02,949 --> 03:11:04,951
UNANIMOUS.

4925
03:11:04,951 --> 03:11:05,952
>> UNANIMOUS.

4926
03:11:05,952 --> 03:11:07,120
>> SO THE NEXT
SUBCOMMITTEE

4927
03:11:07,120 --> 03:11:09,322
REPORT WILL BE BROUGHT TO US BY

4928
03:11:09,322 --> 03:11:11,691
THE CHAIR OF THE AD-HOC SUB

4929
03:11:11,691 --> 03:11:13,960
COMMITTEE ON EXPERIMENTAL

4930
03:11:13,960 --> 03:11:17,830
THERAPEUTICS.

4931
03:11:17,830 --> 03:11:19,198
RICHARD?

4932
03:11:19,198 --> 03:11:20,033
>> THANK YOU VERY MUCH.

4933
03:11:20,033 --> 03:11:21,501
THIS AD-HOC SUBCOMMITTEE WAS

4934
03:11:21,501 --> 03:11:25,204
ESTABLISHED IN 2006 WITH A

4935
03:11:25,204 --> 03:11:28,107
SPECIFIC MISSION AND WITH A

4936
03:11:28,107 --> 03:11:29,609
PARTICULAR PURPOSE AND THEN

4937
03:11:29,609 --> 03:11:31,778
DIDN'T MEET FOR YEARS, FOR NINE

4938
03:11:31,778 --> 03:11:32,045
YEARS.

4939
03:11:32,045 --> 03:11:34,213
BUT RECENTLY OVER THE LAST FEW

4940
03:11:34,213 --> 03:11:37,650
YEARS, THERE HAS BEEN A LOT MORE

4941
03:11:37,650 --> 03:11:39,118
INTEREST IN EXPERIMENTAL

4942
03:11:39,118 --> 03:11:42,021
THERAPEUTICS AND WHAT I DID IN

4943
03:11:42,021 --> 03:11:43,923
ORDER TO EVALUATE WHAT HAS

4944
03:11:43,923 --> 03:11:45,425
HAPPENED IN THE PAST AND WHAT

4945
03:11:45,425 --> 03:11:48,528
HAS BEEN GOING ON, WE READ THE

4946
03:11:48,528 --> 03:11:53,366
FOUR YEARS OF NOTES AND MINUTES

4947
03:11:53,366 --> 03:11:56,803
AND THEN ASKED THE DOCTOR TO

4948
03:11:56,803 --> 03:11:57,670
RESPOND TO THE DIFFERENT

4949
03:11:57,670 --> 03:11:59,706
REQUESTS THE COMMITTEE HAD MADE.

4950
03:11:59,706 --> 03:12:03,176
NOW THIS PARTICULAR COMMITTEE

4951
03:12:03,176 --> 03:12:07,580
YESTERDAY HAD 100% PARTICIPATION

4952
03:12:07,580 --> 03:12:08,948
OF THE MEMBERS WHICH

4953
03:12:08,948 --> 03:12:09,582
DEMONSTRATED THEIR COMMITMENT

4954
03:12:09,582 --> 03:12:11,751
AND ALSO INTEREST AND I THINK

4955
03:12:11,751 --> 03:12:15,254
THIS WILL GO VERY VALUABLE AS WE

4956
03:12:15,254 --> 03:12:16,589
GO FORWARD.

4957
03:12:16,589 --> 03:12:18,291
SO THEN THE DOCTOR GAVE A VERY

4958
03:12:18,291 --> 03:12:19,926
ROBUST REVIEW OF THE

4959
03:12:19,926 --> 03:12:22,528
DEVELOPMENTAL OF THERAPEUTICS

4960
03:12:22,528 --> 03:12:23,162
PROGRAM.

4961
03:12:23,162 --> 03:12:24,764
OUTLINING EACH AND EVERY ONE OF

4962
03:12:24,764 --> 03:12:27,333
THE ASPECTS OF THE PROGRAM THAT

4963
03:12:27,333 --> 03:12:28,568
ANSWERED SPECIFICALLY THE

4964
03:12:28,568 --> 03:12:29,535
QUESTIONS OVER THE LAST FOUR

4965
03:12:29,535 --> 03:12:32,171
YEARS AND PARTICULARLY LAST

4966
03:12:32,171 --> 03:12:34,040
COUPLE OF YEARS THAT THE MEMBERS

4967
03:12:34,040 --> 03:12:36,042
REQUESTED AND SO THEREFORE THE

4968
03:12:36,042 --> 03:12:39,378
NCAB MEMBERS ON THIS COMMITTEE

4969
03:12:39,378 --> 03:12:42,615
ARE HAVING IMPACT AND INPUT BOTH

4970
03:12:42,615 --> 03:12:49,722
OF WHICH WERE GREATLY

4971
03:12:49,722 --> 03:12:50,022
APPRECIATED.

4972
03:12:50,022 --> 03:12:54,026
AND SPECIFICALLY THE DOCTOR

4973
03:12:54,026 --> 03:12:56,262
HIGHLIGHTED COMPLIMENTS

4974
03:12:56,262 --> 03:12:58,264
ACROSS -- IT WAS INTERESTED BY

4975
03:12:58,264 --> 03:12:59,298
THE SUBCOMMITTEE, PARTICULARLY

4976
03:12:59,298 --> 03:13:02,101
CELL THERAPY, CONDUCTING SMALL

4977
03:13:02,101 --> 03:13:03,836
TRIALS AND RATIONAL DRUG

4978
03:13:03,836 --> 03:13:06,606
DISCOVERY AS WELL AS SUPPORTING

4979
03:13:06,606 --> 03:13:09,208
TRANSLATIONAL RESEARCH TRAINING.

4980
03:13:09,208 --> 03:13:12,678
AND SO THE SUBCOMMITTEE WAS VERY

4981
03:13:12,678 --> 03:13:23,156
APPRECIATIVE OF THE EFFORTS.

4982
03:13:23,156 --> 03:13:26,325
OTHER DOCTORS GAVE SOME VERY

4983
03:13:26,325 --> 03:13:26,959
IMPORTANT DISCUSSION POINTS AND

4984
03:13:26,959 --> 03:13:31,030
THESE WERE TAKEN SERIOUSLY AND

4985
03:13:31,030 --> 03:13:31,898
WE'LL REPORT BACK.

4986
03:13:31,898 --> 03:13:34,901
I THINK THE MAIN THING THAT --

4987
03:13:34,901 --> 03:13:45,378
ONE OTHER THING IS THAT EYE

4988
03:13:50,082 --> 03:13:50,650
CHEAP CAME ACROSS OF INTERACTION

4989
03:13:50,650 --> 03:13:54,086
WITH THE FDA AND THEN DR. DORE

4990
03:13:54,086 --> 03:13:58,925
SHAW, JIM GAVE A DESCRIPTION --

4991
03:13:58,925 --> 03:13:59,625
DOROSHOW -- OF THE FACT THAT

4992
03:13:59,625 --> 03:14:03,529
THIS GOES ON COMMONLY SO IT GAVE

4993
03:14:03,529 --> 03:14:05,364
THE COMMITTEE THE FEELING THAT

4994
03:14:05,364 --> 03:14:07,767
ONCE AGAIN THEIR THOUGHTS AND

4995
03:14:07,767 --> 03:14:13,339
THEIR IDEAS WERE BEING ACTED

4996
03:14:13,339 --> 03:14:13,840
UPON AND HAVING IMPACT.

4997
03:14:13,840 --> 03:14:20,546
AT THE END OF THE MEETING, WE

4998
03:14:20,546 --> 03:14:22,348
DECIDED WE THOUGHT THE MISSION

4999
03:14:22,348 --> 03:14:24,617
NEEDED UPGRADING THROUGH 2023.

5000
03:14:24,617 --> 03:14:32,158
WE DECIDED TO DO, WITH THE HELP

5001
03:14:32,158 --> 03:14:35,995
OF THE NCI STAFF, CREATE A NEW

5002
03:14:35,995 --> 03:14:37,530
MISSION FOR THE SUBCOMMITTEE AND

5003
03:14:37,530 --> 03:14:40,900
THEN AFTER WORKING ON IT OVER

5004
03:14:40,900 --> 03:14:42,501
THE NEXT FEW MONTHS, PRESENT IT

5005
03:14:42,501 --> 03:14:47,673
TO THE COMMITTEE, TO THE NCAB

5006
03:14:47,673 --> 03:14:50,910
FOR APPROVAL.

5007
03:14:50,910 --> 03:14:53,145
SO I THINK THE INTEREST AND

5008
03:14:53,145 --> 03:14:59,986
ENTHUSIASM FOR THE SUBCOMMITTEE

5009
03:14:59,986 --> 03:15:01,487
IS IN VIG RATED AND WORKING WITH

5010
03:15:01,487 --> 03:15:04,257
THE NCI STAFF CAREFULLY AND

5011
03:15:04,257 --> 03:15:04,924
CLOSELY.

5012
03:15:04,924 --> 03:15:08,594
SO THANK YOU.

5013
03:15:08,594 --> 03:15:10,263
>> THANK YOU.

5014
03:15:10,263 --> 03:15:13,065
CAN THE N CAT MEMBERS NEED TO

5015
03:15:13,065 --> 03:15:14,767
VOTE TO ACCEPT THE REPORT.

5016
03:15:14,767 --> 03:15:20,039
IS THERE A MOTION?

5017
03:15:20,039 --> 03:15:23,109
>> I MOVE APPROVAL.

5018
03:15:23,109 --> 03:15:26,212
>> SECOND?

5019
03:15:26,212 --> 03:15:26,913
>> SECOND.

5020
03:15:26,913 --> 03:15:29,181
>> ANY FURTHER DISCUSSION?

5021
03:15:29,181 --> 03:15:30,750
IF NOT WE SHOULD VOTE.

5022
03:15:30,750 --> 03:15:36,088
I WILL ASK, ARE THERE ANY NAY

5023
03:15:36,088 --> 03:15:37,323
NAYs?

5024
03:15:37,323 --> 03:15:37,690
ABSTENTIONS?

5025
03:15:37,690 --> 03:15:40,660
>> IT'S UNANIMOUS.

5026
03:15:40,660 --> 03:15:41,527
>> THANK YOU.

5027
03:15:41,527 --> 03:15:44,363
WE'LL NOW MOVE ON TO OTHER

5028
03:15:44,363 --> 03:15:44,797
BUSINESS.

5029
03:15:44,797 --> 03:15:46,232
A FEW BULLET POINTS HERE.

5030
03:15:46,232 --> 03:15:49,402
THE ANNUAL BSA CONCEPT REVIEW

5031
03:15:49,402 --> 03:15:50,836
REPORT IS POSTED ON THE MEMBERS

5032
03:15:50,836 --> 03:15:52,104
ONLY WEBSITE.

5033
03:15:52,104 --> 03:15:54,106
AND AS REQUESTED PRIOR YEARS OF

5034
03:15:54,106 --> 03:15:56,108
THE REPORT, HAVE BEEN ARCHIVED

5035
03:15:56,108 --> 03:15:59,378
SO YOU CAN HAVE ACCESS TO THOSE

5036
03:15:59,378 --> 03:16:00,613
AS WELL.

5037
03:16:00,613 --> 03:16:01,847
I'LL NOW ASK THE BOARDS, ARE

5038
03:16:01,847 --> 03:16:03,950
THERE OTHER THOUGHTS, ISSUES,

5039
03:16:03,950 --> 03:16:05,484
CONCERNS, RECOMMENDATIONS THAT

5040
03:16:05,484 --> 03:16:09,355
ANYONE WOULD LIKE TO SHARE TODAY

5041
03:16:09,355 --> 03:16:12,491
WITH THE BOARDS OR WITH THE NCI

5042
03:16:12,491 --> 03:16:18,698
THAT MIGHT CONSIDER FURTHER

5043
03:16:18,698 --> 03:16:19,966
DISCUSSION?

5044
03:16:19,966 --> 03:16:20,633
RICHARD IS YOUR HAND UP?

5045
03:16:20,633 --> 03:16:22,001
>> YES, IT IS.

5046
03:16:22,001 --> 03:16:22,301
THANK YOU.

5047
03:16:22,301 --> 03:16:25,137
>> THIS MAY NOT BE
POSSIBLE BUT

5048
03:16:25,137 --> 03:16:26,605
THIS ECHOS ONE OF OUR COLLEAGUES

5049
03:16:26,605 --> 03:16:28,074
WHOA MENTIONED IT EARLIER WHICH

5050
03:16:28,074 --> 03:16:31,978
IS AN IN-PERSON MEETING IS VERY

5051
03:16:31,978 --> 03:16:35,348
VALUABLE, I THINK, IN CREATING

5052
03:16:35,348 --> 03:16:37,383
INTERACTION AND DISCUSSION,

5053
03:16:37,383 --> 03:16:37,984
CAMARADERIE.

5054
03:16:37,984 --> 03:16:40,486
AND I KNOW THAT WE OBVIOUSLY

5055
03:16:40,486 --> 03:16:41,687
THIS IS VIRTUAL.

5056
03:16:41,687 --> 03:16:43,522
IT WAS SUPPOSED TO BE IN-PERSON.

5057
03:16:43,522 --> 03:16:45,958
THE NEXT IN-PERSON IS IN JUNE.

5058
03:16:45,958 --> 03:16:48,761
AND I WAS WONDERING IF IT IS

5059
03:16:48,761 --> 03:16:51,163
POSSIBLE THAT MAYBE THE FEBRUARY

5060
03:16:51,163 --> 03:16:52,965
MEETING WOULD BE IN-PERSON SO WE

5061
03:16:52,965 --> 03:16:57,036
HAVE THE OPPORTUNITY OF

5062
03:16:57,036 --> 03:16:58,104
INTERACTING WITH EACH OTHER IN

5063
03:16:58,104 --> 03:17:04,844
THE SAME ROOM?

5064
03:17:04,844 --> 03:17:05,578
>> I PRESUME THAT QUESTION
IS

5065
03:17:05,578 --> 03:17:15,855
DIRECTED TO ME.

5066
03:17:16,188 --> 03:17:18,257
THE WEATHER MAY NOT -- IT

5067
03:17:18,257 --> 03:17:22,395
PROBABLY WILL NOT BE CONDUCIVE.

5068
03:17:22,395 --> 03:17:29,201
SO, WITH COVID BECAME AN ISSUE,

5069
03:17:29,201 --> 03:17:30,603
IT WASN'T DIFFICULT FOR NCI TO

5070
03:17:30,603 --> 03:17:32,038
TRANSITION SINCE WE HAVE BEEN

5071
03:17:32,038 --> 03:17:36,509
DOING VIRTUALLY FOR YEARS.

5072
03:17:36,509 --> 03:17:40,179
SO AT THIS POINT, I WILL SAY NO,

5073
03:17:40,179 --> 03:17:43,282
THERE WILL NOT BE A FACE-TO-FACE

5074
03:17:43,282 --> 03:17:43,849
MEETING.

5075
03:17:43,849 --> 03:17:45,117
>> THANKS, PAULET.

5076
03:17:45,117 --> 03:17:49,388
I WOULD SAY MY OWN EXPERIENCE IS

5077
03:17:49,388 --> 03:17:53,826
TO NOT GO EAST BETWEEN JANUARY

5078
03:17:53,826 --> 03:17:59,565
AND MAY.

5079
03:17:59,565 --> 03:18:02,334
SO I WOULD AGREE BUT I ALSO

5080
03:18:02,334 --> 03:18:04,103
AGREE WITH RICHARD THAT

5081
03:18:04,103 --> 03:18:05,805
FACE-TO-FACE IN-PERSON MEETINGS,

5082
03:18:05,805 --> 03:18:07,306
THERE IS IT A DIFFERENT DYNAMIC

5083
03:18:07,306 --> 03:18:09,008
AND A DIFFERENT LEVEL OF

5084
03:18:09,008 --> 03:18:10,376
EFFECTIVENESS SOMETIMES.

5085
03:18:10,376 --> 03:18:10,676
SO I AGREE.

5086
03:18:10,676 --> 03:18:14,213
I THINK WE HEAR YOU LOUD AND

5087
03:18:14,213 --> 03:18:14,413
CLEAR.

5088
03:18:14,413 --> 03:18:20,286
>> AND I AGREE WITH
RICHARD

5089
03:18:20,286 --> 03:18:20,786
ALSO.

5090
03:18:20,786 --> 03:18:21,454
JUST NOT IN FEBRUARY.

5091
03:18:21,454 --> 03:18:24,123
>> WE CAN AGREE WITH EACH
OTHER

5092
03:18:24,123 --> 03:18:26,392
BUT FLOTIN THE SAME ZIP CODE.

5093
03:18:26,392 --> 03:18:29,061
>> THAT'S RIGHT.

5094
03:18:29,061 --> 03:18:31,263
>> I APOLOGIZE.

5095
03:18:31,263 --> 03:18:33,132
MY HAND RAISE DOESN'T WORK VERY

5096
03:18:33,132 --> 03:18:33,666
WELL.

5097
03:18:33,666 --> 03:18:36,936
I WAS GOING TO SUGGEST, TO THE

5098
03:18:36,936 --> 03:18:40,406
NCAB THAT WE MIGHT THINK ABOUT

5099
03:18:40,406 --> 03:18:42,708
INVITING -- TO GIVE A TALK FOR

5100
03:18:42,708 --> 03:18:44,410
US BECAUSE WE DO HAVE OVER THE

5101
03:18:44,410 --> 03:18:45,878
YEARS, AND JIM SPOKE TO IT AT

5102
03:18:45,878 --> 03:18:49,849
OUR MEETING, AS RICHARD POINTED

5103
03:18:49,849 --> 03:18:51,750
OUT, WE HAVE A CLOSE WORKING

5104
03:18:51,750 --> 03:18:54,620
RELATIONSHIP WITH FDA AND HE

5105
03:18:54,620 --> 03:18:56,388
USED TO COME TO THIS BOARD

5106
03:18:56,388 --> 03:18:57,389
MEETING ALL THE TIME BECAUSE HE

5107
03:18:57,389 --> 03:19:00,626
IS AN AD-HOC MEMBER.

5108
03:19:00,626 --> 03:19:02,061
I SUSPECT PAULET, I DON'T KNOW

5109
03:19:02,061 --> 03:19:04,630
IF HE IS STILL AN AD-HOC MEMBER.

5110
03:19:04,630 --> 03:19:05,898
>> HE IS.

5111
03:19:05,898 --> 03:19:10,302
>> -- TO GET A SENSE OF
WHERE

5112
03:19:10,302 --> 03:19:12,271
ARE WE IN THE CANCER

5113
03:19:12,271 --> 03:19:13,072
THERAPEUTICS SPACE.

5114
03:19:13,072 --> 03:19:15,708
I THINK HE WOULD BE HAPPY TO DO

5115
03:19:15,708 --> 03:19:15,875
IT.

5116
03:19:15,875 --> 03:19:17,977
I THINK IT WOULD BE A GOOD THING

5117
03:19:17,977 --> 03:19:19,345
TO HAVE SOME DISCUSSION ABOUT

5118
03:19:19,345 --> 03:19:22,214
WHERE HE SEES THE FIELD GOING

5119
03:19:22,214 --> 03:19:23,682
AND HE'S GOT HIS HANDS FULL AT

5120
03:19:23,682 --> 03:19:25,317
THE MOMENT BUT I THINK HE WOULD

5121
03:19:25,317 --> 03:19:27,720
BE VERY HAPPY TO DO IT.

5122
03:19:27,720 --> 03:19:31,524
>> I HAVE THAT ON MY --

5123
03:19:31,524 --> 03:19:33,592
>> YOU DEFINITELY JUMPED
FORWARD

5124
03:19:33,592 --> 03:19:37,930
AND A GOOD SEGUE TO FUTURE

5125
03:19:37,930 --> 03:19:39,331
AGENDA ITEMS.

5126
03:19:39,331 --> 03:19:41,567
ANY FUTURE AGENDA ITEMS ANYONE

5127
03:19:41,567 --> 03:19:43,369
WOULD LIKE TO HAVE ADDRESSEDDED?

5128
03:19:43,369 --> 03:19:43,969
>> ABOUT A YEAR AGO WE
WERE

5129
03:19:43,969 --> 03:19:46,071
TALKING ABOUT THE CLINICAL

5130
03:19:46,071 --> 03:19:50,476
TRIALS ACCELERATOR AND IT WOULD

5131
03:19:50,476 --> 03:19:51,076
BE GREAT TO HEAR AN UPDATE IF

5132
03:19:51,076 --> 03:19:52,278
THAT GOT STARTED AND WHAT IS

5133
03:19:52,278 --> 03:19:58,450
HAPPENING WITH THAT.

5134
03:19:58,450 --> 03:20:04,557
JUST AN IDEA.

5135
03:20:04,557 --> 03:20:07,326
>> FROM MY PERSPECTIVE,
GIVEN

5136
03:20:07,326 --> 03:20:11,030
THE KIND OF ENVIRONMENT -- I DO

5137
03:20:11,030 --> 03:20:12,831
REMEMBER WE HAD A CONVERSATION

5138
03:20:12,831 --> 03:20:17,903
ABOUT WHAT COULD WE DO AS A

5139
03:20:17,903 --> 03:20:21,207
BOARD REPORTS TO ASSIST ON THE

5140
03:20:21,207 --> 03:20:22,341
NCI?

5141
03:20:22,341 --> 03:20:23,042
BEYOND THE MEETINGS.

5142
03:20:23,042 --> 03:20:25,544
AND I KNOW WE HAVE TO BE VERY

5143
03:20:25,544 --> 03:20:25,778
CAREFUL.

5144
03:20:25,778 --> 03:20:27,513
WE WORK VERY CLOSELY WITH PAUL

5145
03:20:27,513 --> 03:20:34,620
THE TO MAKE SURE WE VET WHATEVER

5146
03:20:34,620 --> 03:20:34,954
THAT MIGHT BE.

5147
03:20:34,954 --> 03:20:35,654
I THINK THAT IS SOMETHING WE

5148
03:20:35,654 --> 03:20:38,057
HAVE TO FOLLOW-UP ON AND I'LL

5149
03:20:38,057 --> 03:20:40,025
TAKE IT UPON MYSELF TO ENGAGE

5150
03:20:40,025 --> 03:20:41,760
WITH THOSE CONVERSATIONS JUST TO

5151
03:20:41,760 --> 03:20:47,166
SEE IF THERE IS ANYTHING WE CAN

5152
03:20:47,166 --> 03:20:50,069
DO.

5153
03:20:50,069 --> 03:20:50,936
HOWARD?

5154
03:20:50,936 --> 03:20:52,171
>> I THINK TWO THINGS
WOULD HELP

5155
03:20:52,171 --> 03:20:56,508
THE COMMUNITY WORKING IN

5156
03:20:56,508 --> 03:20:59,011
ONCOLOGY AND CELL THERAPIES.

5157
03:20:59,011 --> 03:21:01,080
ONE IS ANY EXPERIENCES THAT CAN

5158
03:21:01,080 --> 03:21:05,517
BE SHARED FROM THE ORGANOID WORK

5159
03:21:05,517 --> 03:21:06,852
THAT IS ONGOING.

5160
03:21:06,852 --> 03:21:09,188
I HEARD OF SOME SPONSORS BEING

5161
03:21:09,188 --> 03:21:11,023
ABLE TO DO ORGANOID STUDIES AND

5162
03:21:11,023 --> 03:21:13,325
BY PASS THE OLD-FASHIONED WAY OF

5163
03:21:13,325 --> 03:21:19,531
USING IRRELEVANT MOUSE MODELS.

5164
03:21:19,531 --> 03:21:23,369
AS A WAY TO HELP JUSTIFY A

5165
03:21:23,369 --> 03:21:26,338
SUCCESSFUL IND.

5166
03:21:26,338 --> 03:21:27,373
SO, HAVING US LEARN MORE ABOUT

5167
03:21:27,373 --> 03:21:28,407
THAT WOULD BE USEFUL.

5168
03:21:28,407 --> 03:21:30,409
THE OTHER IS, ANY PROGRESS THAT

5169
03:21:30,409 --> 03:21:36,515
IS SIMILARLY FROM THE MOONSHOT

5170
03:21:36,515 --> 03:21:42,221
PROGRAM ON BIOMARKERS THAT GARY

5171
03:21:42,221 --> 03:21:43,122
KELLOGG HAS BEEN RUNNING.

5172
03:21:43,122 --> 03:21:45,124
I SUGGESTED SPECIFIC TO IMMUNE

5173
03:21:45,124 --> 03:21:46,158
ONCOLOGY.

5174
03:21:46,158 --> 03:21:46,992
THEY ARE JUST STARTING THE

5175
03:21:46,992 --> 03:21:48,027
PUBLISHED WORK.

5176
03:21:48,027 --> 03:21:51,764
WE HAVE HAD ONE TALK FROM HELEN

5177
03:21:51,764 --> 03:21:53,732
CHEN ABOUT A YEAR OR SO AGO BUT

5178
03:21:53,732 --> 03:21:55,434
THERE HAS BEEN 3 PUBLICATIONS

5179
03:21:55,434 --> 03:22:01,440
SINCE THEN THAT HAVE COME OUT

5180
03:22:01,440 --> 03:22:03,742
MORE COMING AND OTHERS MAY BE

5181
03:22:03,742 --> 03:22:08,647
AWARE OF.

5182
03:22:08,647 --> 03:22:11,417
I'M INTERESTED WORK ON MDSCs

5183
03:22:11,417 --> 03:22:15,587
THAT CAN BE MONITORED FOR RESIST

5184
03:22:15,587 --> 03:22:16,255
EBBS USING TECHNOLOGIES.

5185
03:22:16,255 --> 03:22:19,058
THAT'S JUST ONE EXAMPLE.

5186
03:22:19,058 --> 03:22:19,692
THERE WERE MANY AT THE MEETING

5187
03:22:19,692 --> 03:22:23,395
JUST A MONTH AGO.

5188
03:22:23,395 --> 03:22:25,531
AND I THINK MAYBE THEY WOULD BE

5189
03:22:25,531 --> 03:22:26,265
REALLY HELPFUL.

5190
03:22:26,265 --> 03:22:34,807
>> OKAY, WE HAVE IT.

5191
03:22:34,807 --> 03:22:35,574
>> THANK YOU.

5192
03:22:35,574 --> 03:22:38,010
>> I'M SORRY.

5193
03:22:38,010 --> 03:22:39,445
>> I THINK I HAD MY HAND
UP

5194
03:22:39,445 --> 03:22:42,614
FIRST BUT GO AHEAD.

5195
03:22:42,614 --> 03:22:43,082
>> YOU GO FIRST.

5196
03:22:43,082 --> 03:22:43,349
>> OKAY.

5197
03:22:43,349 --> 03:22:45,684
I'LL TRY TO KEEP MINE QUICK.

5198
03:22:45,684 --> 03:22:47,653
SO ONE OF THE THINGS THAT I

5199
03:22:47,653 --> 03:22:49,822
NOTICED IS THAT CANCER CENTERS

5200
03:22:49,822 --> 03:22:50,756
SEEM TO BE MORE AND MORE

5201
03:22:50,756 --> 03:22:51,623
ENCOURAGED TO INFLUENCE POLICY

5202
03:22:51,623 --> 03:22:53,025
AND I KNOW THERE WAS DISCUSSION

5203
03:22:53,025 --> 03:22:55,160
IN THIS GROUP EARLIER TODAY

5204
03:22:55,160 --> 03:22:58,564
ABOUT THE IMPORTANCE OF POLICY

5205
03:22:58,564 --> 03:23:00,699
AROUND ACCESS TO LUNG CANCER

5206
03:23:00,699 --> 03:23:01,700
SCREENING AND I THINK IT WOULD

5207
03:23:01,700 --> 03:23:03,001
BE GREAT TO REALLY UNDERSTAND

5208
03:23:03,001 --> 03:23:05,170
WHAT HAS BEEN THE SUCCESSFUL

5209
03:23:05,170 --> 03:23:06,505
POLICY INITIATIVESES AND WHAT

5210
03:23:06,505 --> 03:23:09,007
MIGHT BE SOME OPPORTUNITIES TO

5211
03:23:09,007 --> 03:23:11,143
MOVE POLICY FORWARD AND HOW TO

5212
03:23:11,143 --> 03:23:21,387
BEST DO THAT.

5213
03:23:22,221 --> 03:23:23,956
>> THIS IS PERHAPS
SOMEWHAT

5214
03:23:23,956 --> 03:23:26,825
WEIGHTY TOPIC WHICH WE TOUCHED

5215
03:23:26,825 --> 03:23:27,659
ON YESTERDAY.

5216
03:23:27,659 --> 03:23:28,861
IN ONE OF THE SESSIONS.

5217
03:23:28,861 --> 03:23:33,065
AND THE ISSUES ABOUT DIVERSITY

5218
03:23:33,065 --> 03:23:34,133
IN THE WORKFORCE AND HOW THE

5219
03:23:34,133 --> 03:23:38,170
STRATEGIES WE NEED TO ADOPT TO

5220
03:23:38,170 --> 03:23:42,007
USE TO BE SUCCESSFUL AND ALSO BE

5221
03:23:42,007 --> 03:23:43,709
ATTENTIVE TO SOME OF THE AREAS

5222
03:23:43,709 --> 03:23:44,977
OF -- CHALLENGES AND CONCERNS

5223
03:23:44,977 --> 03:23:46,245
THAT HAVE A REASON.

5224
03:23:46,245 --> 03:23:48,480
SO I'M WONDERING IF THERE MIGHT

5225
03:23:48,480 --> 03:23:52,818
BE AN OPPORTUNITY FOR US TO

5226
03:23:52,818 --> 03:23:53,385
COLLECT DUPLICATES AND WHAT

5227
03:23:53,385 --> 03:23:54,086
STRATEGY THERE MIGHT BE TO

5228
03:23:54,086 --> 03:23:55,454
ADDRESS ISSUES OF DIVERSITY

5229
03:23:55,454 --> 03:24:00,259
WITHIN THE CANCER PROGRAMS AND

5230
03:24:00,259 --> 03:24:07,699
WE SAID IT YESTERDAY.

5231
03:24:07,699 --> 03:24:09,067
I DON'T THINK PLANS WILL WORK AS

5232
03:24:09,067 --> 03:24:11,103
WE THINK -- SO WHAT I'M HOPING

5233
03:24:11,103 --> 03:24:14,706
IS WE FIND SOME AVENUE A WAY FOR

5234
03:24:14,706 --> 03:24:17,543
US TO CREATE A CONCENTRATED

5235
03:24:17,543 --> 03:24:19,278
DISCUSSION AROUND ISSUES OF

5236
03:24:19,278 --> 03:24:27,019
ADVANCED DIVERSITY AND CANCER

5237
03:24:27,019 --> 03:24:27,486
PROGRAMS.

5238
03:24:27,486 --> 03:24:28,687
>> I HAVE FOUR HANDS AND
WE'LL

5239
03:24:28,687 --> 03:24:29,588
GO IN THIS ORDER.

5240
03:24:29,588 --> 03:24:35,327
WE HAVE RAY, SYLVIA, MICHELLE

5241
03:24:35,327 --> 03:24:36,762
AND KARIN.

5242
03:24:36,762 --> 03:24:38,597
>> THANKS, JOHN.

5243
03:24:38,597 --> 03:24:40,999
SO, IN TERMS OF ACCESS TO

5244
03:24:40,999 --> 03:24:46,538
CLINICAL TRIALS AND SO ON,

5245
03:24:46,538 --> 03:24:50,075
OBJECTIVE EVIDENCE SUGGESTS

5246
03:24:50,075 --> 03:24:51,710
ABOUT A THIRD OF THE REASON WHY

5247
03:24:51,710 --> 03:24:55,547
PEOPLE DON'T GET INTO CLINICAL

5248
03:24:55,547 --> 03:24:57,583
TRIALS IS THE ELIGIBILITY

5249
03:24:57,583 --> 03:24:59,952
CRITERIA ARE TOO STRINGENT.

5250
03:24:59,952 --> 03:25:02,087
SO SEVER YEARS AGO, FRIENDS OF

5251
03:25:02,087 --> 03:25:04,923
CANCER RESEARCH, NCI,FDI, GOT

5252
03:25:04,923 --> 03:25:06,225
TOGETHER AND IN TWO CYCLES WE

5253
03:25:06,225 --> 03:25:09,461
DID WORK TO MAKE PROPOSALS TO

5254
03:25:09,461 --> 03:25:10,696
SIMPLIFY CLINICAL TRIALS

5255
03:25:10,696 --> 03:25:14,199
ELIGIBILITY CRITERIA.

5256
03:25:14,199 --> 03:25:17,769
AND THE IDEA OF INVITING OR

5257
03:25:17,769 --> 03:25:18,904
JOGGING MY MEMORY ABOUT THIS

5258
03:25:18,904 --> 03:25:21,073
BECAUSE IT'S BEEN SEVERAL YEARS

5259
03:25:21,073 --> 03:25:22,841
NOW AND AS CHAIR OF ASCO'S

5260
03:25:22,841 --> 03:25:25,944
RESEARCH COMMITTEE, I ASK THAT

5261
03:25:25,944 --> 03:25:31,350
WE GO BACK AND SEE WHAT IS THE

5262
03:25:31,350 --> 03:25:33,151
IMPLEMENTATION OF THESE

5263
03:25:33,151 --> 03:25:33,852
PROPOSALS HAS BEEN LIKE AND THE

5264
03:25:33,852 --> 03:25:36,622
EARLY FEEDBACK WE ARE GETTING IS

5265
03:25:36,622 --> 03:25:41,026
THAT THERE IS RESISTANCE AT

5266
03:25:41,026 --> 03:25:41,660
VARIOUS LEVELS INCLUDING WITHIN

5267
03:25:41,660 --> 03:25:42,594
THE FDA.

5268
03:25:42,594 --> 03:25:44,830
I WONDER SINCE THE NCI WAS PART

5269
03:25:44,830 --> 03:25:46,999
OF THAT EFFORT AND THE NCI

5270
03:25:46,999 --> 03:25:49,434
ACTUALLY TOOK THE PROPOSALS AND

5271
03:25:49,434 --> 03:25:54,540
MADE SOME EFFORT TO STREAMLINE

5272
03:25:54,540 --> 03:25:55,274
THINGS, WHETHER THE BOARD

5273
03:25:55,274 --> 03:25:56,608
COULDN'T HAVE A SESSION TO TAKE

5274
03:25:56,608 --> 03:25:58,510
A LOOK AT THIS.

5275
03:25:58,510 --> 03:26:01,680
WHAT IS THE CURRENT STATUS OF

5276
03:26:01,680 --> 03:26:03,382
IMPLEMENTING THESE

5277
03:26:03,382 --> 03:26:03,749
RECOMMENDATIONS?

5278
03:26:03,749 --> 03:26:06,952
WHERE ARE THE BARRIERS AND SO

5279
03:26:06,952 --> 03:26:07,119
ON?

5280
03:26:07,119 --> 03:26:12,190
>> THAT COULD POSSIBLY TIE
INTO

5281
03:26:12,190 --> 03:26:16,962
A DISCUSSION WITH RICK.

5282
03:26:16,962 --> 03:26:17,229
THANKS.

5283
03:26:17,229 --> 03:26:17,529
SYLVIA?

5284
03:26:17,529 --> 03:26:18,997
>> THANK YOU.

5285
03:26:18,997 --> 03:26:19,965
I'D LIKE TO ADVOCATE FOR MORE

5286
03:26:19,965 --> 03:26:23,302
DISCUSSIONS OF THE NCI'S AI AND

5287
03:26:23,302 --> 03:26:25,070
DATA SCIENCE STRATEGY AROUND

5288
03:26:25,070 --> 03:26:28,106
BASIC TRANSLATIONAL AND CLINICAL

5289
03:26:28,106 --> 03:26:28,840
RESEARCH.

5290
03:26:28,840 --> 03:26:31,944
DISCUSSIONS THAT FUTURE BSA AND

5291
03:26:31,944 --> 03:26:33,512
CAB MEETINGS.

5292
03:26:33,512 --> 03:26:35,113
I THINK WE ARE SEEING A LOT OF

5293
03:26:35,113 --> 03:26:35,948
HEADS NODDING.

5294
03:26:35,948 --> 03:26:37,783
WE ARE LIVING THROUGH

5295
03:26:37,783 --> 03:26:39,518
UNPRECEDENTED TIMES ESPECIALLY

5296
03:26:39,518 --> 03:26:41,553
WITH THE REGENERATIVE AI AND IT

5297
03:26:41,553 --> 03:26:44,957
IS GREAT TO SEE WE PARTICIPATED

5298
03:26:44,957 --> 03:26:50,996
WITH ARPA-H IN THE RECENT

5299
03:26:50,996 --> 03:26:52,397
BIODATA MEDICAL FRAMEWORK

5300
03:26:52,397 --> 03:26:53,031
INITIATIVE.

5301
03:26:53,031 --> 03:26:54,499
I'D LIKE TO REQUEST A

5302
03:26:54,499 --> 03:26:55,734
PRESENTATION ON THE JOINT

5303
03:26:55,734 --> 03:26:58,537
INITIATIVE BETWEEN NCI AND

5304
03:26:58,537 --> 03:27:00,906
ARPA-H AT A FUTURE BSA MEETING

5305
03:27:00,906 --> 03:27:06,812
AND ANY OTHER NCI INITIATIVES

5306
03:27:06,812 --> 03:27:08,480
AND EFFORTS AROUND AI AND DATA

5307
03:27:08,480 --> 03:27:08,714
SCIENCE.

5308
03:27:08,714 --> 03:27:10,148
>> I AGREE.

5309
03:27:10,148 --> 03:27:12,584
THAT'S A GREAT TOPIC FOR A

5310
03:27:12,584 --> 03:27:13,452
FUTURE MEETING.

5311
03:27:13,452 --> 03:27:13,885
MICHELLE.

5312
03:27:13,885 --> 03:27:16,188
>> THANK YOU, JOHN.

5313
03:27:16,188 --> 03:27:17,122
AN AREA THAT IS OF GREAT

5314
03:27:17,122 --> 03:27:21,360
INTEREST TO NCI AND NCI IS

5315
03:27:21,360 --> 03:27:24,496
PLANNING SOME VERY IMPACTFUL

5316
03:27:24,496 --> 03:27:26,164
STUDIES, AS WELL AS OF INTEREST

5317
03:27:26,164 --> 03:27:28,233
TO INDUSTRY, ACK DEEM QUAAND

5318
03:27:28,233 --> 03:27:30,502
OTHER GROUPS IS MULTICANCER

5319
03:27:30,502 --> 03:27:31,703
DETECTION TESTS.

5320
03:27:31,703 --> 03:27:33,772
AND FDA IS NOW LAUNCHING ITS

5321
03:27:33,772 --> 03:27:40,178
EVALUATION OF THESE TESTS AND

5322
03:27:40,178 --> 03:27:41,113
SEEKING ADDITIONAL INFORMATION.

5323
03:27:41,113 --> 03:27:44,783
SO THIS MIGHT BE A GOOD TIME FOR

5324
03:27:44,783 --> 03:27:55,127
US TO WEIGH IN ON THESE TOPICS.

5325
03:27:55,127 --> 03:27:57,229
>> THANK YOU, MICHELLE.

5326
03:27:57,229 --> 03:27:57,696
KARIN.

5327
03:27:57,696 --> 03:27:59,231
>> I JUST WANT TO WEAR TWO
HATS

5328
03:27:59,231 --> 03:27:59,564
FOR A SECOND.

5329
03:27:59,564 --> 03:28:02,067
SO ONE IS AS A FORMER CANCER

5330
03:28:02,067 --> 03:28:02,567
CENTER DIRECTOR.

5331
03:28:02,567 --> 03:28:05,237
IT CAN SOMETIMES BE VERY

5332
03:28:05,237 --> 03:28:06,838
DIFFICULT FOR THE 501(C)3s

5333
03:28:06,838 --> 03:28:08,740
ESPECIALLY IF THEY ARE A STATE

5334
03:28:08,740 --> 03:28:10,075
INSTITUTION, TO ENGAGE IN

5335
03:28:10,075 --> 03:28:11,710
POLICY, ESPECIALLY STATE-RELATED

5336
03:28:11,710 --> 03:28:12,611
POLICY CHANGE.

5337
03:28:12,611 --> 03:28:13,912
THAT DOESN'T MEAN THAT THEY ARE

5338
03:28:13,912 --> 03:28:16,081
NOT -- THAT SOME OF THESE

5339
03:28:16,081 --> 03:28:16,581
CENTERS ARE NOT HAVING

5340
03:28:16,581 --> 03:28:18,417
INCREDIBLE IMPACT AT THE STATE

5341
03:28:18,417 --> 03:28:19,317
AND NATIONAL LEVEL ON

5342
03:28:19,317 --> 03:28:21,086
CANCER-RELATED POLICY OR FROM

5343
03:28:21,086 --> 03:28:22,688
SCREENING TO EARLY DETECTION.

5344
03:28:22,688 --> 03:28:23,588
I'M NOT TELLING YOU SOMETHING

5345
03:28:23,588 --> 03:28:24,556
YOU DIDN'T KNOW.

5346
03:28:24,556 --> 03:28:29,461
BUT, THIS IS AN AREA WHERE WE DO

5347
03:28:29,461 --> 03:28:31,663
COLLABORATE QUITE A LOT WITH THE

5348
03:28:31,663 --> 03:28:33,932
CANCER CENTERS AND CAN TAKE THE

5349
03:28:33,932 --> 03:28:36,601
STORIES AND SCIENCE AND PUSH IT

5350
03:28:36,601 --> 03:28:38,303
FORWARD INTO A POLICY CHANGE

5351
03:28:38,303 --> 03:28:39,805
THAT THEN WE CERTAINLY ENCOURAGE

5352
03:28:39,805 --> 03:28:41,306
THE CANCER CENTERS TO INCLUDE IN

5353
03:28:41,306 --> 03:28:43,075
THEIR CCSG.

5354
03:28:43,075 --> 03:28:44,042
THE OFFER IS, IF THIS IS

5355
03:28:44,042 --> 03:28:46,578
HELPFUL, BECAUSE WE DO PROFILE

5356
03:28:46,578 --> 03:28:48,680
THIS OURSELVES, WHAT PROGRESS WE

5357
03:28:48,680 --> 03:28:50,282
HAVE MADE.

5358
03:28:50,282 --> 03:28:51,583
IS IF YOU EVER WANT, HAVE A

5359
03:28:51,583 --> 03:28:54,352
REPORT FROM ACS CAN TO PRESENT

5360
03:28:54,352 --> 03:28:58,757
TO THE NCA OR BSA OF HERE IS

5361
03:28:58,757 --> 03:29:01,860
FEDERAL AND STATE LEVEL, THE

5362
03:29:01,860 --> 03:29:07,099
POLICIES THAT -- POLICY CHANGES

5363
03:29:07,099 --> 03:29:07,666
ENABLED BY SCIENCE THAT CAME

5364
03:29:07,666 --> 03:29:08,500
FROM THE CANCER CENTERS.

5365
03:29:08,500 --> 03:29:10,402
SO JUST AN OFFER.

5366
03:29:10,402 --> 03:29:11,903
>> THANKS, KARIN.

5367
03:29:11,903 --> 03:29:13,105
>> THAT WOULD BE AMAZING.

5368
03:29:13,105 --> 03:29:13,872
>> THANKS.

5369
03:29:13,872 --> 03:29:16,308
SO I BELIEVE PAULET HAS BEEN

5370
03:29:16,308 --> 03:29:17,476
CAPTURING ALL THESE GREAT IDEAS.

5371
03:29:17,476 --> 03:29:20,345
AND IF THERE ARE ANY OTHER IDEAS

5372
03:29:20,345 --> 03:29:24,116
FOR FUTURE TOPICS, JUST SEND

5373
03:29:24,116 --> 03:29:28,820
THOSE SUGGESTIONS ON TO PALEATE.

5374
03:29:28,820 --> 03:29:29,688
INDIVIDUAL BOARD SUGGESTIONS

5375
03:29:29,688 --> 03:29:31,690
SHOULD BE SENT TO THE RESPECTIVE

5376
03:29:31,690 --> 03:29:34,693
BOARD CHAIR OR PAULET AS WELL.

5377
03:29:34,693 --> 03:29:36,161
SO THERE BEING NO FURTHER

5378
03:29:36,161 --> 03:29:38,063
BUSINESS, THE MEETING IS NOW

5379
03:29:38,063 --> 03:29:38,630
ADJOURNED.

5380
03:29:38,630 --> 03:29:40,832
I'D LIKE TO WISH EVERYBODY A

5381
03:29:40,832 --> 03:29:45,871
WONDERFUL HOLIDAY SEASON AND I

5382
03:29:45,871 --> 03:29:48,140
WILL SEE YOU VIRTUALLY IN

5383
03:29:48,140 --> 03:29:51,209
FEBRUARY.

5384
03:29:51,209 --> 03:30:01,553
THANK YOU, EVERYONE.